session plus

session 

2 0 1 6 

tracker 

Pre-Meeting Courses: Friday, November 11 – Saturday, November 12, 2016 

Scientific Sessions: Saturday, November 12 – Wednesday, November 16, 2016 

Exhibits: Sunday, November 13 – Tuesday, November 15, 2016 

plus

2016 ACR/ARHP ANNUAL MEETING 


2 0 1 6 

tracker 

plus 

Use the Session Tracker Plus to record your CME/participation hours throughout 

the meeting. Then use the Session Tracker as a guide when you are ready to claim CME 

credit or participation hours. To record your sessions, claim credit or print a certificate, 

login to your account at www.rheumatology.org. 

EDUCATIONAL TRACKS 

Look for these icons to navigate the meeting by track: 

PRIMARY TRACKS 

BASIC SCIENCE BUSINESS/ADMINISTRATION CLINICAL SCIENCE CLINICAL PRACTICE 

SECONDARY TRACKS 

EdPM 

Pd PS Educators Pd PS PrM PrM FIT FITFellows-In-Training 

PM Ed Pd PS Pediatrics PrM FIT Practice Management Tech Med 

STATE CME DESIGNATIONS 

PM PS E ETHICS 

PM PAIN PS MANAGEMENT E PM PS PATIENT E SAFETY

2 0 1 6 


tracker 


Accreditation Statement: The American College 

of Rheumatology is accredited by the Accreditation 

Council for Continuing Medical Education (ACCME) 

to provide continuing medical education for 

physicians. 

Designation Statement: The ACR designates this 

live educational activity for a maximum of 54.25 AMA 

PRA Category 1 Credits. Physicians should claim only 

the credit commensurate with the extent of their 

participation in the activity. 

CLAIMING CME CREDIT 

You may claim your credit online at your 

convenience by logging into your account at 

www.rheumatology.org. From your account, 

you can also print a CME certificate, certificate 

of participation, or certificate of completion. For 

assistance during the meeting, visit the ACR Help 

Desk, located on the L Street Bridge. 

How Do I Claim Credit? The AMA requires you 

claim credit only for time spent actively participating 

in educational sessions. To facilitate accurate 

reporting, you may login to your account at any time 

to record your activity and you may claim partial 

credit to the nearest quarter hour. 

If you attempt to claim full credit for more than 

one concurrent session, or exceed the maximum 

available AMA/PRA Category 1 Credits TM , you will 

receive an error message and be directed to correct 

your claim before printing your certificate. 

Example: You attend half of a 1-hour session and 

half of another session in the same 1-hour time 

slot. You must report spending 0.5 hours in the first 

session and 0.5 hours in the second session. If you 

attempt to claim full credit (1 hour) for each of the 

two sessions, you will exceed the maximum number 

of credits available. 

How Do I Claim Credit for Poster Sessions? CME 

credit is available for viewing posters from 9:00 – 

11:00 am on Sunday, Monday, and Tuesday, when 

poster presenters are available to engage learners. 

You should claim credit commensurate with the 

extent of your participation in the poster sessions 

during this time slot, and that may be full or partial 

credit up to a maximum of 2.0 hours. 

CERTIFICATES AND PROOF OF ATTENDANCE 

AVAILABLE TO ATTENDEES 

The following certificates can be printed by logging 

into your ACR account at www.rheumatology.org. 

• CME Certificate—For physician attendees who 

would like a record and confirmation of AMA PRA 

Category 1 Credits earned; the CME certificate 

displays the exact number of credits claimed. 

You can record and claim CME credit at any time by 

logging into your ACR account. Once credit has been 

claimed, you can also print a CME certificate at your 

convenience. For assistance during the meeting, visit 

the ACR Help Desk, located on the L Street Bridge. 

• Certificate of Participation—For any meeting 

attendee who would like proof of attendance; 

this certificate acknowledges attendance/ 

participation but does not confirm CME credit 

earned. 

• CME Transcript—For attendees who would like 

a detailed listing of all educational session(s) 

attended and credit claimed for each session. 

European Physicians who would like to receive 

European CME Credits (ECMECs) should login to 

their account at www.rheumatology.org to record 

and claim AMA PRA Category 1 Credits earned at the 

2016 ACR Annual Meeting. After claiming credit, 

print a Certificate of Completion. In accordance 

with the mutual recognition of credits between 

the American Medical Association and the UEMS- 

European Accreditation Council for CME, you must 

submit your certificate of completion to the UEMS/ 

EACCME for conversion of credits. 

1


IMPORTANT LOCATIONS 

ACR Office ................................................102A; Telephone: (202) 249-4102 

ACR Help Desk ............................................L Street Bridge 

Business Center ..........................................Grand Lobby (opposite Salon F) 

Career Connection ........................................Exhibit Hall: Hall A (Discovery Center) 

Child Care ................................................Call for Location; 

Telephone: (202) 249-4108 

Coat/Baggage Check ......................................Level C: Concourse B / 9th Street Atrium 

CollaborationRheum ......................................Exhibit Hall: Hall B (Between Exhibit Hall 

and Poster Hall) 

Discovery Center .........................................Exhibit Hall: Hall A 

Exhibit Hall ...............................................Halls A-B 

First Aid ..................................................Exhibit Hall: Hall A (bottom of escalator) 

Food Court ...............................................Exhibit Hall: Hall B (Between Exhibit Hall 

and Poster Hall) 

Foundation Booth ........................................Exhibit Hall: Hall A (Discovery Center) 

Foundation Donors’ Lounge ...............................East Overlook 

Hotel Reservations .......................................Registration: Hall E 

Industry-Supported Symposia Information ................. L Street Lobby South 

Innovation Theater . ......................................Exhibit Hall: Hall A 

Lost and Found ...........................................ACR Office: 102A 

Membership Booth .......................................Registration: Hall E 

Newsroom ...............................................203A; Telephone: (202) 249-4105 

Nursing Mothers’ Room ...................................Salon D 

Poster Hall ...............................................Halls B-C 

Prayer Room .............................................Salon E 

Registration ..............................................Hall E 

Registration (Exhibitors Only) .............................Hall A Concourse 

Restaurant Reservations ..................................Grand Lobby 

Ribbon Distribution .......................................Registration: Hall E 

Shuttle Bus ...............................................L Street 

2

2 0 1 6 


tracker 


Simple Tasks Booth ........................................Exhibit Hall: Hall A (Discovery Center) 

Speaker Ready Room .....................................156 

Technology Center ........................................L Street Bridge 

Visitor Information .......................................Grand Lobby 

Wheelchairs ..............................................Order through ScootAround, Inc.; 

Telephone: (888) 441-7575 

Special Needs 

If you require special arrangements to participate in this meeting, please contact the ACR Office (102A); 

Telephone: (202) 249-4102. 

Emergency Contact Information 

Space is provided on the back of your badge to list name and telephone numbers of your emergency 

contacts. Please complete this information before inserting your badge in your badge holder. 

Printing of this publication is supported by Amgen, Inc. 

3


MAP CONFERENCE CENTER 

Concourse 

Halls A, B & C 

1 

1 Exhibitor Registration 

2 Coat & Baggage Check 

2 

4

2 0 1 6 


tracker 


Lower Level 

3 First Aid 

4 Exhibit Hall 

5 Discovery Center 

Wi-Fi Way 

6 Innovation Theater 

7 Food Court 

8 Collaboration Rheum 

9 Poster Hall 

4 

5 

CONFERENCE CENTER MAP 

3 

6 

7 

8 

9 

5



11 

12 

13 

14 

15 

RETAIL 

10 

Street Level 

Grand Lobby/Registration/Salons A–I 

Meeting Rooms 101–103 & 140–160 

10 Taxis 

11 City Information 

Restaurant Reservations 

12 Business Center 

13 Nursing Mothers’ Room 

Prayer Room 

14 ACR Office 

15 Industry-Supported Symposia 

Information 

16 Shuttle Buses 

17 Speaker Ready Room 

18 Metro Station 

16 

17 

18 

6

Level Two 

Halls D & E 

Meeting Rooms 201-210 

East and West Overlook 

19 Donors’ Lounge (East Overlook) 

20 West Overlook 

21 Newsroom 

22 ACR Help Desk & Technology Kiosks 

Awards & New Masters 

23 Registration 

21 

19 

2 0 1 6 


tracker 


CONFERENCE CENTER MAP 

GRAND LOBBY BRIDGE 

20 

22 

23 

7



Level Three 

Ballrooms 

24 Attendee Lounge 

24 

8

Fellows 

2016 

Education 

Fund 

RHEUMATOLOGY FELLOWS-IN-TRAINING are truly the future of rheumatology. 

Annual corporate support of fellows-in-training programs and activities ensures that fellowsin-training 

have access to vital educational opportunities and resources designed to advance 

knowledge, skills, and competence. 

THE ACR WOULD LIKE TO THANK the following companies for their support of 

activities for rheumatology fellows-in-training in 2016: 

2016 State-of-the-Art 

Clinical Symposium 

2016 Rheumatology 

Research Workshop 

2016 ACR/ARHP Annual 

Meeting Scholarship 

2016 Distinguished 

Fellow Award 






Fellow Award 

2016 State-of-the-Art 

Clinical Symposium 






Fellow Award


MEETING AT-A-GLANCE 

P R E - M E E T I N G C O U R S E S 

FRIDAY, NOVEMBER 11, 2016 

TIME TITLE LOCATION 

6:30 am – 

5:30 pm 

ACR Musculoskeletal Ultrasound Course for 

Rheumatologists – Fundamentals – Day One of Two ..... 150 A 43 

PAGE 

NO. 

11 

CME/HOURS OF 

PARTICIPATION 

 

9.25 hrs. 

8:00 am – 

5:00 pm 

1:00 pm – 

5:30 pm 

1:00 pm – 

6:00 pm 

1:00 pm – 

6:05 pm 

ACR Advanced Rheumatology Coding Case Study 

Workshop ........................................140 A 44 

ACR Basic Research Conference: Cellular Metabolism 

and Stress Response in Immune-mediated Inflammatory 

Disease – Day One of Two .............................Ballroom A 44 

ACR Clinical Research Conference: Lung Disease 

in Rheumatology – Day One of Two ....................Ballroom C 45 

ACR Maintenance of Certification (MOC) Annual 

Meeting Course – 2016 Update in Rheumatology ........Salon B 46 

 

7 hrs. 

 

4 hrs. 

 

4.75 hrs. 

 

4.5 hrs. 

SATURDAY, NOVEMBER 12, 2016 


PAGE 

NO. 

12 

CME/HOURS OF 

PARTICIPATION 

6:30 am – 

6:00 pm 


Rheumatologists – Fundamentals – Day Two of Two .....150 A 46 

 

9.50 hrs. 

7:00 am – 

4:15 pm 

7:00 am – 

4:00 pm 

ACR Practice Management Course: The Next 

Generation of Business Development for 

Rheumatology Practices ...........................140 A 47 

 

6 hrs. 

ACR Review Course PM Ed Pd PS 

............................Hall PrME 

FIT 

D 48 

6 hrs. 

7:00 am – 

4:15 pm 

7:00 am – 

4:15 pm 

ACR Clinical Research Conference: Lung Disease 

in Rheumatology – Day Two of Two ....................Ballroom C 49 

ARHP Clinical Focus Course: Management of 

Rheumatoid Arthritis Across the Lifespan: A Casebased 

Approach PM Ed Pd PS ...................................152 PrM FIT 

A 50 

 

7 hrs. 

 

7.25 hrs. 

10 

PM Ed Pd PS PrM FIT 

Basic Science Business/Administration Clinical Practice Clinical Science Educators

2 0 1 6 


tracker 


P R E - M E E T I N G C O U R S E S & S C I E N T I F I C S E S S I O N S MEETING AT-A-GLANCE 



7:00 am – 

4:30 pm 

8:00 am – 

4:00 pm 

ACR Basic Research Conference: Cellular Metabolism 

and Stress Response in Immune-mediated Inflammatory 

Disease – Day Two of Two .............................Ballroom A 51 

AAMC Medical Education Research Certificate (MERC) 

Workshops: Data Management and Preparing for Statistical 

Consultation, and Questionnaire Design and Survey 

Research PM Ed Pd PS PrM FIT 

.........................................154 B 52 

PAGE 

NO. 

12 

CME/HOURS OF 

PARTICIPATION 

 

7.75 hrs. 

 

6 hrs. 


S C I E N T I F I C S E S S I O N S 


PAGE 

NO. 

12 

CME/HOURS OF 

PARTICIPATION 

4:30 pm – 

6:15 pm 

6:30 pm – 

8:00 pm 

ACR/ARHP Opening Lecture and Awards 

Opening Lecture: Harnessing the Internet of Healthy 

Things: How Connected Health Can Advance 

Rheumatology .....................................Hall D 52 

Networking Event 

Opening Reception .......................................Marriott Marquis, 

Marquis Ballroom 

52 

 

1.75 hrs. 

SUNDAY, NOVEMBER 13, 2016 


PAGE 

NO. 

13 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

ACR Sessions 

Immunology Update: That’s a fact, Jak: Targeting Signaling Type 

I/II Cytokines in Rheumatic Diseases ...................... 146 A 

Mechanisms of Enthesopathy ........................... 140 A 

Optimizing Lupus Management in Pregnancy 

PM PS E 

.......... Salon G 

Year in Review ......................................... Hall D 

53 

53 

53 

53 

 

1 hr. 

PM Ed Pd PS PrM FIT PM Ed Pd PS PrM FIT ARHP 

Fellows-in-Training Pediatrics Practice Management TechMed Session designed for health professionals 

11




SUNDAY, NOVEMBER 13, 2016 13 


PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

7:45 am – 

9:15 am 


ACR/ARHP Annual Meeting Orientation ......................201 53 

Meet the Professor Sessions 

001 – Controversies in Sjögren’s Syndrome ................ 148 

53 

002 – Macrophage Activation Syndrome 

............... 153 


003 – Pain: Evaluation and Treatment of Back 

Pain PM PS PME 

..................................... 

PS E 

154 A 

004 – Polymyalgia Rheumatica 

PM PS E 

....................... 154 B 

005 – Pulmonary Manifestations of Rheumatic Disease ..... 155 

53 

006 – Rheumatoid Arthritis: Biological Agents 

PM PS E 

.......... 158 A 

007 – Rheumatoid Arthritis: Outcome Measures in 

Clinical Practice – Moving from Measurements to 

Management PM PS ................................. 

E 

158 B 

008 – Systemic Lupus Erythematosus: Novel Treatments – 

How to Treat Systemic Lupus Erythematosus ........ 159 A 

009 – Ultrasound versus Dual CT in Gout . . . . . . . . . . . . . . . . . . 159 B 

010 – Vasculitis Mimics ................................. 160 

53 

53 

53 

54 

54 

54 

54 

54 

 

1.5 hrs. 

7:45 am – 9:45 am 

Workshops 

201 – Advanced Musculoskeletal Ultrasound: Image 

Optimization and Pathology Recognition ............ 144 C 

202 – Clinical Anatomy and Physical Exam: Essential Tools in 

Lower Extremity Regional Pain Syndromes PM PS PME 

.... PS 144 E B 

203 – X-ray Challenges in Rheumatic Diseases ............. 149 A 

54 

54 

54 

 

2 hrs. 

12 



2 0 1 6 


tracker 






8:30 am – 

10:00 am 

9:00 am – 

10:00 am 

9:00 am – 

10:00 am 

ACR Sessions 

Anatomy for the Clinician I: Hip Pain, Not from the Hip Joint – 

Anterior Hip Pain PM ................................... 

PS E 

Salon B 

Holy MACRA! How to Survive and Thrive in the New Era of 

MACRA, MIPS, and APMs PM PS ......................... 

E 

Ballroom C 

Hypereosinophilic Syndromes: Whats a Colorful Cell Like You 

Doing in a Dark Place Like This? .......................... Ballroom A 

Living Well With Lupus PM PS .............................. 

E 

Hall E 

Quality of Life in Juvenile Idiopathic Arthritis: Sleep, Exercise 

and Outcomes Measures PM Ed PM Pd PS PrM PS ........................ 

FIT E 

207 B 

What is the Science Behind Mesenchymal Stem Cells Therapy 

in Arthritis? ........................................... 145 A 

ACR Sessions 

Tech Tools for Rheumatologists Version 2.0 ........... 150 A 

The Role of Alarmins in the Pathogenesis of Rheumatic 

Disease PM ........................................... 

PS E 

202 B 

ARHP Session 

ARHP Keynote Address: Culture, Health, Healing: Humanities 

in Inter-Professional Collaboration and Patient-Centered 

Care .................................................140 A 56 

PAGE 

NO. 

54 

54 

55 

55 

55 

55 

55 

56 

13 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1 hr. 

 

1 hr. 



13






9:00 am – 

11:00 am 

ACR/ARHP Poster Session A and Poster Tours 

(#1-909) ................................................. Hall C (Poster Hall) 56 

Poster Hall Morning Snack Break (8:30 – 10:00 am) 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

10:00 am – 

5:00 pm 

Poster Presenters Available 

9:00 – 11:00 am 

Guided Poster Tours 

9:00 – 9:45 am 

301 – Fellows Only: How to Navigate the Poster Hall 

302 – Epidemiology and Health Services Research 

303 – Rheumatoid Arthritis – Clinical Aspects 

304 – Rheumatoid Arthritis Treatment – Small Molecules, 

Biologics and Gene Therapy 

305 – Spondyloarthropathies and Psoriatic Arthritis: Clinical 

Aspects and Treatment 

306 – Systemic Lupus Erythematosus: Clinical Aspects 

10:15 – 11:00 am 

307 – Imaging of Rheumatic Diseases 

308 – Metabolic and Crystal Arthropathies 

309 – Miscellaneous Rheumatic and Inflammatory Diseases 

310 – Osteoporosis and Metabolic Bone Disease - Clinical 

Aspects and Pathogenesis 


312 – Rheumatoid Arthritis Treatment - Small Molecules, 


313 – Vasculitis 

Exhibits .............................................. 

Exhibit Hall Morning Snack Break (10:00) 

Exhibit Hall Afternoon Snack Break (2:00) 

Hall A (Exhibit Hall) 56 

14

2 0 1 6 


tracker 





13 


10:30 am – 

12:30 pm 

10:30 am – 

11:15 am 

11:00 am – 

12:00 pm 

11:00 am – 

12:00 pm 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 pm 

12:30 pm – 

1:15 pm 

Workshops 

204 – Beyond Musculoskeletal Ultrasound for 

Rheumatologists ................................. 144 C 

205 – Clinical Anatomy and Physical Exam: Essential Tools in 

Upper Extremity Regional Pain Syndromes PM PS .... E 144 B 

206 – Magnetic Resonance Imaging of Peripheral Joints in 

Rheumatology Practice ............................ 149 A 

207 – Synovial Fluid Analysis and Crystal Identification ...... 144 A 

Exhibits 

Innovation Theater A ......................................Hall A (Exhibit Hall) 

ACR Sessions 

Early-Onset Monogenic Inflammatory Diseases PM 

Ed Pd PS PrM FIT 

........207 B 

ARHP Sessions 

Get Your Money: Challenges in Navigating Appeals in 2016 

and Beyond ....................................... 206 

Immunology Boot Camp I: Basis of Targeted Therapy ....... 202 B 

Study Design Interpretation Tools and Tips ................ 140 A 

Supporting Fatigue: Meaning, Mechanisms, Measurement 

and Management PM PS PME 

............................... 

PS E 

201 

ACR Sessions 

Rheumatic Diseases in Native Americans: What We Can 

Learn, How We Can Help? PM PS ........................... 

E 

Ballroom B 

The Value-Based Payment Modifier: How to Prepare Your 

Practice PM PS ........................................ 

E 

Ballroom C 

ACR Plenary Session 1: Discovery 2016 

(#910–914)...............................................Hall D 58 

Exhibits 

Innovation Theater B ......................................Hall A (Exhibit Hall) 194 

Exhibits 

Innovation Theater A ...................................... Hall A (Exhibit Hall) 194 

PAGE 

NO. 

57 

57 

57 

57 

194 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

57 

1 hr . 

57 

57 

57 

57 

58 

58 

 

1 hr . 

 

1.5 hrs. 

 

1.5 hrs. 



15






12:30 pm – 

2:00 pm 

12:30 pm – 

2:15 pm 

12:45 pm – 

2:15 pm 

12:45 pm – 

2:15 pm 

1:00 pm – 

2:00 pm 

ACR Sessions 

2016 CARE: MOC Sessions .............................. 146 A 

New Perspectives on B cells in Autoimmunity ............. 140 A 


ARHP Discipline Round Tables: Networking Forum ............Marriott Marquis 

– Meeting Level 4 

(Liberty Ballroom: 

Salon I) 

ACR Session 

ACR Knowledge Bowl: Preliminary PM EdRound 

Pd PS PrM FIT ..............Ballroom A 59 


011 – Adult Inflammatory Myopathy . . . . . . . . . . . . . . . . . . . . . . 148 

012 – Osteoarthritis: Update 2016 ....................... 153 

013 – Difficult Osteoporosis, DXA Dilemmas, and Novel 

Treatments ...................................... 154 A 

014 – Pediatrics: Periodic Fevers in Children PM Ed Pd PS ........... 

PrM FIT 

154 B 

015 – Pregnancy and Rheumatic Diseases PM PS ............. 

E 

155 

016 – Psoriatic Arthritis PM PS ............................. 

E 

158 A 

017 – Rheumatoid Arthritis: Challenging Cases ............ 160 

018 – Spondylarthropathy: An Update PM PS ................ 

E 

159 A 

019 – Systemic Lupus Erythematosus: Lupus Nephritis ..... 159 B 

020 – Vaccinations for Patients on Biologic 

Therapies PM PS PME 

PS . . . E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 B 

ACR Sessions 

Medical Education Year in Review PM Ed .................... 

Pd PS PrM FIT 

143 A 

Rheumatology Research Foundation Paul Klemperer, MD 

Memorial Lecture: Maybe Lamarck was right? How the 

Genome, Epigenome and Environment Shape Rheumatoid 

Arthritis .............................................. Ballroom C 

PAGE 

NO. 

59 

59 

59 

60 

60 

60 

61 

61 

61 

61 

61 

61 

61 

61 

61 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs. 

 

1 hr. 

16 



2 0 1 6 


tracker 






1:00 pm – 

2:00 pm 

1:15 pm – 

3:15 pm 

1:30 pm – 

2:15 pm 

2:30 pm – 

3:15 pm 

Study Groups 

APLAR: Research Advances in Systemic Lupus Erythematosus 

(SLE) in the Asia Pacific Region Study Group .................. 147 A 

Autonomic Neuroregulation of Autoimmune Disease Study 

Group ................................................... 204 A 

Behcet’s Syndrome: Prognosis and Management ............. 145 A 

Best Practices in Fracture Prevention Clinics Study Group ...... 152 A 

Causal Inference in Rheumatic Disease Research 

Study Group ............................................. 201 

Geriatric Rheumatology Study Group ..................... 207 B 

Juvenile Arthritis Workgroup (JAW) – TMJ arthritis Study 

Group ................................................ 202 B 

Neuroendocrine Immunology Study Group: Adrenal Gland in 

Rheumatoid Arthritis and Related Disorders. . . . . . . . . . . . . . . . . . 209 A 

Outcomes from Recent Innovations in Musculoskeletal 

Education and Implications for Undergraduate, Graduate, 

and Continuing Medical Education Programs Study Group ..... 151 A 

Psoriatic Arthritis Study Group: How can we best define 

remission in PsA? ......................................... 206 

Reproductive Issues in Rheumatology Study Group ........... 150 A 

Workshops 

208 – Joint Injection Techniques PM PS ...................... 

E 

144 C 

209 – Magnetic Resonance Imaging (MRI) in the Diagnosis and 

Management of Spondylarthritis: A Clinician’s Guide .... 149 A 

210 – Physical Examination Skills for Improved Detection of 

Synovitis and Cervical Thoracolumbar Disorders ...... 144 B 

211 – Renal Histopathology in Systemic Lupus Erythematosus 

and Vasculitis .................................... 144 A 

Exhibits 


Exhibits 

Innovation Theater A ......................................Hall A (Exhibit Hall) 194 

PAGE 

NO. 

61 

61 

61 

61 

62 

62 

62 

62 

62 

62 

62 

62 

62 

62 

62 

13 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 



17






2:30 pm – 

3:30 pm 

2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

ACR Session 

Glucocorticoid-Induced Osteoporosis Prevention and 

Treatment: A New ACR Clinical Guideline PM PS ..............Ballroom 

E 

A 63 

ACR Sessions 

How Dead Cells Drive Inflammation ...................... 140 A 

The Great Debate: To Taper or Not to Taper? – Biologic 

DMARDS in Low Rheumatoid Arthritis Disease Activity ...... Hall D 

ACR Concurrent Abstract Sessions 

(#915-920) B Cell Biology and Targets in Autoimmune 

Disease I .............................................. 150 A 

(#921-926) Cytokines, Mediators, Cell-Cell Adhesion, Cell 

Trafficking and Angiogenesis I ........................... 143 A 

(#927-932) Health Services Research I: Workforce and Quality 

of Care in Rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 A 

(#933-938) Imaging of Rheumatic Diseases I: Advanced 

Imaging in RA and Spondyloarthritides ................... Salon G 

(#939-944) Miscellaneous Rheumatic and Inflammatory 

Diseases I ............................................. 145 A 

(#945-950) Pediatric Rheumatology – Clinical and Therapeutic 

Aspects I: Juvenile Arthritis .............................. Ballroom C 

(#951-956) Rheumatoid Arthritis – Small Molecules, Biologics 

and Gene Therapy I: Treatment Strategies ................ Hall E 

(#957-962) Spondylarthropathies and Psoriatic Arthritis – 

Clinical Aspects and Treatment I: Psoriatic Arthritis – 

Treatment ............................................ Salon B 

(#963-968) Systemic Lupus Erythematosus – Clinical Aspects 

and Treatment I: Nephritis .............................. Ballroom B 

(#969-974) Systemic Sclerosis, Fibrosing Syndromes, and 

Raynaud’s – Clinical Aspects and Therapeutics I ............ 151 A 

(#975-980) Vasculitis I: Novel Approaches to Therapy ....... 146 A 

PAGE 

NO. 

63 

63 

63 

64 

65 

66 

67 

68 

70 

71 

73 

73 

74 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

 

1.5 hrs. 

 

1.5 hrs. 

18 



2 0 1 6 


tracker 






2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

3:30 pm – 

4:15 pm 

4:00 pm – 

6:00 pm 

4:30 pm – 

5:30 pm 

4:30 pm – 

6:00 pm 

ARHP Sessions 

Digital Health: Optimize Juvenile Idiopathic Arthritis: A Selfmanagement 

in Youth and Young Adults PM Ed Pd PS 

....... 

PrME 

FIT 

204 A 

Quality Indicators and Tools: Program Evaluation PM PS ... E 206 

Rheumatic Disease: Address Anxiety, Anger and Fear ....... 209 A 

Treating Us Right: Lesbian, Gay, Bisexual, and Transgender 

Considerations ........................................ 201 

ARHP Concurrent Abstract Session 

(#981-986) ARHP I: Exemplary Abstracts ..................202 B 77 

Exhibits 


Workshops 

212 – Dermatopathology of Rheumatic Diseases ........... 144 A 

213 – Optimizing the Electronic Health Record for 

Maximizing Productivity in the Rheumatology 

Clinic PM PS E ................................. 149 A 

214 – Pediatric Musculoskeletal Ultrasound 

Workshop PM Ed Pd PS .................................... 

PrM FIT 

144 C 

215 – Ultrasound Injection Guidance PM PS .................. 

E 

144 B 

ARHP Session 

Interpreting Rheumatologic Lab Tests in Pediatrics and 

Adults PM PS ............................................206 E 

78 

ACR Sessions 

Curbside Consults: Ask the Professors .................... Hall E 

Autoimmunity and the Microbiome ...................... 151 A 

Treatment of Osteoarthritis Using Cell Based Therapy: Beyond 

the Internet and News Magazines PM PS PME 

................. 

PS E 

Hall D 

PAGE 

NO. 

76 

76 

76 

77 

78 

78 

78 

78 

78 

79 

79 

13 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

2 hrs. 

 

1 hr. 

 

1.5 hrs. 



19






4:30 pm – 

6:00 pm 


(#987-992) Epidemiology and Public Health I: Inflammatory 

Arthritis – Risk and Impact .............................. Salon G 

(#993-998) Fibromyalgia, Soft Tissue Disorders, Regional and 

Specific Clinical Pain Syndromes ......................... 150 A 

(#999-1004) Infection-related Rheumatic Disease .......... 140 A 

(#1005-1010) Innate Immunity and Rheumatic Disease ..... 146 A 

(#1011-1016) Muscle Biology, Myositis and Myopathies I .... 143 A 

(#1017-1022) Osteoarthritis – Clinical Aspects I: Epidemiology 

and Progression ....................................... Ballroom C 

(#1023-1028) Osteoporosis and Metabolic Bone Disease – 

Clinical Aspects and Pathogenesis ........................ 145 A 

(#1029-1034) Rheumatoid Arthritis – Animal Models I ...... 147 A 

(#1035-1040) Rheumatoid Arthritis – Clinical Aspects I: Pre-RA 

and Progression to Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . Ballroom A 

(#1041-1046) Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment II: Axial Spondyloarthritis – 

Treatment ............................................ Ballroom B 


and Treatment II: Clinical Trial Design .................... Salon B 

PAGE 

NO. 

79 

80 

81 

82 

83 

84 

84 

86 

87 

88 

89 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

20 



2 0 1 6 


tracker 






4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

6:30 pm – 

9:30 pm 


021 – Antiphospholipid Syndrome PM PS .................... 

E 

148 

022 – Cutaneous Vasculitis .............................. 153 

023 – Dermatological Manifestations of Rheumatic 

Diseases ........................................ 154 A 

024 – SESSION CANCELED: How Are Patients Using Public Data 

to Evaluate You? .............................. 154 B 

025 – Inflammatory Eye Disease/Uveitis .................. 155 

026 – Management of Difficult Raynaud’s and Digital 

Ischemia ........................................ 158 A 

027 – Pediatric Rheumatology for Adult 

Rheumatologists PM Ed Pd PS .............................. 

PrM FIT 

158 B 

028 – Safety of Drugs Used to Treat Rheumatoid 

Arthritis PM PS ...................................... 

E 

159 A 

029 – Systemic Lupus Erythematosus: Novel Treatments – 

How to Treat Systemic Lupus Erythematosus ........ 159 B 

030 – Systemic Sclerosis: Disease Staging and Subsetting 

in Clinical Practice ................................ 160 

ARHP Sessions 

Cloud-Based Fracture Liaison Service Model ............... 201 

The Care Circle: Rheumatologist, Orthopedist and 

Therapist ............................................. 204 A 

The Economic Burden of Osteoarthritis ................... 209 A 


(#1053-1058) ARHP II: Healthcare Disparities and and 

Psychosocial Impact on Rheumatic Disease ...............202 B 91 


Annual Meeting Tweet-Up ...........................West Overlook 92 

Industry-Supported Symposia 

See page 196 or the Annual Meeting App for the full listing of symposia. 196 

PAGE 

NO. 

90 

90 

90 

90 

90 

90 

90 

90 

90 

90 

90 

91 

91 

13 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs. 



21




MONDAY, NOVEMBER 14, 2016 


PAGE 

NO. 

14 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

ACR Sessions 

Clinicopathologic Conference: Back Pain, Aortitis and 

Retroperitoneal Fibrosis: What Is the Differential Diagnosis 

and the Approach? ..................................... Hall E 

Genetics In the Rheumatology Clinic: Can It Change the 

Clinical Care of Patients? ................................ 146 A 

Immuno-Metabolism: Energetics and Inflammation ........ 145 A 

Update on Safety Issues in the Treatment of Rheumatic 

Diseases – From the FDA and Beyond PM PS PME 

............. 

PS E 152 A 

93 

93 

93 

92 

 

1 hr. 

7:30 am – 

8:30 am 

ARHP Sessions 

Biologic Therapy: Prescription, Prior Authorization and 

Beyond PM PS ........................................... 

E 

140 A 

Immunology Boot Camp II: Basic Mechanisms of 

Autoimmunity ......................................... 202 B 

Pharma Update: What You Need to Know PM PS ............. 

E 

147 A 

Weight Loss Counseling Strategies ....................... 206 

93 

93 

93 

93 

 

1 hr. 

7:45 am – 

9:15 am 


031 – Ankylosing Spondylitis: 2016 Update ................ 148 

032 – Approaches to Urticaria and Angiodema ............. 153 

033 – Controversies in Sjögren’s Syndrome ................ 154 A 

034 – Crystal: Diagnosis and Management of Gout PM ..... PS 154 E B 

035 – Dermatological Manifestations of Rheumatic 

Diseases ........................................ 155 

036 – Myopathy: Issues in Diagnosis and Treatment ........ 158 A 

037 – Psoriatic Arthritis ................................. 158 B 

038 – Pulmonary Manifestations of Rheumatic Disease ..... 159 A 

039 – Reactive Arthritis: An Update ....................... 159 B 

040 – Rheumatoid Arthritis: Biological Agents PM PS .......... 

E 160 

94 

94 

94 

94 

94 

94 

94 

94 

94 

94 

 

1.5 hrs. 

22 



2 0 1 6 


tracker 






7:45 am – 

9:45 am 

8:30 am – 

9:30 am 

8:30 am – 

10:00 am 

9:00 am – 

10:00 am 

Workshops 


Optimization and Pathology Recognition ............ 144 C 

217 – Dermatopathology of Rheumatic Diseases ........... 144 A 

218 – How to Use Motivational Interviewing (MI) Skills in 

the Routine Practice of Rheumatology: A Practical 

Workshop ....................................... 149 A 

219 – Tai Chi, Qigong, Feldenkrais, Yoga for your practice: 

Mind Body Practices in Rheumatic Disease PM PS PME 

. . PS . . 144 E B 

ACR Session 

Rheumatology Research Foundation Philip Hench, MD 

Memorial Lecture: Blocking Interleukin-1 beta or Interleukinalpha 

in Inflammatory Diseases from Gout to Cancer .......Ballroom B 95 

ACR Sessions 

Anatomy for the Clinician II: Hip Pain, Not from the Hip Joint – 

Posterior Hip Pain PM .................................. 

PS E 

Salon B 

Digital Scholar Training Series: What Rheumatologists 

Can Learn from Patients’ Online Conversation? 

(Part 1 of 2) ........................................ 150 A 

Osteoporosis Update PM PS ............................... 

E 

Hall D 

Pain Pathways in Arthrtis PM ............................ 

PS E 

151 A 

What a Pediatric Rheumatologist May Want to Know About 

the Kidneys PM Ed PM Pd PS PrM PS .................................... 

FIT E 

207 B 

ACR Sessions 

Creating a High-Performing Practice through Assessment 

and Planning PM PS ................................... 

E 

145 A 

Cutaneous Lupus in All Its Varieties: Judging a Book By 

Its Cover PM .......................................... 

PS E 

Hall E 

Navigating the Market: Recent Fellows’ Experiences in 

Securing Their First PM Ed Pd PS Job PrM FIT .............................. 204 A 

Perioperative Management of Rheumatic Disease 

Medications in Total Joint Arthroplasty of the Hip and 

Knee: New ACR/AAHKS Guideline PM PS ..................... 

E 

Ballroom C 

PAGE 

NO. 

94 

94 

94 

94 

95 

95 

95 

95 

95 

96 

96 

96 

96 

14 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr. 

 

1.5 hrs. 

 

1 hr. 



23




MONDAY, NOVEMBER 14, 2016 14 


9:00 am – 

10:00 am 

9:00 am – 

11:00 am 

ARHP Session 

ARHP Distinguished Lecturer: Doing, Being, Participating: State 

of the Science PM PS ......................................140 E 

A 

ACR/ARHP Poster Session B and Poster Tours 

(#1059-1954)............................................. 

Hall C (Poster Hall) 96 



9:00 – 11:00 am 


9:00 – 9:45 am 


315 – Genetics, Genomics and Proteomics 

316 – NEW: Healthcare Disparities in Rheumatology 

317 – Quality Measures and Quality of Care 


319 – Systemic Lupus Erythematosus – Human Etiology and 

Pathogenesis 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

96 

1 hr. 

 

2 hrs. 

10:00 am – 

5:00 pm 

10:30 am – 

11:15 am 

10:15 – 11:00 am 

320 – Pediatric Rheumatology – Clinical Aspects 



322 – Spondyloarthropathies and Psoriatic Arthritis – Clinical 


323 – Systemic Lupus Erythematosus – Animal Models 

324 – Systemic Lupus Erythematosus – Clinical Aspects 

325 – Vasculitis 

Exhibits 

Exhibit Hall Morning Snack Break (10:00 am) .................. Hall A (Exhibit Hall) 

Exhibit Hall Afternoon Snack Break (2:00 pm) .................. Hall A (Exhibit Hall) 

Exhibits 


97 

97 

. 

24 



2 0 1 6 


tracker 






10:30 am – 

12:30 pm 

11:00 am – 

12:00 pm 

11:00 am – 

12:00 pm 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 pm 

12:00 pm – 

2:00 pm 

12:30 pm – 

1:15 pm 

Workshops 

220 – Histopathology and Imaging of Rheumatic Lung 

Disease ......................................... 149 A 

221 – Joint Injections (Knee, Ankle, Shoulder and 

Wrist) PM PS ........................................ 

E 

144 B 

222 – Musculoskeletal Ultrasound ....................... 144 C 

ACR Sessions 

ACR Knowledge Bowl Final PM EdRound 

Pd PS PrM FIT .................... Ballroom A 

Approach to Cutaneous Manifestations of Childhood 

Rheumatic Disease PM Ed Pd PS ................................. 

PrM FIT 

207 B 

Common Exercise Injuries and How to Avoid Them in 

Patients .............................................. Salon G 

Nucleic Acid Sensors in Autoimmune Diseases ............ Ballroom B 

ARHP Sessions 

Rheumatology Nursing’s Evolving Role .................... 140 A 

Sex and Intimacy in Chronic Disease PM PS .................. 

E 

209 A 

Time-to-Event Data: Introduction to Analysis .............. 204 A 

When to Consider Sjögren’s Syndrome in a Child PM PM Ed PS Pd PS E .... PrM 

201 

FIT 

ACR Session 

Implementing Quality Measurement In Your Practice: How and 

Why (an ACR/ARHP Combined Session) PM PS ............145 E 

A 99 

ACR Plenary Session II: Discovery 2016 

(#1955-1960).............................................Hall D 99 

Exhibits 



ARHP Topic Round Tables: Networking Forum ................Marriott Marquis 

– Meeting Level 4 

(Liberty Ballroom: 

Salon I) 

Exhibits 


PAGE 

NO. 

98 

98 

98 

98 

98 

98 

98 

98 

98 

98 

99 

100 

14 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr. 

 

1 hr. 

 

1.5 hrs. 

 

1.5 hrs. 



25






12:30 pm – 

2:00 pm 

12:45 pm – 

2:15 pm 

1:00 pm – 

2:00 pm 

ACR Sessions 

2016 CARE: MOC Sessions .............................. 146 A 

Hot Topics in Teaching Techniques: Flipped Classroom, 

Technology and Reflection PM Ed Pd PS ....................... 

PrM FIT 

143 A 


041 – Adult Inflammatory Myopathy . . . . . . . . . . . . . . . . . . . . . . 148 

042 – Challenging Cases in Osteoporosis Management ..... 153 

043 – Infections with Biologics PM PS ....................... 

E 

154 A 

044 – Osteoarthritis: Update 2016 ....................... 154 B 

045 – Pregnancy and Rheumatic Diseases PM PS ............. 

E 

155 

046 – Rheumatoid Arthritis: Biological Agents .............. 158 A 

047 – Survival Strategies: Seeking, Joining, Thriving in Private 

Practice 

PM Ed Pd PS PrM FIT .................................. 158 B 

048 – Systemic Lupus Erythematosus: Novel Treatments .... 159 A 

049 – Systemic Sclerosis: Disease Staging and Subsetting 

in Clinical Practice ................................ 159 B 

050 – Vasculitis: Factors That Influence Disease Patterns .... 160 

ACR Sessions 

Immunology Update: Can We Reset the Immunology 

Landscape? ........................................... 202 B 

Inflammatory Bowel Disease and the Rheumatologist ...... Hall E 

Rheumatology Research Foundation Oscar S. Gluck, MD, 

Memorial Lecture: Osteoporosis 2016 – “Breaking 

Crisis” ................................................ Ballroom A 

PAGE 

NO. 

100 

100 

101 

101 

101 

101 

101 

101 

101 

101 

101 

101 

101 

101 

101 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1 hr. 

26 



2 0 1 6 


tracker 






1:00 pm – 

2:00 pm 

1:15 pm – 

3:15 pm 

1:30 pm – 

2:15 pm 

2:30 pm – 

3:15 pm 

2:30 pm – 

4:00 pm 

Study Groups 

Autoantibodies in Diagnosis and Follow-up of Rheumatic 

Diseases: Current Initiatives in International Autoantibody 

Standardization (IAS) and International Consensus on 

Antinuclear Antibody Patterns (ICAP) ........................ 147 A 

Childhood Sjogren Syndrome Study Group ................... 201 

Giant Cell Arteritis Study Group PM Ed ...................... 

Pd PS PrM FIT 

151 A 

Global Musculoskeletal Health Initiatives Study Group ......... 206 

Latin American Study Group/Epidemiological Studies in 

Rheumatology on Indigenous People in Latin America ...... 140 A 

Macrophage Activation Syndrome (MAS) Study Group ...... 145 A 

Osteoarthritis Study Group ............................. 204 A 

Patient Registries – Ups and Downs PM Ed ................... 

Pd PS PrM FIT 

207 B 

Patient Research Partners Study Group ................... 152 A 

Polymyalgia Rheumatica Study Group ....................... 150 A 

Workshops 

223 – How to Apply Statistics to Your Research ............ 144 A 

224 – Joint Injection Techniques PM PS ...................... 

E 

144 C 

225 – Magnetic Resonance Imaging (MRI) in the Diagnosis 

and Management of Spondylarthritis: A Clinician’s 

Guide ........................................... 149 A 

226 – The Rheumatologic Musculoskeletal Screening Exam, 

with Emphasis on Objective Disease-specific 

Measurements PM PS ............................... 

E 

144 B 

Exhibits 


Exhibits 


ACR Sessions 

Advances in Takayasu’s Arteritis ......................... Hall D 

Breakthroughs in Osteoarthritis New Therapeutic 

Targets PM ........................................... 

PS E 

151 A 

Thieves’ Market: Show Me Your Best PM Ed Cases Pd PS PrM FIT ............ Hall E 

PAGE 

NO. 

102 

102 

102 

102 

102 

102 

102 

102 

102 

102 

102 

102 

102 

103 

103 

103 

103 

14 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1.5 hrs. 



27






2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

3:30 pm – 

4:15 pm 


(#1961-1966) Antiphospholipid Syndrome ................ 150 A 

(#1967-1972) Healthcare Disparities in Rheumatology ...... 146 A 

(#1973-1978) Imaging of Rheumatic Diseases II: Ultrasound 

in Rheumatoid Arthritis ................................. Salon G 

(#1979-1984) Pain – Basic and Clinical Aspects ............. 140 A 

(#1985-1989) Pediatric Rheumatology – Pathogenesis and 

Genetics .............................................. 147 A 

(#1990-1995) Rheumatoid Arthritis – Clinical Aspects II: Risk 

and Impact of Comorbidity .............................. Ballroom C 

(#1996-2001) Rheumatoid Arthritis – Small Molecules, Biologics 

and Gene Therapy II: Safety and Cost Effectiveness ......... Salon B 

(#2002-2007) Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment III: Axial Spondyloarthritis – 

Clinical ............................................... Ballroom A 


and Treatment III: Novel and Current Therapies ........... Ballroom B 


Raynaud’s – Clinical Aspects and Therapeutics II ........... 145 A 

ARHP Sessions 

How to Give a Fantastic Talk ............................. 209 A 

EULAR/ARHP Pain Management Trends ............... 201 

The Power of Arthritis Advocacy ......................... 143 A 

The Science Behind Exercise and Body Composition in 

Rheumatoid Arthritis Inflammation ...................... 206 

Update: Skin Features of Rheumatological Diseases ........ 204 A 


(#2020-2025) ARHP III – Education and Community 

Programs ................................................202 B 114 

Exhibits 


PAGE 

NO. 

103 

105 

105 

106 

107 

108 

109 

110 

111 

113 

114 

114 

114 

114 

114 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs. 

28 



2 0 1 6 


tracker 






4:00 pm – 

6:00 pm 

4:30 pm – 

5:30 pm 

4:30 pm – 

5:30 pm 

4:30 pm – 

6:00 pm 

Workshops 

227 – Musculoskeletal Exam Skills: Regional Musculoskeletal 

Examination of the Shoulder and Knee PM PS .......... 

E 144 B 

228 – Musculoskeletal Ultrasonography: Basic ............. 144 C 

229 – Nailfold Capillarscopy Made Easy for the Clinician .... 144 A 

230 – Osteoporosis: Interpreting Dual Energy X-ray 

Absorptiometry and Clinical Risk Factors: The New 

Fracture Risk Assessment Algorithm ................ 149 A 

ACR Session 

Treatment of Rheumatoid Arthritis When the Patient is 

Not Well ..............................................Hall D 116 

ARHP Session 

Smart Office, Smart Home: Adaptations for Rheumatic 

Disease PM PS E .......................................209 A 116 


051 – Antiphospholipid Syndrome ....................... 148 

052 – Behçet’s Syndrome ............................... 153 

053 – Crystal: Diagnosis and Management of Gout PM ..... PS E 

154 A 

054 – Juvenile Dermatomyositis PM Ed Pd PS ...................... 

PrM FIT 

154 B 

055 – Management of Difficult Raynaud’s and Digital 

Ischemia ........................................ 155 

056 – Non-surgical Treatments for Osteoarthritis .......... 158 A 

057 – Psoriatic Arthritis ................................. 158 B 


Arthritis PM PS ...................................... 

E 

159 A 

059 – Still’s Disease and Autoinflammatory Syndromes ..... 159 B 

060 – Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus ..................... 160 

PAGE 

NO. 

115 

115 

115 

116 

116 

116 

116 

116 

116 

116 

116 

116 

116 

116 

14 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr. 

 

1 hr. 

 

1.5 hrs 



29






4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

ACR Sessions 

Central Nervous System Vasculopathies and Antibody- 

Associated Syndromes ................................. Salon B 

More than Skin Deep: Topics in Dermatomyositis .......... Ballroom A 

Intrinsic Renal Injury in Glomerulonephritis ............... 151 A 

The Rheumatology Workforce: Present and Future PM Ed ..... Pd PS PrM 143 A 

FIT 


(#2032-2037) Genetics, Genomics and Proteomics I ........ 147 A 

(#2038-2043) Quality Measures and Quality of Care I ....... Salon G 

(#2044-2049) Reproductive Issues in Rheumatic Disorders .. 150 A 

(#2050-2055) Rheumatoid Arthritis – Clinical Aspects III: 

Prevention of Comorbidity .............................. Hall E 

(#2056-2061) Systemic Lupus Erythematosus – Animal 

Models ............................................... 140 A 

(#2062-2067) Systemic Lupus Erythematosus – Human Etiology 

and Pathogenesis I ..................................... 146 A 

(#2068-2073) Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and Genetics I ... Ballroom B 

(2074-2079) Vasculitis II: Population Studies ............... Ballroom C 

ARHP Sessions 

Social Influences in Rheumatic Disease: An International 

Perspective ........................................... 201 

Surgery and Therapy for the Elbow and Hand PM PS .......... 

E 206 

Update: Emerging Systemic Lupus Erythematosus 

Treatments ........................................... 204 A 

ACR/ARHP Combined Abstract Session 

(#2026-2031) ACR/ARHP Combined Abstract Session: 

Epidemiology and Pubic Health ..........................145 A 126 


(#2080-2085) ARHP IV – Clinical Practice, Patient Care and 

Health Services ........................................202 B 127 

PAGE 

NO. 

117 

117 

117 

117 

117 

119 

120 

121 

122 

123 

124 

125 

126 

126 

126 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 

30 



2 0 1 6 


tracker 




TUESDAY, NOVEMBER 15, 2016 


7:30 am – 

8:30 am 

7:30 am – 

8:30 am 

7:30 am – 

9:00 am 

ACR Sessions 

Between the Sheets: Clinical Review of Sleep 

Disorders PM PS PME 

...................................... 

PS E 

146 A 

Immunology Update: Biologic Agents: From Nature, to 

Protein Engineering to Biosimilars ....................... Salon G 

Legislative and Regulatory Update 2016 .............. 140 A 

Rheumatology Research Foundation Memorial Lecture 

Honoring Dr. Ephraim Engelman: T Cell Receptor 

Signaling ............................................. Hall E 

ARHP Sessions 

Immunology Boot Camp III: Applying Principles of 

Immunology to Treatment Decisions ..................... 151 A 

Long-Term Side Effects of Biologics PM PS ................... 

E 

204 A 

Nutrition for Rheumatic Disease: Diet and 

Supplements PM PS ...................................... 

E 

201 

Statin Induced Myopathy ............................... 143 A 

ACR Sessions 

New Classification Criteria for ANCA-Associated Vasculitis: 

Implications for Clinical Practice PM PS ..................... 

E 

Ballroom A 

The Art of Asking Questions as a Gateway to Effective 

Teaching and Feedback PM Ed ............................. 

Pd PS PrM FIT 

152 A 

PAGE 

NO. 

128 

128 

129 

129 

129 

129 

129 

129 

129 

130 

14 

CME/HOURS OF 

PARTICIPATION 

 

1 hr 

 

1 hr 

 

1.5 hrs 



31




TUESDAY, NOVEMBER 15, 2016 15 


7:45 am – 

9:15 am 

7:45 am – 

9:45 am 

8:30 am – 

10:00 am 

8:30 am – 

10:00 am 


061 – Ankylosing Spondylitis: 2016 Update 

PM PS E 

............ 148 

062 – Biomechanical Interventions for Managing 

Orthoarthritis .................................... 153 

063 – Challenging Cases in Osteoporosis Management ..... 154 A 

064 – Controversies with Vitamin D use for Bone Health .... 154 B 

065 – Crystal: Diagnosis and Management of Gout PM ..... PS 

160 

E 

066 - Fibromyalgia 2016: Update on Management PM ..... PS 

158 

E 

A 

067 – Giant Cell Arteritis in 2016: Diagnosis and 

Management .................................... 158 B 

068 – Myopathy: Issues in Diagnosis and Treatment ....... 159 A 

069 – Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus .................... 159 B 

070 – Vasculitis: Update ................................ 155 

Workshops 


Optimization and Pathology Recognition ................. 144 C 

232 – Histopathology of Vasculitis ....................... 149 A 

233 – Joint Injections (Knee, Ankle, Shoulder and 

Wrist) PM PS ............................................. 

E 

144 B 

ACR Sessions 

Anatomy for the Clinician III: Knee Pain, Not from the Knee 

Joint PM .............................................. 

PS E 

Salon B 

Digital Scholar Training Series: Engaging with Patients Online: 

The Dos and Don’ts, and What’s to Gain (Part 2 of 2 ) ... 150 A 

New Insights Into Mechanism of Fibrosis ................. Ballroom B 

Pediatric Autoimmune Brain Disease PM Ed Pd PS ................. 

PrM FIT 

207 B 

Spondyloarthropathies: Advances in the Science and 

Management PM PS ...................................... 

E 

Ballroom C 

ARHP Sessions 

Comparative Effectiveness Trials in Rheumatology: Rationale, 

Design and Analysis .................................... 206 

Set the Teen Patient Up for Success in Adult Care PM Ed PM Pd PS PS PrM ..... FIT E 209 A 

PAGE 

NO. 

130 

130 

130 

130 

130 

130 

130 

130 

130 

130 

130 

131 

131 

131 

131 

131 

131 

131 

131 

132 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

2 hrs 

 

1.5 hrs 

 

1.5 hrs 

32 



2 0 1 6 


tracker 






9:00 am – 

10:00 am 

9:00 am – 

10:00 am 

9:00 am – 

11:00 am 

ACR Sessions 

Autoimmunity and Tertiary Lymphoid Tissue ............. 201 

Crystal-related Arthropathies: Beyond Urate .............. Salon G 

ARHP Sessions 

Fibromyalgia Symptom Clusters and Patterns of Symptom 

Change: An Individualized Study Approach PM ............ 

PS E 140 A 

The Future of Medicine is in Your Smart Phone ........ 204 A 

ACR/ARHP Poster Session C and Poster Tours 

(#2086-2981)............................................. 

Hall C (Poster Hall) 132 



9:00 – 11:00 am 


9:00 – 9:45 am 

326 – Osteoarthritis – Clinical Aspects 






330 – Systemic Lupus Erythematosus – Clinical Aspects 

331 – Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – 

Clinical Aspects and Therapeutics 

10:15 – 11:00 am 


333 – Health Services Research 

334 – Reproductive Issues in Rheumatic Disorders – Basic and 

Clinical Aspects 


336 – Rheumatology 360 

337 – Rheumatology 360 (En Español) 





PAGE 

NO. 

132 

132 

132 

132 

15 

CME/HOURS OF 

PARTICIPATION 

 

1 hr 

 

1 hr 

 

2 hrs 

33






PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

10:00 am – 

2:30 pm 

10:30 am – 

11:15 am 

10:30 am – 

11:30 am 

10:30 am – 

12:30 am 

10:30 am – 

3:30 pm 

11:00 am – 

12:00 pm 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 pm 

12:30 pm – 

1:15 pm 

Exhibits 

Exhibit Hall Morning Snack Break (10:00 am) ..................Hall A (Exhibit Hall) 133 

Exhibits 

Innovation Theater A ...................................... Hall A (Exhibit Hall) 195 

Workshop 

234 – How to Be an Effective Advocate for Your Practice and 

Patients: Legislative Affairs, Advocacy, Social Media, and 

Technology (A Workshop) ......................149 A 134 

Workshops 

235 – Musculoskeletal Ultrasound ....................... 144 C 

236 – The Rheumatologic Musculoskeletal Screening 

Exam, with Emphasis on Objective Disease-specific 

Measurements PM PS ............................... 

E 

144 B 

Workshop 

237 – Big Data Made Practical (ImmPort) ..............144 A 134 

ACR Sessions 

Advances in Clinical Care through Whole Exome 

Sequencing PM Ed Pd PS ........................................ 

PrM FIT 

207 B 

Mining Big Data for Drug Repurposing ................ 146 A 

Polymyositis Mimics: A Weak Area for Rheumatologists: 

Recognizing Mimics of Polymyositis ...................... Ballroom B 

ACR Session 

Manuscript Peer Review: A Hands-On Session to Hone 

Skills and Provide Tools for Critical Review of Research 

Manuscripts ..........................................143 A 135 

ACR Plenary Session III: Discovery 2016 

(#2982-2987).............................................Hall D 135 

Exhibits 


Exhibits 


134 

134 

135 

135 

135 

 

1 hr 

 

2 hrs 

 

4.5 hrs 

 

1 hr 

 

1.5 hrs 

 

1.5 hrs 

34 



2 0 1 6 


tracker 






12:30 pm – 

2:00 pm 

12:45 pm – 

2:15 pm 

1:00 pm – 

2:00 pm 

ACR Sessions 

2016 CARE: MOC Sessions ..............................146 A 137 


071 – Ankylosing Spondylitis: Disease Modification ........ 148 

072 – Infections with Biologics PM PS ....................... 

E 

153 

073 – Management of Patients with Hepatitis C and 

Rheumatic Diseases .............................. 154 A 

074 – Pediatric Systemic Lupus Erythematosus PM Ed Pd PS ........ 

PrM FIT 

154 B 

075 – Pulmonary Hypertension in the Rheumatic 

Diseases ........................................ 155 

076 – Rheumatoid Arthritis: Biological Agents ............. 158 A 

077 – Rheumatoid Arthritis: Challenging Cases ............ 158 B 

078 – Scleroderma Mimics .............................. 159 A 

079 – Systemic Lupus Erythematosus: Lupus 

Nephritis PM PS .................................... 

E 

159 B 

080 – Vaccinations for Patients on Biologic Therapies ...... 160 

ACR Sessions 

Innovative Educators, Novel Techniques: A Rheumatology 

Research Foundation Special Session PM Ed ................. 

Pd PS PrM FIT 

150 A 

Pediatric Rheumatology Year in Review (Town Hall 

Meeting) PM Ed Pd PS .......................................... 

PrM FIT 

207 B 

Psoriatic Arthritis: Therapeutic Challenges PM Ed Pd PS PM Ed PrM PM Pd PS FIT PrM PS ..... FIT E 

Hall E 

Visualizing Immune Cell Interactions ..................... Ballroom A 

What Determine Tissue Localization in Chronic 

Inflammation ......................................... Salon G 

PAGE 

NO. 

137 

137 

137 

137 

137 

137 

137 

137 

137 

137 

137 

138 

138 

138 

138 

15 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

 

1 hr 



35






PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

1:00 pm – 

2:00 pm 

1:15 pm – 

3:15 pm 

1:30 pm – 

2:00 pm 

1:30 pm – 

2:15 pm 

2:30 pm – 

3:30 pm 

Study Groups 

Antiphospholipid Syndrome Task Forces Study Group ........ 152 A 

Capillaroscopy: The New and Safest Diagnostic/Prognostic 

Tool In Rheumatology? .................................... 209 A 

Developing, Implementing and Assessing Effective 

Patient Education and Support Programs for People with 

Rheumatologic Illness ..................................... 145 A 

Joint Hypermobility Study Group ........................... 147 A 

Myositis Study Group: Exercise in Myositis ................... 206 

Pediatric Rheumatology Imaging Study Group ............... 202 B 

Sexuality and Intimacy in Rheumatic Diseases Study Group .... 201 

Sjögren’s Syndrome: Development of Biomarkers Study 

Group ................................................... 204 A 

SPARTAN-Spondyloarthritis Study Group .................... 140 A 

Veterans Affairs Study Group .............................. 151 A 

Workshops 

238 – Complementary and Alternative Therapies in 

Rheumatic Disease PM ............................ 

PS E 

149 A 

239 – Knee Braces, Foot Orthoses, and Shoe Gear for 

Managing Knee Osteoarthritis PM PS PME 

.............. 

PS E 

144 B 

240 – Musculoskeletal Ultrasonography: Basic ............ 144 C 

ACR Session 

ACR Business Meeting ..................................143 A 139 

Exhibits 


ARHP Session 

The Business of Clinical Trials: Contracts and 

Budgets ...........................................206 139 

138 

138 

138 

138 

138 

139 

139 

139 

139 

139 

139 

139 

139 

 

2 hrs 

 

1 hr 

36 



2 0 1 6 


tracker 






2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

ACR Sessions 

ILAR Session: Innovative Solutions to Deliver Care ..... 143 A 

Mechanisms of Thrombosis: Interface between 

Endothelium and Blood ................................ 201 

Optimizing Care of Gout and Hyperuricemia with 

Personalized Medicine PM PS PME 

PS PME 

....................... 

PS E 

Hall D 

Systemic Sclerosis: Assessment and Treatment of 

Gastrointestinal Manifestations PM PS ...................... 

E 

Hall E 

Transforming The ABIM MOC Program and Its Impact on 

Rheumatologists ............................................... 152 A 


(#2988-2992) 2016 Rheumatology Research Foundation 

Edmond L. Dubois, MD Memorial Lectureship ............. Ballroom A 

(#2993-2998) Biology and Pathology of Bone and Joint ..... 150 A 

(#2999-3004) Orthopedics, Low Back Pain and 

Rehabilitation ......................................... 209 A 

(#3005-3010) Pediatric Rheumatology – Clinical and 

Therapeutic Aspects II: Juvenile Arthritis .................. 146 A 

(#3011-3016) Rheumatoid Arthritis – Clinical Aspects IV: 

Managing Patients in Remission ......................... Ballroom B 

(#3017-3022) Rheumatoid Arthritis – Human Etiology and 

Pathogenesis I ........................................ 145 A 

(#3023-3028) Rheumatoid Arthritis – Small Molecules, 

Biologics and Gene Therapy III: Small Molecules and Early 

Intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom C 

(#3029-3034) Sjögren’s Syndrome I: Clinical Insights ....... 151 A 

(#3035-3040) Spondylarthropathies Psoriatic Arthritis – 

Pathogenesis, Etiology I ................................ 147 A 

(#3041-3046) Vasculitis III: Pathogenic Mechanisms ........ Salon B 

ARHP Sessions 

Connective Tissue Disorders: Not-So-Benign Joint 

Hypermobility and Pain PM Ed Pd PS 

......................... 

PrME 

FIT 

204 A 

Factors to Consider with Non-Pharmacologic Therapies 

for Osteoarthritis PM .................................. 

PS E 

140 A 

PAGE 

NO. 

140 

140 

140 

140 

141 

141 

142 

143 

143 

145 

146 

147 

148 

149 

150 

152 

152 

15 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 



37






2:30 pm – 

4:00 pm 

4:00 pm – 

6:00 pm 

4:30 pm – 

5:30 pm 

4:30 pm – 

6:00 pm 


(#3047-3052) ARHP V – Epidemiology and Public Health ... 202 B 152 

Workshops 

241 – Evaluation and Management of Shoulder 

Pain PM Ed PM Pd PS .................................... 

PrM PS FIT E 

144 B 

242 – MDHAQ/RAPID3 and RHEUMDOC: Quantitative, 

Standard, Scientific Summaries of Patient History and 

Physical Exam, Toward Better Clinical Decisions and 

Outcomes PM PS .................................. 

E 

149 A 

243 – Systemic Sclerosis: How to Perform Skin 

Scores PM PS ..................................... 

E 

144 C 

244 – When is Muscle Biopsy Helpful in the Evaluation 

and Management of Myopathy ................... 144 A 

ACR Session 

Mechanical Cues Determine Mesenchymal Stem Cell 

Fate: Can Exercise Improve Osteoporosis? ............... 209 A 153 


081 – Antiphospholipid Syndrome ...................... 148 

082 – Behçet’s Syndrome ............................. 153 

083 – Hypermobility .................................. 154 A 

084 – IgG4-Related Disease ............................ 154 B 

085 – Immunodeficiency Syndromes .................... 155 

086 – Pediatrics: Difficult to Treat Juvenile Idiopathic 

Arthritis PM Ed Pd PS .................................... 

PrM FIT 

158 A 

087 – Reactive Arthritis: An Update ..................... 158 B 

088 – Systemic Lupus Erythematosus: Central Nervous 

System ........................................ 159 A 

089 – Vasculitis: Factors That Influence Disease 

Patterns ....................................... 159 B 

090 – What is Not Central Nervous Angiitis: Making the Right 

Diagnosis ...................................... 160 

PAGE 

NO. 

153 

153 

153 

153 

153 

153 

153 

154 

154 

154 

154 

154 

154 

154 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

2 hrs 

 

1 hr 

 

1.5 hrs 

38 



2 0 1 6 


tracker 





15 


4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

ACR Sessions 

Clinical Conundrums in Sjögren’s Syndrome ............. Ballroom A 

Is Your Patient Googling You? How the Sunshine Act and 

Public Websites Allow Patients to Learn about Their 

Doctors PM PSPM Ed PM Ed Ed Pd PS E Pd PS Pd PS PrM PrM FIT FIT FIT ............................ 143 A 

Rheumatoid Arthritis in Real Life: How Do You Treat to 

Target in 2016 PM PS . . . E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E 


(#3059-3064) Education ............................... 202 B 

(#3065-3070) Epidemiology and Public Health II: Obesity, 

Cancer and Mortality ................................. 146 A 

(#3071-3076) Metabolic and Crystal Arthropathies I: 

Mechanisms of Disease ............................... 145 A 

(#3077-3082) Miscellaneous Rheumatic and Inflammatory 

Diseases II .......................................... 147 A 

(#3083-3088) Rheumatoid Arthritis – Clinical Aspects V: 

Challenges in the Assessment and Management of 

Established RA ....................................... Salon B 


Biologics and Gene Therapy IV: Biomarkers .............. Ballroom C 


Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical .. Salon G 

(#3101-3106) Systemic Lupus Erythematosus – Clinical 

Aspects and Treatment IV: Biomarkers .................. Ballroom B 

(#3107-3112) T Cell Biology and Targets in Autoimmune 

Disease ............................................. 150 A 

PAGE 

NO. 

154 

154 

154 

155 

155 

156 

157 

158 

159 

160 

161 

162 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

ACR Late-breaking Abstract Session ..................... Hall D 162 

1.5 hrs 

4:30 pm – 

6:00 pm 

ARHP Sessions 

Be a Better Leader, Manager or Mentor PM Ed Pd PS PrM PM Ed FIT Pd PS .......... 

PrM FIT 

Pediatric Amplified Pain: A Comprehensive Treatment 

Approach PM Ed Pd PS PrM PM .................................... 

PS FIT E 

Physical and Occupational Therapies Through the Lifespan 

in the Biologic Era .................................... 

Update Small Vessel Vasculitis PM Ed Pd PS ...................... 

PrM FIT 

201 

206 

140 A 

151 A 

163 

163 

163 

163 

 

1.5 hrs 

39






4:30 pm – 

6:00 pm 

6:30 pm – 

9:30 pm 



Rehabilitation ....................................... 204 A 163 

Industry-Supported Symposia 

See page 196 or the Annual Meeting App for the full listing of 

symposia. 

PAGE 

NO. 

196 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

WEDNESDAY NOVEMBER 16, 2016 

16 


PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

7:30 am – 

8:30 am 

9:00 am – 

10:00 am 

9:00 am – 

10:30 am 

ACR Sessions 

Emerging Biosimilars in Therapeutic 

Management PM PS E ................................. 143 A 

Innovative Research in Inflammatory Arthritis: 

A Rheumatology Research Foundation Special 

Session ............................................. 146 A 

Rheumatology Roundup: Highlights from the 2016 

Annual Meeting ...................................... Hall D 

ARHP Session 

Mental Health in the Transition to Adulthood: Patient 

Stories PM Ed PM Pd PS PrM PS ....................................... FIT E 

201 165 

ARHP Session 

Update: Sarcopenia in Rheumatic Disease ............... 204 A 165 

ACR Sessions 

Fibromyalgia PM ..................................... 

PS E 

Ballroom A 

Novel Pathways in Muscle Diseases .................... 140 A 

Relevance of the National Institutes of Health (NIH) 

Strategic Plan: Roadmap from Concept to Successful 

Grant Application .................................... 206 

165 

165 

165 

165 

166 

166 

 

1 hr 

 

1 hr 

 

1 hr 

 

1.5 hrs 

40 



2 0 1 6 


tracker 




WEDNESDAY, NOVEMBER 16, 2016 


9:00 am – 

10:30 am 

9:00 am – 

10:30 am 

9:00 am – 

10:30 am 

11:00 am – 

12:30 pm 

ACR Concurrent Abstract Session 

(#3119-3124) Genetics, Genomics and Proteomics II ...... 

(#3125-3130) Metabolic and Crystal Arthropathies II: 

Clinical Practice ...................................... 

(#3131-3136) Osteoarthritis – Clinical Aspect II: Treatment 

and Imaging ......................................... Salon G 

(#3137-3142) Quality Measures and Quality of Care II ..... Ballroom B 

(#3143-3148) Rheumatoid Arthritis – Animal Models II .... 147 A 

(#3149-3154) Rheumatoid Arthritis – Clinical Aspects VI: 

Management of Early Rheumatoid Arthritis .............. 


Clinical Aspects and Treatment V: Imaging of 

Spondyloarthritis .................................... 


Pathogenesis, Etiology II .............................. 


Aspects and Treatment V: Damage and Morbidity ........ 

(#3173-3178) Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and 

Genetics II .......................................... 

(#3179-3184) Vasculitis: Diagnosis and Assessment of 

Disease Activity ...................................... 

146 A 

202 B 

Hall E 

Salon B 

145 A 

Hall D 

151 A 

Ballroom C 



Pediatric Rheumatology ............................... 207 B 177 

ARHP Session 

Move More, Sit Less: We All Need to Say the Same 

Thing PM PS ........................................... E 

201 178 

ACR Sessions 

Single Cell Analysis: Promises and Challenges ............ 140 A 

Tuberculosis Update PM PS .............................. 

E 

Ballroom B 

PAGE 

NO. 

166 

167 

168 

169 

170 

170 

172 

172 

173 

175 

176 

178 

179 

16 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 



41




WEDNESDAY, NOVEMBER 16, 2016 16 


11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 


(#3185-3190) Epidemiology and Public Health III: Psoriatic 

Arthritis and More ................................... 

(#3191-3196) Health Services Research II ................ 

(#3197-3202) Imaging of Rheumatic Diseases III: Crystal 

Arthritis, Osteoarthritis, Connective Tissue Disease and 

Vasculitis ........................................... 

(#3203-3208) Pediatric Rheumatology – Clinical and 

Therapeutic Aspects III: Autoinflammatory Diseases and 

Juvenile Dermatomyositis ............................. 

(#3209-3214) Rheumatoid Arthritis – Clinical Aspects VII: 

The Impact of Treating to Target ....................... 

(#3215-3220) Rheumatoid Arthritis – Human Etiology and 

Pathogenesis II ...................................... 


Biologics and Gene Therapy V: New Biologics and Remission 

Induction ........................................... 

(#3227-3232) Sjögren’s Syndrome II: Basic Insights ....... 


Aspects and Treatment VI: Quality of Life ................ 

(#3239-3244) Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis II ........................... 


Raynaud’s – Clinical Aspects and Therapeutics III ......... 

ARHP Session 

Spondyloarthopathies: Beyond Medications 

PM PS PME 

PS E 

Ballroom C 

202 B 

Salon B 

207 B 

Ballroom A 

151 A 

Hall E 

145 A 

Hall D 

147 A 

146 A 

PAGE 

NO. 

179 

180 

181 

182 

184 

185 

186 

187 

189 

190 

191 

...... 201 192 


(#3251-3256) ARHP VI – Rehabilitation Sciences .......... Salon G 192 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs 

 

1.5 hrs 

 

1.5 hrs 

1:00 pm – 

4:00 pm 

Industry-Supported Post-Meeting Symposia 

See page 196 or the Annual Meeting App for the full listing of 

symposia. 

196 

42 



Friday 


PRE-MEETING COURSES 

FRIDAY 

NOVEMBER 11 

P R E - M E E T I N G 

C O U R S E S 

ACR MUSCULOSKELETAL ULTRASOUND 

COURSE FOR RHEUMATOLOGISTS – 

FUNDAMENTALS – DAY ONE OF TWO 

6:30 am – 5:30 pm 

150 A 

Moderator: Paul DeMarco, MD 

6:30 – 7:45 am 

Continental Breakfast 

7:45 – 8:00 am 

Introduction and Opening Remarks 

Speaker: Paul DeMarco, MD 

10:00 – 10:15 am 

Live Demonstration: Hand and Wrist 

Speaker: Eugene Y. Kissin, MD 

10:15 – 11:45 am 

Hands-On Scanning: The Hand and Wrist 

Speakers: All Faculty 

11:45 am – 12:45 pm 

Boxed Lunch 

Optional Practice Scanning Session 

12:45 – 1:15 pm 

The Elbow: Lecture: Standard Scans, 

Sonographic Anatomy, and Basic Sonographic 

Pathology 

Speaker: Amy M. Evangelisto, MD 

1:15 – 1:30 pm 

Live Demonstration: Scanning of the Elbow 

Speaker: Amy M. Evangelisto, MD 

8:00 – 8:30 am 


Rheumatologists – Principles of Musculoskeletal 

Ultrasound for Rheumatologists 

Speaker: Jay B. Higgs, MD 

8:30 – 9:15 am 


Rheumatologists – Introduction to Typical 

Sonographic Findings and Tissue Characteristics 

in Rheumatology 

Speaker: Clara Lin, MD 

9:15 – 9:30 am 

Morning Break 

9:30 – 10:00 am 

Hand and Wrist: Lecture: Standard Scans, 


Pathology 


1:30 – 2:15 pm 

Hands-on Scanning: The Elbow 


2:15 – 2:30 pm 

Afternoon Break 

2:30 – 3:00 pm 

The Shoulder: Lecture: Standard Scans, 


Pathology 

Speaker: Gurjit S. Kaeley, MBBS, MRCP 

3:00 – 3:15 pm 

Live Demonstration: Scanning of the Shoulder 

Speaker: Gurjit S. Kaeley, MBBS, MRCP 

3:15 – 4:30 pm 

Hands-On Scanning: The Shoulder 


ACRannualmeeting.org 

43


Friday 


ACR MUSCULOSKELETAL ULTRASOUND COURSE - 

DAY ONE OF TWO continued 

4:30 – 5:00 pm 

Optional Hands-On Scanning 


4:30 – 5:00 pm 

Lecture: Pediatric Anatomy in Musculoskeletal 

Ultrasound 

Speaker: Johannes Roth, MD, PhD, FRCPC, RhMSUS 

5:00 – 5:30 pm 

Hands-On Scanning: The Upper Extremity in 

Pediatrics 

Speakers: Bethany A. Marston, MD; Clara Lin, MD; 

Johannes Roth, MD, PhD, FRCPC, RhMSUS 

ACR ADVANCED RHEUMATOLOGY CODING 

CASE STUDY WORKSHOP 

8:00 am – 5:00 pm 

140 A 

Moderator: Antanya Chung, CPC, CPC-I, CRHC, CCS-P 

8:00 – 9:00 am 


9:00 am – Noon 

Strategies for Achieving Accurate Coding Levels 

and Optimal Reimbursement 

Speaker: Melesia Tillman, CPC, CPC-I, CRHC, CHA 

Noon – 1:00 pm 

Boxed Lunch 

1:00 pm – 5:00 pm 

Integrating Clinical Documentation 

Improvement into Revenue Cycle 

Speaker: Antanya Chung, CPC, CPC-I, CRHC, CCS-P 

ACR BASIC RESEARCH CONFERENCE: 

CELLULAR METABOLISM AND STRESS 

RESPONSE IN IMMUNE-MEDIATED 

INFLAMMATORY DISEASE – DAY ONE OF 

TWO 

1:00 pm – 5:30 pm 

Ballroom A 

Moderator: Laurence Morel, PhD 

1:00 – 1:10 pm 

Introduction 

Speaker: Laurence Morel, PhD 

1:10 – 1:50 pm 

Bioenergetics: Lipid-Dependent Cellular 

Signaling 

Speaker: Elizabeth Jury, PhD 

1:50 – 2:30 pm 

Bioenergetics: Mitochondrial Dysfunction in 

Inflammatory Disease 

Speaker: Richard M. Siegel, MD, PhD 

2:30 – 3:00 pm 


3:00 – 3:40 pm 

Metabolism and Inflammation in Rheumatoid 

Arthritis: Energy Deficiency, DNA Damage, and 

Premature Immune Aging 

Speaker: Cornelia M. Weyand, MD, PhD 

3:40 – 4:20 pm 


Arthritis: The Mammalian Target of Rapamycin: 

Linking T Cell Differentiation, Function, and 

Metabolism 

Speaker: Jonathan Powell, MD, PhD 

44 

For the most up-to-date meeting content, download the 2016 ACR/ARHP Annual Meeting App from the App Store or Google Play.

Friday 



ACR BASIC RESEARCH CONFERENCE - DAY ONE OF 

TWO continued 

4:20 – 5:00 pm 


Arthritis: Reactive Oxygen Species as Protectors 

from Joint Inflammation 

Speaker: Rikard Holmdahl, PhD, MD 

1:50 – 2:35 pm 

Overview of Lung Disease in Rheumatology: 

Keynote Lecture Two: Autoimmunity and the 

Lungs 

Speaker: Antony Rosen, MD 

5:00 – 5:15 pm 

Abstract Presentation: AMP-Activated 

Protein Kinase: A Target for Methotrexate 

in Macrophages 

Speaker: Cornelia Cudrici, MD 

2:35 – 2:45 pm 


Wrap-Up and Question and Answer 

Speakers: Paul F. Dellaripa, MD; Carol A. Feghali- 

Bostwick, PhD 

5:15 – 5:30 pm 

Abstract Presentation: Glutamine Metabolism 

Plays a Crucial Role in the Pathogenesis of 

Rheumatoid Arthritis 

Speaker Soshi Takahashi, MD 

ACR CLINICAL RESEARCH CONFERENCE: 

LUNG DISEASE IN RHEUMATOLOGY – DAY 

ONE OF TWO 

1:00 pm – 6:00 pm 

Ballroom C 

Moderators: Paul F. Dellaripa, MD; Carol A. Feghali- 

Bostwick, PhD; Joyce Sujin Lee, MD; Shikha Mittoo, MD, 

MHS 

1:00 – 1:05 pm 

Introduction 

Speaker: Aryeh Fischer, MD 

1:05 – 1:50 pm 


Keynote Lecture One: Clinical Overview 

and Clinical Landscape of Lung Disease in 

Rheumatology 

Speaker: Steven Nathan, MD 

2:45 – 3:00 pm 


3:00 – 3:30 pm 

The Lungs and Rheumatoid Arthritis: Are the 

Lungs the Site of Initiation of Rheumatoid 

Arthritis? 

Speaker: Kevin D. Deane, MD, PhD 

3:30 – 4:00 pm 

The Lungs and Rheumatoid Arthritis: Risk 

Factors/Biomarkers of Interstitial Lung Disease 

in RA 

Speaker: Ivan O. Rosas, MD 

4:00 – 4:30 pm 

The Lungs and Rheumatoid Arthritis: Interstitial 

Lung Disease in RA: The Next Frontier 

Speaker: Eric L. Matteson, MD, MPH 

4:30 – 5:00 pm 

The Lungs and Rheumatoid Arthritis: Future 

Research Initiatives in RA-Interstitial Lung 

Disease 

Speaker: Joyce Sujin Lee, MD 


45


Saturday 


ACR CLINICAL RESEARCH CONFERENCE - DAY ONE 

OF TWO continued 

5:00 – 5:15 pm 

Abstract Presentation: Common Biomarker 

Elevations in Idiopathic Pulmonary Fibrosis and 

Rheumatoid Arthritis-Associated Interstitial 

Lung Disease 

Speaker: Karen Fernandez, MD 

5:15 – 5:30 pm 

Abstract Presentation: Progressive Decline 

of Lung Function in Rheumatoid Arthritis 

Associated Interstitial Lung Disease 

Speaker: Alex Zamora-Legoff, MD 

5:30 – 6:00 pm 

The Lungs and Rheumatoid Arthritis: Panel 

Discussion, Wrap-Up, and Question and Answer 

Joyce Sujin Lee, MD; Shikha Mittoo, MD, MHS 

4:20 – 4:30 pm 

Evening Break 

4:30 – 6:00 pm 

Session III: Questions from 2016 Update in 

Rheumatology 

Speaker: Carol A. Langford, MD, MHS 

6:00 – 6:05 pm 

Wrap-Up 

Speaker: Juliet Aizer, MD, MPH 

SATURDAY 

NOVEMBER 12 

ACR MAINTENANCE OF CERTIFICATION 

(MOC) ANNUAL MEETING COURSE – 2016 

UPDATE IN RHEUMATOLOGY 

1:00 pm – 6:05 pm 

Salon B 

Moderator: Juliet Aizer, MD, MPH 

1:00 – 1:10 pm 

Introduction/Overview 


1:10 – 2:40 pm 

Session I: Questions from 2016 Update in 

Rheumatology 


2:40 – 2:50 pm 


2:50 – 4:20 pm 

Session II: Questions from 2016 Update in 

Rheumatology 

Speaker: Erika H. Noss, MD, PhD 

ACR MUSCULOSKELETAL ULTRASOUND COURSE 

FOR RHEUMATOLOGISTS – FUNDAMENTALS – 

DAY TWO OF TWO 

6:30 am – 6:00 pm 

150 A 

Moderator: Paul DeMarco, MD 

6:30 – 7:15 am 


7:15 – 7:30 am 

Opening Remarks 


7:30 – 8:00 am 

The Hip: Lecture: Standard Scans, Sonographic 

Anatomy, and Basic Sonographic Pathology 

Speaker: Midori Jane Nishio, MD, RhMSUS 

8:00 – 8:15 am 

Live Demonstration: Scanning of the Hip 

Speaker: Midori Jane Nishio, MD, RhMSUS 

46 For the most up-to-date meeting content, download the 2016 ACR/ARHP Annual Meeting App from the App Store or Google Play.

Saturday 



ACR MUSCULOSKELETAL ULTRASOUND COURSE - 

DAY TWO OF TWO continued 

8:15 – 9:00 am 

Hands-On Scanning: The Hip 


9:00 – 9:15 am 

Morning Break 

9:15 – 9:45 am 

The Knee: Lecture: Standard Scans, Sonographic 

Anatomy, and Basic Sonographic Pathology 

Speaker: Gary A. Kunkel, MD 

9:45 – 10:00 am 

Live Demonstration: Scanning of the Knee 

Speaker: Gary A. Kunkel, MD 

3:00 – 3:15 pm 


3:15 – 3:45 pm 

Ultrasound Needle Guidance: Lecture: Evidence 

Base and Technique of Ultrasound Guidance of 

Procedures 


3:45 – 4:15 pm 

Panel Discussion – Implementing 

Musculoskeletal Ultrasound in the Practice of 

Rheumatology 

Speakers: Catherine Bakewell, MD; Paul DeMarco, MD; 

Eugene Y. Kissin, MD; Ralf G. Thiele, MD, RhMSUS 

10:00 – 11:15 am 

Hands-On Scanning: The Knee 


3:45 – 4:15 pm 

Optional Hands-On Scanning 


11:15 – 11:45 am 


Rheumatologists – Billing, Coding, and Report 

Generation 


11:45 am – 12:45 pm 

Boxed Lunch 

Optional Practice Scanning Session 

12:45 – 1:15 pm 

Foot and Ankle: Lecture: Standard Scans, 


Pathology 

Speaker: Ralf G. Thiele, MD, RhMSUS 

1:15 – 1:30 pm 

Live Demonstration: Scanning of Foot and Ankle 


1:30 – 3:00 pm 

Hands-On Scanning: Foot and Ankle 


4:15 – 5:00 pm 

Hands-On Scanning: Ultrasound in Procedure 

Guidance 


5:00 – 5:20 pm 

Lecture: The Lower Extremity in Pediatrics 


5:20 – 6:00 pm 

Hands-On Scanning: Pediatrics 

Speakers: Bethany A. Marston, MD; Johannes Roth, MD, 

PhD, FRCPC, RhMSUS 

ACR PRACTICE MANAGEMENT COURSE: 

THE NEXT GENERATION OF BUSINESS 

DEVELOPMENT FOR RHEUMATOLOGY 

PRACTICES 

7:00 am – 4:15 pm 

140 A 

Moderator: Catherine Rutsky, CPC, CRHC 


47


Saturday 


ACR PRACTICE MANAGEMENT COURSE continued 

7:00 – 8:00 am 


8:00 – 9:15 am 

Keynote Address: MACRA: Putting Together the 

Pieces for Your Practice 

Speaker: Timothy Laing, MD 

9:15 – 10:00 am 

A Roadmap for Successful Payer Negotiations 

Speaker: Larry Kemp, MS, MPA, FACHE 

10:00 – 10:15 am 

Morning Break 

10:15 am – 11:00 am 

Effective Leadership in the Medical Practice 

Speaker: Sean M. Weiss, CMCO, CPMA, CPC, CPC-P, 

CCP-P, ACS-EM 

3:15 – 4:15 pm 

Compliance Strategies and Focus Areas for 2017 


CCP-P, ACS-EM 

ACR REVIEW COURSE 

7:00 am – 4:00 pm 

Hall D 

PM Ed PM Pd PS PS PrME 

FIT 

Moderators: Philip Seo, MD; Peter A. Valen, MD, FACP 

7:00 – 8:00 am 


8:00 – 8:45 am 

Rheumatoid Arthritis – A Case-Based Approach 

to Selected Extra-Articular Challenges and What 

You Are Missing with Better Therapies 

Speaker: Jonathan Coblyn, MD 

11:00 – 12:00 am 

Auditing an Audit 


CCP-P, ACS-EM 


Boxed Lunch 

1:00 – 2:00 pm 

Legal/Compliance Trends Update & Roundtable 

Speakers: Bryan Hull, JD; Larry Kemp, MS, MPA, FACHE; 

Sean M. Weiss, CMCO, CPMA, CPC, CPC-P, CCP-P, ACS- 

EM 

2:00 – 3:00 pm 

Medicare Program: Reporting and Returning 

Overpayment 

Speaker: Larry Kemp, MS, MPA, FACHE 

8:45 – 9:30 am 

Giant Cell Arteritis and Polymyalgia Rheumatica 

Speaker: Rebecca L. Manno, MD, MHS 

9:30 – 10:00 am 

Morning Break 

10:00 – 10:45 am 

New and Emerging Therapies for Gout 

Speaker: N. Lawrence Edwards, MD 

10:45 – 11:30 am 

Pediatric Rheumatology for the Adult 

Rheumatologist 

Speaker: Sangeeta Sule, MD, PhD 

11:30 am – 12:30 pm 

Boxed Lunch 

3:00 – 3:15 pm 


12:30 – 1:15 pm 

Rheumatic Manifestations of Endocrine Disease 

Speaker: Joseph A. Markenson, MD 


Saturday 



ACR REVIEW COURSE continued 

1:15 – 2:00 pm 

Shoulder Orthopedics for the Rheumatologist 

Speaker: Andrew Neviaser, MD 

2:00 – 2:30 pm 


2:30 – 3:15 pm 

Neglected Vasculitis 

Speaker: Philip Seo, MD 

3:15 – 4:00 pm 

Neutrophilic Dermatoses 

Speaker: Joseph Jorizzo, MD 

ACR CLINICAL RESEARCH CONFERENCE: 

LUNG DISEASE IN RHEUMATOLOGY – DAY 

TWO OF TWO 

7:00 am – 4:15 pm 

Ballroom C 

Moderators: Virginia D. Steen, MD; Rohit Aggarwal, 

MD, MS; Stephen C. Mathai, MD, MHS; Eric L. Matteson, 

MD, MPH; Sonye K. Danoff, MD, PhD, MPhil; Lesley Ann 

Saketkoo, MD, MPH; Kristin B. Highland, MD 

7:00 – 7:45 am 


7:45 – 8:00 am 

Introduction 

Speaker: Stephen C. Mathai, MD, MHS 

8:00 – 8:50 am 

Lung Disease in Systemic Sclerosis (SSc): From 

Pathogenesis to Targeted Therapy 

Speaker: Christopher Denton, MD, PhD 

8:50 – 9:25 am 

Lung Disease in Systemic Sclerosis (SSc): Current 

(and Future) Therapies for SSc-Interstitial Lung 

Disease: Review Clinical Therapies for SSc-ILD 

and On-going Clinical Trials 

Speaker: Richard Silver, MD 

9:25 – 10:00 am 

Lung Disease in Systemic Sclerosis (SSc): 

Current (and Future) Therapies for SSc- 

Interstitial Lung Disease 

Speaker: Dinesh Khanna, MD, MS 

10:00 – 10:15 am 

Morning Break 

10:15 – 10:50 am 

Lung Disease in Systemic Sclerosis (SSc): 

Pulmonary Hypertension in SSc: Epidemiology 

and Diagnosis in 2016 

Speaker: Lorinda Chung, MD, MS 

10:50 – 11:30 am 

Lung Disease in Systemic Sclerosis: Current (and 

Future) Therapies for Pulmonary Hypertension– 

SSc 

Speaker: Stephen C. Mathai, MD, MHS 

11:30 am – Noon 

Lung Disease in Systemic Sclerosis (SSc): Panel 


Speakers: Virginia D. Steen, MD; Stephen C. Mathai, MD, 

MHS; Kristin B. Highland, MD 


Boxed Lunch 

1:00 – 1:30 pm 

Myositis and Interstitial Pneumonia with 

Autoimmune Features: Other Connective Tissue 

Disease-Interstitial Lung Disease (ILD): Myositis- 

ILD: What Are the Important Clinical Research 

Questions? 

Speaker: Sonye K. Danoff, MD, PhD, MPhil 

1:30 – 2:00 pm 


Autoimmune Features: Other Connective Tissue 

Disease-Interstitial Lung Disease (ILD): Myositis- 

ILD: From Pathogenesis to Targeted Therapy 

Speaker: Dana P. Ascherman, MD 


49


Saturday 


ACR CLINICAL RESEARCH CONFERENCE - DAY TWO 

OF TWO continued 

2:00 – 2:30 pm 


Autoimmune Features: Other Connective 

Tissue Disease-Interstitial Lung Disease (ILD): 

Interstitial Pneumonia with Autoimmune 

Features (IPAF): What It Is and Why You Should 

Care 

Speaker: Aryeh Fischer, MD 

2:30 – 2:45 pm 


2:45 – 3:15 pm 

OMERACT and Clinical Trial Designs: 

Controversies in Clinical Trial Design: Discuss 

State of Current and Future CTD-PAH and CTD- 

ILD Clinical Research Trials 

Speaker: Lesley Ann Saketkoo, MD, MPH 

3:15 – 3:45 pm 

OMERACT and Clinical Trial Designs: 

Controversies in Clinical Trial Design 

Speaker: Paul F. Dellaripa, MD 

3:45 – 4:10 pm 

OMERACT and Clinical Trial Designs: Panel 


Speakers: Eric L. Matteson, MD, MPH; Lesley Ann 

Saketkoo, MD, MPH; Flavia V. Castelino, M.D. 

4:10 – 4:15 pm 

Closing Remarks 

Speakers: Aryeh Fischer, MD; Stephen C. Mathai, MD, 

MHS 

ARHP CLINICAL FOCUS COURSE: 

MANAGEMENT OF RHEUMATOID 

ARTHRITIS ACROSS THE LIFESPAN: A CASE- 

BASED APPROACH PM Ed Pd PS PrM FIT 

7:00 am – 4:15 pm 

152 A 

Moderator: Maura D. Iversen, BSc, DPT, SD, MPH, FNAP, 

FAPTA 

7:00 – 7:45 am 


7:45 – 8:00 am 

Introduction and Overview 

Speaker: Maura D. Iversen, BSc, DPT, SD, MPH, FNAP, 

FAPTA 

8:00 – 9:00 am 

Inflammatory Arthritis in the Pediatric Patient 

Speaker: Annelle Reed, MSN, CRNP 

9:00 – 9:45 am 

Transitioning to Adult Care: Growing Up with 


Speaker: Karla B. Jones, MS, RN, CNP 

9:45 – 10:00 am 

Morning Break 

10:00 – 11:00 am 

Case Discussions 

Speaker: Annelle Reed, MSN, CRNP; Karla B. Jones, MS, 

RN, CNP 

11:00 am – 12:15 pm 

Rheumatoid Arthritis in the Adult: Treat 

to Target, Barriers to Care, Comorbidities, 

Secondary Prevention 

Speaker: John M. Davis III, MD, MS 

12:15 – 1:00 pm 

Lunch Break 

1:00 – 1:45 pm 

Integration of Technology in RA Management 

Throughout Life 

Speaker: Linda Li, BSc(PT), MSc, PhD 


Saturday 



ARHP CLINICAL FOCUS COURSE continued 

1:45 – 2:45 pm 

Rheumatoid Arthritis in the Geriatric Patient, 

Secondary Prevention, Polypharmacy, and 

Challenges 

Speaker: Beth Resman-Targoff, PharmD 

2:45 – 3:00 pm 


3:00 – 4:15 pm 

Interprofessional Case Discussion 

Speakers: John M. Davis III, MD, MS; Linda Li, BSc(PT), 

MSc, PhD; Beth Resman-Targoff, PharmD 

ACR BASIC RESEARCH CONFERENCE: 

CELLULAR METABOLISM AND STRESS 

RESPONSE IN IMMUNE-MEDIATED 

INFLAMMATORY DISEASE – DAY TWO OF 

TWO 

7:00 am – 4:30 pm 

Ballroom A 

Moderator: Cornelia M. Weyand, MD, PhD 

9:10 – 9:50 am 

Metabolism and Inflammation: IFN-Gamma 

Regulates Macrophage Metabolism 

Speaker: Lionel Ivashkiv, MD 

9:50 – 10:20 am 

Morning Break 

10:20 – 11:00 am 

Tumor Metabolism: Nutrient Control of Cellular 

Survival 

Speaker: Craig Thompson, MD 

11:00 am – 11:40 pm 

Tumor Metabolism: Nutrient Control of 

Biomass Generation 

Speaker: Matthew Vander Heiden, MD, PhD 

11:40 – 12:20 pm 

Tumor Metabolism: Clinical Trials 

Speaker: Jason Chesney, MD, PhD 

12:20 – 1:20 pm 

Boxed Lunch 

7:00 – 7:45 am 


7:45 – 8:00 am 

Introduction 

Speaker: Cornelia M. Weyand, MD, PhD 

8:00 – 8:40 am 

Inflammation, Obesity, and Aging: 

Immunometabolic Control of Age-Related 

Inflammation 

Speaker: Vishwa Dixit, DVM, PhD 

8:40 – 9:10 am 

Inflammation, Obesity, and Aging: Immune 

Regulation of Fatty Tissue 

Speaker: Ajay Chawla, Md, PhD 

1:20 – 2:00 pm 

Systemic Autoimmunity: T Cell Metabolism in 

Systemic Lupus Erythematosus 

Speaker: Laurence Morel, PhD 

2:00 – 2:40 pm 

Systemic Autoimmunity: Mitochondrial 

Dysfunction and Oxidative Stress in Systemic 

Lupus Erythematosus 

Speaker: Andras Perl, MD, PhD 

2:40 – 3:00 pm 


3:00 – 3:40 pm 

Systemic Autoimmunity: Metformin Treatment 

in Systemic Lupus Erythematosus 

Speaker: Shuang Ye, MD 


51


Saturday 


ACR BASIC RESEARCH CONFERENCE - DAY TWO OF 

TWO continued 

3:40 – 4:20 pm 

Systemic Autoimmunity: Immunometabolism 

Regulation of Graft vs. Host Disease 

Speaker: Gary D. Glick, PhD 

4:20 – 4:30 pm 

Wrap-up 

Speakers: Cornelia M. Weyand, MD, PhD; Laurence 

Morel, PhD 

AAMC MEDICAL EDUCATION RESEARCH 

CERTIFICATE (MERC) WORKSHOPS: DATA 

MANAGEMENT AND PREPARING FOR 

STATISTICAL CONSULTATION, AND 

QUESTIONNAIRE DESIGN AND SURVEY 


RESEARCH 

8:00 am – 4:00 pm 

154 B 

Moderator: Deana M. Lazaro, MD 

8:00 – 9:00 am 


9:00 am – Noon 

Questionnaire Design and Survey Research 

Speaker: Larry D. Gruppen, PhD 


Boxed Lunch 

1:00 – 4:00 pm 

Data Management and Preparation for 

Statistical Consultation 

Speaker: Larry D. Gruppen, PhD 

S C I E N T I F I C 

S E S S I O N S 

ACR/ARHP OPENING LECTURE AND 

AWARDS 

4:30 pm – 6:15 pm 

Hall D 

Moderators: Joan M. Von Feldt, MD, MSEd; Elizabeth A. 

Schlenk, PhD, RN 

4:30 pm 

ACR Presidential Address 

5:00 pm 

Recognition of 2016 ACR Masters 

Recognition of 2016 ACR Awards of Distinction 

Recipients 

Recognition of 2016 ARHP Merit Awards Recipients 

Recognition of 2016 ACR Distinguished Fellows 

Awards Recipients 

Recognition of 2016 Rheumatology Research 

Foundation Corporate Roundtable Donors 

5:30 pm 

Opening Lecture: Harnessing the Internet of 

Healthy Things: How Connected Health Can 

Advance Rheumatology 

Speaker: Joseph Kvedar, MD 

ACR/ARHP NETWORKING EVENT 

6:30 pm – 8:00 pm 

Marriott Marquis, Marquis Ballroom 

Opening Reception 

After the Opening Lecture and Awards, plan to socialize 

and network with your colleagues from around the world. 


Sunday 


SCIENTIFIC SESSIONS 

S C I E N T I F I C 

S E S S I O N S 

SUNDAY 

NOVEMBER 13 

ACR SESSIONS 

7:30 am – 8:30 am 

146 A 

Immunology Update: That’s a Fact, Jak: 

Targeting Signaling Type I/II Cytokines in 

Rheumatic Diseases 

Moderator: Lionel Ivashkiv, MD 

Speaker: John J. O’Shea, MD 

140 A 

Mechanisms of Enthesopathy 

Moderator: Gregg J. Silverman, MD 

Speaker: Jonathan Sherlock, MD 

Salon G 

Optimizing Lupus Management in Pregnancy 

PM PS E 

Moderators: Kristine M. Lohr, MD, MS; Amanda 

Sammut, MD 

Speaker: Megan E. B. Clowse, MD, MPH 

Hall D 

Year in Review 

Moderator: Richard F. Loeser, MD 

7:30 am 

The Year in Review: Clinical Rheumatology 

Speaker: Ingrid E. Lundberg, MD, PhD 

8:00 am 

The Year in Review: Basic Science Rheumatology 

Speaker: Bruce Cronstein, MD 

NETWORKING EVENT 

7:30 am – 8:30 am 

201 

ACR/ARHP Annual Meeting Orientation 

First-time ACR/ARHP attendees are invited to an orientation 

to learn the “ins and outs” of the Annual Meeting so that 

you can get the most out of your first Annual Meeting 

experience. 

MEET THE PROFESSOR SESSIONS 

7:45 am – 9:15 am 

Admission to Meet the Professor sessions requires a 

separate registration and ticket. To verify which session 

you are registered for, the registration code on your ticket 

needs to match the 3-digit code in front of the session 

title. If you are interested in participating in one of these 

sessions or exchanging your ticket, visit the ACR registration 

desk to check space availability. View the session overview 

and learning objectives online in the Annual Meeting App. 

Access and download the app at ACRannualmeeting.org. 

148 

001 – Controversies in Sjögren’s Syndrome 

Speaker: Frederick B. Vivino, MD, MS 

153 

002 – Macrophage Activation Syndrome 

Speaker: Rayfel Schneider, MBBCh 

154 A 

003 – Pain: Evaluation and Treatment of Back 

Pain PM PS PME 

PS E 

Speaker: David G. Borenstein, MD 

154 B 

004 – Polymyalgia Rheumatica 

Speaker: Antoine Sreih, MD 

PM PS E 



155 

005 – Pulmonary Manifestations of Rheumatic 

Disease 


53


Sunday 


MEET THE PROFESSOR SESSIONS continued 

158 A 


PM PS E 

Speaker: Michael Weinblatt, MD 

158 B 

007 – Rheumatoid Arthritis: Outcome 

Measures in Clinical Practice – Moving from 

Measurements to Management PM PS E 

Speaker: Eric Newman, MD 

159 A 

008 – Systemic Lupus Erythematosus: Novel 

Treatments – How to Treat Systemic Lupus 

Erythematosus 

Speaker: Richard A. Furie, MD 

159 B 

009 – Ultrasound versus Dual CT in Gout 


160 

010 – Vasculitis Mimics 

Speaker: Peter A. Merkel, MD, MPH 

WORKSHOPS 

7:45 am – 9:45 am 

Admission to Workshops requires a separate registration 

and ticket. To verify which session you registered for, the 

registration code on your ticket needs to match the 3-digit 

code in front of the session title. If you are interested 

in participating in one of these sessions or exchanging 

your ticket, visit the ACR registration desk to check space 

availability. View the session overview and learning 

objectives online in the Annual Meeting App. Access and 

download the app at ACRannualmeeting.org. 

144 C 

201 – Advanced Musculoskeletal Ultrasound: 

Image Optimization and Pathology Recognition 

144 B 

202 – Clinical Anatomy and Physical Exam: 

Essential Tools in Lower Extremity Regional 

Pain Syndromes 

PM PS PME 

PS E 

Speakers: Robert A. Kalish, MD; Pablo Villaseñor Ovies, 

MD 

149 A 

203 – X-Ray Challenges in Rheumatic Diseases 

Speaker: Donald J. Flemming, MD 

ACR SESSIONS 

8:30 am – 10:00 am 

Salon B 

Anatomy for the Clinician I: Hip Pain, Not from 

the Hip Joint – Anterior Hip Pain 

PM PS E 

Moderator: Gurjit S. Kaeley, MBBS, MRCP 

Speaker: Ingrid Moller, MD, PhD 

Ballroom C 

Holy MACRA! How to Survive and Thrive in the 

New Era of MACRA, MIPS, and APMs PM PS E 

Moderators: William F. Harvey, MD, MSc; Douglas White, 

MD, PhD 

8:30 am 

Introduction to the Medicare Access and CHIP 

Reauthorization Act of 2015 (MACRA) 

Speakers: Douglas White, MD, PhD; William F. Harvey, 

MD, MSc 

9:00 am 

Introduction to Alternative Payment Models (APMs) 

Speaker Harold D. Miller 

9:30 am 

Introduction to the Merit-Based Incentive Payment 

System (MIPS) 

Speaker Harold D. Miller 

Speaker: Jay B. Higgs, MD; Catherine Bakewell, MD 


Sunday 



ACR SESSIONS continued 

Ballroom A 

Hypereosinophilic Syndromes: What’s a Colorful 

Cell Like You Doing in a Dark Place Like This? 

Moderators: Rebecca L. Manno, MD, MHS; Philip Seo, 

MD 

8:30 am 

Hypereosinophilic Syndromes 

Speaker: Bruce Bochner, MD 

9:15 am 

Eosinophilic Granulomatosis with Polyangiitis 

Speaker: Michael E. Wechsler, MMSc, MD 

Hall E 

Living Well With Lupus PM PS E 

Moderators: Swamy Venuturupalli, MD; Lindsy Forbess, 

MD 

8:30 am 

Monitoring Lupus Patients for Comorbid Disease: 

Malignancy and Other Comorbid Disease in Lupus 

Speaker: Karen H. Costenbader, MD, MPH 

9:00 am 

How Do You Know Your Patient Is Better: Biomarkers 

and Patient Outcomes 

Speaker: Meenakshi Jolly, MD, MS 

9:30 am 

Sticking With It: How to Assess and Address 

Adherence in Lupus 

Speaker: Hermine I. Brunner, MD, MSc 

9:00 am 

Evidence-Based Physical Activity and Exercise in 

Children with Arthritis 

Speaker: Paula Melson, DPT, MMS 

9:30 am 

Quality of Life Outcomes Measures in Juvenile 

Idiopathic Arthritis 

Speaker: Brian Feldman, MD, FRCPC, MSc 

145 A 

What Is the Science Behind Mesenchymal Stem 

Cells Therapy in Arthritis? 

Moderator: Francisco J. Blanco, MD, PhD; Elena Jones, 

PhD 

8:30 am 

Stem Cell Therapy for Joint Tissue Repair: State-of-the- 

Science 

Speaker: Johnny Huard, PhD 

9:00 am 

Stem Cell Niches Within the Joint and Elsewhere 

Speaker: Cosimo De Bari, MD, PhD 

9:30 am 

Application of Immunosuppressive and Anti- 

Inflammatory Activity of Mesenchymal Stem/ 

Precursor Cells in Rheumatic Diseases 

Speaker: Christian Jorgensen 

ACR SESSIONS 

207 B 

Quality of Life in Juvenile Idiopathic Arthritis: 

Sleep, Exercise, and Outcomes Measures PM PS 

PM PS E 

Moderator: Sarah Ringold, MD, MS 

8:30 am 

Sleep Fragmentation and Biomarkers in Juvenile 


Speaker: Teresa M. Ward, RN, PhD 

Ed Pd PrM FIT 

9:00 am – 10:00 am 

150 A 

Tech Tools for Rheumatologists Version 2.0 

Moderator: Jonathan S. Hausmann, MD 

Speaker: Suleman Bhana, MD 


55


Sunday 



202 B 

The Role of Alarmins in the Pathogenesis of 

Rheumatic Disease 

PM PS E 

Moderator: Reinhard Voll, MD 

Speaker: Helena E. Harris, BSc, PhD 

ARHP SESSION 

9:00 am – 10:00 am 

140 A 

ARHP Keynote Address: Culture, Health, 

Healing: Humanities in Inter-Professional 

Collaboration and Patient-Centered Care 

Moderator: Hazel L. Breland, PhD, OTR/L 

Speaker: Paulette C. Hahn, MD 

ACR POSTER SESSION A AND POSTER 

TOURS 

8:30 am – 4:00 pm 

Poster presenters will be available from 9:00 – 11:00 am 

(abstracts # 1-909). Poster tours will be held from 9:00 

– 9:45 am and 10:15 – 11:00 am. Morning snacks will be 

available at 8:30 AM. 

Hall C (Poster Hall) 


Guided poster tours allow scientific attendees to ask 

questions and gain insights from some of the bestknown 

rheumatology leaders. Tours are complimentary; 

however, registration is required and is limited to scientific 

attendees. If you pre-registered for a tour, you should have 

received a ticket with your meeting materials. Once you 

have your ticket, check in at the tour desk 15 minutes prior 

to the start of your tour to receive your headset. 

IMPORTANT: Your reservation will be held only until 5 

minutes prior to the start of the tour. After this time, your 

reservation is not guaranteed and may be released to 

standby attendees. If you did not pre-register, tickets may 

be available in the registration area (Hall E). Alternatively, 

you may go directly to the poster tour desk and wait for 

a standby ticket. Standby tickets will be assigned on a 

first-come, first-served basis 5 minutes prior to the start 

of each tour. Each tour participant will receive a wireless 

headset, which will be registered against the participants’ 

registration ID. Participants will be charged $50 if the 

headset is not returned within 15 minutes of the end of the 

tour. 

9:00 – 9:45 am 

Poster Tours # 301 – 306 

Please check the Annual Meeting App for the most current 

poster tour titles. 

10:15 – 11:00 am 




EXHIBITS 

10:00 am – 5:00 pm 

Hall A (Exhibit Hall) 

Join your colleagues in the Exhibit Hall for morning and 

afternoon refreshments at 10:00 am and 2:00 pm. 

Located in Hall A (Exhibit Hall) 

Innovation Theater A and B 

Non-CME accredited presentations have been planned and 

will be implemented in accordance with the requirements 

of the FDA and applicable standards of the PhRMA Code 

on Interactions with Healthcare Professionals. Innovation 

Theater A presentations will be held from 10:30 – 11:15 

am, 12:30 – 1:15 pm, and 2:30 – 3:15 pm. Innovation Theater 

B presentations will be held from 11:30 am – 12:15 pm, 

1:30 – 2:15 pm, and 3:30 – 4:15 pm. For a complete listing of 

Innovation Theater presentations, see page 194. 


Sunday 



WORKSHOPS 

10:30 am – 12:30 pm 










144 C 

204 – Beyond Musculoskeletal Ultrasound for 

Rheumatologists 

Speakers: Richard Hoppmann, MD; Victor Rao, MBBS, 

DMRD, RDMS 

144 B 

205 – Clinical Anatomy and Physical Exam: 

Essential Tools in Upper Extremity Regional 

Pain Syndromes PM PS E 

Speakers: Robert A. Kalish, MD; Pablo Villaseñor Ovies, 

MD 

149 A 

206 – Magnetic Resonance Imaging of 

Peripheral Joints in Rheumatology Practice 

Speakers: Philip G. Conaghan; Mikkel Ostergaard 

144 A 

207 – Synovial Fluid Analysis and Crystal 

Identification 

Speakers: Brian F. Mandell, MD, PhD; Gilda M. 

Clayburne, MLT; Lan Chen, MD, PhD 

ACR SESSION 

11:00 am – 12:00 pm 

207 B 

Early-Onset Monogenic Inflammatory Diseases 


11:00 am 

Inflammasome-Associated Disorders 

Speaker: Hal M. Hoffman 

11:30 am 

Monogenic Immunodeficiencies in Early-Onset 

Inflammatory Bowel Disease 

Speaker: Scott Snapper, MD, PhD 

ARHP SESSIONS 

11:00 am – 12:00 pm 

206 

Get Your Money: Challenges in Navigating 

Appeals in 2016 and Beyond 

Moderator: Victoria Ruffing, RN-BC 

11:00 am 

Talk 1 

Speaker: Lisa Shanahan 

11:30 am 

Talk 2 

Speaker: Jacqueline Fritz, RN, MSN, CNS RNBC 

202 B 

Immunology Boot Camp I: Basis of Targeted 

Therapy 

Moderators: Jeanne Scott, NP; Sandro Perazzio, MD, 

PhD 

Speaker: Troy R. Torgerson, MD, PhD 

140 A 

Study Design Interpretation Tools and Tips 

Moderator: Rebecca J. Cleveland, PhD 

Speaker: David Culliford, BSc MSc 

201 

Supporting Fatigue: Meaning, Mechanisms, 

Measurement, and Management PM PS E 

Moderator: Susan J. Bartlett 

Speaker: Sarah Hewlett, FRCN, PhD, MA, RN 

Moderators: Scott Canna, MD; Erin Janssen, MD, PhD 


57


Sunday 


ACR SESSIONS 

11:00 am – 12:30 pm 

ACR PLENARY SESSION 

11:00 am – 12:30 pm 

Ballroom B 

Rheumatic Diseases in Native Americans: What 

We Can Learn, How We Can Help? PM PS E 

Moderators: Fredrica Smith, MD; Elizabeth Ferucci, MD, 

MPH 

11:00 am 

Spectrum of Rheumatic Diseases in Native North 

Americans: Differences from and Similarities to Other 

Populations 

Speaker: Judith A. James, MD, PhD 

11:30 am 

Why Do Some Native Americans Have Such High 

Rates of Rheumatic Disease: The Role of Genetics 

and Environment 

Speaker: Hani El-Gabalawy 

12:00 pm 

An Underserved Population: What Can We Do to Make 

a Difference? Panel Discussion 

Speakers: Elizabeth Ferucci, MD, MPH; Gregory 

Gardner, MD, FACP; Atul A. Deodhar, MD 

Ballroom C 

The Value-Based Payment Modifier: How to 

Prepare Your Practice PM PS E 

Moderator: Amar Majjhoo, MD 

11:00 am 

The ABCs of the Value-Based Modifier 

Speaker: Brenda Jenkins, RN, DAy, CDOE, CPEHR, PCMH- 

CCE 

11:30 am 

The Relationship Between Physician Quality Reporting 

System (PQRS) and Value-Based Modifier (VBM) 

Speaker: Leila Volinsky, MHA, MSN, RN 

Hall D 

ACR Plenary Session 1: Discovery 2016 

Moderators: Joan Marie Von Feldt, MD, MSEd; Richard F. 

Loeser, MD 

11:00 am 

Rheumatology Research Foundation Corporate 

Roundtable Awards 

11:15 am 

910. Survival Benefit of Statin Use in Ankylosing 

Spondylitis and Psoriatic Arthritis: A General 

Population-Based Cohort Study 

Amar Oza 1 , Na Lu 2 and Hyon K. Choi 3 , 1 Massachusetts 

General Hospital, Boston, MA, 2 Boston University 

School of Medicine, Boston, MA, 3 Massachusetts 

General Hospital and Harvard Medical School, Boston, 

MA 

11:30 am 

911. Efficacy and Safety of Tocilizumab in Patients 

with Giant Cell Arteritis: Primary and Secondary 

Outcomes from a Phase 3, Randomized, Double- 

Blind, Placebo-Controlled Trial 

John H. Stone 1 , Katie Tuckwell 2 , Sophie Dimonaco 2 , 

Micki Klearman 3 , Martin Aringer 4 , Daniel Blockmans 5 , 

Elisabeth Brouwer 6 , Maria C. Cid 7 , Bhaskar Dasgupta 8 , 

Juergen Rech 9 , Carlo Salvarani 10 , Robert F. Spiera 11 , 

Sebastian H. Unizony 1 , Neil Collinson 2 and the 

GiACTA Investigators, 1 Massachusetts General 

Hospital Rheumatology Unit, Harvard Medical 

School, Boston, MA, 2 Roche Products Ltd., Welwyn 

Garden City, United Kingdom, 3 Genentech, South San 

Francisco, CA, 4 Abteilung für Rheumatologie, Dresden, 

Germany, 5 University Hospitals Gasthuisberg, Leuven, 

Belgium, 6 Department of Rheumatology and Clinical 

Immunology, University of Groningen, University 

Medical Center Groningen, Groningen, Netherlands, 

7 

Hospital Clínic. University of Barcelona. IDIBAPS, 

Barcelona, Spain, 8 Southend University Hospital NHS 

Foundation Trust, Westcliff-on-Sea, United Kingdom, 

9 

Friedrich-Alexander-University Erlangen-Nürnberg, 

12:00 pm 

Successfully Navigate the Practice in the Value-Based 

Era 

Speaker: Chris Hopwood, QMP, PCMH-CCE 

Universitätsklinikum Erlangen, Erlangen, Germany, 


Sunday 



ACR PLENARY SESSION continued 

10 

Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 

Italy, 11 Hospital for Special Surgery, Cornell, New York, 

NY 

11:45 am 

912. Urate Lowering Therapy in Moderate to Severe 

Chronic Kidney Disease 

Gerald D. Levy 1 , Craig Cheetham 2 , Nazia Rashid 3 and Jiaxiao 

Shi 2 , 1 Southern California Kaiser Permanente, Downey, CA, 

2 

Southern California Medical Group, Pasadena, CA, 3 Kaiser 

Permanente, Downey, CA 

12:00 am 

913. Aggregatibacter Actinomycetemcomitans-Induced 

Hypercitrullination Links Periodontal Infection to 

Autoimmunity in Rheumatoid Arthritis 

Maximilian F. Konig 1 , Loreto Abusleme 2 , Jesper Reinholdt 3 , 

Robert J. Palmer 2 , Kevon Sampson 4 , Ricardo P. Teles 5 , Peter 

A. Nigrovic 6 , Antony Rosen 4 , Jeremy Sokolove 7 , Jon T. Giles 8 , 

Niki M. Moutsopoulos 2 and Felipe Andrade 4 , 1 Massachusetts 

General Hospital, Harvard Medical School, Boston, MA, 

2 

National Institute of Dental and Craniofacial Research, 

National Institutes of Health, Bethesda, MD, 3 Aarhus 

University, Aarhus, Denmark, 4 Division of Rheumatology, 

The Johns Hopkins University School of Medicine, Baltimore, 

MD, 5 University of North Carolina at Chapel Hill, Chapel Hill, 

NC, 6 Division of Rheumatology, Immunology and Allergy, 

Brigham and Women’s Hospital, Harvard Medical School, 

Boston, MA, 7 Division of Immunology and Rheumatology, 

Stanford University School of Medicine, Stanford, CA, 

8 

Columbia University, College of Physicians and Surgeons, 

Division of Rheumatology, New York, NY 

12:15 pm 

914. Longitudinal Blood Transcriptomics Uncovers 

Immune Networks Associated with Complications in 

Lupus Pregnancy 

Seunghee Hong 1 , Romain Banchereau 1 , Marta M. Guerra 2 , 

Jane E. Salmon 3 and Virginia Pascual 1 , 1 Baylor Research 

Institute, Dallas, TX, 2 Hospital for Special Surgery, New York, 

NY, 3 Weill Cornell Medicine, New York, NY 

ACR SESSIONS 

12:30 pm – 2:00 pm 

146 A 

2016 CARE: MOC Sessions 1 of 3: Lupus 


Speaker: Maria Dall’Era, MD 

140 A 

New Perspectives on B Cells in Autoimmunity 

Moderators: Jennifer Rogers, MD; Teresa K. Tarrant, MD 

12:30 pm 

Antigen-Specific B10 Cells in Autoimmunity 

Speaker: Thomas Tedder, PhD 

1:00 pm 

Lysosomal Acidification Defects in Lupus 

Speaker: Barbara J. Vilen, PhD 

1:30 pm 

Diversity and Origins of Autoreactive B Cells in Lupus 

Speaker: Ignacio Sanz, MD 


12:30 pm – 2:15 pm 

Marriott Marquis – Meeting Level 4 (Liberty 

Ballroom: Salon I) 

ARHP Discipline Round Tables: Networking 

Forum 

ARHP attendees are invited to this kickoff forum for the 

Annual Meeting. A box lunch will be provided for the first 

250 people. You will have an opportunity to meet and 

network with other health professionals. Discipline tables 

will be arranged to help facilitate connections. This session 

is not eligible for CME credit. 

ACR SESSION 

12:45 pm – 2:15 pm 

Ballroom A 

ACR Knowledge Bowl: Preliminary PM Round PS 


Ed Pd PrM FIT 


59


Sunday 


ACR SESSION continued 

Competing Teams: 

Mississippi Mayhem 

Vikas Majithia, MD; Swathi Gonnalagadda, MD; Teresa 

Crout, MD 

The Trojan Force 

Daniel Arkfeld, MD; Christina Chen, DO; Beatrice Kenol, 

MD 

The Hawkeyes 

Namrata Singh, MD; Bharat Kumar, MD; Sanjeev Patil, 

MD 

Immuno-Globe Trotters 

Stacy P. Ardoin, MD, MS; Alexa Meara, BA, MD; Kimberly 

Fisher, MD 

Fibro Fog 

Dominick Sudano, MD; Zaynb Hassan, MD; Emily Jeffrey, 

MD 

MHC “sans” complex 

Elana J. Bernstein, MD; Isabelle Amigues, MD; Alexandra 

Perel-Winkler, MD 

LSU Hooked – Osteofighters 

Nirupa J. Patel, MD; Smita Pechitty, MD; Shilpa Kollipara, 

MD 

The Team Who Says NiH 

Daniella Schwartz, MD; Robinder Dhillon, MD; Sara 

Alehashemi, MD 

The Hot Joints 

Rodolfo Curiel, MD; Sam Serafi, MD; Marc Phillpotts, MD 

Tram-a-dolls 

Pascale Schwab, Marcia Friedman and Julianna 

Desmarais, Oregon Health & Science University, 

Portland, OR 

The Krzyzewskimabs 

E. William St.Clair, MD; Tayseer Haroun, MBBS; Jason 

Weiner, MD 

No Rheumorse 

Raquel Cuchacovich, MD; Sarah Perryman, DO; Suliman 

Alradawi, MD 

Know Bones About It 

Jason R. Kolfenbach, MD; Lindsay Kelmenson, MD; 

Patrick R. Wood, MD 

The 1:80 Titer Fighters 

Keith Burwell, DO; Abhishek Nandan, MD; Nehal Shah, 

MD 

Rheum-Nados 

Keith Reich, DO, FACOI, FACR, RhMSUS; Mark Vercel, 

DO; Nisha Dsilva, DO 

Ropes-a-Dopes 

Eli Miloslavsky, MD; April Jorge, MD; Mazen Nasrallah, 

MD, MSc 

Team Smallbany 

Ruben Peredo-Wende, MD; Vivek Mehta, MD; Birju 

Bhatt, MD 


12:45 pm – 2:15 pm 


separate registration and ticket. To verify which session you 

registered for, the registration code on your ticket needs 

to match the 3-digit code in front of the session title. If you 

are interested in participating in one of these sessions or 

exchanging your ticket, visit the ACR registration desk to 

check space availability. View the session overview and 

learning objectives online in the Annual Meeting App. 


148 

011 – Adult Inflammatory Myopathy 

Speaker: Frederick Miller, MD, PhD 

153 

012 – Osteoarthritis: Update 2016 

Speaker: Timothy E. McAlindon, MD, MPH, MRCP 

154 A 

013 – Difficult Osteoporosis, DXA Dilemmas, 

and Novel Treatments 

Speaker: Kenneth G. Saag, MD, MSc 


Sunday 




154 B 

014 – Pediatrics: Periodic Fevers in Children 


Speaker: Marco Gattorno, MD 

155 

015 – Pregnancy and Rheumatic Diseases 

Speaker: Jill P. Buyon, MD 

PM PS E 

Ballroom C 

Rheumatology Research Foundation Paul 

Klemperer, MD, Memorial Lecture: Maybe 

Lamarck Was Right? How the Genome, 

Epigenome, and Environment Shape 


Moderator: Abby Abelson, MD 

Speaker: Gary Firestein, MD 

158 A 

016 – Psoriatic Arthritis PM PS E 

Speaker: Dafna D. Gladman, MD, FRCPC 

160 

017 – Rheumatoid Arthritis: Challenging Cases 

Speaker: Stephen A. Paget, MD 

159 A 

018 – Spondylarthropathy: An Update PM PS E 

Speaker: Christopher T. Ritchlin, MD, MPH 

159 B 


Nephritis 

Speaker: Rosalind Ramsey-Goldman, MD, DrPH 

158 B 


Therapies PM PS PME 

PS E 

Speaker: Jeffrey R. Curtis, MD, MS, MPH 

ACR SESSIONS 

1:00 pm – 2:00 pm 

STUDY GROUPS 

1:00 pm – 2:00 pm 

Take advantage of these unique social forums, designed 

to bring together small groups of attendees with common 

interest in a single disease, a group of related disorders 

or a specialized field of study. Study Groups are non-CME 

activities open to all attendees. 

147 A 

APLAR: Research Advances in Systemic Lupus 

Erythematosus (SLE) in the Asia Pacific Region 

Study Group 

Speakers: Yeong Wook Song, MD; Yoshiya Tanaka, MD, 

PhD; Sang-Cheol Bae, MD, MPH, PhD; Chi Chiu Mok, 

MD; Eric F. Morand, MBBS, FRACP, PhD 

204 A 

Autonomic Neuroregulation of Autoimmune 

Disease Study Group 

Speakers: Andrew Holman, MD; Paul P. Tak, MD, PhD 

145 A 

Behçet’s Syndrome: Prognosis and Management 

Speakers: Yusuf Yazici, MD; Emire Seyahi, MD; Gulen 

Hatemi, MD; Ahmet Gul, MD; Hasan Yazici, MD 

143 A 

Medical Education Year in Review PM PS 

Moderator: Chaim Putterman, MD 

Speaker: Beth L. Jonas, MD 

Ed Pd PrM FIT 

152 A 

Best Practices in Fracture Prevention Clinics 

Study Group 

Speakers: George A. W. Bruyn, MD; Lai-Shan TAM, MD; 

Marian de Waal, MD; Joop van den Bergh, MD, PhD 


61


Sunday 


STUDY GROUPS continued 

201 

Causal Inference in Rheumatic Disease 

Research Study Group 

Speakers: Hyon Choi, MD, DrPH; Yuqing Zhang, DSc 

207 B 

Geriatric Rheumatology Study Group 

Speakers: Devyani Misra, MD, MSc; Luigi Ferrucci, MD, 

PhD 

202 B 

Juvenile Arthritis Workgroup (JAW) – TMJ 

Arthritis Study Group 

Speakers: Randy Q. Cron; N. Tzaribachev, MD; Rotraud 

Saurenmann, MD; Cory M. Resnick, DMD, MD; Matthew 

L. Stoll, MD, PhD, MSCS 

209 A 

Neuroendocrine Immunology Study Group: 

Adrenal Gland in Rheumatoid Arthritis and 

Related Disorders 

Speakers: Georg Pongratz, Prof. Dr. Med.; Johannes W. 

J. Bijlsma, MD, PhD; Richard Imrich, MD, PhD; Alfonse T. 

Masi, MD, DrPH 

151 A 

Outcomes from Recent Innovations in 

Musculoskeletal Education and Implications 

for Undergraduate, Graduate, and Continuing 

Medical Education Programs Study Group 

Speakers: Michael J. Battistone, MD; Andrea M. Barker, 

MPAS, PA-C; David I. Daikh, MD, PhD; Deana M. Lazaro, 

MD; Grant W. Cannon, MD 

206 

Psoriatic Arthritis Study Group: How Can We 

Best Define Remission in PsA? 

Speakers: Alexis Ogdie, MD; Joseph Merola, MD, MMSC; 

Laura Coates, MBChB, PhD; Alice B Gottlieb; Musaab 

Elmamoun 

150 A 

Reproductive Issues in Rheumatology Study 

Group 

Speakers: Bonnie L. Bermas, MD; Lisa R. Sammaritano, 

MD; Eliza Chakravarty, MD, MS; Christina Chambers, 

PhD, MPH; Megan E. B. Clowse, MD, MPH 

WORKSHOPS 

1:15 pm – 3:15 pm 










144 C 

208 – Joint Injection Techniques PM PS E 

Speakers: Atul A. Deodhar, MD; Kenneth S. O’Rourke, 

MD 

149 A 

209 – Magnetic Resonance Imaging (MRI) in the 

Diagnosis and Management of Spondylarthritis: 

A Clinician’s Guide 

Speaker: Walter Maksymowych 

144 B 

210 – Physical Examination Skills for 

Improved Detection of Synovitis and Cervical 

Thoracolumbar Disorders 

Speaker: Edward C. Keystone, MD, FRCP(C) 

144 A 

211 – Renal Histopathology in Systemic Lupus 

Erythematosus and Vasculitis 

Speaker: Anthony Chang, MD 


Sunday 



ACR SESSIONS 

2:30 pm – 3:30 pm 

Ballroom A 

Glucocorticoid-Induced Osteoporosis 

Prevention and Treatment: A New ACR Clinical 

Guideline PM PS E 

Moderator: Marcy Bolster, MD 

2:30 pm 

Overview of Guideline Development, Including 

Methods and Literature Review 


2:50 pm 

Presentation of the New ACR Glucocorticoid-Induced 

Osteoporosis (GIOP) Guideline 

Speaker: Lenore Buckley, MD, MPH 

3:10 pm 

Case Discussions 

Speaker: Mary Beth Humphrey, MD, PhD 

ACR SESSIONS 

2:30 pm – 4:00 pm 

140 A 

How Dead Cells Drive Inflammation 

Moderator: Keith B. Elkon, MD 

2:30 pm 

The Role of Autophagy in Cell Death and Its 

Consequences 

Speaker:Michael T. Lotze, MD 

3:15 pm 

The Role of Mitochondrial DAMPs in Inflammation 

Speaker: Augustine M. K. Choi, MD 

Hall D 

The Great Debate: To Taper or Not to Taper? – 

Biologic DMARDs in Low Rheumatoid Arthritis 

Disease Activity 

Moderators: Daniel H. Solomon, MD, MPH; Jasvinder A. 

Singh, MD, MPH 

2:30 pm 

PRO 

Speaker: Paul Emery, MA, MD, FRCP 

3:15 pm 

AGAINST 

Speaker: Arthur F. Kavanaugh, MD 

ACR CONCURRENT ABSTRACT SESSIONS 

2:30 pm – 4:00 pm 

150 A 

B Cell Biology and Targets in Autoimmune 

Disease I 

Moderators: Jennifer H. Anolik, MD, PhD; Shaun Jackson, 

MD PhD 

2:30 pm 

915. Establishment of a Powerful Method to Identify 

Autoantigens Expressed on the Cell Surface 

Tsuyoshi Shirai, Hiroshi Fujii, Tomoyuki Muto, Yuko 

Shirota, Yoko Fujita, Tomonori Ishii and Hideo Harigae, 

Tohoku University Graduate School of Medicine, Sendai, 

Japan 

2:45 pm 

916. Novel Immunosignature Stratifies Patients 

with Rheumatoid Arthritis into Distinct Disease 

Sub-Groups and Predicts Response to Anti-Tnfα 

Therapies 

Laura Magill 1 , Marsilio Adriani 1 , Victoria Howard 2 , Jessica 

Manson 2 , Elizabeth Jury 1 and Claudia Mauri 1 , 1 University 

College London, London, United Kingdom, 2 University 

College London Hospitals NHS Trust, London, United 

Kingdom 

3:00 pm 

917. B Cells Inhibit Osteoblast Differentiation in 

Inflammatory Arthritis 

Wen Sun 1 , Nida Meednu 2 , Alex Rosenberg 2 , Javier 

Rangel-Moreno 2 , Victor Wang 2 , Teresa Owen 2 , Hengwei 

Zhang 2 , Brendan Boyce 2 , Jennifer H. Anolik 2 and 

Lianping Xing 2 , 1 Nanjing Medical University, Nanjing, 

China, 2 University of Rochester Medical Center, 

Rochester, NY 


63


Sunday 


ACR CONCURRENT ABSTRACT SESSIONS continued 

3:15 pm 

918. Anergic B Cells May Preserve Peripheral 

Tolerance in Lupus-Prone Congenic Mice 

Kieran Manion 1 , Yuriy Baglaenko 1 , Nan-Hua Chang 1 , 

Nafiseh Talaei 2 and Joan Wither 1 , 1 Krembil Research 

Institute, University Health Network, Toronto, ON, 

2 

Krembil Research Institute, Toronto, ON 

3:30 pm 

919. IL-17 Receptor a Signaling Impedes NF-ĸB p50/ 

p50 Repressor and Subverts B-Cell Anergy in BXD2 

Mice 

Jennie Hamilton 1 , Qi Wu 1 , PingAr Yang 1 , Bao Luo 1 , 

Woongjai Won 1 , Shanrun Liu 1 , Jun Li 1 , Hui-Chen 

Hsu 1 and John D. Mountz 2 , 1 University of Alabama at 

Birmingham, Birmingham, AL, 2 University of Alabama at 

Birmingham, birmingham, AL 

3:45 pm 

920. Autoantigen-Specific T Cell and Antibody 

Reactivity to a Human Gut Commensal in 

Antiphospholipid Syndrome 

William Ruff 1 , Carina Dehner 2 , Alex Roth 1 , Silvio M. 

Vieira 1 , Cassyanne L. Aguiar 3 , Andrew Goodman 1 , Doruk 

Erkan 4 and Martin Kriegel 1 , 1 Yale School of Medicine, 

New Haven, CT, 2 Yale School of Medicine, new haven, 

CT, 3 Hospital for Special Surgery, New York, NY, 

4 

Hospital for Special Surgery- NewYork-Presbyterian / 

Weill Cornell Medicine, New York, NY 

143 A 

Cytokines, Mediators, Cell-Cell Adhesion, Cell 

Trafficking, and Angiogenesis I 

Moderators: Hendrik Schulze-Koops, MD, PhD; Ian P. 

Wicks, MBBS, PhD, FRACP 

2:30 pm 

921. The Anti-IL-17A Antibody Secukinumab 

(Cosentyx ® , AIN457) Diminishes the Expression of 

the NFκB Pathway Modulator Iκbζ 

Robert Hennze 1 , Thomas Schlitt 1 , Thomas Peters 1 , 

Irina Koroleva 2 , Rebecca Torene 2 , Xiaoyu Jiang 3 , Marija 

Curcic Djuric 1 , Anis Mir 1 , Frank Kolbinger 1 and Christine 

Huppertz 1 , 1 Novartis Institutes for BioMedical Research, 

Novartis Pharma AG, Basel, Switzerland, 2 Novartis 

Institutes for BioMedical Research, Novartis Pharma 

AG, Cambridge, MA, 3 Novartis Institutes for BioMedical 

Research, Novartis Pharma AG, Cambdrige, MA 

2:45 pm 

922. Negative Regulation of IL-17 Receptor Signaling 

By Regnase-1 Limits Immunopathology in a Mouse 

Model of Psoriatic Skin Disease 

Sarah L. Gaffen 1 , Leticia Monin 2 , Nicole Ward 3 , Johann 

Gudjonsson 4 , Abhishek Garg 2 , Alicia Mathers 2 and 

Pappachan Kolattukudy 5 , 1 University of Pittsburgh 

School of Medicine, Pittsburgh, PA, 2 University of 

Pittsburgh, Pittsburgh, PA, 3 Case Western Reserve 

University, Cleveland, OH, 4 University of Michigan, Ann 

Arbor, MI, 5 University of Central Florida, Orlando, FL 

3:00 pm 

923. Retinoic Acid Inhibits Expression of Interleukin 

9 By Altering Enhancer Architecture 

Daniella Schwartz 1 , Francoise Meylan 2 , Hong-Wei 

Sun 3 , Han-Yu Shih 1 , Kan Jiang 1 , Franziska Petermann 1 , 

Richard M. Siegel 4 , Arian Laurence 5 and John J O’Shea 6 , 

1 

National Institutes of Health, Bethesda, MD, 2 NIAMS, 

NIH, Bethesda, MD, 3 National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, National Institutes 

of Health, Bethesda, MD, 4 National Institute of Arthritis 

and Musculoskeletal and Skin Diseases, Bethesda, 

MD, 5 University of Oxford, Oxford, United Kingdom, 

6 

National Institute of Arthritis and Musculoskeletal and 

Skin Diseases, NIH, Bethesda, MD 

3:15 pm 

924. Intestinal Dysbiosis Influences Gut-Joint 

Lymphocyte Trafficking 

Kristine Kuhn, Hanna Schulz, Jason Hendrickson and 

Neha Ohri, University of Colorado School of Medicine, 

Aurora, CO 

3:30 pm 

925. Complement C5a Receptor Is the Key Initiator 

of Neutrophil Adhesion and Inflammation in 

Immune Complex-Induced Arthritis 

Yoshishige Miyabe 1 , Chie Miyabe 1 , Thomas Murooka 2 , 

Edward Kim 3 , Nancy Kim 3 , Thorsten R. Mempel 4 and 

Andrew D. Luster 1 , 1 Massachusetts General Hospital, 

Harvard Medical School, Boston, MA, 2 University of 

Manitoba, Winnipeg, MB, 3 Massachusetts General 

Hospital, Boston, MA, 4 Massachusetts General Hospital, 

Charlestown, MA 


Sunday 




3:45 pm 

926. Increased Concentration of Receptor Activator 

of Nuclear Factor Kappa-B Ligand (RANKL) Predate 

Onset of Rheumatoid Arthritis 

Linda Johansson 1 , Lisbeth Ärlestig 1 , Heidi Kokkonen 1 

and Solbritt Rantapaa-Dahlqvist 2 , 1 Umeå University, 

Umeå, Sweden, 2 Umeå University, Department of Public 

Health and Clinical Medicine/ Rheumatology, Umeå, 

Sweden 

147 A 

Health Services Research I: Workforce and 

Quality of Care in Rheumatology 

Moderators: Linda T. Hiraki, MD, SM, SD; Ami A. Shah, 

MD, MHS 

2:30 pm 

927. 2015 ACR/ARHP Workforce Study in the United 

States: Pediatric Rheumatologist Supply and 

Demand Projections for 2015-2030 

Daniel Battafarano 1 , Seetha Monrad 2 , Marcia Ditmyer 3 , 

Lisa Imundo 4 and Marisa Klein-Gitelman 5 , 1 San Antonio 

Military Medical Center, San Antonio, TX, 2 University 

of Michigan, Ann Arbor, MI, 3 University of Nevada, 

Las Vegas, NV, 4 Columbia University, New York, NY, 

5 

Northwestern University, Chicago, IL 

2:45 pm 

928. 2015 ACR/ARHP Workforce Study in the United 

States: A Maldistribution of Adult Rheumatologists 

Katrina Lawrence-Wolff 1 , Bernard Hildebrand 1 , Seetha 

Monrad 2 , Marcia Ditmyer 3 , John Fitzgerald 4 , Alan 

Erickson 5 , Anne R. Bass 6 and Daniel Battafarano 1 , 

1 

San Antonio Military Medical Center, San Antonio, 

TX, 2 University of Michigan, Ann Arbor, MI, 3 University 

of Nevada, Las Vegas, NV, 4 UCLA, Los Angeles, CA, 

5 

University of Nebraska, LaVista, NE, 6 Hospital for 

Special Surgery, New York, NY 

3:00 pm 

929. Retinal Examinations Among SLE Patients 

Newly-Initiating Hydroxychloroquine in a U.S. 

Medicaid SLE Population, 2000-10 

Tzu-Chieh Lin 1 , CH Feldman 2 , Hongshu Guan 3 , Sarah 

Chen 4 , Medha Barbhaiya 1 and Karen H. Costenbader 1 , 

1 

Brigham and Women’s Hospital and Harvard Medical 

School, Boston, MA, 2 Harvard T. H. Chan School of 

Public Health, Boston, MA, 3 Division of Rheumatology, 

Immunology and Allergy, Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA, 4 Beth 

Israel Deaconess Medical Center, Boston, MA 

3:15 pm 

930. How to Implement Cardiovascular Disease 

Risk Assessment for Patients with Inflammatory 

Joint Diseases in Daily Rheumatology Practice: An 

Overview of a Nationwide Norwegian Project 

Eirik Ikdahl 1 , Silvia Rollefstad 1 , Grunde Wibetoe 1 , Anne 

Salberg 2 , Dag Magnar Soldal 3 , Inge C Olsen 1 , Tore K 

Kvien 1 , Glenn Haugeberg 4 and Anne Grete Semb 1 , 

1 

Diakonhjemmet Hospital, Oslo, Norway, 2 Hospital for 

Rheumatic Diseases, Lillehammer, Norway, 3 Hospital 

of Southern Norway, Kristiansand, Norway, 4 Martina 

Hansens Hospital, Bærum, Norway 

3:30 pm 

931. Rates of Lipid Testing and Statin Prescriptions 

Among SLE and Diabetes Mellitus Patients in a 

Nationwide Medicaid Cohort 

Sarah K. Chen 1 , Medha Barbhaiya 2 , Michael A. Fischer 2 , 

Hongshu Guan 2 , Tzu-Chieh Lin 2 , Candace H. Feldman 3 , 

Brendan M. Everett 2 and Karen H. Costenbader 2 , 1 Beth 

Israel Deaconess Medical Center, Boston, MA, 2 Brigham 

and Women’s Hospital and Harvard Medical School, 

Boston, MA, 3 Harvard T. H. Chan School of Public 

Health, Boston, MA 

3:45 pm 

932. High Symptom Prevalence and Under- 

Utilisation of Palliative Care at End-of-Life of 

Patients with Systemic Rheumatic Diseases 

Jiacai Cho 1 , Dominic Lo 2 , Anselm Mak 1 , Jamie Zhou 3 and 

Sen Hee Tay 2 , 1 Division of Rheumatology, Department 

of Medicine, National University Hospital, National 

University Health System, Singapore, Singapore, 

Singapore, 2 Department of Medicine, Yong Loo Lin 

School of Medicine, National University of Singapore, 

Singapore, Singapore, Singapore, 3 Department of 

Haematology-Oncology, National University Cancer 

Institute, National University Hospital, National 

University Health System, Singapore, Singapore, 

Singapore 


65


Sunday 



Salon G 

Imaging of Rheumatic Diseases I: Advanced 

Imaging in RA and Spondyloarthritides 

Moderators: Charles Peterfy, MD, PhD; Orrin M. Troum, 

MD 

Denmark, 11 Department of Medicine, Vejle Regional 

Hospital, Vejle, Denmark, 12 Gentofte University 

Hospital, Gentofte, Denmark, 13 Department of 

Rheumatology, Aarhus University Hospital, Aarhus, 

Denmark, 14 Hvidovre University Hospital, Denmark, 

Hvidovre, Denmark 

2:30 pm 

933. Erosion Patterns in Seropositive and 

Seronegative Rheumatoid Arthritis: A Joint-By-Joint 

Approach 

Ottar Gadeholt 1 , Katharina Hausotter 2 , Hannes Eberle 3 , 

Hans-Peter Tony 4 , Marc Schmalzing 5 and Thorsten 

Klink 2 , 1 Medical Clinic II, University Clinic Wuerzburg, 

Wuerzburg, Germany, 2 University Clinic Wuerzburg, 

Wuerzburg, Germany, 3 Kreiskliniken Esslingen, 

Nürtingen, Germany, 4 University of Würzburg, 

Würzburg, Germany, 5 Medical Clinic II, University Clinic 

Wuerzburg, Würzburg, Germany 

2:45 pm 

934. Magnetic Resonance Imaging (MRI) Joint 

Space Narrowing Is an Independent Predictor 

of Radiographic and MRI Damage Progression in 

Patients with Early Rheumatoid Arthritis 

Signe Møller-Bisgaard 1 , Bo Jannik Ejbjerg 2 , Iris Eshed 3 , 

Kim Hørslev-Petersen 4 , Merete Lund Hetland 5 , Anne 

Grethe Jurik 6 , Henrik S Thomsen 7 , Trine Torfing 8 , 

Kristian Stengaard-Pedersen 6 , Peter Junker 9 , Niels 

Steen Krogh 10 , Tine Lottenburger 11 , Torkell Ellingsen 8 , 

Lis Smedegaard Andersen 12 , Henrik Skjødt 1 , Anders 

Svendsen 8 , Ulrik Tarp 6 , Ib Tønder Hansen 13 , Jan 

Pødenphant 12 , Jens Kristian Pedersen 8 , Hanne 

Lindegaard 8 , Aage Vestergaard 14 , Daniel Glinatsi 1 

and Mikkel Østergaard 1 , 1 Copenhagen Center for 

Arthritis Research, Center for Rheumatology and Spine 

Diseases, Rigshospitalet, Copenhagen, Denmark, 

Glostrup, Denmark, 2 Slagelse University Hospital, 

Slagelse, Denmark, 3 Sheba Medical Center, Israel, 

Tel Hashomer, Israel, 4 King Christian X Hospital 

for Rheumatic Diseases, Graasten, Denmark, 

5 

Copenhagen Center for Arthritis Research, Center 

for Rheumatology and Spine Diseases, Rigshospitalet, 

Denmark,, Copenhagen, Denmark, 6 Aarhus University 

Hospital, Aarhus, Denmark, 7 Herlev University Hospital, 

Copenhagen, Denmark, 8 Odense University Hospital, 

Odense, Denmark, 9 University of Southern Denmark, 

Odense, Denmark, 10 ZiteLab ApS, Copenhagen, 

3:00 pm 

935. Pretreatment Plasma IL-6 Levels Are 

Responsible for Bone Erosion Progression on 

Magnetic Resonance Imaging in Patients with 


Yasushi Kondo 1 , Yuko Kaneko 2 , Hiroaki Sugiura 2 , 

Shunsuke Matsumoto 2 , Naoshi Nishina 2 , Masahiro 

Jinzaki 2 and Tsutomu Takeuchi 1 , 1 Keio University School 

of Medcine, Division of Rheumatology, Department of 

Internal Medicine, Tokyo, Japan, 2 Keio University School 

of Medicine, Tokyo, Japan 

3:15 pm 

936. Reliability and Responsiveness of an Omeract 

Tenosynovitis Magnetic Resonance Imaging Scoring 

System for the Rheumatoid Arthritis Wrist and 

Hand 

Daniel Glinatsi 1 , Paul Bird 2 , Frédérique Gandjbakhch 3 , 

Espen A. Haavardsholm 4 , Philip G. Conaghan 5 

and Mikkel Østergaard 6 , 1 Copenhagen Center 

for Arthritis Research, Center for Rheumatology 

and Spine Diseases, Rigshospitalet, Copenhagen, 

Denmark, Glostrup, Denmark, 2 University of New 

South Wales, Sydney, NSW, Australia, 3 MD, Paris, 

France, 4 Diakonhjemmet Hospital, Oslo, Norway, 

5 

Leeds Institute of Rheumatic and Musculoskeletal 

Medicine, University of Leeds, Leeds, United Kingdom, 

6 



Denmark, Copenhagen, Denmark 

3:30 pm 

937. Distal Interphalangeal Joint Erosions Assessed 

By HR-pQCT in Patients with Psoriatic Onycholysis 

Axel Patrice VILLANI 1 , Stéphanie Boutroy 2 , Hubert 

Marotte Sr. 3 , Loïs Barets 4 , Marie-Christine Carlier 4 , 

Roland Chapurlat 5 , Denis Jullien 1 and Cyrille B 

Confavreux 5 , 1 Hôpital Edouard Herriot, Dermatology 

department, Lyon I University, Lyon, France, 2 Inserm 

UMR1033, Lyon, France, 3 Service de rhumatologie, 

St Etienne, France, 4 Hôpital Edouard Herriot, Lyon, 

France, 5 Hôpital Edouard Herriot, Hospices Civils de 

Lyon, University of Lyon, Lyon, France 


Sunday 




3:45 pm 

938. Prevalence of Non-Radiographic Axial 

Spondyloarthritis in Psoriatic Arthritis – a Single 

Center Observational Study 

Victoria Furer 1 , Moshe Stark 2 , Hagit Matz 3 , David 

Levartovsky 4 , Jonathan Wallman 5 , Irena Wigler 6 , Hagit 

Sarvagyl-Maman 7 , Ofir Elalouf 8 , Sara Borok Lev-Ran 9 , 

Daphna Paran 6 , Gideon Flusser 3 , Iddo Drukman 3 , Iris 

Eshed 10 and Ori Elkayam 3 , 1 Tel Aviv Sourasky Medical 

Center, The Sackler Faculty of Medicine, Tel Aviv 

University, Tel Aviv, Israel, 2 Tel Aviv Medical Center, 

Tel Aviv, Tel Aviv, Israel, 3 Tel Aviv Medical Center, Tel 

Aviv, Israel, 4 Tel-Aviv Sourasky Medical Center, Sackler 

Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 

5 

Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, 6 Tel 

Aviv Sourasky Medical Center and the Sackler Faculty 

of Medicine, Tel Aviv University, Tel Aviv, Israel, 7 Tel 

Aviv Sourasky Medical Center and the Sackler Faculty 

of Medicine, Tel Aviv University, Tel-aviv, Israel, 8 Tel Aviv 

Medical Center and the Sackler Faculty of Medicine, 

Tel Aviv University, Tel-Aviv, Israel, 9 Tel Aviv Sourasky 

Medical Center and the Sackler Faculty of Medicine,Tel 

Aviv University, Tel AViv, Israel, 10 Sheba Medical Center, 

Israel, Tel Hashomer, Israel 

145 A 

Miscellaneous Rheumatic and Inflammatory 

Diseases I 

Moderators: Mehrdad Maz, MD; Qingping Yao, MD, PhD 

2:30 pm 

939. Circulating IgG4 Antibody Secreting Cells Are 

Better Biomarker of Disease Activity Compared to 

Serum IgG4 Levels in Patients with IgG4-Related 

Disease 

Arezou Khosroshahi 1 , Alessia Corrado 1 , Takashi 

Muraki 1 , Shuya Kyu 1 , Xiaoqian Wang 1 , Ignacio Sanz 2 

and F. Eun-Hyung Lee 1 , 1 Emory University School of 

Medicine, Atlanta, GA, 2 Emory University School of 

Medicine and Lowance Center for Human Immunology, 

Atlanta, GA 

2:45 pm 

940. A Trial of XmAb ® 5871, a Reversible Inhibitor of 

CD19+ Cells, in IgG4-Related Disease 

John H. Stone 1 , Zachary S. Wallace 2 , Cory A. Perugino 2 , 

Ana D. Fernandes 2 , Paul A. Foster 3 and Debra J. Zack 3 , 

1 

Massachusetts General Hospital Rheumatology Unit, 

Harvard Medical School, Boston, MA, 2 Massachusetts 

General Hospital, Boston, MA, 3 Xencor, Inc., San Diego, CA 

3:00 pm 

941. An International, Multi-Specialty Validation 

Study of the IgG4-Related Disease Responder Index 

Zachary Wallace 1 , Arezou Khosroshahi 2 , Mollie 

Carruthers 3 , Campochiaro Corrado 4 , Hyon K. Choi 5 , 

Emma Culver 6 , Frank Cortazar 1 , Mikael Ebbo 7 , 

Ana Fernandes 1 , Luca Frulloni 8 , Omer Karadag 9 , 

Shigeyuki Kawa 10 , Mitsuhiro Kawano 11 , MH Kim 12 , 

Marco Lanzillotta 13 , Shoko Matsui 14 , Cory Perugino 1 , 

Kazuichi Okazaki 15 , Philip Hart 16 , Jay H. Ryu 17 , Takako 

Saeki 18 , Nicolas Schleinitz 19 , Paula Tanasa 20 , Hisanori 

Umehara 21 , George Webster 22 , Wen Zhang 23 and John 

H. Stone 24 , 1 Massachusetts General Hospital, Boston, 

MA, 2 Emory University School of Medicine, Atlanta, GA, 

3 

University of British Columbia, Vancouver, BC, 4 San 

Raffaele Scientific Institute, Milan, Italy, 5 Massachusetts 

General Hospital and Harvard Medical School, Boston, 

MA, 6 Translational Gastroenterology Unit and NDM 

Oxford University, John Radcliffe Hospital/Oxford 

University, Oxford, United Kingdom, 7 Aix-Marseille 

Université, AP-HM, Marseille, France, 8 University of 

Verona, Verona, Italy, 9 Hacettepe University Faculty 

of Medicine, Ankara, Turkey, 10 Shinshu University, 

Matsumoto, Japan, 11 Division of Rheumatology, 

Kanazawa University Hospital, Kanazawa, Japan, 

12 

University of Ulsan College of Medicine, Seoul, Korea, 

The Republic of, 13 Vita-Salute San Raffaele University, 

Milan, Italy, 14 University of Toyama, Toyama, Japan, 

15 

Kansai Medical University, Osaka, Japan, 16 Ohio 

State University Wexner Medical Center, Columbus, 

OH, 17 Mayo Clinic, Rochester, MN, 18 Nagaoka Red 

Cross Hospital, Niigata, Japan, 19 La Timone University 

Hospital, Marseille, France, 20 Emory University, Atlanta, 

GA, 21 Kyoto University, Kyoto, Japan, 22 University 

College Hospital, London, United Kingdom, 23 Peking 

Union Medical College Hospital, Beijing, China, 

24 


Harvard Medical School, Boston, MA 

3:15 pm 

942. A Nationwide Experience with the Off Label 

Use of Interleukin 1 Targeting Treatment in 

Familial Mediterranean Fever Patients 

Servet Akar 1 , Pınar Cetin 2 , Umut Kalyoncu 3 , Omer 

Karadag 4 , Ismail Sari 5 , Muhammed Cinar 6 , Sedat 

Yılmaz 7 , Ahmet Mesut Onat 8 , Bunyamin Kisacik 9 , 

Abdulsamet Erden 3 , Ayşe Balkarli 10 , Orhan 


67


Sunday 



Kucuksahin 11 , Sibel Yilmaz Oner 12 , Soner Senel 13 , 

Abdurrahman Tufan 13 , Haner Direskeneli 12 , Mustafa 

Ferhat Oksuz 14 , Yavuz Pehlivan 14 , Ozun Bayndır 15 , 

Gokhan Keser 15 , Kenan Aksu 16 , Ahmet Omma 17 , Timucin 

Kasifoglu 18 , Ali Ugur Unal 19 , Fatih Yildiz 20 , Mehmet Ali 

Balci 21 , Sule Yavuz 13 , Sukran Erten 22 , Metin Ozgen 23 , 

Mehmet Sayarlioglu 24 , Atalay Dogru 25 , Gozde Yildirim 

Cetin 26 , Fatma Alibaz-Oner 19 , Mehmet Engin Tezcan 27 , 

Omer Nuri Pamuk 28 and Fatos Onen 29 , 1 Izmir Katip 

Celebi University School of Medicine, Izmir, Turkey, 

2 

Dokuz Eylul University, izmir, Turkey, 3 Hacettepe 

University, Ankara, Turkey, 4 Hacettepe University 

Faculty of Medicine, Ankara, Turkey, 5 Toronto 

Western Hospital, University of Toronto, Spondylitis 

Clinic, Toronto, ON, 6 GATA, Ankara, Turkey, 7 Gülhane 

Military Medical Academy, School of Medicine, 

Ankara, Turkey, 8 Gaziantep University School of 

Medicine, Ankara, Turkey, 9 Gaziantep University 

School of Medicine, Gaziantep, Turkey, 10 Antalya EAH, 

Antalya, Turkey, 11 Yildirim Beyazit University Faculty 

of Medicine, Ankara, Turkey, 12 Marmara University, 

School of Medicine, Istanbul, Turkey, 13 PsART study 

group, Ankara, Turkey, 14 Uludag University Medcal 

Faculty, Bursa, Turkey, 15 Ege University Medical 

Faculty, Izmir, Turkey, 16 Ege University, İzmir, 

Turkey, 17 Ankara Numune Hospital, Ankara, Turkey, 

18 

Osmangazi University, Faculty of Medicine, Eskisehir, 

Turkey, 19 Marmara University, School of Medicine, 

Rheumatology, Istanbul, Turkey, 20 Van EAH, Adana, 

Turkey, 21 Trakya University Medical Faculty, Edirne, 

Turkey, 22 Yildirim Beyazit University Faculty Of 

Medicine, Ankara, Turkey, 23 Ondokuz Mayıs University, 

Faculty of Medicine, Samsun, Turkey, 24 Ondokuz 

Mayis University Faculty of Medicine, Samsun, Turkey, 

25 

Suleyman Demirel University, Isparta, Turkey, 26 Sutcu 

Imam University, School of Medicine, Department 

of Internal Medicine, Division of Rheumatology, 

Kahramanmaras, Turkey, 27 Gazi University 

Medical School, Ankara, Turkey, 28 Department of 

Rheumatology, Trakya University Medical Faculty, 

Edirne, Turkey, Edirne, Turkey, 29 Dokuz Eylul University 

Faculty of Medicine, Izmir, Turkey 

3:30 pm 

943. Efficacy and Safety of IL-1 Inhibitors 

in Amyloidosis Associated with Familial 

Mediterranean Fever Who Underwent Kidney 

Transplantation 

Bahtiyar Toz 1 , Yaşar Kerem Çalışkan 2 , Burak Erer 1 , Lale 

Ocal 1 and Ahmet Gul 1 , 1 Istanbul University, Istanbul 

Faculty of Medicine, Istanbul, Turkey, 2 Istanbul School 

of Medicine, Istanbul University, Istanbul, Turkey 

3:45 pm 

944. A New Syndrome in the Spectrum of Cryopyrin- 

Associated Periodic Syndromes (CAPS) Caused By 

the Novel R918Q NLRP3 Mutation 

Gineth Pinto-Patarroyo 1 , Daniel L. Kastner 1 , Andrew 

Griffith 2 , H. Jeffrey Kim 2 , Camilo Toro 1 , Ariane Soldatos 3 , 

John Butman 4 , Bibi Bielekova 3 , JaeJin Chae 1 , Ivona 

Aksentijevich 1 , Hal M. Hoffman 5 , Lori Broderick 5 , Tina 

Romeo 1 , Anne Jones 1 , Jessica Ratay 2 and Susannah 

Wargo 2 , 1 National Human Genome Research Institute, 

National Institutes of Health, Bethesda, MD, 2 National 

Institute of Deafness and Other Communication 

Disorders, Bethesda, MD, 3 National Institute of 

Neurological Disorders and Stroke, National Institutes 

of Health, Bethesda, MD, 4 Warren Grant Magnuson 

Clinical Center, Bethesda, MD, 5 University of California 

at San Diego/Rady Children Hospital, La Jolla, CA 

Ballroom C 

Pediatric Rheumatology – Clinical and Therapeutic 

Aspects I: Juvenile Arthritis 

Moderators: Bryce A. Binstadt; Mara L Becker 

2:30 pm 

945. When and Where Musculoskeletal Ultrasound 

Might Replace Magnetic Resonance in the 

Assessment of Patients with Juvenile Idiopathic 

Arthritis? 

Stefano Lanni 1 , Francesca Magnaguagno 1 , Erica Ricci 2 , 

Angela Pistorio 1 , Cecilia Bava 1 , Alberto Martini 3 and 

Clara Malattia 1 , 1 Istituto Giannina Gaslini, Genoa, Italy, 

2 

Istituto G. Gaslini, Pediatria 2 -Reumatologia, genova, 

Italy, 3 PRINTO-IRCCS, Genova, Italy 


Sunday 




2:45 pm 

946. Comparative Effectiveness of Second-Line 

Treatment Strategies for Lyme Arthritis in Children 

Daniel B. Horton 1 , Alysha J. Taxter 2 , Brandt Groh 3 , David 

D. Sherry 4 and Carlos D. Rosé 5 , 1 Division of Pediatric 

Rheumatology, Rutgers Robert Wood Johnson Medical 

School, Rutgers Biomedical and Health Sciences, New 

Brunswick, NJ, 2 Brenner Children’s Hospital, Wake 

Forest Baptist Medical Center, Winston-Salem, NC, 

3 

Penn State Milton S. Hershey Medical Center, Hershey, 

PA, 4 Children’s Hospital of Philadelphia, Division of 

Pediatric Rheumatology, Perelman School of Medicine, 

University of Pennsylvania, Philadelphia, PA, 5 Division 

of Rheumatology, Nemours/A.I. duPont Hospital for 

Children, Thomas Jefferson University, Wilmington, DE 

3:00 pm 

947. A Multi-Center, Open-Label Study to Assess 

the Pharmacokinetics, Efficacy and Safety of 

Certolizumab Pegol in Children and Adolescents 

with Moderately to Severely Active Polyarticular- 

Course Juvenile Idiopathic Arthritis: Week 24 

Results 

Hermine I. Brunner 1 , Nicolino Ruperto 2 , Vladimir 

Keltsev 3 , Ekaterina Alexeeva 4 , Carlos Abud-Mendoza 5 , 

Heinrike Schmeling 6 , María del Rocío Maldonado- 

Velázquez 7 , Nadina Rubio-Pérez 8 , Marina Stanislav 9 , 

Vyacheslav Chasnyk 10 , Diane Brown 11 , Michael 

Henrickson 1 , Daniel Kingsbury 12 , C. Egla Rabinovich 13 , 

Andrew Zeft 14 , Earl Silverman 15 , Maggie Wang 16 , 

Philippa Charlton 16 , Rocio Lledo-Garcia 17 , Laura 

Shaughnessy 16 , Daniel J. Lovell 1 and Alberto Martini 2 , 

1 

PRCSG, Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 2 PRINTO, Istituto Gaslini, Genoa, 

Italy, 3 Togliatti City Clinical Hospital №5, Togliatti, 

Russian Federation, 4 Children’s Health of RAMS and 

IM Sechenov First Moscow State Medical University, 

Moscow, Russian Federation, 5 Hospital Central & 

Facultad de Medicina, Universidad Autónoma de 

San Luis Potosí, San Luis Potosí, Mexico, 6 Alberta 

Children’s Hospital, University of Calgary, Calgary, AB, 

7 

Hospital Infantil de Mexico Federico Gomez, Mexico 

City, Mexico, 8 Universidad Autónoma de Nuevo León, 

Nuevo León, Mexico, 9 Research Rheumatology Institute 

V.A. Nassonova, Moscow, Russia, 10 St Petersburg 

State Pediatric Medical Academy, St Petersburg, 

Russian Federation, 11 Children’s Hospital of Los 

Angeles and University of Southern California, Los 

Angeles, CA, 12 Randall Children’s Hospital at Legacy 

Emanuel, Portland, OR, 13 Duke University Medical 

Center, Durham, NC, 14 Cleveland Clinic, Pediatric 

Rheumatology, Cleveland, OH, 15 Hospital for Sick 

Children, Toronto, ON, 16 UCB Pharma, Raleigh, NC, 

17 

UCB Pharma, Slough, United Kingdom 

3:15 pm 

948. Subcutaneous Abatacept in Patients with 

Polyarticular-Course Juvenile Idiopathic Arthritis 

and Inadequate Response to Biologic or Non- 

Biologic Disease-Modifying Antirheumatic Drugs: 

Pharmacokinetics, Efficacy and Safety 

DJ Lovell 1 , N Ruperto 2 , N Tzaribachev 3 , G Vega- 

Cornejo 4 , I Louw 5 , A Berman 6 , I Calvo 7 , R Cuttica 8 , 

G Horneff 9 , F Avila-Zapata 10 , J Anton 11 , R Cimaz 12 , E 

Solau-Gervais 13 , R Joos 14 , G Espada 15 , X Li 16 , M Nys 17 , R 

Wong 16 , S Banerjee 16 , Hermine I. Brunner 1 , A Martini 18 

and For Pediatric Rheumatology International Trials 

Organization (PRINTO)/Pediatric Rheumatology 

Collaborative Study Group (PRCSG), 1 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 

2 

Istituto G. Gaslini Pediatria II Reumatologia, Genoa, 

Italy, 3 Pediatric Rheumatology, Bad Bramstedt, 

Germany, 4 Clinica de Rheumatología y Enfermedades 

Autoinmunes (CREA), Hospital México Americano, 

Guadalajara Jalisco, Mexico, 5 Panorama Medical 

Centre, Cape Town, South Africa, 6 Universidad 

Nacional de Tucuman and Centro Médico Privado de 

Reumatología, Tucumán, Argentina, 7 Hospital Univ. La 

Fe, Valencia, Spain, 8 Hospital General de Niños Pedro 

de Elizalde, Buenos Aires, Argentina, 9 Centre Paediatric 

Rheumatology, Asklepios Clinic Sankt Augustin, Sankt 

Augustin, Germany, 10 Star Medica Hospital, Merida, 

Mexico, 11 Hospital Sant Joan de Déu, Barcelona, Spain, 

12 

Ospedale Pediatrico Anna Meyer, Florence, Italy, 

13 

Hôpital de la Miletrie, Poitiers, France, 14 University 

Hospital Gent, Gent, Belgium, 15 Hospital de Ninos Dr 

Ricardo Gutierrez, Buenos Aires, Argentina, 16 Bristol- 

Myers Squibb, Princeton, NJ, 17 Bristol-Myers Squibb, 

Braine-l’Alleud, Belgium, 18 Istituto G. Gaslini Pediatria II 

Reumatologia and University of Genova, Genoa, Italy 


69


Sunday 



3:30 pm 

949. Comparison of Treatment Response, Remission 

Rate and Drug Adherence in Polyarticular 

Juvenile Idiopathic Arthritis Patients Treated with 

Etanercept, Adalimumab or Tocilizumab 

Gerd Horneff 1 , Ariane Klein 2 , Kirsten Minden 3 , Hans- 

Iko Huppertz 4 , Frank Weller-Heinemann 5 , Jasmin 

B. Kuemmerle-Deschner 6 , Johannes Peter Haas 7 

and Toni Hospach 8 , 1 Asklepios Klinik Zentrum für 

Allgemeine Paediatrie und Neonatologie, Sankt 

Augustin, Germany, 2 Asklepios Clinic Sankt Augustin, 

Sankt Augustin, Germany, 3 Children’s University 

Hospital Charite/German Rheumatism Research 

Centre Berlin, Berlin, Germany, 4 Klinikum Bremen- 

Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, 

5 

Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, 

6 

Universitätsklinikum Tübingen, Klinik fuer Kinder- und 

Jugendmedizin, Tübingen, Germany, 7 German Center 

for Pediatric and Adolescent Rheumatology, Garmisch- 

Partenkirchen, Germany, 8 Olgahospital, Klinikum 

Stuttgart, Stuttgard, Germany 

3:45 pm 

950. Flares after Withdrawal of Biotherapies in JIA: 

Clinical and Laboratory Correlates of Remission 

Duration 

Gabriele Simonini 1 , Erika Scoccimarro 1 , Irene Pontikaki 2 , 

Giovanna Ferrara 3 , Teresa Giani 1 , Andrea Taddio 3 , 

Pier Luigi Meroni 4 and Rolando Cimaz 1 , 1 Pediatric 

Rheumatology Unit, Anna Meyer Children’s Hospital- 

University of Florence, Firenze, Italy, 2 Gaetano Pini 

Institute, University of Milan, Milano, Italy, 3 Institute 

for Maternal and Child Health - IRCCS “Burlo Garofolo”, 

University of Trieste, Trieste, Italy, 4 University of Milan, 

Istituto Ortopedico Gaetano Pini, Milano, Italy 

Hall E 

Rheumatoid Arthritis – Small Molecules, Biologics, 

and Gene Therapy I: Treatment Strategies 

Moderators: Howard Fuchs, MD; Roy Fleischmann, MD 

2:30 pm 

951. A Nationwide Non-Medical Switch from 

Originator to Biosimilar Infliximab in Patients with 

Inflammatory Arthritis. Eleven Months’ Clinical 

Outcomes from the Danbio Registry 

Bente Glintborg 1 , Inge Juul Sørensen 2 , Dorte Vendelbo 

Jensen 2 , Niels Steen Krogh 3 , Anne Gitte Loft 4 , Jakob 

Espesen 2 , Jimmi Olsen 2 , Oliver Hendricks 5 , Jolanta 

Grydehøj 2 , Inger Marie Jensen Hansen 2 , Michael 

Veedfald Sørensen 2 , Stavros Chrysidis 2 , Birgitte 

Lange Andersen 2 , Natalia Manilo 2 , Mette Klarlund 2 , 

Lis Smedegaard Andersen 2 , Henrik Nordin 2 , Salome 

Kristensen 2 , Jesper Nørregaard 2 and Merete Lund 

Hetland 1 , 1 Danish Rheumatologic Biobank and DANBIO 

registry, Rigshospitalet, Glostrup, Gentofte and 

Herlev University Hospital, Copenhagen, Denmark, 

2 

The DANBIO registry and the Danish Departments 

of Rheumatology, Copenhagen, Denmark, 3 ZiteLab 

ApS, Copenhagen, Denmark, 4 Departments of 

Rheumatology at Vejle and Aarhus Hospitals, Vejle 

and Aarhus, Denmark, 5 Dep. of Rheumatology, 

King Christians Hospital for Rheumatic Diseases, 

Copenhagen, Denmark 

2:45 pm 

952. A Randomized, Double-Blind, Placebo- 

Controlled Phase 3 Study Evaluating Treatment 

Strategies (Continuation Versus Withdrawal) for 

Maintaining Low Disease Activity after 1 Year of 

Certolizumab Pegol in DMARD-Naive Patients with 

Early and Progressive, Active RA 

Michael Weinblatt 1 , Clifton Bingham III 2 , Gerd-Rüdiger 

Burmester 3 , Vivian P. Bykerk 4 , Daniel E. Furst 5 , Xavier 

Mariette 6 , Désirée van der Heijde 7 , Ronald van 

Vollenhoven 8 , Brenda VanLunen 9 , Cécile Ecoffet 10 , 

Christopher Cioffi 9 and Paul Emery 11 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Johns Hopkins 

University, Baltimore, MD, 3 Charité – University 

Medicine Berlin, Berlin, Germany, 4 Divison of 

Rheumatology, Hospital for Special Surgery, New 

York, NY, 5 David Geffen School of Medicine at UCLA, 

Los Angeles, CA, 6 Université Paris-Sud, Paris, France, 

7 

Leiden University Medical Center, Leiden, Netherlands, 

8 

Amsterdam Rheumatology and Immunology Center 

(ARC), Amsterdam, Netherlands, 9 UCB Pharma, Raleigh, 

NC, 10 UCB Pharma, Brussels, Belgium, 11 University of 

Leeds, Leeds, United Kingdom 


Sunday 




3:00 pm 

953. Comparison of 10-Years Disease Outcomes of 

Rheumatoid Arthritis Patients with Continued Low 

Disease Activity on Methotrexate with or without 

Initial Combination Therapy with Infliximab or 

Prednisone and Sulfasalazine 

SA Bergstra 1 , RBM Landewé 2 , TWJ Huizinga 1 and CF 

Allaart 1 , 1 Department of Rheumatology, LUMC, Leiden, 

Netherlands, Leiden, Netherlands, 2 Amsterdam 

Rheumatology & Immunology Center, Netherlands, 

Amsterdam, Netherlands 

3:15 pm 

954. Effectiveness of Different Dosages of 

Retreatment of Rituximab in Combination 

with Leflunomide: Results from a Multicenter 

Randomized Placebo Controlled Investigator 

Initiated Clinical Trial in Active Rheumatoid 

Arthritis (Amara-Study 

Frank Behrens 1 , Tanja Rossmanith 2 , Michaela Koehm 3 , 

Rieke Alten 4 , Martin Aringer 5 , GR Burmester 6 , Eugen 

Feist 7 , Klaus Krüger 8 , Ulf Müller-Ladner 9 , Andrea 

Rubbert-Roth 10 , Siegfried Wassenberg 11 , Hans- 

Peter Tony 12 , Herbert Kellner 13 , Marina Backhaus 14 

and Harald Burkhardt 1 , 1 Division of Rheumatology 

and Fraunhofer IME-Project-Group Translational 

Medicine and Pharmacology, Goethe University, 

Frankfurt, Germany, 2 Fraunhofer Institute for 

Molecular Biology and Applied Ecology IME, Project 

Group Translational Medicine & Pharmacology TMP, 

Frankfurt, Germany, 3 Division of Rheumatology and 

Fraunhofer IME-Project-Group Translational Medicine 

and Pharmacology, Goethe University, Frankfurt/Main, 

Germany, 4 Schlosspark-Klinik University Medicine, 

Berlin, Germany, 5 Abteilung für Rheumatologie, 

Dresden, Germany, 6 Charité – University Medicine 

Berlin, Berlin, Germany, 7 Charité-Universitätsmedizin 

Berlin, Berlin, Germany, 8 Praxiszentrum St. Bonifatius, 

München, Germany, 9 Justus-Liebig-University Giessen, 

Department of Internal Medicine and Rheumatology, 

Kerckhoff-Klinik, Bad Nauheim, Germany, Bad- 

Nauheim, Germany, 10 Division Rheuamatology, 

University Köln, Köln, Germany, 11 Rheumazentrum, 

Ratingen, Germany, 12 Medical Clinic II, University Clinic 

Wuerzburg, Würzburg, Germany, 13 Rheumatology 

Patient Care, Munchen, Germany, 14 Park-Klinik 

Weissensee, Berlin, Germany 

3:30 pm 

955. Tocilizumab Infusion Intervals Can be 

Extended to 5 or 6 Weeks in RA Patients Who 

Sustained Low Disease Activity By 4 Weeks Interval 

of Tocilizumab Infusion 

Hiroshi Uda and Osamu Saiki, Higashiosaka City 

General Hospital, Higashiosaka, Japan 

3:45 pm 

956. The Effect of Treatment Adjustments Aimed 

at DAS Remission on Physical Functioning in 

Undifferentiated and Rheumatoid Arthritis 

Patients in Low Disease Activity 

SA Bergstra 1 , OM Olivas Vergara 1 , G Akdemir 1 , 

GM Steup-Beekman 2 , HK Ronday 3 , JB Harbers 4 , 

RBM Landewé 5 and CF Allaart 1 , 1 Department of 

Rheumatology, LUMC, Leiden, Netherlands, Leiden, 

Netherlands, 2 Department of Rheumatology, 

Bronovo Hospital, The Hague, Netherlands, The 

Hague, Netherlands, 3 Department of Rheumatology, 

HAGA hospital, The Hague, Netherlands, The Hague, 

Netherlands, 4 Department of Rheumatology, 

Franciscus Hospital, Roosendaal, Netherlands, 

Roosendaal, Netherlands, 5 Amsterdam Medical Center, 


Salon B 

Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment I: Psoriatic 

Arthritis – Treatment 

Moderators: Christopher T. Ritchlin, MD, MPH; Siba P. 

Raychaudhuri, MD 

2:30 pm 

957. International Patient and Physician Consensus 

on Psoriatic Arthritis Outcomes for Clinical Trials 

Ana-Maria Orbai 1 , Maarten de Wit 2 , Philip J Mease 3 , 

Judy A. Shea 4 , Laure Gossec 5 , Ying Ying Leung 6 , William 

Tillett 7 , Musaab Elmamoun 8 , Kristina Callis Duffin 9 , 

Willemina Campbell 10 , Robin Christensen 11 , Laura C. 

Coates 12 , Emma Dures 13 , Lihi Eder 14 , Oliver FitzGerald 15 , 

Dafna D. Gladman 16 , Niti Goel 17 , Suzanne Grieb 18 , 

Sarah Hewlett 19 , Pil Hoejgaard 20 , Umut Kalyoncu 21 , 

Christine Lindsay 22 , Neil J. McHugh 23 , Bev Shea 24 , Ingrid 

Steinkoenig 25 , Vibeke Strand 26 and Alexis Ogdie 4 , 1 Johns 

Hopkins University School of Medicine, Baltimore, 

MD, 2 VU Medical Centre, Amsterdam, Netherlands, 


71


Sunday 



3 

Swedish Medical Center, Seattle, WA, 4 University of 

Pennsylvania, Philadelphia, PA, 5 Paris 06 University, 

Paris, France, 6 North District Hospital, Hong Kong, 

China, 7 Royal National Hospital for Rheumatic Diseases, 

Bath, United Kingdom, 8 St. Vincent’s University 

Hospital, Dublin 4, Ireland, 9 University of Utah, Salt 

Lake City, UT, 10 Toronto Western Hospital, Toronto, ON, 

11 

Musculoskeletal Statistics Unit, The Parker Institute, 

Copenhagen University Hospital, Bispebjerg and 

Frederiksberg, Copenhagen, Denmark, 12 University of 

Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, 

United Kingdom, 13 University of the West of England, 

Bristol, Bristol, United Kingdom, 14 Women’s College 

Research Institute, University of Toronto, Toronto, ON, 

15 

St Vincent’s University Hospital and Conway Institute, 

University College, Dublin, Ireland, 16 Centre for 

Prognosis Studies in the Rheumatic Diseases, Toronto 

Western Hospital and University of Toronto, Toronto, 

ON, 17 Quintiles; Duke University School of Medicine, 

Durham, NC, 18 Center for Child and Community 

Health Research, Baltimore, MD, 19 University of West 

of England, Bristol, United Kingdom, 20 The Parker 

Institute, Bispebjerg and Frederiksberg Hospital, The 

Capital Region of Denmark, Denmark, 21 Johns Hopkins 

University, Baltimore, MD, 22 Amgen Inc, Thousand 

Oaks, CA, 23 Royal National Hospital for Rheumatic 

Diseases, Upper Borough Walls, United Kingdom, 

24 

University of Ottawa, Ottawa, ON, 25 Patient Research 

Partner,, Cleveland, OH, 26 Stanford University, Palo 

Alto, CA 

2:45 pm 

958. Safety and Efficacy of ABT-122, a TNF and 

IL-17–Targeted Dual Variable Domain (DVD)–Ig, 

in Psoriatic Arthritis Patients with Inadequate 

Response to Methotrexate: Results from a Phase 2 

Trial 

Philip J Mease 1 , Mark C. Genovese 2 , Michael Weinblatt 3 , 

Paul M. Peloso 4 , Kun Chen 4 , Yihan Li 4 , Heikki T. 

Mansikka 4 , Amit Khatri 4 , Ahmed A. Othman 4 , Neil 

Wishart 4 , John Liu 4 and Robert J. Padley 4 , 1 Swedish 

Medical Center and University of Washington, Seattle, 

WA, 2 Stanford University Medical Center, Palo Alto, CA, 

3 

Brigham and Women’s Hospital, Boston, MA, 4 AbbVie 

Inc., North Chicago, IL 

3:00 pm 

959. Efficacy and Safety of Ixekizumab in Patients 

with Active Psoriatic Arthritis: 52 Week Results 

from a Phase 3 Study 

Philip J Mease 1 , Masato Okada 2 , Mitsumasa Kishimoto 2 , 

Catherine L. Shuler 3 , Hilde Carlier 3 , Chen-Yen Lin 3 , 

Jiani Mou 3 , Susan R Moriarty 3 , Chin H. Lee 3 and Dafna 

D Gladman 4 , 1 Swedish Medical Center and University 

of Washington, Seattle, WA, 2 St. Luke’s International 

Hospital, Tokyo, Japan, 3 Eli Lilly and Company, 

Indianapolis, IN, 4 University of Toronto, Toronto, ON 

3:15 pm 

960. Ultrasonographic Improvement of Peripheral 

Subclinical Enthesopathy in Therapy-Naive Patients 

Treated with Ustekinumab for Chronic Plaque 

Psoriasis: A 52-Week, Prospective, Open Label, 

Controlled Cohort Study 

Laura Savage 1 , Mark Goodfield 2 , Elizabeth M.A. 

Hensor 3 , Paul Emery 3 and Dennis McGonagle 1 , 

1 

University of Leeds, Leeds, United Kingdom, 2 Leeds 

Teaching Hospitals NHS Trust, Leeds, United Kingdom, 

3 

NIHR-Leeds Musculoskeletal Biomedical Research 

Unit, Leeds, United Kingdom 

3:30 pm 

961. Secukinumab Provides Sustained 

Improvements in the Signs and Symptoms of Active 

Psoriatic Arthritis through 3 Years: Efficacy and 

Safety Results from a Phase 3 Trial 

Philip J Mease 1 , Arthur Kavanaugh 2 , Andreas Reimold 3 , 

Hasan Tahir 4 , Juergen Rech 5 , Stephen Hall 6 , Piet 

Geusens 7 , Pellet Pascale 8 , Evie Maria Delicha 9 , Luminita 

Pricop 10 and Shephard Mpofu 9 , 1 Swedish Medical 

Center and University of Washington, Seattle, WA, 2 UC 

San Diego School of Medicine, La Jolla, CA, 3 Dallas VA 

Medical Center and University of Texas Southwestern 

Medical Center, Dallas, TX, 4 Barts Health NHS Trust, 

London, United Kingdom, 5 Friedrich-Alexander- 

University Erlangen-Nürnberg (FAU), Erlangen, 

Germany, 6 Monash University, Melbourne, Australia, 

7 

University of Hasselt, Hasselt, Belgium, 8 Novartis 

Pharma AG, basel, Switzerland, 9 Novartis Pharma 

AG, Basel, Switzerland, 10 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ 


Sunday 




3:45 pm 

962. No Increased Risk of Inflammatory Bowel 

Disease Among Secukinumab-Treated Patients with 

Moderate to Severe Psoriasis, Psoriatic Arthritis, or 

Ankylosing Spondylitis: Data from 14 Phase 2 and 

Phase 3 Clinical Studies 

Atul A. Deodhar 1 , Stefan Schreiber 2 , Kunal Gandhi 3 , 

Todd Fox 4 , Corine Gaillez 4 and Chetan Karyekar 3 , 

1 

Oregon Health & Science University, Portland, OR, 

2 

Christian-Albrechts-Universität Kiel, Kiel, Germany, 

3 

Novartis Pharmaceuticals Corporation, East Hanover, 

NJ, 4 Novartis Pharma AG, Basel, Switzerland 

Ballroom B 

Systemic Lupus Erythematosus – Clinical 

Aspects and Treatment I: Nephritis 

Moderators: Maureen A. McMahon, MD; Maria Dall’Era, 

MD 

2:30 pm 

963. Treatment of Homocysteine Improves Urine 

Protein/Cr Ratio in SLE 

Wei Fu and Michelle Petri, Johns Hopkins University 

School of Medicine, Baltimore, MD 

2:45 pm 

964. Tubulointerstitial Damage Is an Independent 

Predictor of End Stage Renal Disease in Lupus 

Nephritis Patients with Mild to Moderate Renal 

Impairment 

Bojana Jovanovic 1 , Hina N. Khan 1 , Wenzhu Mowrey 1 , 

Peter M. Izmirly 2 , Daniel Schwartz 1 , Jill P. Buyon 2 , Chaim 

Putterman 1 , Beatrice Goilav 1 and Anna R. Broder 1 , 

1 

Albert Einstein College of Medicine/Montefiore 

Medical Center, New York, NY, 2 New York University 

School of Medicine, New York, NY 

3:00 pm 

965. Clinical and Serologic Variables Associated 

with Renal Response Among Lupus Nephritis Phase 

III Trial Patients Treated with Standard of Care 

Immunosuppression 

Matthew D. Cascino 1 , Peter Lambert 2 , Anna Decker 2 , 

Tamiko Katsumoto 2 , Jay Garg 2 , Paul Brunetta 2 , 

Maria Dall’Era 1 and Leonard L. Dragone 2 , 1 University 

of California, San Francisco, San Francisco, CA, 

2 

Genentech, Inc., South San Francisco, CA 

3:15 pm 

966. Renal Activity in Lupus (RAIL) Urinary 

Biomarkers Predict Treatment Response 

Gaurav Gulati 1 , Michael Bennett 2 , Khalid Abulaban 3 , 

Qing Ma 4 , Marisa S. Klein-Gitelman 5 , Kelly A. Rouster- 

Stevens 6 , Christopher Haffner 4 , Kasha Wiley 7 , Stacy P. 

Ardoin 8 , Jun Ying 1 , Prasad Devarajan 2 and Hermine I. 

Brunner 7 , 1 University of Cincinnati College of Medicine, 

Cincinnati, OH, 2 Cincinnati Children`s Hospital Medical 

Center, Cincinnati, OH, 3 Helen DeVos Children’s 

Hospital, Grand Rapids, MI, 4 Cincinnati Children’s 

Hospital and Medical Center, Cincinnati, OH, 5 Lurie 

Children’s Hospital of Chicago/NW University, Chicago, 

IL, 6 Emory Children’s Center, Atlanta, GA, 7 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 

8 

Ohio State University, Columbus, OH 

3:30 pm 

967. Using a Hazard Index Tool Based on Short Term 

Renal Parameters to Predict Long Term Outcomes 

in Lupus Nephritis: A Novel Way to Assess New 

Therapies 

Meggan Mackay 1 , Joanna Fishbein 1 , Maria Dall’Era 2 , 

Kenneth Kalunian 3 , Martin Lesser 4 and Brad H. 

Rovin 5 , 1 The Feinstein Institute for Medical Research, 

Manhasset, NY, 2 University of California, San Francisco, 

San Francisco, CA, 3 UCSD School of Medicine, La 

Jolla, CA, 4 Feinstein Institute for Medical Reasearch, 

Manhasset, NY, 5 Ohio State University Medical Center, 

Columbus, OH 

3:45 pm 

968. Urinary Soluble CD163, an M2 Macrophage 

Marker, Reflects the Renal Disease Activity in 

Lupus Nephritis: A Cross Sectional and Longitudinal 

Assessment 

Ranjan Gupta, Akhilesh Yadav and Amita Aggarwal, 

Sanjay Gandhi Postgraduate Institute of Medical 

Sciences, Lucknow, India 

151 A 

Systemic Sclerosis, Fibrosing Syndromes, and 

Raynaud’s – Clinical Aspects and Therapeutics I 

Moderators: Ariane L. Herrick, MD, PhD; Susanna 

Proudman 


73


Sunday 



2:30 pm 

969. Safety and Efficacy of Subcutaneous 

Tocilizumab in Early Systemic Sclerosis: Results 

from the Open-Label Period of a Phase 2 

Randomized, Controlled Trial 

Dinesh Khanna 1 , Christopher Denton 2 , Helen 

Spotswood 3 , Angelika Jahreis 4 , Jacob M. van Laar 5 , 

Laura Burke 3 , Celia J. F. Lin 4 , Janet E. Pope 6 , Yannick 

Allanore 7 , Ulf Müller-Ladner 8 , Jeffrey Siegel 3 , Daniel 

E. Furst 9 and faSScinate Clinical Trial Investigators, 

1 

University of Michigan, Ann Arbor, MI, 2 University 

College London, London, United Kingdom, 3 Roche 

Products Ltd., Welwyn Garden City, United Kingdom, 

4 

Genentech, South San Francisco, CA, 5 University 

Medical Center Utrecht, Utrecht, Netherlands, 

6 

University of Western Ontario, St Joseph’s Health Care, 

London, ON, 7 Paris Descartes University, Paris, France, 

8 

Justus-Liebig-University Giessen, Department of 

Internal Medicine and Rheumatology, Kerckhoff-Klinik, 

Bad Nauheim, Germany, Bad-Nauheim, Germany, 

9 

University of California, Los Angeles, Los Angeles, CA 

2:45 pm 

970. The Serotonin Receptor 2 Inhibitor Terguride 

Has Beneficial Effects on Skin Fibrosis: Results from 

a Phase 2 Proof of Concept Study 

Oliver Distler 1 , Britta Maurer 1 , Serena Vettori 2 , Sandra 

Blumhardt 3 , Diana Frey 4 , Alfiya Distler 5 , Christian Beyer 6 

and Joerg HW Distler 7 , 1 Department of Rheumatology, 

University Hospital Zurich, Zurich, Switzerland, 

2 

Rheumatology Unit, Second University of Naples, 

Naples, Italy, 3 USZ, zurich, Switzerland, 4 USZ, Zurich, 

Switzerland, 5 Dept Int Med 3, Univ Erlangen, Erlangen, 

Germany, 6 University of Erlangen-Nuremberg, 

Erlangen, Germany, 7 Friedrich-Alexander-University 

Erlangen-Nürnberg (FAU), Erlangen, Germany 

3:00 pm 

971. Reliability and Minimal Clinically Important 

Differences (MCID) of Forced Vital Capacity: Post- 

Hoc Analyses from the Scleroderma Lung Studies 

(SLS-I and II) 

Suzanne Kafaja 1 , Philip J. Clements 2 , Holly Wilhalme 2 , 

Daniel E. Furst 3 , Chi-hong Tseng 2 , Kim Hyun 4 , Jonathan 

Goldin 2 , Elizabeth R. Volkmann 2 , Michael Roth 2 , 

Donald P. Tashkin 5 and Dinesh Khanna 6 , 1 University 

of California Los Angeles, David Geffen School of 

Medicine, Los Angeles, CA, 2 University of California, 

Los Angeles, David Geffen School of Medicine, Los 

Angeles, CA, 3 David Geffen School of Medicine at UCLA, 

Los Angeles, CA, 4 David Geffen School of Medicine, 

University of California, Los Angeles, Los Angeles, CA, 

5 

University of California, Los Angeles, Los Angeles, CA, 

6 

University of Michigan, Ann Arbor, MI 

3:15 pm 

972. Outcome of the Scleroderma Population 

“at Risk” to Develop Pulmonary Hypertension in 

the Pulmonary Hypertension Assessment and 

Recognition of Outcomes in Scleroderma Cohort 

Study 

Vivien Hsu 1 , Virginia D. Steen 2 and PHAROS 

Investigators, 1 RWJ Med Schl Scleroderma Prog, New 

Brunswick, NJ, 2 Georgetown University Medical Center, 

Washington, DC 

3:30 pm 

973. Clinical Characterization of Patients with 

World Health Organization Group 2 Pulmonary 

Hypertension in the Pulmonary Hypertension 

Assessment and Recognition of Outcomes in 

Scleroderma Cohort 

Jessica K. Gordon 1 , Jackie Szymonifka 1 , Matthew R. 

Lammi 2 , Virginia D. Steen 3 and PHAROS Investigators, 

1 

Hospital for Special Surgery, New York, NY, 2 Louisiana 

State University Health Sciences Center, Pulmonary 

and Critical Medicine, New Orleans, LA, 3 Georgetown 

University Medical Center, Washington, DC 

3:45 pm 

974. Diffuse Scleroderma, Male Sex, and Myopathy 

Are Associated with Severe Gastrointestinal 

Dysmotility in Scleroderma 

Zsuzsanna McMahan 1 , Livia Casciola-Rosen 2 and 

Fredrick M. Wigley 2 , 1 Johns Hopkins University, 

Baltimore, MD, 2 Johns Hopkins University School of 

Medicine, Baltimore, MD 

146 A 

Vasculitis I: Novel Approaches to Therapy 

Moderators: Robert F. Spiera, MD; Sebastian Unizony, 

MD 


Sunday 




2:30 pm 

975. Maintenance Therapy Improves Long-Term 

Outcomes in Patients with Primary Angiitis of the 

Central Nervous System 

Hubert de Boysson 1 , Caroline Arquizan 2 , Grégoire 

Boulouis 3 , Nicolas Gaillard 4 , Alexis Regent 5 , Antoine 

Néel 6 , Olivier Detante 7 , Emmanuel Touzé 8 , Achille 

Aouba 1 , Boris Bienvenu 9 , Loïc Guillevin 10 , Olivier 

Naggara 3 , Mathieu Zuber 11 and Christian Pagnoux 12 , 

1 

Department of Internal Medicine, Caen University 

Hospital, Caen, France, 2 Department of Neurology, 

Hôpital Gui de Chauliac, Université Montpellier, 

Montpellier, France, 3 Department of Neuroradiology, 

Hôpital Sainte-Anne, Paris, France, 4 Department of 

Neurology, CH Perpignan, Perpignan, France, 5 National 

Referral Center for Rare Systemic Autoimmune 

Diseases, Hôpital Cochin, AP–HP, Université Paris 

Descartes, Paris, France, 6 Department of Internal 

Medicine, Nantes University Hospital, Nantes, France, 

7 

Department of Neurology, Centre Hospitalier 

Universitaire de Grenoble, Grenoble, France, 

8 

Department of Neurology, Cane University Hospital, 

CAEN, France, 9 Caen University Hospital, Caen, France, 

10 

Department of Internal Medicine, Referral Center 

for Rare Autoimmune and Systemic Diseases, Hôpital 

Cochin, AP–HP, Université Paris Descartes, Paris, 

France, Paris, France, 11 Department of Neurology, 

Groupe Hospitalier Saint-Joseph, Université Paris 

Descartes, Paris, France, 12 Division of Rheumatology, 

Mount Sinai Hospital, University Health Network, 

University of Toronto, Toronto, Canada, Toronto, ON 

2:45 pm 

976. Efficacy and Safety of Tocilizumab in Patients 

with Refractory Takayasu Arteritis: Results from 

a Randomized, Double-Blind, Placebo-Controlled, 

Phase 3 Trial in Japan 

Yoshikazu Nakaoka 1 , Mitsuaki Isobe 2 , Syuji Takei 3 , 

Yoshiya Tanaka 4 , Tomonori Ishii 5 , Shumpei Yokota 6 , 

Akira Nomura 7 , Seitaro Yoshida 7 and Norihiro 

Nishimoto 8 , 1 National Cerebral and Cardiovascular 

Center Research Institute, Osaka, Japan, 2 Tokyo Medical 

and Dental University, Tokyo, Japan, 3 School of Health 

Sciences, Faculty of Medicine, Kagoshima University, 

Kagoshima, Japan, 4 University of Occupational and 

Environmental Health, Kitakyushu, Japan, 5 Tohoku 

University Graduate School of Medicine, Sendai, Japan, 

6 

Medical Research Institute of Tokyo Medical School, 

Tokyo, Japan, 7 Chugai Pharmaceutical Co., Ltd., Tokyo, 

Japan, 8 Osaka Rheumatology Clinic, Osaka, Japan 

3:00 pm 

977. Tocilizumab As an Add-on Therapy to 

Glucocorticoids during the First 3 Months of 

Treatment of Giant Cell Arteritis: Results of a 

French Multicenter Prospective Open-Label Study 

Maxime Samson 1 , Hervé Devilliers 2 , Kim Heang Ly 3 , 

Francois Maurier 4 , Boris Bienvenu 5 , Benjamin Terrier 6 , 

Pierre Charles 7 , Jean-François Besancenot 2 , Anne- 

Laure Fauchais 8 , Christine Binquet 9 , Sylvain Audia 10 

and Bernard Bonnotte 1 , 1 Department of Internal 

Medicine and Clinical Immunology, Hôpital François 

Mitterrand, CHU de Dijon, Dijon, France, 2 Department 

of Internal Medicine and Systemic Diseases, Hôpital 

François Mitterrand, CHU de Dijon, Dijon, France, 

3 

University Hospital of Limoges, Limoges, France, 

4 

Department of Internal Medicine, HP Metz Belle Isle 

Hospital, Metz, France, 5 Caen University Hospital, Caen, 

France, 6 Cochin University Hospital, Paris, France, 

7 

Department of Internal Medicine, Institut Mutualiste 

Montsouris, Paris, France, 8 Department of Internal 

Medicine, CHU de Limoges, Limoges, France, 9 INSERM, 

CIC 1432, Clinical Epidemiology Unit, Hôpital François 

Mitterrand, CHU de Dijon, Dijon, France, 10 Department 

of Internal Medicine and Clinical Immunology, Hôpital 

François Mitterrand, CHU de Dijon; INSERM, UMR1098, 

University of Bourgogne Franche-Comté, FHU 

INCREASE, Dijon, France 

3:15 pm 

978. A Randomized Clinical Trial of CCX168, an 

Orally Administered C5aR Inhibitor for Treatment 

of Patients with ANCA-Associated Vasculitis 

Peter A. Merkel 1 , John Niles 2 , Richard Jimenez 3 , Robert 

F. Spiera 4 , Brad H. Rovin 5 , Andrew Bomback 6 , Christian 

Pagnoux 7 , Antonia Potarca 8 , Thomas J. Schall 9 and 

Pirow Bekker 9 , 1 Univ of Pennsylvania; Perelman 

School of Med, Philadelphia, PA, 2 Massachusetts 

General Hospital, Boston, MA, 3 The Seattle Arthritis 

Clinic, University of Washington Medicine, Northwest 

Hospital and Medical Center, Seattle, WA, 4 Hospital 

for Special Surgery, Cornell, New York, NY, 5 Ohio State 

University Medical Center, Columbus, OH, 6 Columbia 

University Medical Center, New York, NY, 7 Division of 


75


Sunday 



Rheumatology, Mount Sinai Hospital, University Health 

Network, University of Toronto, Toronto, Canada, 

Toronto, ON, 8 ChemoCentryx, Inc., Mountain View, CA, 

9 

ChemoCentryx, Mountain View, CA 

3:30 pm 

979. A Randomized Double-Blind Trial of Abatacept 

and Glucocorticoids for the Treatment of 

Takayasu’s Arteritis 

Carol A. Langford 1 , David Cuthbertson 2 , Steven 

R. Ytterberg 3 , Nader A. Khalidi 4 , Paul A. Monach 5 , 

Simon Carette 6 , Philip Seo 7 , Larry W. Moreland 8 , 

Michael Weisman 9 , Curry L. Koening 10 , Antoine 

G. Sreih 11 , Robert F. Spiera 12 , Carol A McAlear 11 , 

Kenneth J. Warrington 3 , Christian Pagnoux 6 , Kathleen 

Maksimowicz-McKinnon 8 , Lindsy J. Forbess 9 , Gary S. 

Hoffman 1 , Renee Borchin 2 , Jeffrey Krischer 2 and Peter 

A. Merkel 11 , 1 Cleveland Clinic, Cleveland, OH, 2 University 

of South Florida, Tampa, FL, 3 Mayo Clinic, Rochester, 

MN, 4 McMaster University, St Joseph’s Healthcare 

Hamilton, Hamilton, ON, 5 Boston University School of 

Medicine, Boston, MA, 6 Mount Sinai Hospital, University 

of Toronto, Toronto, ON, 7 Johns Hopkins University, 

Baltimore, MD, 8 University of Pittsburgh, Pittsburgh, 

PA, 9 Cedars-Sinai Medical Center, Los Angeles, CA, 

10 

University of Utah, Salt Lake City, UT, 11 University of 

Pennsylvania, Philadelphia, PA, 12 Hospital for Special 

Surgery, Cornell, New York, NY 

3:45 pm 

980. Short-Course Glucocorticoids in ANCA- 

Associated Vasculitis: A Proof of Concept Study 

Eli Miloslavsky 1 , John Niles 2 , Karen Laliberte 2 , Katherine 

Cosgrove 2 and John H. Stone 3 , 1 Massachusetts 

General Hospital, Harvard Medical School, Boston, 

MA, 2 Massachusetts General Hospital, Boston, MA, 

3 



ARHP SESSIONS 

2:30 pm – 4:00 pm 

204 A 

Digital Health: Optimize Juvenile Idiopathic 

Arthritis: A Self-Management in Youth and 

Young Adults 

PM Ed Pd PS 

PrME 

FIT 

Moderator: Erica Lawson, MD 

2:30 pm 

iCanCope with Pain: User-Centered Design of an 

Integrated Smartphone and Web-Based Pain Self- 

Management Program for Youth and Young Adults 

Speaker: Jennifer N. Stinson, RN-EC, PhD, CPNP 

3:00 pm 

Teens Taking Charge: Online Pain Self-Management 

for Adolescents with Juvenile Idiopathic Arthritis 

Speaker: Mark Connelly, PhD 

3:30 pm 

Online Peer Mentoring for Youth with Juvenile 


Speaker: Lynn R. Spiegel, MDCM, FAAP, FRCPC 

206 

Quality Indicators and Tools: Program 

Evaluation PM PS E 

Moderator: Alison Hoens, BSc(PT), MSc 

2:30 pm 

Making Measurement Meaningful: A Guide to Merit- 

Based and Value-Based Care and Reimbursement 

Speaker: Lisa Gale Suter, MD 

3:00 pm 

Quality Measures and Federal Reporting for 

Rheumatology Practices 

Speaker: Jinoos Yazdany, MD, MPH 

3:30 pm 

Implementing the RISE Registry into your Practice 

Speaker: Robin K. Dore, MD 

209 A 

Rheumatic Disease: Address Anxiety, Anger, 

and Fear 

Moderator: Charmayne M. Dunlop-Thomas, MS, MPH 

2:30 pm 

Emotions Matter: Working with the Powerful 

Emotions of Clients with a New Diagnosis of 

Rheumatoid Arthritis to Support Adaptation and 

Treatment Adherence 

Speaker: Joan Westreich, MSW 


Sunday 



ARHP SESSIONS continued 

3:00 pm 

Exploring and Understanding Patient and Clinician 

Emotional Responses to Chronic Rheumatic Illness: 

Impact on Interventions and Partnerships 

Speaker: Adena Batterman, LCSW, MS 

3:30 pm 

Considerations for Working with Multicultural 

Populations: The Impact of Culture on How Clients 

Express, Experience, and Perceive Emotional 

Responses When Coping with a Chronic Rheumatic 

Illness 

Speaker: Jillian A. Rose, LCSW 

201 

Treating Us Right: Lesbian, Gay, Bisexual, and 

Transgender Considerations 

Moderator: Donah Z. Crawford, BS, MA 

2:30 pm 

Treating Us Right: Part I 

Speaker: Caroline Hill, MSW, LCSW 

3:00 pm 

Treating Us Right: Part II 

Speaker: Barbara Snyder, MD 

3:30 pm 

Panel Discussion with Question and Answer 

ARHP CONCURRENT ABSTRACT SESSION 

2:30 pm – 4:00 pm 

202 B 

ARHP I: Exemplary Abstracts 

Moderator: Karen Huisinga, MN, ARNP, FNP 

2:30 pm 

981. Effectiveness of a Six-Week Hand 

Osteoarthritis Program in a Primary Care Setting 

Nina Brodin 1 , Linda Bjurehed 2 and Mathilda Björk 3 , 

1 

Karolinska Institutet, Huddinge, Sweden, 2 Linköping 

University Hospital, Linköping, Sweden, 3 Linköping 

University, Linköping, Sweden 

2:45 pm 

982. High Financial Strain, but Not Poverty or 

Lower Education, Increases the Risk of Incident 

Depression in Systemic Lupus Erythematosus (SLE) 

Natalie McCormick 1 , Laura Trupin 2 , Edward H. Yelin 2 

and Patricia P. Katz 2 , 1 University of British Columbia/ 

Arthritis Research Canada, Vancouver, BC, 2 University 

of California, San Francisco, San Francisco, CA 

3:00 pm 

983. Objectively Assessed Sedentary Behaviour and 

Light Physical Activity Are Associated with Long- 

Term Cardiovascular Risk in People Living with 

Rheumatoid Arthritis Independently of Moderateto-Vigorous 

Physical Activity 

Sally Fenton 1 , Jet Veldhuijzen van Zanten 2 , George 

D. Kitas 1 , Joan Duda 1 , Peter Rouse 3 , Chen-an Yu 1 

and George Metsios 2 , 1 University of Birmingham, 

Birmingham, United Kingdom, 2 Russells Hall Hospital, 

Dudley Group of Hospitals NHS Foundation Trust, 

Dudley, United Kingdom, 3 University of Bath, Bath, 

United Kingdom 

3:15 pm 

984. Clinical Characteristics of Inflammatory 

Myopathies Associated with Cancer: A Report from 

the Remicam Registry 

Isabel de la Cámara Fernández 1 , Patricia Carreira 2 , 

Beatriz E. Joven 3 , Francisco Javier López Longo 4 , 

Tatiana Cobo-Ibáñez 5 , Leticia Lojo 6 , Carmen Larena 4 , 

Carmen Barbadillo 7 , Julia Martínez-Barrio 8 , Juan Carlos 

Lopez-Robledillo 9 , Paloma Garcia De La Peña 10 , Eva 

Tomero 11 , Irene Llorente 12 , Henry Moruno Cruz 13 , 

Ana Pérez Gómez 13 , Laura Nuño 14 , Raquel Almodóvar 

González 15 , VALENTINA MALDONADO 16 , Lucía Ruiz 

Gutiérrez 13 and MARIA JESUS GARCIA DE YEBENES Y 

PROUS 17 , 1 RHEUMATOLOGY DEPARTMENT. HOSPITAL 

12 DE OCTUBRE, MADRID, Spain, 2 Department 

of Rheumatology, Hospital Universitario 12 de 

Octubre, Madrid, Spain, 3 Hospital Universitario 12 de 

Octubre, Madrid, Spain, 4 Hospital Gregorio Marañón, 

Madrid, Spain, 5 Hospital Universitario Reina Sofía, 

Universidad Europea de Madrid, Madrid, Spain, 

6 

Hospital Universitario La Paz, Spain, Spain, 7 Hospital 

Universitario Puerta de Hierro, Madrid, Spain, 

8 

Hospital General Universitario Gregorio Marañón, 

Madrid, Spain, 9 Hospital Niño Jesus, Madrid, Spain, 


77


Sunday 


ARHP CONCURRENT ABSTRACT SESSION continued 

10 

Hospital Madrid Norte Sanchinarro, Madrid, Spain, 

11 

Hospital La Princesa. Madrid., Madrid, Spain, 12 H.U. 

La Princesa, Madrid, Spain, 13 University Hospital 

Príncipe de Asturias, Immune System Diseases, 

Rheumatology department, Alcalá de Henares, Madrid, 

Spain, 14 Hospital Universitario La Paz, Madrid, Spain, 

15 

Hospital Universitario Fundación Alcorcón, Madrid, 

Spain, 16 RHEUMATOLOGY DEPARTMENT. HOSPITAL 

RAMON Y CAJAL, MADRID, Spain, 17 INSTITUTO DE 

SALUD MUSCULOESQUELÉTICA, MADRID, Spain 

3:30 pm 

985. Effectiveness of a Web-Based Personalized 

Rheumatoid Arthritis Risk Tool with or without a 

Health Educator for Knowledge of RA Risk Factors 

Maria G. Prado 1 , Rachel Miller Kroouze 1 , Zhi Yu 1 , Maura 

D. Iversen 1 , Nellie A. Triedman 1 , Sarah S. Kalia 1 , Kevin 

D. Deane 2 , Karen H. Costenbader 1 , Bing Lu 1 , Robert C. 

Green 1 , Elizabeth W. Karlson 1 and Jeffrey A. Sparks 1 , 

1 


School, Boston, MA, 2 University of Colorado School of 

Medicine, Aurora, CO 

3:45 pm 

986. Sex-Specific Associations Between 

Improvement in Gait Mechanics and Improvement 

in Pain, Function, and Abductor Strength after 

Total Hip Arthroplasty 

J. Heather Brunner and Kharma C. Foucher, University 

of Illinois at Chicago, Chicago, IL 

WORKSHOPS 

4:00 pm – 6:00 pm 










144 A 

212 – Dermatopathology of Rheumatic Diseases 

Speaker: Daniel Miller, MD 

149 A 

213 – Optimizing the Electronic Health 

Record for Maximizing Productivity in the 

Rheumatology Clinic PM PS E 

Speaker: Salahuddin Kazi, MD 

144 C 

214 – Pediatric Musculoskeletal Ultrasound 

Workshop PM Ed Pd PS PrM FIT 


144 B 

215 – Ultrasound Injection Guidance PM PS E 

Speakers: Paul DeMarco, MD; Gurjit S. Kaeley, MBBS, 

MRCP 

ARHP SESSION 

4:30 pm – 5:30 pm 

206 

Interpreting Rheumatologic Lab Tests in 

Pediatrics and Adults PM PS E 

Moderator: Leonard H. Sigal, MD 

4:30 pm 

Principles of Test Interpretation 

Speaker: Amy Nowacki, PhD 

5:00 pm 

Practical Examples of Testing and Interpretation 

Speaker: Brian F. Mandell, MD, PhD 

ACR SESSIONS 

4:30 pm – 6:00 pm 

Hall E 

Curbside Consults: Ask the Professors 

Moderator: Mathilde H. Pioro, MD 

4:30 pm 

Autoimmune Hearing Loss 

Speaker: Michael Ruckenstein, MD 


Sunday 




5:00 pm 

Recurrent Idiopathic Pericarditis 

Speaker: Daniel L. Kastner, MD, PhD 

5:30 pm 

Vascular Ehlers Danlos 

Speaker: Peter Byers, MD 

151 A 

Autoimmunity and the Microbiome 


4:30 pm 

Immune-Microbiota Interactions in Health and 

Disease 

Speaker: Noah Palm, PhD 

5:15 pm 

The Microbiota in Rheumatic Diseases 

Speaker: Martin Kriegel, MD, PhD 

Hall D 

Treatment of Osteoarthritis Using Cell Based 

Therapy: Beyond the Internet and News 

Magazines 

PM PS PME 

PS E 

Moderators: Jasvinder A. Singh, MD, MPH; Kevin Byram, 

MD 

4:30 pm 

Platelet Rich Plasma: Is It Better Than Corticosteroids 

and Hyaluronic Acid? 

Speaker: Joel Block, MD 

5:00 pm 

Stem Cells for the Treatment of Osteoarthritis: Are 

We There Yet? 

Speaker: David T. Felson, MD, MPH 

5:30 pm 

Chondrocyte Transplant and Injections: What Is the 

Evidence? 

Speaker: Andreas Gomoll, MD 


4:30 pm – 6:00 pm 

Salon G 

Epidemiology and Public Health I: Inflammatory 

Arthritis – Risk and Impact 

Moderators: Yvonne C. Lee, MD, MMSc; Maureen 

Dubreuil, MD 

4:30 pm 

987. Pesticide Exposure and Risk of Rheumatoid 

Arthritis in Licensed Male Pesticide Applicators in 

the Agricultural Health Study 

Armando Meyer 1 , Dale Sandler 2 , Laura Beane- 

Freeman 3 , Jonathan Hoffman 4 and Christine G. 

Parks 5 , 1 Federal University of Rio de Janeiro, Rio de 

Janeiro, Brazil, 2 NIH/NIEHS, Research Triangle Park, 

NC, 3 Division of Cancer Epidemiology and Genetics, 

National Cancer Institute,, Bethesda, MD, 4 Division of 

Cancer Epidemiology and Genetics, National Cancer 

Institute, National Institutes of Health, Bethesda, 

MD, 5 Epidemiology Branch, National Institute of 

Environmental Health Sciences, NIH, Durham, NC 

4:45 pm 

988. Risk of Rheumatoid Arthritis after 

Transfusion of Blood from Donors Later Diagnosed 

with Rheumatoid Arthritis: A Retrospective Cohort 

Study 

Søren Andreas Just 1 , Kjell Titlestad 2 , Gustaf 

Edgren 3 , Klaus Rostgaard 4 , Johan Askling 5 , Hanne 

Lindegaard 1 and Henrik Hjalgrim 4 , 1 Department of 

Rheumatology, Odense University Hospital, Odense, 

Denmark, Odense, Denmark, 2 Department of Clinical 

Immunology, Odense Unversity Hospital, Odense, 

Denmark, Odense, Denmark, 3 Department of Medical 

Epidemiology and Biostatistics, Karolinska Institutet, 

Stockholm, Sweden, Stockholm, Sweden, 4 Department 

of Epidemiology Research, Statens Serum Institut, 

Copenhagen, Denmark, Copenhagen, Denmark, 

5 

Clinical Epidemiology Unit, Department of Medicine, 

Karolinska Institutet, Stockholm, Sweden, Stockholm, 

Sweden 


79


Sunday 



5:00 pm 

989. A Randomized Controlled Trial of Rheumatoid 

Arthritis Risk Disclosure Personalized to Genetics, 

Autoantibodies, and Lifestyle Among Unaffected 

First-Degree Relatives: The Personalized Risk 

Estimator for RA (PRE-RA) Family Study 

Jeffrey A. Sparks 1 , Maura D. Iversen 2 , Zhi Yu 1 , Nellie A. 

Triedman 1 , Maria G. Prado 1 , Rachel Miller Kroouze 1 , 

Sarah S. Kalia 1 , Elinor A. Mody 1 , Simon M. Helfgott 1 , 

Derrick J. Todd 1 , Paul F. Dellaripa 1 , Bonnie L. Bermas 1 , 

Kevin D. Deane 3 , Karen H. Costenbader 1 , Bing Lu 1 , 

Robert C. Green 1 and Elizabeth W. Karlson 1 , 1 Brigham 

and Women’s Hospital and Harvard Medical School, 

Boston, MA, 2 Northeastern University, Boston, MA, 

3 

University of Colorado School of Medicine, Aurora, CO 

5:15 pm 

990. Autoimmunity to Multiple Antigens Is 

Expanded in At-Risk Family Members Beyond the 

Disease Specific Patterns of the SLE or RA Proband 

Judith A. James 1 , Krista M. Bean 1 , Hua Chen 1 , Kendra 

A. Young 2 , Elizabeth A. Bemis 3 , Jennifer Seifert 4 , Maria 

Sargent 1 , Kevin D. Deane 5 , Bill Robinson 6 , David A. 

Hafler 7 , Kevin O’Conner 8 , Jane H. Buckner 9 , Joel M. 

Guthridge 1 , Jill M. Norris 2 and V. Michael Holers 5 , 

1 

Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 2 University of Colorado Denver, Aurora, 

CO, 3 Colorado School of Public Health, Aurora, CO, 

4 

University of Colorado, Denver, CO, 5 University of 

Colorado School of Medicine, Aurora, CO, 6 Stanford 

University School of Medicine, Stanford, CA, 7 Yale 

School of Medicine, New Haven, CT, 8 Yale University, 

New Haven, CT, 9 Benaroya Research Institute at 

Virginia Mason, Seattle, WA 

5:30 pm 

991. Familial Aggregation of Rheumatoid Arthritis 

in Sarcoidosis: A Register-Based Case-Control Study 

in Sweden 

Elizabeth V. Arkema, Karolinska Institutet, Stockholm, 

Sweden 

5:45 pm 

992. The Impact of Inflammatory Arthritis 

(rheumatoid arthritis, spondyloarthritis, psoriatic 

arthritis, reactive arthritis) on Maternal and 

Neonatal Outcomes: A Population-Level Analysis 

Stephanie Keeling 1 , Anamaria Savu 2 and Padmaja Kaul 3 , 

1 

Division of Rheumatology, Edmonton, AB, 2 Canadian 

Vigour Center, Edmonton, AB, 3 University of Alberta, 

Edmonton, AB 

150 A 

Fibromyalgia, Soft Tissue Disorders, Regional 

and Specific Clinical Pain Syndromes 

Moderators: Jacob N. Ablin; Kim D. Jones, PhD 

4:30 pm 

993. Chronic Widespread Pain Associated with 

Premature Mortality in a UK National Prospective 

Study 

Gary J. Macfarlane 1 and Gareth T. Jones 2 , 1 University 

of Aberdeen, Aberdeen, United Kingdom, 2 Aberdeen 

Centre for Arthritis and Musculoskeletal Health, 

University of Aberdeen, Aberdeen, United Kingdom 

4:45 pm 

994. Validation Studies of the American College of 

Rheumatology (ACR) 2010 Fibromyalgia Diagnostic 

Criteria and the 2011 Self-Report Modification for 

Survey and Clinical Research 

Frederick Wolfe 1 , Daniel J. Clauw 2 , MaryAnn 

FitzCharles 3 , Don Goldenerberg 4 , Winfried Häuser 5 , 

Robert S. Katz 6 , Philip J. Mease 7 , Anthony Russell 8 , I 

Jon Russell 9 and Brian Walitt 10 , 1 National Data Bank, 

Wichita, KS, 2 University of Michigan, Ann Arbor, MI, 

3 

McGill University, Montreal, QC, 4 Newton-Wellesley 

Hospital and Tufts University School of Medicine, 

Newton, MA., Newton, MA, 5 Technische Universität 

München, Munich, Germany, 6 Rush University Medical 

Center, Chicago, IL, 7 Swedish Medical Center and 

University of Washington, Seattle, WA, 8 University of 

Alberta, Edmonton, AB, 9 Arthritis & Osteoporosis Ctr 

of South Texas, San Antonio, TX, 10 National Institute of 

Nursing Research, Bethesda, DC 

5:00 pm 

995. Use of Opiate Diminished the Treatment 

Benefits of Motivational Interviewing for 

Fibromyalgia 

Dennis Ang 1 and James Slaven 2 , 1 Wake Forest 

University, Winston-Salem, NC, 2 Indiana University, 

Indianapolis, IN 


Sunday 




5:15 pm 

996. Use of a Shared Medical Appointment for 

Patients with Fibromyalgia in a Rural, Academic 

Medical Center: A Process Improvement Initiative 

for the Development of a New Care Model 

Nicole M. Orzechowski 1 , Debra Lloyd 2 , Katherine 

Tuthill 1 , Julie Puttgen 1 and Rachael Bergeron 1 , 

1 

Dartmouth Hitchcock Medical Center, Lebanon, NH, 

2 

Dartmouth-Hitchcock Med Ctr, Lebanon, NH 

5:30 pm 

997. 2016 Revisions to the 2010/2011 Fibromyalgia 

Diagnostic Criteria 

Frederick Wolfe 1 , Daniel J. Clauw 2 , MaryAnn 

FitzCharles 3 , Don Goldenerberg 4 , Winfried Häuser 5 , 

Robert S. Katz 6 , I Jon Russell 7 , Philip J. Mease 8 , Anthony 

Russell 9 and Brian Walitt 10 , 1 National Data Bank, 

Wichita, KS, 2 University of Michigan, Ann Arbor, MI, 

3 

McGill University, Montreal, QC, 4 Newton-Wellesley 

Hospital and Tufts University School of Medicine, 

Newton, MA., Newton, MA, 5 Technische Universität 

München, Munich, Germany, 6 Rush University Medical 

Center, Chicago, IL, 7 Arthritis & Osteoporosis Ctr of 

South Texas, San Antonio, TX, 8 Swedish Medical Center 

and University of Washington, Seattle, WA, 9 University 

of Alberta, Edmonton, AB, 10 National Institute of 

Nursing Research, Bethesda, DC 

5:45 pm 

998. Brain Responses to Other’s Pain in 

Fibromyalgia – A Magnetoencephalography 

(MEG) Study 

Abraham Goldstein 1 , Maor Wolf 2 and Jacob N. Ablin 3 , 

1 

Bar-Ilan University, Ramat Gan, Israel, 2 Bar-Ilan 

University, Ramat - Gan, Israel, 3 Tel Aviv Sourasky 

Medical Center, Tel Aviv, Israel 

140 A 

Infection-Related Rheumatic Disease 

Moderator: Luis R. Espinoza, MD 

4:30 pm 

999. Utility of Neutrophil CD64 Expression & 

sTREM-1 in Distinguishing Bacterial Infection from 

Disease Flare in SLE and ANCA Associated Vasculitis 

Sajal Ajmani, Harshit Singh, Saurabh Chaturvedi, 

Mohit kumar Rai and Vikas Agrawal, Sanjay Gandhi 

Postgraduate Institute of Medical Sciences, Lucknow, 

India 

4:45 pm 

1000. Subclinical Cytomegalovirus Viremia Is 

Associated with Increased Nosocomial Infections 

and Prolonged Hospitalization in Patients with 

Systemic Autoimmune Diseases 

John McKinnon, Junying Zhou, Jenna Hudy, Sara Hegab 

and Kathleen Maksimowicz-McKinnon, Henry Ford 

Hospital, Detroit, MI 

5:00 pm 

1001. Cytomegalovirus Reactivation in Connective 

Tissue Disease By Immunosuppressive Therapy 

Predicts Severe Infection and High Mortality 

Yuichiro Ota 1 , Yuko Kaneko 1 and Tsutomu Takeuchi 2 , 

1 

Keio University School of Medicine, Tokyo, Japan, 

2 

Division of Rheumatology, Keio University School of 

Medicine, Tokyo, Japan 

5:15 pm 

1002. Pneumocystis Jiroveci in Rheumatic Disease: 

A 20 Year Single-Center Experience 

Christopher A. Mecoli, Deanna Saylor, Allan C. Gelber 

and Lisa Christopher-Stine, Johns Hopkins University 

School of Medicine, Baltimore, MD 

5:30 pm 

1003. Ultrasonography Changes During the Course 

of Septic Arthritis ARE Associated with Functional 

Outcome 

Emeline Gaigneux 1 , Grégoire Cormier 2 , Oriane Merot 3 , 

Yves Maugars 1 and Benoit Le Goff 1 , 1 Nantes University 

Hospital, Nantes, France, 2 Hospital, La roche sur Yon, 

France, 3 Hospital, Saint Nazaire, France 

5:45 pm 

1004. Herpes Zoster Virus Infection in Patients 

Treated with Biological Therapies (BIOBADASAR) 

Juan Pablo Pirola 1 , Soledad Retamozo 2 , Diego Baenas 1 , 

Alejandro Alvarellos 3 , Francisco Caeiro 1 , María Celina 

De La Vega 4 , Gustavo Casado 5 , Gimena Gomez 4 , Javier 

Roberti 4 , Osvaldo Luis Cerda 6 , Maria de los Angeles 

Gallardo 7 , Ana Quinteros 8 , Ida Exeni 9 , Juan Manuel 

Bande 10 , Pablo Astesana 11 , Analia Alvarez 12 , Amelia 

Granel 13 , Alejandra Peluzzon 14 , Ana Capuccio 15 , Romina 

Nieto 16 , Rossana Quintana 17 , Eduardo Mussano 18 , 

Santiago Scarafia 19 , Carolina Costi 20 , Mercedes De La 

Sota 21 , Monica Patricia Diaz 22 , Edson Javier Velozo 23 , 

Santiago Aguero 24 , Cristina Battagliotti 25 , Sidney Soares 


81


Sunday 



de Souza 26 , Emilia Cavillon 27 , Analia Bohr 28 , Andrea 

Smichowski 29 , Alejandro Benitez 30 , Daniela Vidal 31 , 

Dora Pereira 32 , Liliana Martinez 33 , Luis Somma 34 , Marta 

Zalazar 35 , Pablo Finucci Curi 36 , Leandro Carlevaris 37 , 

Guillermo Berbotto 38 and Veronica Saurit 1 , 1 Hospital 

Privado Centro Médico de Córdoba, Córdoba, 

Argentina, 2 Rheumatology Unit, Hospital Privado 

Centro Médico de Córdoba, Argentina, Córdoba, 

Argentina, 3 Hospital Privado Centro Médico de 

Córdoba, Cordoba, Argentina, 4 SAR, CABA, Argentina, 

5 

Sociedad Argentina de Reumatologia, CABA, 

Argentina, 6 IREP, CABA, Argentina, 7 Hospital Italiano 

de Buenos Aires, CABA, Argentina, 8 Centro Integral 

Reumatológico, Tucuman, Argentina, 9 Sanatorio 

Parque, Córdoba, Argentina, 10 Hospital Tornú, CABA, 

Argentina, 11 Sanatorio Allende, Cordoba, Argentina, 

12 

Hospital Penna, Bahía Blanca, Argentina, 13 Centro 

Platense de Reumatología, La Plata, Argentina, 

14 

Hospital Clínica José de San Martín, CABA, Argentina, 

15 

Hospital Cesar Milstein, CABA, Argentina, 16 Hospital 

Provincial, Rosario, Argentina, 17 Sanatorio Parque, 

Rosario, Argentina, 18 Hospital Nacional de Clínicas, 

Córdoba, Argentina, 19 Hospital Bernardino Rivadavia, 

CABA, Argentina, 20 Hospital San Martín, LaPlata, 

Argentina, 21 Consultorios, Bahia Blanca, Argentina, 

22 

Hospital Zonal Bariloche, Bariloche, Argentina, 

23 

Sanatorio Adventista del Plata, Entre Rios, Argentina, 

24 

Sanatorio Pasteur, Catamarca, Argentina, 25 Hospital 

de Niños Dr Orlando Alasia, Santa Fé, Argentina, 

26 

REUMAR, CABA, Argentina, 27 Consultorio, Cordoba, 

Argentina, 28 Hospital de Rehabilitación Rocca, CABA, 

Argentina, 29 Atención Integral de Reumatología, 

CABA, Argentina, 30 CEIM, CABA, Argentina, 31 Hospital 

de Niños de Córdoba, Córdoba, Argentina, 32 Centro 

Raquis, Buenos Aires, Argentina, 33 Hospital Fernandez, 

CABA, Argentina, 34 SOMMA, Buenos Aires, Argentina, 

35 

Hospital Pirovano, CABA, Argentina, 36 Centro Médico 

Mitre, Entre Rios, Argentina, 37 IARI, CABA, Argentina, 

38 

Sanatorio Británico, Rosario, Argentina 

146 A 

Innate Immunity and Rheumatic Disease 

Moderators: J. Michelle Kahlenberg, MD, PhD; Ranjeny 

Thomas 

4:30 pm 

1005. Biallelic Hypomorphic Mutations in a Linear 

Deubiquitinase Define Otulipenia, an Early-Onset 

Systemic Autoinflammatory Disease 

Qing Zhou 1 , Xiaomin Yu 2 , Erkan Demirkaya 3 , Natalie 

Deuitch 4 , Deborah L. Stone 4 , Wanxia L. Tsai 5 , Hongying 

Wang 1 , Yong Hwan Park 1 , Amanda K. Ombrello 6 , Tina 

Romeo 4 , Elaine F. Remmers 4 , JaeJin Chae 4 , Massimo 

G. Gadina 7 , Steven B. Welch 8 , Seza Ozen 9 , Rezan 

Topaloglu 9 , Mario Abinun 10 , Daniel L. Kastner 1 and 

Ivona Aksentijevich 6 , 1 National Human Genome 

Research Institute, Bethesda, MD, 2 National Institute 

of Allergy and Infectious Diseases, Bethesda, MD, 

3 

Gulhane Military Medical Academy, FMF Arthritis 

Vasculitis and Orphan disease Research Center 

(FAVOR), Ankara, Turkey, 4 National Human Genome 

Research Institute, National Institutes of Health, 

Bethesda, MD, 5 National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, Bethesda, 

MD, 6 National Institutes of Health, Bethesda, MD, 

7 

gadinama@mail.nih.gov, Bethesda, MD, 8 Heart of 

England NHS Foundation Trust, Birmingham, United 

Kingdom, 9 Hacettepe University Faculty of Medicine, 

Ankara, Turkey, 10 Institute of Cellular Medicine, 

Newcastle University, Newcastle, United Kingdom 

4:45 pm 

1006. Immune Complex-Mediated TLR8 Activation 

Shifts Neutrophils from Phagocytosis to Netosis 

through Furin-Dependent Shedding of Fcgriia 

Christian Lood, Sabine Arve, Laura Durcan, Jeffrey 

Ledbetter and Keith B. Elkon, University of Washington, 

Seattle, WA 

5:00 pm 

1007. Interferon Regulatory Factor 1 Is the Key 

Driver of Inflammasome Activity in Systemic Lupus 

Erythematosus 

Jianhua Liu 1 and J. Michelle Kahlenberg 2 , 1 University of 

Michigan, Ann Arbor, MI, 2 Division of Rheumatology, 

University of Michigan Medical Center, Ann Arbor, MI 

5:15 pm 

1008. Advantageous Effect of an Endogenous 

Retroviral Envelope Protein in Systemic Lupus 

Erythematosus with Ex Vivo and In Vivo Anti- 

Inflammatory Potential 

Anne Troldborg 1 , Magdalena Janina Laska 1 , Ellen- 


Sunday 




Margrethe Hauge 1 , Shervin Bahrami 1 and Kristian 

Stengaard-Pedersen 2 , 1 Aarhus University, Aarhus, 

Denmark, 2 Department of Rheumatology, Aarhus 

University Hospital, Aarhus, Denmark 

5:30 pm 

1009. Plasmacytoid Dendritic Cells Are Activated in 

Systemic Sclerosis and Contribute to the Disease By 

Inducing Ifnα and CXCL4 

Marie-Dominique Ah Kioon 1 , Eliza Pelrine 1 , Robert 

F. Spiera 2 , Jessica K. Gordon 1 and Franck J. Barrat 1 , 

1 

Hospital for Special Surgery, New York, NY, 2 Hospital 

for Special Surgery, Cornell, New York, NY 

5:45 pm 

1010. Elucidating the Activation Profile of Systemic 

Sclerosis Macrophages 

Michael S. Ball 1 , Emilie P. Shipman 1 , Mohamed 

A. Eltanbouly 1 , Viktor Martyanov 1 , Kimberly A. 

Archambault 1 , Mary A. Carns 2 , Esperanza Arroyo 2 , 

Kathleen Aren 2 , Monique Hinchcliff 3 , Michael L. 

Whitfield 1 and Patricia A. Pioli 1 , 1 Geisel School of 

Medicine at Dartmouth, Hanover, NH, 2 Northwestern 

University, Chicago, IL, 3 Northwestern University, 

Feinberg School of Medicine Scleroderma Program, 

Chicago, IL 

143 A 

Muscle Biology, Myositis, and Myopathies I 

Moderators: Wael Jarjour, MD; Dawn Wahezi, MD, MS 

4:30 pm 

1011. Correlations Between B Cell Epitope 

Specificity and Clinical Features in Patients with 

Jo-1 Antibodies and the Anti-Synthetase Syndrome 

Joseph LaConti 1 , Fanny Kippelen 2 , Rohit Aggarwal 3 

and Dana P. Ascherman 1 , 1 University of Miami Miller 

School of Medicine, Miami, FL, 2 Children’s Hospital of 

Philadelphia, Philadelphia, PA, 3 University of Pittsburgh 

Medical Center, Pittsburgh, PA 

4:45 pm 

1012. Exploratory Effects of REGN1033, a Human 

Monoclonal Antibody Specific to Myostatin, in a 

Subset of Patients with Sporadic Inclusion Body 

Myositis 

Kumaraswamy Sivakumar 1 , Stephen Donahue 2 , Rinal 

Patel 2 , Shazia Ali 2 , Richard Kao 2 and Robert Pordy 2 , 

1 

Arizona Neurological Research Center, Scottsdale, AZ, 

2 

Regeneron Pharmaceuticals, Inc., Tarrytown, NY 

5:00 pm 

1013. The Risk of Colchicine Associated Myopathy in 

Gout: Influence of Concomitant Use of Statin 

Oh Chan Kwon 1 , Byeongzu Ghang 2 , Seokchan Hong 3 , 

Yong-Gil Kim 4 , Chang-Keun Lee 3 and Bin Yoo 4 , 

1 

University of Ulsan College of Medicine, Asan Medical 

Center, Seoul, Korea, The Republic of, 2 Univerisy of 

Ulsan College of Medicine, Asan Medical Center, Seoul, 

South Korea, 3 University of Ulsan College of Medicine, 

Asan Medical Center, Seoul, South Korea, 4 University of 

Ulsan Collage of Medicine, Asan Medical Center, Seoul, 

South Korea 

5:15 pm 

1014. Juvenile Dermatomyositis: What Comes Next? 

Christina A. Boros 1 , Liza J. McCann 2 , Nicola Ambrose 3 , 

Mario Cortina-Borja 4 , Stephanie Simou 4 , Clarissa 

Pilkington 4 and Lucy R Wedderburn 5 , 1 UCL INstiute of 

Chuld Health, London, United Kingdom, 2 Alder Hey 

Children’s NHS Foundation Trust, Liverpool, United 

Kingdom, 3 Imperial College, London, United Kingdom, 

4 

UCL Institute of Child Health, London, United 

Kingdom, 5 Paediatric Rheumatology Department, 

Great Ormond Street Hospital for Children NHS Trust, 

London, United Kingdom 

5:30 pm 

1015. Pro-Inflammatory Cytokines Produced By 

Different Subsets of Peripheral Blood Mononuclear 

Cells Are Associated with Ro52/TRIM21 Deficiency 

in Patients with Inflammatory Myopathies 

Ana Barrera-Vargas, Angeles Shunashy Galindo-Feria, 

Diana Gómez-Martín, Javier Merayo-Chalico and Jorge 

Alcocer-Varela, Instituto Nacional de Ciencias Médicas y 

Nutrición Salvador Zubirán, Mexico City, Mexico 

5:45 pm 

1016. Soluble BAT-3: A New Biomarker for 

Antisynthetase Syndrome 

Baptiste Hervier 1 , Samra Ouaras 1 , Laurent Gilardin 2 , 

Hanane Ouakrim 3 , Damien Amelin 4 , Fleur Cohen 5 , 

Yurdagul Uzunhan 6 , Yves Allenbach 7 , Anne Bourgarit- 

Durand 8 , Olivier Benveniste 7 and Vincent Vieillard 9 , 

1 

INSERM & UPMC, Paris, France, 2 APHP, Hôpital Pitié 

Salpêtrière, Paris, France, 3 INSERM UMR-S 1138, Centre 

des cordeliers & APHP, Cochin Hospital, Laboratory 

of Pathology, Paris, France, 4 Sorbonne Universités 

UPMC Univ Paris 06, Myology research center, INSERM 

ACRannualmeeting.org 83


Sunday 



UMRS974, CNRS FRE3617, Pitié-Salpêtrière University 

Hospital, Paris, France, Paris, France, 5 Hôpital Pitié- 

Salpêtrière, AP-HP, UPMC Univ Paris 06 & French 

National Reference Center For Systemic Lupus and 

Antiphospholipid Syndrome, Paris, France, 6 Avicenne 

Hospital (AP-HP), Bobigny, France, 7 Pitié-Salpêtrière 

University Hospital, Paris, France, 8 CHU Bondy, Bondy, 

France, 9 INSERM 543, Paris, France 

Ballroom C 

Osteoarthritis – Clinical Aspects I: Epidemiology 

and Progression 

Moderators: Philip G. Conaghan; Francis Berenbaum, 

MD, PhD 

4:30 pm 

1017. Statistical Simulation Using Data from the 

Foundation for the National Institute of Health/ 

Osteoarthritis Initiative Biomarkers Consortium 

to Evaluate the Clinical Utility of Prognostic Knee 

Osteoarthritis Biomarkers in Designing a Knee 

Osteoarthritis Clinical Trial 

Sheng Feng, Zheng (Roger) Liu, Feng Hong, Jeroen 

Medema, Rajesh Kamath and Marc C. Levesque, 

AbbVie Bioresearch Center, Worcester, MA 

4:45 pm 

1018. Dietary Intake of Fiber and Risk of Knee 

Osteoarthritis 

Zhaoli (Joy) Dai 1 , Jingbo Niu 1 , Yuqing Zhang 1 , Paul 

Jacques 2 and David T. Felson 1 , 1 Boston University 

School of Medicine, Boston, MA, 2 Jean Mayer USDA 

Human Nutrition Research Center on Aging and 

Friedman School of Nutrition Science and Policy, Tufts 

University, Boston, Boston, MA 

5:00 pm 

1019. The Impact of Hip and Knee Osteoarthritis 

on the Subsequent Risk of Incident Diabetes: A 

Population-Based Cohort Study 

Tetyana Kendzerska 1 , Lauren King 1 , Ruth Croxford 2 , Ian 

Stanaitis 3 , Angela Wall 3 and Gillian Hawker 1 , 1 University 

of Toronto, Toronto, ON, 2 Institute for Clinical 

Evaluative Sciences, Toronto, ON, 3 Women’s College 

Research Institute/Women’s College Hospital, Toronto, 

ON 

5:15 pm 

1020. Risk Factors Can Classify Individuals Who 

Develop Accelerated Knee Osteoarthritis 

Jeffrey Driban 1 , Timothy E. McAlindon 1 , Mamta Amin 2 , 

Lori Lyn Price 1 , Charles B. Eaton 3 , Julie Davis 1 , Bing Lu 4 , 

Grace H. Lo 5 , Jeffrey Duryea 6 and Mary Barbe 2 , 1 Tufts 

Medical Center, Boston, MA, 2 Temple University School 

of Medicine, Philadelphia, PA, 3 Alpert Medical School of 

Brown University, Pawtucket, RI, 4 Brigham & Women’s 

Hospital and Harvard Medical School, Boston, MA, 

5 

Baylor College of Medicine, Houston, TX, 6 Brigham & 

Women’s Hospital/ Harvard Medical School, Boston, 

MA 

5:30 pm 

1021. Maintaining Sufficient Serum Vitamin D 

Levels over 2 Years Is Associated with Reduced 

Knee Structural and Symptomatic Changes in 

Patients with Knee Osteoarthritis 

Shuang Zheng 1 , Xingzhong Jin 1 , Flavia M Cicuttini 2 , Xia 

Wang 1 , Zhaohua Zhu 1 , Anita E Wluka 3 , Weiyu Han 1 , 

Tania Winzenberg 1 , Leigh Blizzard 1 , Graeme Jones 1 

and Changhai Ding 1 , 1 Menzies Institute for Medical 

Research, University of Tasmania, Hobart, Australia, 

2 

Monash University, Department of Epidemiology and 

Preventive Medicine, Melbourne, Australia, 3 Australia, 

Armadale, Australia 

5:45 pm 

1022. The Risk of Symptomatic Knee Osteoarthritis 

after Arthroscopic Meniscus Repair vs. Partial 

Meniscectomy vs. the General Population 

Martin Englund 1 , Aleksandra Turkiewicz 2 , Dan 

Bergkvist 3 , Paul Neuman 4 and Fredrik Persson 4 , 1 Lund 

University, Skåne University Hospital, Department of 

Clinical Sciences Lund, Orthopedics, Lund, Sweden, 

2 

Lund University, Department of Clinical Sciences Lund, 

Orthopedics, Lund, Sweden, 3 Orthopedics, Department 

of Clinical Sciences Lund, Lund University, Lund, 

Sweden, 4 Lund University, Skåne University Hospital, 

Orthopedics, Malmoe, Sweden 

145 A 

Osteoporosis and Metabolic Bone Disease – 

Clinical Aspects and Pathogenesis 

Moderators: Stephen Honig; Stephen Smiles 


Sunday 




4:30 pm 

1023. Fracture Risk Reduction with Romosozumab: 

Results of a Phase 3 Study in Postmenopausal 

Women with Osteoporosis 

F Cosman 1 , DB Crittenden 2 , JD Adachi 3 , N Binkley 4 , 

E Czerwinski 5 , S Ferrari 6 , LC Hofbauer 7 , E Lau 8 , EM 

Lewiecki 9 , A Miyauchi 10 , CAF Zerbini 11 , CE Milmont 2 , 

L Chen 2 , J Maddox 2 , PD Meisner 12 , C Libanati 12 and 

A Grauer 2 , 1 Helen Hayes Hospital, West Haverstraw, 

and Columbia University, New York, NY, 2 Amgen Inc., 

Thousand Oaks, CA, 3 McMaster University, Hamilton, 

ON, 4 University of Wisconsin–Madison Osteoporosis 

Clinical Center and Research Program, Madison, WI, 

5 

Krakow Medical Center, Krakow, Poland, 6 Geneva 

University Hospital, Geneva, Switzerland, 7 Division 

of Endocrinology, Diabetes, and Bone Diseases, TU 

Dresden Medical Center, Dresden, Germany, 8 Center 

for Clinical and Basic Research, Hong Kong, China, 

9 

New Mexico Clinical Research & Osteoporosis Center, 

Albuquerque, NM, 10 Miyauchi Medical Center, Osaka, 

Japan, 11 Centro Paulista de Investigação Clinica, São 

Paulo, Brazil, 12 UCB Pharma, Brussels, Belgium 

4:45 pm 

1024. Superior Gains in Bone Mineral Density and 

Estimated Strength at the Hip for Romosozumab 

Compared with Teriparatide in Women with 

Postmenopausal Osteoporosis Transitioning from 

Bisphosphonate Therapy: Results of a Phase 3, 

Open-Label Clinical Trial 

B Langdahl 1 , C Libanati 2 , DB Crittenden 3 , MA 

Bolognese 4 , JP Brown 5 , NS Daizadeh 3 , K Engelke 6 , 

HK Genant 7 , S Goemaere 8 , Lars Hyldstrup 9 , E Jodar- 

Gimeno 10 , TM Keaveny 11 , D Kendler 12 , P Lakatos 13 , J 

Maddox 3 , J Malouf 14 , FE Massari 15 , JF Molina 16 , MR Ulla 17 

and A Grauer 3 , 1 Aarhus University Hospital, Aarhus, 

Denmark, 2 UCB Pharma, Brussels, Belgium, 3 Amgen 

Inc., Thousand Oaks, CA, 4 Bethesda Health Research 

Center, Bethesda, MD, 5 Laval University and CHU 

de Québec (CHUL) Research Centre, Quebec City, 

QC, 6 BioClinica Inc., Hamburg, Germany, 7 University 

of California San Francisco, San Francisco, CA, 

8 

Ghent University Hospital, Gent, Belgium, 9 Hvidovre 

University Hospital, Hvidovre, Denmark, 10 Servicio de 

Endocrinología, Hospital Universitario Quirón, Madrid, 

Spain, 11 University of California at Berkeley, Berkeley, 

CA, 12 University of British Columbia, Vancouver, 

BC, 13 Semmelweis University, Budapest, Hungary, 

14 

Universitat Autònoma de Barcelona, Barcelona, 

Spain, 15 Instituto de Investigaciones Metabólicas, 

Buenos Aires, Argentina, 16 Reumalab Centro Integral 

de Reumatologia, Medellin, Colombia, 17 Instituto 

Latinoamericano de Investigaciones Médicas, Córdoba, 

Argentina 

5:00 pm 

1025. Assessment of the Effects of Switching 

Bisphosphonates to Denosumab or Daily 

Teriparatide in Patients with Rheumatoid Arthritis 

Kosuke Ebina 1 , Makoto Hirao 2 , Jun Hashimoto 3 , Masao 

Yukioka 4 , Takaaki Noguchi 5 and Hideki Yoshikawa 6 , 

1 

Osaka University Graduate School of Medicine, 

Osaka, Japan, 2 Osaka University, Graduate School of 

Medicine, Suita, Japan, 3 Osaka-Minami Medical Center, 

Kawachinagano City, Japan, 4 Yukioka Hospital, Osaka, 

Japan, 5 Osaka University, Graduate School of Medicine, 

Osaka, Japan, 6 Osaka University Graduate School of 

Medicine, Suita Osaka, Japan 

5:15 pm 

1026. Morphea-Like Skin Lesions Reported in the 

Phase 3 Long-Term Odanacatib Fracture Trial 

and Extension in Postmenopausal Women with 

Osteoporosis 

Kenneth G. Saag 1 , Tobie de Villiers 2 , Peter 

Alexandersen 3 , Heidi Jacobe 4 , Carrie Kovarik 5 , 

Victoria P. Werth 6 , Albert Leung 7 , Avani Desai- 

Merchant 8 , Julie Mattaliano 8 and Deborah Gurner 8 , 

1 

University of Alabama at Birmingham, Birmingham, 

AL, USA, Birmingham, AL, 2 Mediclinic Panorama 

and Department of Obstetrics & Gynecology, 

University of Stellenbosch, Cape Town, South 

Africa, Cape Town, South Africa, 3 Center for Clinical 

and Basic Research, Vejle, Denmark, Ballerup, 

Denmark, 4 Department of Dermatology, University 

of Texas Southwestern Medical Center, Dallas, 

TX, USA, Dallas, TX, 5 Department of Dermatology, 

University of Pennsylvania, Philadelphia, PA, USA, 

Philadelphia, PA, 6 Philadelphia VAMC, Philadelphia, 

PA, USA, Philadelphia, PA, 7 Formerly Merck & Co., Inc., 

Kenilworth, NJ, USA, Kenilworth, NJ, 8 Merck & Co., Inc., 

Kenilworth, NJ, USA, Kenilworth, NJ 


85


Sunday 



5:30 pm 

1027. Odanacatib Efficacy and Safety in 

Postmenopausal Women with Osteoporosis: 5-Year 

Data from the Extension of the Phase 3 Long-Term 

Odanacatib Fracture Trial 

Michael R. McClung 1 , Bente Langdahl 2 , Socrates 

Papapoulos 3 , Kenneth G. Saag 4 , Henry Bone 5 , Douglas 

P. Kiel 6 , Kurt Lippuner 7 , Toshitaka Nakamura 8 , Ian 

Reid 9 , Norman Heyden 10 , Carolyn DaSilva 10 , Boyd 

B. Scott 10 , Rachid Massaad 11 , Keith D. Kaufman 10 , S. 

Aubrey Stoch 10 , Arthur Santora 10 , Deborah Gurner 10 

and Antonio Lombardi 10 , 1 Oregon Osteoporosis Center, 

Portland, OR, USA, Portland, OR, 2 Aarhus University 

Hospital, Aarhus, Denmark, Aarhus, Denmark, 3 Leiden 

University Medical Center, Leiden, The Netherlands, 

Leiden, Netherlands, 4 University of Alabama at 

Birmingham, Birmingham, AL, 5 Michigan Bone & 

Mineral Clinic, Detroit, MI, USA and The Osteoporosis 

Center at St. Luke’s Hospital, Chesterfield, MO, USA, 

Detroit, MI, 6 Institute for Aging Research, Hebrew 

Senior Life, Harvard Medical School, Boston, MA, 

USA, Boston, MA, 7 Bern University Hospital, Bern, 

Switzerland, Bern, Switzerland, 8 University of 

Occupational and Environmental Health, Fukuoka, 

Japan, Fukuoaka, Japan, 9 University of Auckland, 

Auckland, New Zealand, Auckland, New Zealand, 

10 

Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, 

NJ, 11 MSD Europe Inc., Brussels, Belgium, Brussels, 

Belgium 

5:45 pm 

1028. Discontinuation of Denosumab and 

Associated Vertebral Fracture Incidence: Analysis 

from a Phase 3 Placebo-Controlled Study of 

Denosumab and Its Open-Label Extension 

Jacques P Brown 1 , S Ferrari 2 , N Gilchrist 3 , Jens-Erik 

Beck Jensen 4 , N Pannacciulli 5 , Chris Recknor 6 , Christian 

Roux 7 , Shawna Smith 5 , Ove Törring 8 , Ivo Valter 9 , Rachel 

B Wagman 5 , A Wang 5 and SR Cummings 10 , 1 Centre 

Hospitalier de l’Université Laval (CHUL), Quebec City, 

QC, 2 Geneva University Hospital, Geneva, Switzerland, 

3 

The Princess Margaret Hospital, Christchurch, New 

Zealand, 4 Hvidovre University Hospital, Hvidovre, 

Denmark, 5 Amgen Inc., Thousand Oaks, CA, 6 United 

Osteoporosis Centers, Gainesville, GA, 7 Paris Descartes 

University, Paris, France, 8 Karolinska Institutet 

Sodersjukhuset, Stockholm, Sweden, 9 Center for 

Clinical and Basic Research, Tallinn, Estonia, 10 SFCC, 

CPMC Research Institute & UCSF, San Francisco, CA 

147 A 

Rheumatoid Arthritis – Animal Models I 

Moderators: Nunzio Bottini, MD, PhD; Richard M. Pope, 

MD 

4:30 pm 

1029. Functional Genetics of PTPN2 in Rheumatoid 

Arthritis: Haploinsufficiency of PTPN2 Promotes 

Severity of Th17-Cell Mediated Autoimmune 

Arthritis 

Mattias N. D. Svensson 1 , Karen M. Doody 1 , Cristiano 

Sacchetti 2 , Dennis J. Wu 1 , Gisen Kim 1 , Annelie Hellvard 3 , 

Brith Bergum 3 , Piotr Mydel 3 , Mitchell Kronenberg 1 , 

Michel L. Tremblay 4 and Nunzio Bottini 2 , 1 La Jolla 

Institute for Allergy and Immunology, La Jolla, CA, 

2 

University of California, San Diego, La Jolla, CA, 

3 

Broegelmann Research Laboratory, Bergen, Norway, 

4 

McGill University, Montréal, QC 

4:45 pm 

1030. Synovial Tissue Resident Macrophages 

Play the Protective Role in the Development of 

Inflammatory Arthritis in CD11c-Flip-KO Mice 

Qi Quan Huang 1 , Renee E. Doyle 1 , Robert Birkett 2 and 

Richard M. Pope 1 , 1 Northwestern University Feinberg 

School of Medicine, Chicago, IL, 2 Northwestern 

University, Chicago, IL 

5:00 pm 

1031. Glucocorticoid Receptor Dimerization in 

Stromal Cells Modulates Macrophage Polarization 

during Serum Transfer-Induced Arthritis 

Mascha Koenen 1 , Ulrike Baschant 2 , Stephan Culemann 3 , 

Tobias Kockmann 4 , Hans-Michael Kaltenbach 5 , Sabine 

Vettorazzi 3 , Paolo Nanni 6 , Bernd Roschitzki 7 , Ulrich 

Auf dem Keller 8 and Jan P. Tuckermann 3 , 1 Institute for 

Comparative Molecular Endocrinology, University of 

Ulm, Ulm, Germany, 2 Dep. of Medicine III, TU Dresden, 

Dresden, Germany, 3 Leibniz Institute on Aging, FLI Jena, 

Jena, Germany, 4 Institute for Molecular Health Sciences, 

ETH Zürich, Zürich, Switzerland, 5 Dep. of Biosystems 

Science and Engineering, ETH Zürich, Zürich, Germany, 

6 

Functional Genomics Center Zurich, University and 

ETH Zurich, Zürich, Switzerland, 7 Functional Genomics 

Center Zurich, University and ETH Zurich, Zurich, 

Switzerland, 8 Institute for Molecular Health Sciences, 

ETH Zürich, Zürich, Germany 


Sunday 




5:15 pm 

1032. Early In Vivo Induction of Mouse Interferon- 

Alpha1 Overexpression Triggers an Expansion of 

Highly Suppressive Regulatory T Lymphocytes 

Protecting Against Experimental Arthritis 

Katarzyna Matyja 1 , Matthieu Ribon 2 , Roxane Hervé 2 , 

Delphine Lemeiter 1 , Ken Tsumiyama 3 , Natacha Bessis 1 , 

Shunichi Shiozawa 3 , Marie-Christophe Boissier 1 and 

Patrice Decker 2 , 1 University of Paris 13, Sorbonne 

Paris Cité, Bobigny, France, 2 Inserm, Bobigny, France, 

3 

Kyushu University Beppu Hospital, Beppu, Japan 

5:30 pm 

1033. Targeting Notch-Activated M1 Macrophages 

Attenuates Joint Tissue Damage in a Mouse Model 

of Inflammatory Arthritis 

Wen Sun 1 , Hengwei Zhang 2 , Hua Wang 1 , Yahui Grace 

Chiu 2 , Christopher T. Ritchlin 2 , Amy Kiernan 2 , Brendan 

Boyce 2 and Lianping Xing 2 , 1 Nanjing Medical University, 

Nanjing, China, 2 University of Rochester Medical 

Center, Rochester, NY 

5:45 pm 

1034. Microrna-146a Controls Local Bone 

Destruction By Regulating Fibroblast Induced 

Osteoclastogenesis in Inflammatory Arthritis 

Victoria Saferding 1 , Antonia Puchner 1 , Eliana Goncalves- 

Alves 1 , Melanie Hofmann 1 , Julia Brunner 1 , Emine Sahin 1 , 

Silvia Hayer 1 , Philippe Georgel 2 , Marije M. Koenders 3 , 

Gernot Schabbauer 1 , Josef S. Smolen 1 , Günter Steiner 1 , 

Kurt Redlich 1 and Stephan Blüml 1 , 1 Medical University 

of Vienna, Vienna, Austria, 2 Université de Strasbourg, 

Strasbourg, France, 3 Radboud University Nijmegen 

Medical Center, Nijmegen, Netherlands 

Ballroom A 

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA 

and Progression to Rheumatoid Arthritis 

Moderators: Paul Emery, MA, MD, FRCP; Lin Brown, MD 

4:30 pm 

1035. The Prognostic Value of Different Auto- 

Antibodies for Arthritis Development in Patients 

with Clinically Suspect Arthralgia 

Robin M ten Brinck 1 , Hanna W van Steenbergen 1 , 

Marije K. Verheul 1 , Leendert A. Trouw 2 and Annette HM 

van der Helm-van Mil 3 , 1 Department of Rheumatology, 


2 


3 

Rheumatology, Leiden University Medical Center, 

Leiden, Netherlands 

4:45 pm 

1036. Dominant B-Cell Receptor Clones in 

Peripheral Blood Predict Onset of Arthritis in 

Individuals at Risk for Rheumatoid Arthritis 

Paul P. Tak 1 , Marieke E. Doorenspleet 2 , Maria de Hair 3 , 

Paul L. Klarenbeek 4 , Marian van Beers-Tas 5 , Antoine 

H.C. van Kampen 6 , Dirkjan van Schaardenburg 7 , 

Danielle M. Gerlag 8 , Frank Baas 6 and Niek de Vries 2 , 

1 

currently: Ghent University, Ghent, Belgium & 

Cambridge University, Cambridge, United Kingdom, 

2 

Academic Medical Center/University of Amsterdam, 

Amsterdam, Netherlands, 3 University Medical 

Center Utrecht, Utrecht, Netherlands, 4 Amsterdam 

Rheumatology and immunology Center | Academic 

Medical Center/University of Amsterdam, Amsterdam, 

Netherlands, 5 Amsterdam Rheumatology & 

Immunology Center, Reade, Amsterdam, Netherlands, 

6 

Academic Medical Center/Univ. of Amsterdam, 

Amsterdam, Netherlands, 7 Amsterdam Rheumatology 

and immunology Center | Academic Medical Center, 

Amsterdam, Netherlands, Amsterdam, Netherlands, 

8 

ARC | Division of Clinical Immunology and 

Rheumatology, Academic Medical Center, University of 

Amsterdam, Amsterdam, Netherlands 

5:00 pm 

1037. Evaluation of 14-3-3η as a Tool for Diagnosis 

of Early RA in a European Cohort 

Monika Hansson 1 , Linda Mathsson-Alm 2 , Anthony 

Marotta 3 and Sascha Swiniarski 4 , 1 Rheumatology 

Unit, Department of Medicine, Karolinska Institute, 

Karolinska University Hospital, Stockholm, Sweden, 

2 

Thermo Fisher Scientific, Uppsala, Sweden, 3 Augurex 

Life Sciences Corp., Vancouver, BC, 4 Phadia GmbH, 

Freiburg, Germany 

5:15 pm 

1038. Functional Disability in Patients Presenting 

with Clinically Suspect Arthralgia and Progression 

to Clinical Arthritis 

Robin M ten Brinck 1 , Hanna W van Steenbergen 1 , Lukas 

Mangnus 1 , Leonie E Burgers 1 , Monique Reijnierse 2 , 

Tom WJ Huizinga 3 and Annette HM van der Helm-van 

Mil 4 , 1 Department of Rheumatology, Leiden University 


87


Sunday 



Medical Center, Leiden, Netherlands, 2 Department of 

Radiology, Leiden University Medical Center, Leiden, 

Netherlands, 3 Leiden University Medical Center, Leiden, 

Netherlands, 4 Rheumatology, Leiden University Medical 

Center, Leiden, Netherlands 

5:30 pm 

1039. Estimation of the Risk of Developing 

Rheumatoid Arthritis in High-Risk Subjects: 

Systematic Review and Meta-Analysis 

François Vercruysse 1 , Vincent Germain 1 , Thomas 

Barnetche 2 , Marie-Elise Truchetet 2 and Thierry 

Schaeverbeke 2 , 1 CHU Pellegrin, Bordeaux, France, 

BORDEAUX, France, 2 CHU Pellegrin, Bordeaux, France, 

Bordeaux, France 

5:45 pm 

1040. Stressful Life Events: A Trigger for 

Rheumatoid Arthritis Onset within a Year: A Case- 

Control Study 

Jimmy Gross 1 , Nadia Oubaya 2 , Florent Eymard 1 , Alexia 

Hourdille 1 , Xavier Chevalier 1 and Sandra Guignard 1 , 

1 

APHP Henri Mondor hospital, Créteil, France, 

2 

Université Paris-Est, UPEC,, Créteil, France 

Ballroom B 


– Clinical Aspects and Treatment II: Axial 

Spondyloarthritis – Treatment 

Moderators: John D. Reveille, MD; Andreas Reimold, 

MD 

4:30 pm 

1041. Abatacept in the Treatment of Active 

Psoriatic Arthritis: 24-Week Results from a Phase III 

Study 

P Mease 1 , AB Gottlieb 2 , D van der Heijde 3 , Oliver 

FitzGerald 4 , A Johnsen 5 , M Nys 6 , S Banerjee 5 and D 

Gladman 7 , 1 Swedish Medical Center and University 

of Washington, Seattle, WA, 2 Tufts University School 

of Medicine (affiliation at the time of the study), 

Boston, MA, 3 Leiden University Medical Center, Leiden, 

Netherlands, 4 St Vincent’s University Hospital and 

University College Dublin, Dublin, Ireland, 5 Bristol- 

Myers Squibb, Princeton, NJ, 6 Bristol-Myers Squibb, 

Braine-l’Alleud, Belgium, 7 University of Toronto and 

Toronto Western Hospital, Toronto, ON 

4:45 pm 

1042. Four Year Imaging Outcomes in Patients 

with Axial Spondyloarthritis Treated with 

Certolizumab Pegol, Including Patients with 

Ankylosing Spondylitis and Non-Radiographic Axial 

Spondyloarthritis 

Desiree van der Heijde 1 , Xenofon Baraliakos 2 , Kay- 

Geert Hermann 3 , Robert Landewé 4 , Pedro Machado 5 , 

Walter Maksymowych 6 , Owen Davies 7 , Natasha de 

Peyrecave 7 , Bengt Hoepken 8 , Lars Bauer 8 , Tommi 

Nurminen 8 and Jürgen Braun 9 , 1 Department of 

Rheumatology, Leiden University Medical Center, 

Leiden, Netherlands, 2 Ruhr-University Bochum, 

Herne, Germany, 3 Charité – University Medicine 

Berlin, Berlin, Germany, 4 Academic Medical Center, 

Amsterdam & Zuyderland Medical Center Heerlen, 

Amsterdam, Netherlands, 5 Centre for Rheumatology 

Research & MRC Centre for Neuromuscular Diseases, 

University College London, London, United Kingdom, 

6 

Department of Medicine, University of Alberta, 

Edmonton, AB, 7 UCB Pharma, Slough, United Kingdom, 

8 

UCB Pharma, Monheim, Germany, 9 Rheumazentrum 

Ruhrgebiet, Herne, Germany 

5:00 pm 

1043. Safety and Efficacy of Intravenous 

Golimumab in Adult Patients with Active 

Ankylosing Spondylitis: Results through Week 28 

Atul A. Deodhar 1 , John D. Reveille 2 , Diane D. Harrison 3 , 

Lilianne Kim 4 , Kim Hung Lo 4 and Elizabeth C. Hsia 4 , 

1 


2 

University of Texas-McGovern Medical School, 

Houston, TX, 3 Janssen Research & Development, LLC., 

Horsham, PA, 4 Janssen Research & Development, LLC., 

Spring House, PA 

5:15 pm 

1044. Treatment with Tofacitinib Is Associated 

with Clinically Meaningful Reductions in Axial 

MRI Inflammation in Patients with Ankylosing 

Spondylitis 

Walter Maksymowych 1 , Désirée van der Heijde 2 , 

Xenofon Baraliakos 3 , Atul A. Deodhar 4 , Matt Brown 5 , 

Sarah Sherlock 6 , David Li 7 , Dona Fleishaker 8 and Thijs 

Hendrikx 7 , 1 Department of Medicine, University of 

Alberta, Edmonton, AB, 2 Department of Rheumatology, 



Sunday 




3 

Rheumazentrum Ruhrgebiet, Herne, Germany, 

4 

Division of Arthritis and Rheumatic Diseases, Oregon 

Health and Science University, Portland, OR, 5 Institute 

for Health and Biomedical Innovation, Queensland 

University of Technology, Brisbane, Australia, 6 Pfizer 

Inc, Cambridge, MA, 7 Pfizer Inc, Collegeville, PA, 8 Pfizer 

Inc, Groton, CT 

5:30 pm 

1045. 2016 Update of the ASAS-EULAR Management 

Recommendations for Axial Spondyloarthritis 

Désirée van der Heijde 1 , Sofia Ramiro 1 , Robert 

Landewé 2 , Xenofon Baraliakos 3 , Filip van Den Bosch 4 , 

Alexandre Sepriano 1 , Andrea Regel 5 , John D. Reveille 6 

and Jürgen Braun 5 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Amsterdam Rheumatology 

Center, Amsterdam, Netherlands, 3 Rheumazentrum 

Ruhrgebiet Herne, Ruhr-University Bochum, Herne, 

Germany, 4 Ghent University Hospital, Ghent, Belgium, 

5 

Rheumazentrum Ruhrgebiet, Herne, Germany, 

6 

University of Texas-McGovern Medical School, 

Houston, TX 

5:45 pm 

1046. Anti-TNF Therapy in Axial Spondyloarthritis: 

Prediction of Therapeutic Responses Using 

Immunological Signatures 

Lars Rogge 1 , Silvia Menegatti 2 , Eleonora Latis 1 , Elena 

Mascia 1 , Hanane Yahia 1 , Claire Leloup 1 , Anna Molto 3 , 

Corinne Miceli-Richard 4 , Maxime Dougados 3 and 

Elisabetta Bianchi 1 , 1 Institut Pasteur, Paris, France, 

2 

Immunoregulation Unit, Institut Pasteur, Paris, France, 

3 

Paris Descartes University, Paris, France, 4 Hôpital 

Cochin, Paris, France 

Salon B 


Aspects and Treatment II: Clinical Trial Design 

Moderators: Ian N. Bruce, FRCP, MD; Elena Massarotti, 

MD 

4:30 pm 

1047. Negative Results of Antinuclear Antibody 

(ANA) Testing in Clinical Trials of Systemic 

Lupus Erythematosus (SLE) May Be Due to Assay 

Variability 

David Pisetsky 1 , Dana Thompson 1 , Joseph Wajdula 2 , 

Annette Diehl 2 and Sudhakar Sridharan 3 , 1 Duke 

University Medical Center and Durham VAMC, Durham, 

NC, 2 Pfizer Inc, Collegeville, PA, 3 PPD Inc, Rockville, MD 

4:45 pm 

1048. Differences in Clinical Manifestations of SLE 

Across Four Racial/Ethnic Groups: The California 

Lupus Surveillance Project (CLSP) 

Ernest Maningding 1 , Jinoos Yazdany 2 , Laura Trupin 2 , 

Chris Tonner 2 , Charles G. Helmick 3 and Maria Dall’Era 2 , 

1 

Santa Clara Valley Medical Center, San Jose, CA, 

2 

University of California, San Francisco, San Francisco, 

CA, 3 CDC, Atlanta, GA 

5:00 pm 

1049. High Titer ANA Not Necessarily a Valid 

Criterion for Lupus – Proposal of a Modification to 

the Criteria for Classification of SLE 

Luis E C Andrade 1 , Jan Damoiseaux 2 , Minoru Satoh 3 , 

Edward K.L. Chan 4 , Mônica Prado 5 , Henrique Mariz 6 , 

Renan Agustinelli 7 and Alessandra Dellavance 8 , 

1 

Universidade Federal de São Paulo, São Paulo, Brazil, 

2 

Maastricht University Medical Center, Maastricht, 

Netherlands, 3 University of Occupational and 

Environmental Health, Kitakyushu, Japan, 4 University 

of Florida, Gainesville, FL, 5 Escola Paulista de Medicina 

- Universidade Federal de São Paulo, Sao Paulo, 

Brazil, 6 Hospital das Clínicas - UFPE, Recife, Brazil, 

7 

Escola Paulista de Medicina, São Paulo, Brazil, 8 Fleury 

Medicine and Health Laboratories, São Paulo, Brazil 

5:15 pm 

1050. Defining Low Disease Activity in Systemic 


Ari Polachek 1 , Dafna D Gladman 1 , Jiandong Su 2 and 

Murray Urowitz 3 , 1 University of Toronto, Toronto 

Western Hospital, Toronto, ON, 2 Centre for Prognosis 

Studies in the Rheumatic Diseases, Toronto Western 

Hospital and University of Toronto, Toronto, ON, 

3 

Toronto Western Hospital and University of Toronto, 

Toronto, ON 

5:30 pm 

1051. Determining the Minimal Clinically Important 

Difference for Improvement for Systemic Lupus 

Erythematosus Disease Activity Index-2000 

Responder Index-50 (S2K RI-50) 

Zahi Touma 1 , Dafna D Gladman 1 , Dorcas Beaton 2 , 

Jiandong Su 3 and Murray Urowitz 1 , 1 University of 


89


Sunday 



Toronto, Toronto Western Hospital, Toronto, ON, 2 St 

Michael’s Hospital, Toronto, ON, 3 Toronto Western 

Hospital and University of Toronto, Toronto, ON 

5:45 pm 

1052. Longitudinal Patterns in SLE Response to 

Standard of Care Therapy: Implications for SLE 

Clinical Trial Design 

Mimi Kim 1 , Joan T Merrill 2 , Kenneth Kalunian 3 , Bevra 

H. Hahn 4 , Anita Roach 5 , Peter M. Izmirly 6 and the 

Lupus Foundation of America Collective Data Analysis 

Initiative Group., 1 Albert Einstein Coll Med, Bronx, NY, 

2 

OMRF, Oklahoma, OK, 3 UCSD School of Medicine, 

La Jolla, CA, 4 UCLA David Geffen School of Medicine, 

Los Angeles, CA, 5 Lupus Foundation of America, 

Washington, DC, 6 New York University School of 

Medicine, New York, NY 


4:30 pm – 6:00 pm 


separate registration and ticket. To verify which session you 

registered for, the registration code on your ticket needs 

to match the 3-digit code in front of the session title. If you 

are interested in participating in one of these sessions or 

exchanging your ticket, visit the ACR registration desk to 

check space availability. View the session overview and 

learning objectives online in the Annual Meeting App. 


148 

021 – Antiphospholipid Syndrome PM PS E 

Speaker: Alana B. Levine, MD 

153 

022 – Cutaneous Vasculitis 

Speaker: Rebecca L. Manno, MD, MHS 

154 A 

023 – Dermatological Manifestations of 


Speaker: Laura Winterfield, MD, MPH 

154 B 

024 – How Are Patients Using Public Data to 

Evaluate You? 

Canceled 

155 

025 – Inflammatory Eye Disease/Uveitis 

Speaker: Debra Anne Goldstein, MD, FRCSC 

158 A 

026 – Management of Difficult Raynaud’s and 

Digital Ischemia 

Speaker: Fredrick M. Wigley, MD 

158 B 

027 – Pediatric Rheumatology for Adult 

Rheumatologists PM Ed Pd PS PrM FIT 

Speaker: Patience White, MD, MA 

159 A 


Arthritis PM PS E 

Speaker: Eric M. Ruderman, MD 

159 B 


Treatments – How to Treat Systemic Lupus 

Erythematosus 


160 

030 – Systemic Sclerosis: Disease Staging and 

Subsetting in Clinical Practice 

Speaker: Robyn T. Domsic, MD, MPH 

ARHP SESSIONS 

4:30 pm – 6:00 pm 

201 

Cloud-Based Fracture Liaison Service Model 

Moderator: Debbie Zeldow, MBA 


Sunday 




4:30 pm 

Fracture Liaison Service Model of Care: Improving 

Health Outcomes and Quality of Care In Osteoporosis 

and Post-Fracture Care 

Speaker: David Lee, MPA 

5:00 pm 

Georgetown MedStar Implementation of a Fracture 

Liaison Service Model of Care 

Speaker: Andrea Singer 

5:30 pm 

Fracture Liaison Service Implementation at University 

of Pittsburgh Medical Center 

Speaker: Susan Greenspan, MD 

204 A 

The Care Circle: Rheumatologist, Orthopedist, 

and Therapist 

Moderator: Neal Moskowitz, MD, PhD 

4:30 pm 

The Circle of Care: The Rheumatologist 

Speaker: Bruce Hoffman, MD 

5:00 pm 

The Circle of Care: The Orthopedist 

Speaker: Ryan Hoffman, MD 

5:30 pm 

The Circle of Care: The Physical Therapist 

Speaker: Carol A. Oatis, PT, PhD 

209 A 

The Economic Burden of Osteoarthritis 

Moderator: Elena Losina, PhD 

4:30 pm 

Global Economic Burden of Osteoarthritis 

Speaker: Anthony Woolf, MD 

5:00 pm 

The Prevalence and Economic Impact of 

Osteoarthritis in the United States: Estimates from 

Medical Expenditures Panel Survey 

Speaker: Edward H. Yelin, PhD 

5:30 pm 

Priorities for Health Care, Health Policy, and 

Osteoarthritis Research 

Speaker: Elizabeth M. Badley, PhD 


4:30 pm – 6:00 pm 

202 B 

ARHP II: Healthcare Disparities and 

Psychosocial Impact on Rheumatic Disease 

Moderators: Charmayne M. Dunlop-Thomas, MS, MPH; 

Arif Jetha, PhD 

4:30 pm 

1053. Evaluating the Charla De Lupus (Lupus Chat)® 

Program’s Teen, Young Adult, and Parent Support 

Group: Reaching the Hispanic/Latino Community 

Through a Family Model of Support 

Melissa T. Flores 1 , Jillian A. Rose 1 , Priscilla Toral 1 , 

Roberta Horton 1 , Dariana M. Pichardo 1 , Lillian Mendez 1 

and Lisa F. Imundo 2 , 1 Hospital for Special Surgery, New 

York, NY, 2 Columbia University Medical Center, New 

York, NY 

4:45 pm 

1054. Self-Reported Psychological Impact and 

Coping Strategies of Men with RA 

Caroline Flurey 1 , Sarah Hewlett 2 , Karen Rodham 3 , Alan 

White 4 , Robert Noddings 5 and John Kirwan 6 , 1 University 

of the West of England, Bristol, United Kingdom, 

2 

University of West of England, Bristol, United Kingdom, 

3 

Staffordshire University, Stoke on Trent, United 

Kingdom, 4 Leeds Beckett University, Leeds, United 

Kingdom, 5 Bristol Royal Infirmary, Bristol, United 

Kingdom, 6 University of Bristol, Bristol, United Kingdom 

5:00 pm 

1055. Physical Activity Behavior in Men with 

Inflammatory Arthritis: A Cross-Sectional Register 

Based Study of Physical Activity Correlates, 

Motivators, Barriers, and Preferences 

Nanna Maria Hammer 1 , Julie Midtgaard 2 , Merete 

Lund Hetland 3 , Niels Steen Krogh 4 and Bente Appel 

Esbensen 5 , 1 The DANBIO registry and Copenhagen 

Center for Arthritis Research, Glostrup, Denmark, 


91


Monday 



2 

Department of Public Health, Copenhagen, Denmark, 

3 



Denmark, Copenhagen, Denmark, 4 Zitelab, 

Frederiksberg, Denmark, 5 Department of Clinical 

Medicine, Faculty of Health and Medical Sciences, 

University of Copenhagen Copenhagen, Denmark, 

Copenhagen, Denmark 

5:15 pm 

1056. Mind-Body Skills Training and Supportive 

Counseling for Depression in SLE: Positive Effects in 

a Randomized Controlled Trial 

Carol Greco 1 , Ling-Wan Chen 1 , Yu Cheng 2 , Christine 

McFarland 2 and Susan Manzi 3 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 UNIVERSITY OF PITTSBURGH, 

Pittsburgh, PA, 3 West Penn Allegheny Health System, 

Pittsburgh, PA 

5:30 pm 

1057. Effect of Quantitative Information Concerning 

Medication Side-Effects on Risk Perception 

Susan J. Blalock 1 and Matthew Dixon 2 , 1 UNC at Chapel 

Hill, Chapel Hill, NC, 2 University of North Carolina at 

Chapel Hill, Chapel Hill, Namibia 

5:45 pm 

1058. Adjustment Profiles Comprising Objective 

and Subjective Measures in Fibromyalgia Patients 

Fernando Estévez-López 1 , Inmaculada C Álvarez 

Gallardo 1 , Víctor Segura-Jiménez 1 , Milkana Borges- 

Cosic 1 , Manuel Pulido-Martos 2 , Ana Carbonell-Baeza 3 , 

Virginia A Aparicio 1 , Rinie Geenen 4 and Manuel 

Delgado-Fernández 1 , 1 University of Granada, Granada, 

Spain, 2 University of Jaén, Jaén, Spain, 3 University 

of Cádiz, Cádiz, Spain, 4 Utrecht University, Utrecht, 

Netherlands 


4:30 pm – 6:00 pm 

West Overlook 

Annual Meeting Tweet-Up 

A great way to get connected and stay connected to the 

latest trends, research, and ideas pulsing through the 

rheumatology community! 

INDUSTRY-SUPPORTED SYMPOSIA 

6:30 – 9:30 pm 

These symposia are both CME-accredited and non- 

CME company-directed programs. For CME-accredited 

symposia, the sponsoring organization is responsible 

for planning and providing CME credit. All non-CME 

programsare wholly sponsored and supported by 

commercial entities. Please visit the organization’s 

exhibit booth or the industry-supported symposia booth 

or download the ACR Annual Meeting App for more 

information on each symposium. 

MONDAY 

NOVEMBER 14 

ACR SESSIONS 

7:30 am – 8:30 am 

152 A 

Update on Safety Issues in the Tratment of 

Rheumatic Diseases – From the FDA and Beyond 

PM PS PME 

PS E 

Moderators: Michael Weisman, MD; Arthur Kavanaugh, 

MD 

7:30 am 

Update and Safety Issues on Recently Approved 

Agents for Rheumatic Disease 

Speaker: Sally Seymour, MD 

7:50 am 

The Year in Review—Update on Safety Issues at the 

Food and Drug Administration for the Last 12 Months 

Speaker: Janet W. Maynard, MD, MHS 

8:10 am 

Update on Biosimilars 

Speaker: Nikolay P. Nikolov, MD 


Monday 




Hall E 

Clinicopathologic Conference: Back Pain, 

Aortitis, and Retroperitoneal Fibrosis: What Is 

the Differential Diagnosis and the Approach? 

Moderators: Victoria K. Shanmugam, MBBS, MRCP; 

Arthur Weinstein, MD 

7:30 am 

Case Presentation 

Speaker: Shubhasree D. Choudhury, MD 

7:45 am 

Radiology Consultation 

Speaker: Kathleen Brindle, MD 

8:00 am 

A Diagnostic Test and the Next Steps 

Speaker: Juvianee Veras, MD; Elaine Jaffe, MD 

146 A 

Genetics In the Rheumatology Clinic: Can It 

Change the Clinical Care of Patients? 

Moderators: Gloria Salazar, MD; Jonathan S. Hausmann, 

MD 

Speaker: Peter K. Gregersen, MD 

145 A 

Immuno-Metabolism: Energetics and 

Inflammation 

Moderators: Jon T. Giles, MD, MPH; Connie Weyand, 

MD, PhD 

Speaker: Luke A. O’Neill, PhD 

ARHP SESSIONS 

7:30 am – 8:30 am 

140 A 

Biologic Therapy: Prescription, Prior 

Authorization, and Beyond PM PS E 

Moderator: Andrew Hochradel, PharmD 

7:30 am 

Biologics and Small Molecule Therapy: A Patient and 

Provider Perspective 

Speaker: Susan Olsson, BSN 

8:00 am 

Biologics and Small Molecule Therapy: Who Are the 

Players Involved? 

Speaker: Sammuel V. Anderegg, PharmD, MS, BCPS 

202 B 

Immunology Boot Camp II: Basic Mechanisms of 

Autoimmunity 

Moderators: Sandro Perazzio, MD, PhD; Christine A. 

Stamatos, DNP, ANP-C 


147 A 

Pharma Update: What You Need to Know PM PS E 

Moderator: Deborah McCloskey, BSN, RN 

Speaker: Kamala Nola, PharmD, MS 

206 

Weight Loss Counseling Strategies 

Moderator: Brandi Young, DNP, NP-C 

7:30 am 

Advice from the Clinical Practioner 

Speaker: Benjamin J. Smith, PA-C, DFAAPA 

8:00 am 

Counseling Strategies from the Health Psychologist 

Speaker: Shannon Mihalko, PhD 


7:45 am – 9:15 am 











93


Monday 



148 


Speaker: Lianne S. Gensler, MD 

153 

032 – Approaches to Urticaria and Angiodema 

Speaker: Bruce L. Zuraw, MD 

154 A 

033 – Controversies in Sjögren’s Syndrome 

Speaker: Frederick B. Vivino, MD, MS 

154 B 

034 – Crystal: Diagnosis and Management of 

Gout 

PM PS E 

Speaker: N. Lawrence Edwards, MD 

155 

035 – Dermatological Manifestations of 


Speaker: Laura Winterfield, MD, MPH 

158 A 

036 – Myopathy: Issues in Diagnosis and 

Treatment 

Speaker: Mary E. Cronin, MD 

158 B 

037 – Psoriatic Arthritis 

Speaker: Dafna D. Gladman, MD, FRCPC 

159 A 

038 – Pulmonary Manifestations of Rheumatic 

Disease 


159 B 

039 – Reactive Arthritis: An Update 

Speaker: Siba P. Raychaudhuri, MD 

160 


PM PS E 

Speaker: Michael Weinblatt, MD 

WORKSHOPS 

7:45 am – 9:45 am 










144 C 



Speaker: Jay B. Higgs, MD; Catherine Bakewell, MD 

144 A 

217 – Dermatopathology of Rheumatic Diseases 

Speaker: Daniel Miller, MD 

149 A 

218 – How to Use Motivational Interviewing (MI) 

Skills in the Routine Practice of Rheumatology: 

A Practical Workshop 

Speaker: Steven Cole, MD 

144 B 

219 – Tai Chi, Qigong, Feldenkrais, Yoga for Your 

Practice: Mind Body Practices in Rheumatic 

Disease PM PS PME 

PS E 

Speaker: Mary L. Jurisson, MD 


Monday 



ACR SESSION 

8:30 am – 9:30 am 

Ballroom B 

Rheumatology Research Foundation Philip 

Hench, MD, Memorial Lecture: Blocking 

Interleukin-1 Beta or Interleukin-Alpha in 

Inflammatory Diseases from Gout to Cancer 

Moderator: Kenneth J. Warrington, MD 

Speaker: Charles Dinarello, MD 

ACR SESSIONS 

8:30 am – 10:00 am 

Salon B 

Anatomy for the Clinician II: Hip Pain, Not from 

the Hip Joint – Posterior Hip Pain 

PM PS E 


Speaker: David Bong, MD 

150 A 

Digital Scholar Training Series: What 

Rheumatologists Can Learn from Patients’ 

Online Conversation? (Part 1 of 2) 

Moderator: Swamy Venuturupalli, MD 

Speaker: Lea LeAnna Carey, MBA 

8:45 am 

The Art of Social Listening 

9:00 am 

To Like or Not to Like – How Social Media Has 

Impacted Healthcare; The Tribes We Build; 

Engagement Reimagined 

9:20 am 

Symplur Signals – Bringing Patients into Focus; This IS 

Digital Transformation 

9:45 am 

Q & A – Get on With Your Bad Self 

Hall D 

Osteoporosis Update PM PS E 

Moderators: Mathilde H. Pioro, MD; Chad Deal, MD 

8:30 am 

Managing Osteoporosis in Patients on Long Term 

Bisphosphonate Treatment 

Speaker: Robert A. Adler, MD 

8:55 am 

Update on Long Term Therapy with Denosumab, 

Mechanism of Action, and Implication for Drug 

Holidays 

Speaker: Nelson Watts, MD 

9:20 am 

Anabolic Therapy, Current and Future: Teriparatide, 

Abaloparatide, and Romosozumab 

Speaker: Michael McClung 

9:45 am 

Panel Discussion 

151 A 

Pain Pathways in Arthrtis 

PM PS E 

Moderators: Anne-Marie Malfait, MD, PhD; Yvonne C. 

Lee, MD, MMSc 

8:30 am 

Pain Pathways (Basic Mechanisms) 

Speaker: Tony Yaksh, PhD 

9:00 am 

Nerve Growth Factor as a Target for Arthritis Pain 

Speaker: Stephen B. McMahon, FMedSci, FSB 

9:30 am 

Emerging Targets for the Management of Joint Pain 

Speaker: Richard J. Miller, PhD 

207 B 

What a Pediatric Rheumatologist May Want to 

Know About the Kidneys PM Ed PM Pd PS PrM PS FIT E 

Moderators: Stacy P. Ardoin, MD, MS; Mileka Gilbert, 

MD, PhD 


95


Monday 



8:30 am 

A Systems-Based Approach to Managing Blood 

Pressure in Children With Pediatric Rheumatic 

Diseases 

Speaker: Mark Mitsnefes, MD 

9:00 am 

Thrombotic Microangiopathies: Atypical Hemolytic- 

Uremic Syndrome, Thrombotic Thrombocytopenic 

Purpura, Antiphospholipid, and May Be More 

Speaker: Bradley Dixon, MD 

9:30 am 

Lupus Nephritis in Children – How to Diagnose at 

Early, Monitor Well, and Provide Evidence-Based 

Therapies 

Speaker: Stephen Marks, MD, MSc, MRCP, FRCPCH 

ACR SESSIONS 

9:00 am – 10:00 am 

145 A 

Creating a High-Performing Practice through 

Assessment and Planning PM PS E 

Moderator: J. Eugene Huffstutter, MD 

Speaker: Valora S. Gurganious, MBA, CHBC 

Hall E 

Cutaneous Lupus in All Its Varieties: Judging a 

Book By Its Cover 

PM PS E 

Moderator: Gregory Gardner, MD, FACP; Laura Durcan, 

MD 

Speaker: Andrea Kalus, MD 

204 A 

Navigating the Market: Recent Fellows’ 

Experiences in Securing Their First Job 

Trainee 

Moderators: Kevin Byram, MD; Jiha Lee, MD 

9:00 am 

Contract Negotiations 

Speaker: Jeffrey B. Sansweet, Esquire 

9:20 am 

Private Practice 

Speaker: Dee Dee Wu, MD 

9:40 am 

Academic Practice 

Abhijeet Danve, MD 

Ballroom C 

Perioperative Management of Anti-rheumatic 

Medication in Patients with Rheumatic 

Diseases Undergoing Elective Total Hip or 

Knee Arthroplasty: A New ACR/AAHKS Clinical 

PM PS E 

Guideline 

Moderator: Bryan Springer, MD 

9:00 am 

Overview of Guideline Development, Including 

Methods and Literature Review 

Speaker: Jasvinder A. Singh, MD, MPH 

9:30 am 

Presentation of the new ACR/AAHKS Guideline 

Speaker: Susan M. Goodman, MD 

ARHP SESSION 

9:00 am – 10:00 am 

140 A 

ARHP Distinguished Lecturer: Doing, Being, 

Participating: State of the Science PM PS E 

Speaker: Catherine L. Backman, PhD, FCAOT 

ACR POSTER SESSION A AND POSTER 

TOURS 

8:30 am – 4:00 pm 


(abstracts #1059-1954). Poster tours will be held from 

9:00 – 9:45 am and 10:15 – 11:00 am. Morning snacks will be 

available at 8:30 am. 


Monday 



ACR POSTER SESSION A AND POSTER TOURS continued 


Thieves’ Market Posters – ACR/ARHP Poster 

Sessions B 

A Nerve-Racking Case of Rapidly Progressive 

Weakness 

Jennifer Mandal, MD 

A Swollen Knee in the Faint of Heart 

Sherly Mathew, MD 

Adding a Feather to Your Cap: Expanding the 

Differential for Suspected Infiltrative Disease 

Heather Berens-Norman, MD, PhD 

Beware of Bony Pagodas 

Kristina E.N. Clark, MBBS, MA, MRCP 

Falling into the Transverse Myelitis Trap 

Alana Nevares 

Grave Side of Graves Disease 

Maryam Gul, MD 

Insights into a Rare Case Mimicking Autoimmune 

Diseases 

Li Jiang, MD 

Medically Unexplained? Or New Entity? 

Takeshi Yoshida, MD 

More than Just a Fall 

Nicole Yang, MD 

A Case of Eosinophilic Myositis 

Shazdeh Butt, MD 






















headset is not returned within 15 minutes of the end of the 

tour. 

9:00 – 9:45 am 




10:15 – 11:00 am 




EXHIBITS 

10:00 am – 5:00 pm 










Theater A presentations will be held from 10:30 – 11:15 

am, 12:30 – 1:15 pm, and 2:30 – 3:15 pm. Innovation Theater 

B presentations will be held from 11:30 am – 12:15 pm, 

1:30 – 2:15 pm, and 3:30 – 4:15 pm. For a complete listing of 

Innovation Theater presentations, see page 194. 


97


Monday 


WORKSHOPS 

10:30 am – 12:30 pm 










149 A 

220 – Histopathology and Imaging of Rheumatic 

Lung Disease 

Speaker: Ganesh Raghu, MD 

144 B 

221 – Joint Injections (Knee, Ankle, Shoulder, 

and Wrist) PM PS E 

Speakers: Jemima Albayda, MD; Pari Basharat, MD 

144 C 

222 – Musculoskeletal Ultrasound 

Speakers: Eugene Y. Kissin, MD; Amy M. Evangelisto, MD 

ACR SESSIONS 

11:00 am – 12:00 pm 

Ballroom A 

ACR Knowledge Bowl Final PM Round PS 


Ed Pd PrM FIT 

207 B 

Approach to Cutaneous Manifestations of 

Childhood Rheumatic Disease PM PS 

Moderator: Kathryn S. Torok, MD; Heidi Jacobe 

Speaker: Julie Schaffer, MD 

Ed Pd PrM FIT 

Salon G 

Common Exercise Injuries and How to Avoid 

Them in Patients 

Moderators: Gurjit S. Kaeley, MBBS, MRCP; Catherine A. 

McAuley, BSc, MSc, PT 

11:00 am 

Exercise in Motion: Putting Physical Activity 

Recommendations into Practice in Rheumatology 

Speaker: Thea P. M. Vliet Vlieland, MD, PT, PhD 

11:30 am 

Common Exercise Injuries 

Speaker: Karl Fields, MD 

Ballroom B 

Nucleic Acid Sensors in Autoimmune Diseases 

Moderator: Mary K. Crow, MD 

Speaker: Zhijian ‘James’ Chen, PhD 

ARHP SESSIONS 

11:00 am – 12:00 pm 

140 A 

Rheumatology Nursing’s Evolving Role 

Moderator: Kori Dewing, DNP 

11:00 am 

Rheumatology Nurse Certification: How to Get It 

Speaker: Jacqueline Fritz, RN, MSN, CNS RNBC 

11:30 am 

Rheumatology Nurses and Their Practice Roles 

Speaker: Sheree Carter, PhD, RN 

209 A 

Sex and Intimacy in Chronic Disease PM PS E 

Moderator: Cindy Cabrera, MSN, BA 

Speaker: Iris Zink, RN, MSN, NP 

204 A 

Time-to-Event Data: Introduction to Analysis 

Moderator: Rebecca J. Cleveland, PhD 

11:00 am 

Overview of Time-to-Event Data 

Speaker: Carolina Alvarez, MS 


Monday 




11:30 am 

Statistical Modeling of Time-to-Event Data 

Speaker: Todd A. Schwartz, DrPH 

201 

When to Consider Sjögren’s Syndrome in a Child 

PM PM Ed PS Pd PSE 

PrM FIT 

Moderator: Jay Mehta, MD, MS 

Speaker: Scott Lieberman, MD, PhD 

ACR SESSIONS 

11:00 am – 12:30 pm 

145 A 

Implementing Quality Measurement In 

Your Practice: How and Why (an ACR/ARHP 

Combined Session) PM PS E 

Moderators: Alex Limanni, MD; Lisa Gale Suter, MD 

11:00 am 

Upcoming Federal Mandates for Quality Improvement 

Speaker: Alex Limanni, MD 

11:15 am 

Merit-Based Incentive Payment System (MIPS) Versus 

Alternative Payment Models (APMs) Explained: What 

Will Work for Your Practice? 

Speaker: Jinoos Yazdany, MD, MPH 

11:40 am 

Rheumatology Informatics System for Effectiveness 

(RISE) Explained: How Does It Work? How Does It 

Impact Practice? 

Speaker: Catalina Orozco, MD 

12:05 pm 

Rheumatology Informatics System for Effectiveness 

(RISE): The Practice Manager’s Perspective 

Speaker: Brian Loggins, MBA 


11:00 am – 12:30 pm 

Hall D 

ACR Plenary Session II: Discovery 2016 

Moderators: David Pisetsky, MD, PhD; Gregory Gardner, 

MD, FACP 

11:00 am 

1955. Rituximab Versus Azathioprine to Maintain 

Remission of ANCA-Associated Vasculitides 

(MAINRITSAN): Follow-Up at 60 Months 

Benjamin Terrier 1 , Christian Pagnoux 2 , Elodie 

Perrodeau 3 , Alexandre Karras 4 , Chahéra Khouatra 5 , 

Olivier Aumaître 6 , Pascal Cohen 7 , Francois Maurier 8 , 

Olivier Decaux 9 , Hélène Desmurs-Clavel 10 , Pierre 

Gobert 11 , Thomas Quémeneur 12 , Claire Blanchard- 

Delaunay 13 , Pascal Godmer 14 , Xavier Puéchal 15 , Luc 

Mouthon 15 , Philippe Ravaud 16 and Loïc Guillevin 15 , 

1 

National Referral Center for Rare Systemic 

Autoimmune Diseases, Hôpital Cochin, AP–HP, 

Université Paris Descartes, Paris, France, 2 Mount 

Sinai Hospital, Toronto, ON, 3 Hopital Hotel Dieu, Paris 

Descartes University, Paris, France, 4 HEGP, Paris, 

France, 5 CHU Lyon, Lyon, France, 6 CHU Pitié-Salpêtrière 

- Department of Internal Medicine 2. Referal center 

for SLE/APS, Paris, France, 7 Cochin Hospital, Paris, 

France, 8 Department of Internal Medicine, HP Metz 

Belle Isle Hospital, Metz, France, 9 Rennes University 

Hospital, Rennes, France, 10 CHU Pitié-Salpêtrière, 

Paris, France, 11 Centre Hospitalier d’Avignon, Avignon, 

France, 12 Hôpital de Valenciennes, Valenciennes, 

France, 13 Centre Hospitalier, Niort, France, 14 CH Vannes, 

Vannes, France, 15 Department of Internal Medicine, 

Referral Center for Rare Autoimmune and Systemic 

Diseases, Hôpital Cochin, AP–HP, Université Paris 

Descartes, Paris, France, Paris, France, 16 Hôpital Hôtel 

Dieu, Paris, France 

11:15 am 

1956. High Dose Nonsteroidal Anti-Inflammatory 

Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor 

Use Results in Less Radiographic Progression in 

Ankylosing Spondylitis – A Longitudinal Analysis 

Lianne S. Gensler 1 , John D. Reveille 2 , MinJae Lee 2 , 

Thomas Learch 3 , Matthew Brown 4 , Mohammad H. 

Rahbar 2 , Michael Weisman 5 and Michael Ward 6 , 1 UCSF, 

San Francisco, CA, 2 University of Texas-McGovern 

Medical School, Houston, TX, 3 Cedars Sinai Medical 

Center, Los Angeles, CA, 4 Queensland University of 

Technology, Brisbane, Australia, 5 Cedars-Sinai Medical 

Center, Los Angeles, CA, 6 NIH/NIAMS, Bethesda, MD 


99


Monday 



11:30 am 

1957. No Increased Risk of Chronic Kidney Disease 

with Allopurinol Use 

Ana Beatriz Vargas-Santos, Christine Peloquin, Yuqing 

Zhang and Tuhina Neogi, Boston University School of 

Medicine, Boston, MA 

11:45 am 

1958. Effect of Poverty Status in 2009, % of Years 

in Poverty Between 2003 and 2009, and Exiting 

Poverty Permanently by 2009 on SLE Damage in 

2015 

Edward H. Yelin 1 , Jinoos Yazdany 2 and Laura Trupin 3 , 

1 

UC San Francisco, San Francisco, CA, 2 University of 

California, San Francisco, San Francisco, CA, 3 University 

of California San Francisco, San Francisco, CA 

12:00 pm 

1959. How Do Bone Marrow Lesions Cause 

Osteoarthritis Pain? A Structural and Functional 

Tissue-Based Study 

Nidhi Sofat 1 , Lena Assi 2 , Anasuya Kuttapitiya 2 , Alan 

Boyde 3 , Vivian Ejindu 4 and Christine Heron 4 , 1 St. 

George’s, University of London, London, United 

Kingdom, 2 Institute for Infection & Immunity, London, 

United Kingdom, 3 Queen Mary University of London, 

London, United Kingdom, 4 St George’s Hospital, 


12:15 pm 

1960. 2015 ACR/ARHP Workforce Study in the U.S.: 

The Role of Graduate Medical Education (GME) in 

Adult Rheumatology 

Marcy Bolster 1 , Anne R. Bass 2 , Jonathan S. Hausmann 3 , 

Marcia Ditmyer 4 , Seetha Monrad 5 and Daniel 

Battafarano 6 , 1 Massachusetts General Hospital, Boston, 

MA, 2 Hospital for Special Surgery Weill Cornell Medical 

College, New York, NY, 3 Beth Israel Deaconess Medical 

Center, Boston, MA, 4 Academy for Academic Research, 

Las Vegas, NV, 5 University of Michigan, Ann Arbor, MI, 

6 

San Antonio Military Medical Center, San Antonio, TX 


12:00 pm – 2:00 pm 

Marriott Marquis – Meeting Level 4 (Liberty 

Ballroom: Salon I) 

ARHP Topic Round Tables: Networking Forum 

Sit down with your colleagues over a complimentary lunch, 

and participate in open discussion on various research, 

practice, and clinical topics. Each roundtable discussion 

will be facilitated by a rheumatology expert. All ARHP 

attendees are welcome to participate in this event. This 

session is not eligible for CME credit. 

ACR SESSIONS 

12:30 pm – 2:00 pm 

146 A 

2016 CARE: MOC Sessions 2 of 3: Nonarticular 

and Regional Musculoskeletal Disorders 


Speaker: Seetha Monrad, MD 

143 A 

Hot Topics in Teaching Techniques: Flipped 

Classroom, Technology, and Reflection PM Ed Pd PS PrM FIT 

Moderators: Eli Miloslavsky, MD; Karen Law, MD 

12:30 pm 

Flipping the Classroom for Medical learners: Theory, 

Evidence, and Practical Strategies 

Speaker: Jeremy Richards, MD 

1:00 pm 

Gadgets and Gizmos A-Plenty: Using Digital Tools to 

Enhance Medical Education 

Speaker: Aaron Kamer, MD 

1:30 pm 

Incorporating Reflection into Medical Education: A 

Path to Deeper Learning 

Speaker: C. Christopher Smith, MD 


Monday 




12:45 pm – 2:15 pm 










148 

041 – Adult Inflammatory Myopathy 


153 

042 – Challenging Cases in Osteoporosis 

Management 

Speaker: Nancy Lane, MD 

154 A 

043 – Infections with Biologics PM PS E 


154 B 

044 – Osteoarthritis: Update 2016 


159 A 


Treatments 

Speaker: Liz Lightstone, MD, PhD 

159 B 

049 – Systemic Sclerosis: Disease Staging and 

Subsetting in Clinical Practice 

Speaker: Robyn T. Domsic, MD, MPH 

160 


Patterns 

Speaker: Kenneth J. Warrington, MD 

ACR SESSIONS 

1:00 pm – 2:00 pm 

202 B 

Immunology Update: Can We Reset the 

Immunology Landscape? 


Speaker: David A. Hafler, MD 

Hall E 

Inflammatory Bowel Disease and the 

Rheumatologist 

Moderators: Kristine M. Lohr, MD, MS; Kevin Byram, MD 

Speaker: Joshua Korzenik, MD 

155 

045 – Pregnancy and Rheumatic Diseases 


158 A 


Speaker: Stanley B. Cohen, MD 

158 B 

047 – Survival Strategies: Seeking, Joining, 

Thriving in Private Practice 


Speaker: Herbert S. B. Baraf, MD, FACP, MACR 

PM PS E 

Ballroom A 

Rheumatology Research Foundation Oscar S. 

Gluck, MD, Memorial Lecture: Osteoporosis 

2016 – “A Breaking Crisis?” 

Moderator: Michael J. Maricic, MD 


STUDY GROUPS 

1:00 pm – 2:00 pm 

Take advantage of these unique social forums, designed 

to bring together small groups of attendees with common 

interest in a single disease, a group of related disorders 

or a specialized field of study. Study Groups are non-CME 

activities open to all attendees. 


101


Monday 



147 A 

Autoantibodies in Diagnosis and Follow-up 

of Rheumatic Diseases: Current Initiatives in 

International Autoantibody Standardization 

(IAS) and International Consensus on 

Antinuclear Antibody Patterns (ICAP) 

Speakers: Luis Eduardo C. Andrade, MD, PhD; Edward 

K.L. Chan, PhD; Pier Luigi Meroni 

201 

Childhood Sjögren’s Syndrome Study Group 

Speakers: Jay Mehta, MD, MS; Scott Lieberman, MD, 

PhD 

151 A 

Giant Cell Arteritis Study Group PM Ed Pd PS PrM FIT 

Speakers: Bhaskar Dasgupta; Eric L. Matteson, MD, MPH 

206 

Global Musculoskeletal Health Initiatives Study 

Group 

Speakers: Anthony Woolf, MD; Lyn March, FRACP, 

MBBS, MSc, PhD; Alan Silman, DSc; Lydia A. Alcazar 

140 A 

Latin American Study Group/Epidemiological 

Studies in Rheumatology on Indigenous People 

in Latin America 

Speakers: Loreto Massardo, MD; Ruben Burgos-Vargas, 

MD; Bernado Pons-Estel, MD; Ingris P Ballestas, MD, 

PhD 

145 A 

Macrophage Activation Syndrome (MAS) Study 

Group 

Speakers: Randy Q. Cron; Edward M. Behrens; Alexei 

Grom, MD; Claudio Giraudo, PhD 

207 B 

Patient Registries – Ups and Downs PM Ed Pd PS PrM FIT 

Speaker: Yusuf Yazici, MD; Hasan Yazici, MD; Theodore 

Pincus, MD; Kaleb Michaud, PhD 

152 A 

Patient Research Partners Study Group 

Speakers: Jennifer R. Horonjeff, PhD; Kaleb Michaud, 

PhD 

150 A 

Polymyalgia Rheumatica Study Group 

Speakers: Bhaskar Dasgupta, FRCP, MD; Eric L. 

Matteson, MD, MPH 

WORKSHOPS 

1:15 pm – 3:15 pm 










144 A 

223 – How to Apply Statistics to Your Research 

Speakers: Dorothy D. Dunlop, PhD; Julia (Jungwha) Lee, 

PhD, MPH 

144 C 

224 – Joint Injection Techniques PM PS E 

Speakers: Atul A. Deodhar, MD; Kenneth S. O’Rourke, 

MD 

204 A 

Osteoarthritis Study Group 

Speakers: Carla R. Scanzello, MD, PhD; Simon M. 

Helfgott, MD; Gillian Hawker, MD 

149 A 

225 – Magnetic Resonance Imaging (MRI) in the 

Diagnosis and Management of Spondylarthritis: 

A Clinician’s Guide 

Speaker: Walter Maksymowych 


Monday 



WORKSHOPS continued 

144 B 

226 – The Rheumatologic Musculoskeletal 

Screening Exam, with Emphasis on Objective 

Disease-Specific Measurements PM PS E 

Speakers: Arthur M. Mandelin II, MD, PhD; Sharon 

Tymkiw, MSN, MBA, RN 

ACR SESSIONS 

2:30 pm – 4:00 pm 

Hall D 

Advances in Takayasu’s Arteritis 

Moderators: Eli Miloslavsky, MD; Rebecca L. Manno, 

MD, MHS 

2:30 pm 

Genetics and Pathogenesis of Takayasu’s Arteritis 

Speaker: Amr H. Sawalha, MD 

3:00 pm 

Assessment of Disease Activity and Damage in 

Takayasu’s Arteritis 

Speaker: Haner Direskeneli, MD, Professor 


3:30 pm 

PPAR Mediated Pathways as Targets in Osetoarthritis 

Speaker: Frank Beier, PhD 

Hall E 

Thieves’ Market: Show Me Your Best Cases 

Moderator: Mathilde H. Pioro, MD; Grant Hughes, MD 

2:50 pm 

Case Presentation 1 

Speaker: Suhas Ganguli, MD, DCH 

3:00 pm 


Speaker: Brittany Bettendorf, MD 

3:10 pm 


Speaker: Kaitlin A. Quinn, MD 

3:20 pm 


Speaker: Latisha Heinlen, MD, PhD 

3:30 pm 

Management of Takayasu’s Arteritis 

Speaker: Peter A. Merkel, MD, MPH 

151 A 

Breakthroughs in Osteoarthritis: New 

Therapeutic Targets 

PM PS E 

Moderators: Carla R. Scanzello, MD, PhD; Tom Appleton, 

MD, PhD, FRCPC 

2:30 pm 

Epigenetic Regulation of Zinc Transport and 

Inflammation in Osteoarthritis 

Speaker: Louise Reynard, PhD 

3:00 pm 

New Scientific Breakthroughs in Osteoarthritis 

Suggest New Treatment Targets 

Speaker: Anne-Marie Malfait, MD, PhD 

3:30 pm 


Speaker: Gineth Pinto-Patarroyo, MD 

3:40 pm 


Speaker: Paul Bird, MD 


2:30 pm – 4:00 pm 

150 A 

Antiphospholipid Syndrome 

Moderators: Maria Laura Bertolaccini, PhD; Martin 

Kriegel, MD, PhD 


103


Monday 



2:30 pm 

1961. Identification of Novel Genetic Susceptibility 

Loci in Primary Antiphospholipid Syndrome 

Elizabeth Gensterblum 1 , Travis Hughes 2 , Manuel 

Martínez-Bueno 3 , Maria Orietta Borghi 4 , Guillermo J. 

Pons-Estel 5 , Gerard Espinosa 6 , Alexandra Zhernakova 7 , 

Cisca Wijmenga 8 , Ricard Cervera 5 , Pier Luigi Meroni 9 , 

Marta Alarcón-Riquelme 3 and Amr Sawalha 1 , 1 Division 

of Rheumatology, University of Michigan, Ann Arbor, 

MI, 2 Division of Health Sciences and Technology, 

Harvard Medical School, Boston, MA, 3 Center for 

Genomics and Oncological Research (GENYO), 

Pfizer-University of Granada-Andalusian Regional 

Government, Health Sciences Technology Park, 

Granada, Spain, 4 University of Milan, IRCCS Istituto 

Auxologico Italiano, Milan, Italy, 5 Department of 

Autoimmune Diseases, Institut Clínic de Medicina i 

Dermatologia, Hospital Clínic de Barcelona, Barcelona, 

Spain, 6 Autoimmune Diseases Department. Hospital 

Clínic de Barcelona, Barcelona, Spain, 7 University of 

Groningen, University Medical Center, Groningen, 

Netherlands, 8 University Medical Hospital Groningen, 

University of Groningen, Groningen, Netherlands, 

9 

Hospital G.Pini, University of Milano, IRCSS Instute 

Auxologico Italiano, Milan, Italy 

2:45 pm 

1962. Antiphospholipid Syndrome Neutrophils Are 

Characterized by Overexpression of P-Selectin 

Glycoprotein Ligand 1, a Potential Therapeutic 

Target 

Jason S Knight 1 , Patrick S. Coit 1 , He Meng 1 , Srilakshmi 

Yalavarthi 1 , Paul Renauer 1 , Robert C Grenn 1 , Levi F 

Mazza 1 , Hui Wang 1 , Daniel T Eitzman 1 and Amr H 

Sawalha 2 , 1 University of Michigan, Ann Arbor, MI, 

2 

Division of Rheumatology, University of Michigan, Ann 

Arbor, MI 

3:00 pm 

1963. Thrombospondin-1 Is Elevated in the Plasma 

of Patients with Antiphospholipid Syndrome and 

Is Correlated with Free Active TGF-b1 Levels, IL-1b 

and IL-17A 

Markos Patsouras, Athanasios G. Tzioufas and 

Panayiotis G Vlachoyiannopoulos, School of 

Medicine, Pathophysiology Department, National and 

Kapodistrian University of Athens, Athens, Greece 

3:15 pm 

1964. The Frequency and Clinical Significance of 

IgA Anticardiolipin and Anti-β 2 

-Glycoprotein-I 

Antibodies in Antiphospholipid Antibody Patients 

with and without Lupus 

Ayten Yazici 1 , OZAN UNLU 2 , Cecilia B. Chighizola 3 , 

Doruk Erkan 4 , Michelle Petri 5 and On Behalf of APS 

ACTION . 6 , 1 Hospital for Special Surgery, Cornell Weill 

Cornell Medicine, NEW YORK CITY, Turkey, 2 Hospital 

for Special Surgery, Weill Cornell Medicine, New York, 

NY, 3 University of Milan, IRCCS Istituto Auxologico 

Italiano, Milano, Italy, 4 Hospital for Special Surgery- 

NewYork-Presbyterian / Weill Cornell Medicine, New 

York, NY, 5 Johns Hopkins University School of Medicine, 

Baltimore, MD, 6 ., New York, NY 

3:30 pm 

1965. Antiphospholipid Syndrome Alliance for 

Clinical Trials & International Networking Registry 

Analysis: First and Recurrent Thrombosis Risk after 

720 Patient-Years of Follow-up 

Ozan Unlu 1 , W. David Branch 2 , Paul R. Fortin 3 , Maria 

Gerosa 4 , Guillermo J. Pons-Estel 5 , Maria Tektonidou 6 , 

Amaia Ugarte 7 , Doruk Erkan 8 and On Behalf of APS 

ACTION . 9 , 1 Hospital for Special Surgery, Weill Cornell 

Medicine, New York, NY, 2 University of Utah and 

Intermountain Healthcare, Salt Lake City, UT, 3 CHU 

de Québec - Université Laval, Québec, QC, 4 University 

of Milan, Istituto Ortopedico Gaetano Pini, Milano, 

Italy, 5 Department of Autoimmune Diseases, Institut 

Clínic de Medicina i Dermatologia, Hospital Clínic 

de Barcelona, Barcelona, Spain, 6 First Department 

of Internal Medicine, School of Medicine, National 

University of Athens, Athens, Greece, 7 Hospital 

Universitario Cruces, Biscay, Spain, 8 Hospital for 

Special Surgery- NewYork-Presbyterian / Weill Cornell 

Medicine, New York, NY, 9 ., New York, NY 

3:45 pm 

1966. Antibodies Against Domain 1 and Domain 4/5 

of β2 Glycoprotein I: Clinical Relevance in Obstetric 

Anti-Phospholipid Syndrome 

Cecilia B. Chighizola 1 , Laura Andreoli 2 , Marta Tonello 3 , 

Maria Gabriella Raimondo 4 , Francesca Pregnolato 5 , 

Cecilia Nalli 6 , Elena Mattia 7 , Laura Cesana 8 , Rajesh 

Kumar 6 , Chiara Comerio 9 , Claudia Grossi 8 , Francesco 

Mombelli 10 , Maria Gerosa 11 , Maria Orietta Borghi 12 , 


Monday 




Amelia Ruffatti 13 , Angela Tincani 14 and Pier Luigi 

Meroni 11 , 1 University of Milan, IRCCS Istituto Auxologico 

Italiano, Milano, Italy, 2 University of Brescia, Spedali 

Civili, Brescia, Italy, 3 Rheumatology Unit, Department 

of Medicine DIMED, University of Padua, Padova, Italy, 

4 

University of Milan, Istituto Ortopedico Gaetano Pini, 

Milan, Italy, 5 IRCCS Istituto Auxologico Italiano, Milano, 

Italy, 6 Spedali Civili, Brescia, Italy, 7 Azienda Ospedaliera 

of Padova, Padua, Italy, 8 IRCCS Istituto Auxologico 

Italiano, Milan, Italy, 9 University of Milan, Milan, Italy, 

10 

University of Brescia, Brescia, Italy, 11 University 

of Milan, Istituto Ortopedico Gaetano Pini, Milano, 

Italy, 12 University of Milan, IRCCS Istituto Auxologico 

Italiano, Milan, Italy, 13 Azienda Ospedaliera of Padova, 

University of Padova, Padova, Italy, 14 Rheumatology 

and Clinical Immunology, Spedali Civili and University 

of Brescia, Brescia, Italy 

146 A 

Healthcare Disparities in Rheumatology 

Moderators: Jim Oates, MD; Amanda Sammut, MD 

2:30 pm 

1967. Depression Is a Risk Factor for Low Treatment 

Adherence in African American People with 


Cristina Drenkard 1 , Sonia Mathew 2 , Gaobin Bao 1 and 

S. Sam Lim 1 , 1 Emory University School of Medicine, 

Atlanta, GA, 2 Mercer School of Medicine, Macon, GA 

2:45 pm 

1968. Adverse Childhood Experiences and 

Outcomes of Systemic Lupus Erythematosus 

Laura Trupin 1 , Patricia P. Katz 1 , Cristina Lanata 1 , Edward 

H. Yelin 1 , Lindsey A. Criswell 1 , Charles G. Helmick 2 , 

Jinoos Yazdany 1 and Maria Dall’Era 1 , 1 University of 

California, San Francisco, San Francisco, CA, 2 Centers 

for Disease Control and Prevention, Atlanta, GA 

3:00 pm 

1969. Peer Approaches to Lupus Self-Management 

(PALS): A Novel Lupus Peer Mentorship 

Intervention 

Edith M. Williams, Leonard Egede, Jim Oates, Delia 

Voronca and Mulugeta Gebregziabher, Medical 

University of South Carolina, Charleston, SC 

3:15 pm 

1970. Disparities in Access to Specialist Care 

at the Time of Diagnosis of Systemic Lupus 

Erythematosus 

Lisa Gaynon 1 , Patricia P. Katz 2 , Maria Dall’Era 2 , Laura 

Trupin 2 , Lindsey A. Criswell 3 , Cristina Lanata 3 , Charles 

Hemlick 4 and Jinoos Yazdany 2 , 1 California Pacific 

Medical Center, San Francisco, CA, 2 University of 

California, San Francisco, San Francisco, CA, 3 UCSF, 

San Francisco, CA, 4 Centers for Disease Control and 

Prevention, Atlanta, GA 

3:30 pm 

1971. Predictors of Delays to Care and Associated 

Outcomes in Pediatric Lupus Patients from the 

Childhood Arthritis and Rheumatology Research 

Alliance Registry 

Tamar Rubinstein 1 , Norman Ilowite 2 and Dawn 

Wahezi 3 , 1 Albert Einstein College of Medicine, Children’s 

Hospital at Montefiore, Bronx, NY, 2 Children’s Hospital 

at Montefiore, Bronx, NY, 3 The Children’s Hospital at 

Montefiore, Bronx, NY 

3:45 pm 

1972. Creatine Kinase in the United States 

Population: Impact of Demographics, 

Comorbidities, and Body Composition on the 

Normal Range 

Neilia-Kay McGill, Joshua F. Baker and Michael D. 

George, University of Pennsylvania, Philadelphia, PA 

Salon G 

Imaging of Rheumatic Diseases II: Ultrasound in 


Moderators: Jay B. Higgs, MD; Eugene Y. Kissin, MD 

2:30 pm 

1973. Intramuscular Versus Ultrasound Guided 

Peritendinous Glucocorticoid Injection for 

Tenosynovitis in Patients with Rheumatoid 

Arthritis – A Randomized, Double-Blind, Controlled 

Study 

Mads Ammitzbøll-Danielsen 1 , Mikkel Ostergaard 2 , 

Viktoria Fana 1 , Daniel Glinatsi 3 , Uffe Møller Døhn 1 , 

Lykke Midtbøll Ørnbjerg 4 , Esperanza Naredo 5 and Lene 

Terslev 1 , 1 Copenhagen Center for Arthritis Research 

(COPECARE), Copenhagen, Denmark, 2 Copenhagen 


105


Monday 



Center for Arthritis Research, Copenhagen, Denmark, 

3 



Copenhagen, Denmark, Glostrup, Denmark, 

4 



Copenhagen, Denmark, 5 Hospital General Universitario 

Gregorio Marañón and Universidad Complutense, 

Madrid, Spain 

2:45 pm 

1974. Is Ultrasound of the Hands Enough to Reveal 

Ongoing Subclinical Inflammation in Rheumatoid 

Arthritis Patients in Clinical Remission According to 

Composite Scores? 

Hilde Berner Hammer 1 , Tore K Kvien 1 and Lene 

Terslev 2 , 1 Diakonhjemmet Hospital, Oslo, Norway, 

2 

Copenhagen Center for Arthritis Research 

(COPECARE), Copenhagen, Denmark 

3:00 pm 

1975. Severity and Improvement of Morning 

Stiffness Independently Associate with 

Tenosynovitis in Patients with Rheumatoid 

Arthritis 

Yoshihisa Kobayashi 1 , Kei Ikeda 2 , Takayuki Nakamura 3 , 

Mieko Yamagata 4 , Takuya Nakazawa 5 , Shigeru 

Tanaka 2 , Shunsuke Furuta 2 , Takeshi Umibe 6 and 

Hiroshi Nakajima 2 , 1 Chiba Aoba Municipal Hospital, 

Chiba, Japan, 2 Chiba University Hospital, Chiba, Japan, 

3 

Asahi General Hospital, Asahi, Japan, 4 National 

Hospital Organization Shimoshizu National Hospital, 

Yotsukaido, Japan, 5 National Hospital Organization 

Chiba-East Hospital, Chiba, Japan, 6 Matudo City 

Hospital, Matudo, Japan 

3:15 pm 

1976. Ultrasound Inflammation in Patients 

Presenting with Arthralgia Is Associated with 

Developing Arthritis 

Myrthe van der Ven 1 , Marjolein Van der Veer- 

Meerkerk 1 , David F. Ten Cate 1 , Nigara Rasappu 2 , Marc 

R. Kok 3 , Dora Csakvari 4 , Johanna M.W. Hazes 1 , Andreas 

H. Gerards 5 and Jolanda J. Luime 2 , 1 Erasmus University 

Medical Centre, Rotterdam, Netherlands, 2 Erasmus 

Medical Centre, Rotterdam, Netherlands, 3 Maasstad 

Hospital, Rotterdam, Netherlands, 4 Erasmus University 

Medical Centre, ROTTERDAM, Netherlands, 5 Vlietland 

Hospital, Schiedam, Netherlands 

3:30 pm 

1977. Impact of Ultrasound in Treatment Decision 

of Rheumatoid Arthritis Assessed in Routine 

Clinical Practice 

César Sifuentes-Cantú 1 , Lina Saldarriaga-Rivera 2 , 

Ana Cecilia Lozada 2 , Irazu Contreras-Yañez 3 , Marwin 

Gutierrez 4 and Virginia Pascual-Ramos 1 , 1 Instituto 

Nacional de Ciencias Médicas y Nutrición Salvador 

Zubirán, Mexico City, Mexico, 2 Instituto Nacional de 

Rehabilitación, Mexico City, Mexico, 3 Instituto Nacional 

de Ciencias Médicas y Nutrición Salvador Zubirán, 

Mexico, Mexico, 4 Instituto Nacional de Rehabilitación, 

Mexico, Mexico 

3:45 pm 

1978. Differential Pattern of Doppler Signals at 

Lower Extremity Entheses of Healthy Children 

Johannes Roth 1 , Sara Stinson 2 and Luca Di Geso 3 , 

1 

Children’s Hospital Eastern On, Ottawa, ON, 

2 

Children’s Hospital of Eastern Ontario, Ottawa, ON, 

3 

Department of Internal Medicine Ospedale Madonna 

del Soccorso, San Benedetto del Tronto, Italy 

140 A 

Pain – Basic and Clinical Aspects 

Moderators: Terence Starz, MD; Alfonso Bello, MD, MHS 

2:30 pm 

1979. Post-Arthroplasty Pain Trajectories after 

Total Knee Arthroplasty and Their Association with 

6- and 12-Month Pain 

Jasvinder A. Singh 1 , Lisa Nobel 2 , Norman Weissman 2 , 

Kenneth G. Saag 1 , Phillip J. Foster 1 , Jeroan J. Allison 3 , 

Celeste Lemay 3 and Patricia D. Franklin 3 , 1 University of 

Alabama at Birmingham, Birmingham, AL, 2 University 

of Massachusetts, Boston, MA, 3 University of 

Massachusetts Medical School, Worcester, MA 

2:45 pm 

1980. Relation of Pain Sensitization to the Evolution 

from Intermittent to Chronic, Persistent Pain in 

Knee Osteoarthritis: The Multicenter Osteoarthritis 

Study 

Jia Liu 1 , Laura Frey-Law 2 , Gillian Hawker 3 , Carrie 

Brown 4 , Cora E. Lewis 5 , Michael C. Nevitt 6 and Tuhina 

Neogi 7 , 1 Boston Medical Center, Boston, MA, 2 UIowa, 

Iowa City, IA, 3 University of Toronto, Toronto, ON, 

4 

Boston University School of Public Health, Boston, MA, 


Monday 




5 

University of Alabama Birmingham, Birmingham, AL, 

6 


CA, 7 Boston University School of Medicine, Boston, MA 

3:00 pm 

1981. A Pilot Pulsed Arterial Spin Labeling Study of 

Regional Cerebral Blood Flow in Response to Pain in 

RA, before and after DMARD Treatment 

Yvonne C. Lee 1 , Alexander Fine 1 , Ekaterina Protsenko 2 , 

Elena Massarotti 3 , Robert R. Edwards 4 , Vitaly Napadow 5 

and Marco Loggia 2 , 1 Brigham and Women’s Hospital, 

Boston, MA, 2 Massachusetts General Hospital, 

Boston, MA, 3 Brigham & Women’s Hospital, Boston, 

MA, 4 Brigham & Womens Hospital, Chestnut Hill, MA, 

5 

Massachusetts General Hospital, Charlestown, MA 

3:15 pm 

1982. Comparative Safety of Long-Acting Opioids 

for Non-Cancer Pain 

Cecilia P. Chung, William Dupont, Katherine Murray, 

Kathi Hall, C. Michael Stein and Wayne Ray, Vanderbilt 

University Medical Center, Nashville, TN 

3:30 pm 

1983. Pain and Sensitization in Women with 

Aromatase Inhibitor-Associated Arthralgias 

Monica Crespo-Bosque 1 , Carrie Brown 2 , Brenda 

Cartmel 3 , Maura Harrigan 3 , Melinda Irwin 3 and Tuhina 

Neogi 4 , 1 Boston Medical Center, Boston, MA, 2 Boston 

University School of Public Health, Boston, MA, 3 Yale 

School of Public Health, New Haven, CT, 4 Boston 

University School of Medicine, Boston, MA 

3:45 pm 

1984. Which Factors Associate with Localized Knee 

Pain and Generalized Pain: A 10-Year Longitudinal 

Study? 

Feng Pan 1 , Dawn Aitken 2 , Jing Tian 2 , Flavia M Cicuttini 3 , 

Changhai Ding 2 and Graeme Jones 2 , 1 Menzies Institute 

for Medical Research, University of Tasmania, 

Hobart,7000, Australia, 2 Menzies Institute for Medical 

Research, University of Tasmania, Hobart, Australia, 

3 

Monash University, Department of Epidemiology and 

Preventive Medicine, Melbourne, Australia 

147 A 

Pediatric Rheumatology – Pathogenesis and 

Genetics 

Includes 2015 Lee C. Howley, Sr. Prize for Arthritis Research 

Introductory Talk 

Moderators: Theresa Lu, MD, PhD; Edward M. Behrens 

2:00 pm 

2015 Lee C. Howley, Sr. Prize for Arthritis Research 

Introductory Talk 

Speaker: Levi Watkin, PhD 

2:45 pm 

1985. IL-18 Elevation in Macrophage Activation 

Syndrome: Human Evidence for a Chronic Set-Point 

and Murine Evidence for a Non-Hematopoietic 

Source 

Zeshan Tariq 1 , Eric Weiss 2 , Wendy Goodspeed 2 , 

Raphaela Goldbach-Mansky 3 and Scott Canna 2 , 

1 

NIAMS/NIH, Bethesd, MD, 2 NIAMS/NIH, Bethesda, MD, 

3 

National Institute of Allergy and Infectious Diseases 

(NIAID), NIH, Bethesda, MD 

3:00 pm 

1986. Murine Model of Arthritis Flare Identifies 

Tissue Resident Memory T Cells in Recurrent 

Synovitis 

Margaret H Chang 1 , Anais Levescot 2 , Allyn Morris 2 , 

Robert Fuhlbrigge 1 and Peter Nigrovic 1 , 1 Boston 

Children’s Hospital, Boston, MA, 2 Brigham and 

Women’s Hospital, Boston, MA 

3:15 pm 

1987. Recessive Coding and Regulatory Mutations 

in FBLIM1 Underlie the Pathogenesis of Sterile 

Osteomyelitis 

Allison Cox 1 , Benjamin W Darbro 1 , Ronald Laxer 2 , Xinyu 

Bing 1 , Alexis Finer 1 , Albert Erives 1 , Vinit Mahajan 1 , 

Alexander G Bassuk 1 and Polly Ferguson 1 , 1 University 

of Iowa Carver College of Medicine, Iowa City, IA, 2 The 

Hospital for Sick Children, Toronto, ON 

3:30 pm 

1988. Oral Health and Anti-Citrullinated Peptide 

Antibodies in Juvenile Idiopathic Arthritis 

Sriharsha Grevich 1 , Peggy Lee 1 , Sarah Ringold 1 , Brian 

Leroux 1 , Hannah Leahey 2 , Megan Yuasa 2 , Jessica 

Foster 2 , Jeremy Sokolove 3 , Lauren Lahey 4 , William 



Monday 



Robinson 4 , Joshua Newson 1 and Anne Stevens 2 , 

1 

University of Washington, Seattle, WA, 2 Seattle 

Children’s Research Institute, Seattle, WA, 3 Division of 

Immunology and Rheumatology, Stanford University 

School of Medicine, Stanford, CA, 4 Stanford University, 

Stanford, CA 

Wolfe 2 and Kaleb Michaud 4 , 1 Marmara University 

Faculty of Medicine, Istanbul, Turkey, 2 National Data 

Bank for Rheumatic Diseases, Wichita, KS, 3 Clinical 

Epidemiology Unit, Dept of Medicine, Karolinska 

Institutet, Stockholm, Sweden, 4 University of Nebraska 

Medical Center, Omaha, NE 

3:45 pm 

1989. Mechanism of STAT3 Gain-of-Function in a 

Patient with JIA 

Tiphanie P. Vogel 1 , Nermina Saucier 2 , Molly P. Keppel 2 

and Megan A. Cooper 2 , 1 Washington University in St. 

Louis, St. Louis, MO, 2 Washington University in St. 

Louis, Saint Louis, MO 

Ballroom C 

Rheumatoid Arthritis – Clinical Aspects II: Risk 

and Impact of Comorbidity 

Moderator: Kimme L. Hyrich, FRCP, PhD 

2:30 pm 

1990. Increased Risk of Cardiovascular Events in 

Patients with Rheumatoid Arthritis over a 15 Year 

Time Period That Is Comparable to Type 2 Diabetes 

Rabia Agca 1 , Luuk H.G.A. Hopman 1 , Vokko P. van Halm 2 , 

Mike J.L. Peters 2 , Jacqueline M. Dekker 2 , Giel Nijpels 2 , 

Coen D.A. Stehouwer 3 , Yvo M. Smulders 2 , Alexandre 

E. Voskuyl 4 , Maarten Boers 4 , Willem F. Lems 5 and Mike 

T. Nurmohamed 6 , 1 Amsterdam Rheumatology and 

immunology Center, Location Reade, Amsterdam, 

Netherlands, 2 VU University Medical Center, 

Amsterdam, Netherlands, 3 Department of Internal 

Medicine, Maastricht University Medical Centre, 

Maastricht, Netherlands, 4 Amsterdam Rheumatology 

and immunology Center, Location VU University 

Medical Center, Amsterdam, Netherlands, 5 Amsterdam 

Rheumatology and immunology Center, location VU 

University Medical Center, Amsterdam, Netherlands, 


and immunology Center, Location VU University 

Medical Center, Amsterdam, Netherlands, Amsterdam, 

Netherlands 

2:45 pm 

1991. Risk of Incident Diabetes Mellitus and Its 

Association with Disease-Modifying Antirheumatic 

Drugs and Statins in Rheumatoid Arthritis 

Gulsen Ozen 1 , Sofia Pedro 2 , Marie Holmqvist 3 , Frederick 

3:00 pm 

1992. Rheumatoid Arthritis Is an Independent 

Risk Factor for Increased Insulin Resistance and 

Impaired Beta-Cell Function: Impact of Disease 

Activity 

Gorica Ristic 1 , Vesna Subota 1 , Dejana Stanisavljevic 2 , 

Branislava Glisic 1 , Milan Petronijevic 1 and Dusan 

Stefanovic 1 , 1 Military Medical Academy, Belgrade, 

Serbia, 2 Belgrade University School of Medicine, 

Belgrade, Serbia 

3:15 pm 

1993. The Risk of Stroke in Patients with 

Rheumatoid Arthritis and the Association with 

Competing Adverse Events 

Yvette Meißner 1 , Adrian Richter 1 , Joern Kekow 2 , Hans 

Peter Tony 3 , Elke Wilden 4 , Angela Zink 5 , Joachim Listing 1 

and Anja Strangfeld 1 , 1 German Rheumatism Research 

Center, Berlin, Germany, 2 University of Magdeburg, 

Clinic of Rheumatology, Magdeburg, Germany, 

3 

University Hospital Würzburg, Würzburg, Germany, 

4 

Rheumatologist, Köln, Germany, 5 Charité - University 

Medicine Berlin, Berlin, Germany 

3:30 pm 

1994. Associations of Chronic Lung Comorbidity 

with Medications, Disease Activity, and All-Cause 

Mortality in Rheumatoid Arthritis 

Bryant R. England 1 , Harlan Sayles 2 , Kaleb Michaud 2 , 

Liron Caplan 3 , Lisa A. Davis 3 , Grant W. Cannon 4 , Brian 

Sauer 5 , E. Blair Solow 6 , Andreas Reimold 7 , Gail S. Kerr 8 , 

Pascale Schwab 9 , Joshua F. Baker 10 , Namrata Singh 11 

and Ted R. Mikuls 12 , 1 VA Nebraska-Western Iowa, 

Omaha, NE, 2 University of Nebraska Medical Center, 

Omaha, NE, 3 Denver VAMC and Univ of Colorado 

School of Medicine, Aurora, CO, 4 Veterans Affairs Salt 

Lake City Health Care System and University of Utah 

School of Medicine, Salt Lake City, UT, 5 HSR&D SLC 

VA Medical Center and University of Utah, Salt Lake 

City, UT, 6 UT Southwestern Medical Center, Dallas, 

TX, 7 Dallas VA Medical Center and University of Texas 


Monday 




Southwestern Medical Center, Dallas, TX, 8 Washington 

DC VAMC, Georgetown University Hospital, Howard 

University Hospital, Washington, DC, 9 Portland VA and 


10 

University of Pennsylvania and Philadelphia VAMC, 

Philadelphia, PA, 11 University of Iowa Hospitals and 

Clinics and Iowa City VA, Iowa City, IA, 12 Veteran Affairs 

Nebraska-Western Iowa Health Care System and 

University of Nebraska Medical Center, Omaha, NE 

3:45 pm 

1995. Smoking Is Associated with Unfavorable 

Flare/Remission Pattern in Patients with 


Shafay Raheel, Cynthia S. Crowson, Eric L. Matteson 

and Elena Myasoedova, Mayo Clinic, Rochester, MN 

Salon B 

Rheumatoid Arthritis – Small Molecules, 

Biologics, and Gene Therapy II: Safety and Cost 

Effectiveness 

Moderators: Andreas M. Reimold, MD; Maya H. Buch 

2:30 pm 

1996. Comparative Safety of Biologic DMARD 

Initiation with Abatacept in Rheumatoid Arthritis: 

A Real-World, Population-Based, Observational 

Study 

S Suissa 1 , S Dell’Aniello 1 , H Kawabata 2 and TA Simon 2 , 

1 

McGill University, Montreal, QC, 2 Bristol-Myers Squibb, 

Princeton, NJ 

2:45 pm 

1997. Non-Medical Switch from Originator to 

Biosimilar Infliximab in Patients with Inflammatory 

Arthritis – Impact on s-Infliximab and Antidrug- 

Antibodies. Results from the Danish Rheumatologic 

Biobank and the Danbio Registry 

Bente Glintborg 1 , Tina Marie Kringelbach 1 , Estrid 

Høgdall 1 , Inge Juul Sørensen 2 , Dorte Vendelbo Jensen 2 , 

Anne Gitte Loft 3 , Oliver Hendricks 4 , Inger Marie Jensen 

Hansen 2 , Asta Linauskas 2 , Salome Kristensen 2 , Hanne 

Lindegaard 5 , Henrik Nordin 2 , Nils Bolstad 6 , David 

Warren 6 , Johanna Gehin 6 , Guro Løvik Goll 6 , Kathrine 

Lederballe Grøn 2 , Grith Eng 2 , Christian Enevold 1 , Claus 

Henrik Nielsen 1 , Julia Sidenius Johansen 1 and Merete 

Lund Hetland 1 , 1 Danish Rheumatologic Biobank and 

DANBIO registry, Rigshospitalet, Glostrup, Gentofte 

and Herlev University Hospital, Copenhagen, Denmark, 

2 

The DANBIO registry and the Danish Departments of 

Rheumatology, Copenhagen, Denmark, 3 Departments 

of Rheumatology at Vejle and Aarhus Hospitals, 

Vejle and Aarhus, Denmark, 4 Dep. of Rheumatology, 

King Christians Hospital for Rheumatic Diseases, 

Copenhagen, Denmark, 5 The DANBIO registry and 

the Danish Departments of Rheumatology, Odense, 

Denmark, 6 Department of Medical Biochemistry, OUS- 

Radiumhospitalet and Diakonhjemmet Sykehus, Oslo, 

Norway 

3:00 pm 

1998. Long-Term Registry Data in 4498 Patients 

with Rheumatoid Arthritis Indicate a Similar Safety 

but a Different Drug Retention Between Abatacept, 

Rituximab, and Tocilizumab 

Jacques-Eric Gottenberg 1 , Jacques Morel 2 , Arnaud 

Constantin 3 , Thomas Bardin 4 , Alain G. Cantagrel 5 , 

Bernard Combe 6 , Maxime Dougados 7 , Rene-Marc 

Flipo 8 , Alain Saraux 9 , Thierry Schaeverbeke 10 , Jean 

Sibilia 11 , Martin Soubrier 12 , Olivier Vittecoq 13 , Elodie 

Perrodeau 14 , Philippe Ravaud 15 , Xavier Mariette 16 and 

on behalf of the French Society of Rheumatology and 

of all the investigators participating to the AIR, ORA 

and REGATE registries, 1 Department of Rheumatology, 

Strasbourg University Hospital, Strasbourg, France, 

2 

Department of Rheumatology, Montpellier University 

Hospital, Montpellier, France, 3 CHU Purpan - Hopital 

Pierre-Paul Riquet, Toulouse, France, 4 Hopital 

Lariboisiere, Paris Cedex 10, France, 5 Centre Hospitalier 

Universitaire, Toulouse Purpan, Toulouse, France, 

6 

Hôpital Lapeyronie, Montpellier, France, 7 Paris 

Descartes University, Paris, France, 8 University Hospital, 

Lille, France, 9 Brest University Hospital, Brest, France, 

10 

CHU Bordeaux, Bordeaux, France, 11 Department 

of Rheumatology, Strasbourg University Hospital, 

Strasbourg, France, 12 Department of Rheumatology, 

CHU Gabriel Montpied, Clermont-Ferrand, France, 

13 

Rouen University Hospital &INSERM U905, Rouen, 

France, 14 Hopital Hotel Dieu, Paris Descartes University, 

Paris, France, 15 Epidemiologist, PARIS, France, 

16 

Rheumatology department, Bicetre Hospital, Paris- 

Sud University, Le Kremlin Bicetre, France 


109


Monday 



3:15 pm 

1999. Claims-Based Analysis of Cost-Effectiveness 

Among Patients with Rheumatoid Arthritis Who 

Switched from a Tumor Necrosis Factor Inhibitor to 

Another Targeted Disease-Modifying Antirheumatic 

Drug 

Machaon Bonafede 1 , Wenhui Wei 2 , Chieh-I Chen 3 , 

Donna McMorrow 1 , Stefano Fiore 4 , Jonathan Fay 3 , 

Toshio Kimura 3 and Jeffrey R. Curtis 5 , 1 Truven Health 

Analytics, Cambridge, MA, 2 Sanofi US, Inc., Bridgewater, 

NJ, 3 Regeneron Pharmaceuticals, Inc., Tarrytown, 

NY, 4 Sanofi Genzyme, Bridgwater, NJ, 5 University of 

Alabama at Birmingham, Birmingham, AL 

3:30 pm 

2000. Incidence of Cancer in Patients with 

Rheumatoid Arthritis and a History of Cancer 

Treated with Rituximab or Abatacept 

Jacques-Eric Gottenberg 1 , Philippe Ravaud 2 , 

Thomas Bardin 3 , Alain Cantagrel 4 , Bernard Combe 5 , 

Maxime Dougados 6 , RENE MARC FLIPO 7 , Olivier 

Vittecoq 8 , Thierry Schaeverbeke 9 , Isabelle Pane 10 , 

Jean Sibilia 11 , Xavier Mariette 12 and on behaf of all 

of the investigators of the AIR registry and of the 

French Society of Rheumatology , 1 Department 


Strasbourg, France, 2 Hotel Dieu, PARIS, France, 

3 

Hopital Lariboisiere, Paris Cedex 10, France, 4 INSERM 

CNRS UMR 1043, Paul Sabatier University Toulouse, 

Purpan Teaching Hospital, Toulouse, France, 

5 

Hôpital Lapeyronie, Montpellier, France, 6 Paris 

Descartes University, Paris, France, 7 Department of 

Rheumatology, CHU Teaching Hospital Lille, France., 

Lille, France, 8 INSERM U905 & Normandy University, 

Institute for Research and Innovation in Biomedicine, 

Rouen, France, 9 CHU Bordeaux, Bordeaux, France, 

10 

Hotel Dieu, Paris, France, 11 Department of 

Rheumatology, Strasbourg University Hospital, 

Strasbourg, France, 12 Université Paris-Sud, AP-HP, 

Hôpitaux Universitaires Paris-Sud, Paris, France 

3:45 pm 

2001. Perioperative Use of Synthetic Disease- 

Modifying Anti-Rheumatic Drugs or Tumor Necrosis 

Factor α Inhibitors Does Not Associate with 

Increased Rates of Post-Operative Infections 

Hsin-Hsuan Juo 1 , Anders Peck 2 , Nancy Gove 3 and 

Bernard Ng 1 , 1 VA Puget Sound Healthcare System, 

Seattle, WA, 2 The Seattle Arthritis Clinic, Seattle, WA, 

3 

Seattle Children’s Research Institute, Seattle, WA 

Ballroom A 


– Clinical Aspects and Treatment III: Axial 

Spondyloarthritis – Clinical 

Moderators: Lianne S. Gensler, MD; Liron Caplan, MD, 

PhD 

2:30 pm 

2002. Differences in Features of Chronic Back 

Pain in First Degree Relatives of Patients with 

Ankylosing Spondylitis (AS) Compared to the U.S. 

Population 

David Kung 1 , Michael Weisman 2 , MinJae Lee 1 , Lianne 

S. Gensler 3 , Michael Ward 4 , Amirali Tahanan 1 , Laura A. 

Diekman 1 , Shervin Assassi 1 , Mohammad H. Rahbar 1 

and John D. Reveille 1 , 1 University of Texas-McGovern 

Medical School, Houston, TX, 2 Cedars-Sinai Medical 

Center, Los Angeles, CA, 3 UCSF, San Francisco, CA, 4 NIH/ 

NIAMS, Bethesda, MD 

2:45 pm 

2003. Validation of the ASAS Health Index: Results 

of a Multicenter International Study in 23 Countries 

Uta Kiltz 1 , Désirée van der Heijde 2 , Annelies Boonen 3 , 

Jürgen Braun 1 and ASAS HI international validation 

study, 1 Rheumazentrum Ruhrgebiet, Herne, Germany, 

2 


3 

Department of Internal Medicine, Division of 

Rheumatology, Maastricht University Medical Center, 

Maastricht, Netherlands 

3:00 pm 

2004. Is Disease Activity Associated with Work 

Productivity Loss, Presenteeism, and Absenteeism 

in Patients with Early Axial Spondyloarthritis? 

Results from the Spondyloarthritis Caught Early 

(SPACE)-Cohort 

Miranda van Lunteren 1 , Pauline Bakker 1 , Zineb Ez- 

Zaitouni 1 , Camilla Fongen 2 , Robert Landewé 3 , Maikel 

van Oosterhout 4 , Roberta Ramonda 5 , Floris van Gaalen 1 

and Désirée van der Heijde 1 , 1 Leiden University Medical 

Center, Leiden, Netherlands, 2 Diakonhjemmet Hospital, 

Oslo, Norway, 3 Academic Medical Center, Amsterdam, 

Netherlands, 4 Groene Hart Hospital, Gouda, 

Netherlands, 5 University of Padova, Padova, Italy 


Monday 




3:15 pm 

2005. Exploring the Window of Opportunity for 

Drug-Free Clinical Remission in Patients with 

Active, Very Early Peripheral Spondyloarthritis 

Philippe Carron 1 , Gaëlle Varkas 2 , Heleen Cypers 2 , 

Liesbet Van Praet 1 , Dirk Elewaut 2 and Filip van Den 

Bosch 1 , 1 Ghent University Hospital, Ghent, Belgium, 

2 

VIB, Ghent University and Ghent University Hospital, 

Ghent, Belgium 

3:30 pm 

2006. Tuberculosis Incidence in Ankylosing 

Spondylitis, Psoriatic Arthritis, and Other 

Spondyloarthropathies in Sweden: A Population- 

Based Cohort Study 

Mirjam K. de Vries 1 , Elizabeth V. Arkema 1 , Jerker 

Jonsson 2 , Judith Bruchfeld 3 , Lennart TH Jacobsson 4 and 

Johan Askling 5 , 1 Clinical Epidemiology Unit, Department 

of Medicine, Karolinska Institutet, Stockholm, Sweden, 

Stockholm, Sweden, 2 The Public Health Agency of 

Sweden, Stockholm, Sweden, 3 Department of Medicine, 

Infectious Diseases Unit, Karolinska Institutet, 

Stockholm, Sweden, 4 Department of Rheumatology 

and Inflammation Research, Sahlgrenska Academy 

at University of Gothenburg, Gothenburg, Sweden, 

5 

Rheumatology Unit, Karolinska University Hospital, 

Stockholm, Sweden 

3:45 pm 

2007. Sensitivity and Specificity of Autoantibodies 

Against CD74 in Early Axial Spondyloarthritis 

Torsten Witte 1 , Elke Riechers 2 , Niklas Thomas 

Baerlecken 3 , Xenofon Baraliakos 4 , Katrin Achilles- 

Mehr Bakhsh 5 , Peer Aries 6 , Bettina Bannert 7 , Klaus 

Becker 8 , Jan Brandt-Juergens 9 , Juergen Braun 10 , Boris P. 

Ehrenstein 11 , Hartwig Euler 12 , Martin Fleck 13 , Reinhard 

Hein 14 , Kirsten Karberg 15 , Lars Koehler 16 , Torsten 

Matthias 17 , Regina Max 18 , Adelheid Melzer 19 , Dirk 

Meyer-Olson 20 , Juergen Rech 21 , Karin Rockwitz 22 , Martin 

Rudwaleit 23 , Eva Schweikhard 17 , Joachim Sieper 24 , 

Carsten Stille 16 , Ulrich von Hinüber 25 , Peter Wagener 26 , 

Heike Weidemann 27 and Silke Zinke 15 , 1 Hannover 

Medical School, Hannover, Germany, 2 Medical 

University Hannover, Hannover, Germany, 3 MD, 

Hannover, Germany, 4 Rheumazentrum Ruhrgebiet 

Herne, Ruhr-University Bochum, Herne, Germany, 

5 

Rheumatology, Hannover, Hannover, Germany, 

6 

Rheumatologie im Struenseehaus, Hamburg, 

Germany, 7 Clinic for Rheumatology and Clinical 

Immunology, Freiburg, Germany, 8 Rheumapraxis 

Blaubeuren, Blaubeuren, Germany, 9 Praxis Brandt- 

Juergens/Karberg, Berlin, Germany, 10 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 11 Department of 

Rheumatology/Clinical Immunology, Asklepios Medical 

Center, 93077 Bad Abbach, Germany, 12 Rheumapraxis 

Hamburg, Hamburg, Germany, 13 Department of 

Internal Medicine I, University of Regensburg, 93042 

Regensburg, Germany, 14 Rheumapraxis Nienburg, 

Nienburg, Germany, 15 Rheumapraxis, Berlin, Germany, 

16 

Rheumapraxis, Hannover, Germany, 17 Aesku. 

Diagnostics, Wendelsheim, Germany, 18 University of 

Heidelberg, Heidelberg, Germany, 19 Rheumapraxis, 

Seesen, Germany, 20 m&i Fachklinik Bad Pyrmont, 

Bad Pyrmont, Germany, 21 Friedrich-Alexander- 


Germany, 22 Rheumatologic Practice, Goslar, Germany, 

23 

Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, 

24 

Charité – University Medicine Berlin, Berlin, Germany, 

25 

Rheumapraxis Hildesheim, Hildesheim, Germany, 

26 

Rheumapraxis, Nienburg, Germany, 27 Rheumapraxis 

Hannover, Hannover, Germany 

Ballroom B 


Aspects and Treatment III: Novel and Current 

Therapies 

Moderators: Lisa R. Sammaritano, MD; Karen H. 

Costenbader, MD, MPH 

2:30 pm 

2008. Rapamycin Elicits Rapid and Lasting 

Improvement of Disease Activity through Blocking 

Pro-Inflammatory T Cell Lineage Specification in 

Patients with Active SLE 

Zhi-Wei Lai 1 , Ivan Marchena 1 , Hajra Tily 1 , Ricardo 

Garcia 1 , Julie Yu 1 , Lisa Francis 1 , Maha Dawood 1 , Ryan 

Kelly 1 , Stephen Faraone 1 , Paul E. Phillips 2 and Andras 

Perl 3 , 1 SUNY, Syracuse, NY, 2 SUNY-Upstate Medical 

Univ, Syracuse, NY, 3 Upstate Medical University, 

Syracuse, NY 


111


Monday 



2:45 pm 

2009. The Effect of Anifrolumab on Cutaneous 

Manifestations and Arthritis in Moderate to 

Severe Systemic Lupus Erythematosus (SLE) Using 

Categorical SLEDAI–2K Responses and Continuous 

Measures of Activity as Outcome Measures 

JT Merrill 1 , R Furie 2 , Victoria P. Werth 3 , M Khamashta 4 , 

J Drappa 5 , L Wang 5 and G Illei 5 , 1 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 2 Northwell 

Health, Great Neck, NY, 3 University of Pennsylvania, 

Philadelphia, PA, 4 Graham Hughes Lupus Research 

Laboratory, London, United Kingdom, 5 MedImmune, 

Gaithersburg, MD 

3:00 pm 

2010. Predictive Factors of Adherence to 

Treatment in an International Prospective Study of 

Blood Hydroxychloroquine Levels in SLE Patients 

with Flares 

Nathalie Costedoat-Chalumeau 1 , Frédéric A. 

Houssiau 2 , Peter M. Izmirly 3 , Véronique Le Guern 4 , 

Sandra V. Navarra 5 , Meenakshi Jolly 6 , Guillermo 

RUIZ-IRASTORZA 7 , Eric Hachulla 8 , Nancy Agmon- 

Levin 9 , Yehuda Shoenfeld 10 , Francesca Dall’Ara 11 , Jill 

P. Buyon 3 , Christophe Deligny 12 , Ricard Cervera 13 , 

Estibaliz Lazaro 14 , Holy Bezanahary 15 , Gabriel Baron 16 , 

Gaëlle Leroux 17 , Nathalie Morel 4 , Jean-Francois 

Viallard 18 , Christian Pineau 19 , Lionel Galicier 20 , 

Ronald van Vollenhoven 21 , Angela Tincani 22 , Hanh 

Nguyen 23 , Guillaume Gondran 24 , Noel Zahr 25 , Jacques 

Pouchot 26 , Jean Charles Piette 27 , Michelle Petri 28 and 

David A. Isenberg 29 , 1 Cochin University Hospital, 

Paris, France, 2 Pôle de Maladies Rhumatismales, 

Université catholique de Louvain, Brussels, Belgium, 

3 

New York University School of Medicine, New 

York, NY, 4 Internal Medicine Department, Cochin 

Hospital, “René-Descartes Paris V” University, Paris, 

France, 5 University of Santo Tomas Hospital, Manila, 

Philippines, 6 Rush, Chicago, IL, 7 Cruces University 

Hospital, Barakaldo, Spain, 8 Lille University Hospital, 

Lille, France, 9 Zabludowicz Center for Autoimmune 

Diseases, Sheba Medical Center, Tel Aviv, Israel, 

10 

Zabludowicz Center for Autoimmune Diseases, Chaim 

Sheba Medical Center, Tel Hashomer, Israel Incumbent 

of the Laura Schwarz-Kipp Chair for Research of 

Autoimmune Diseases, Sackler Faculty of Medicine, 

Tel-Aviv University, Tel Aviv, Israel, 11 University of Pavia, 

Pavia, Italy, 12 Zobda Quitman Hospital, Rheumatology 

and Internal Medicine, Fort de France, Martinique, 

13 

Department of Autoimmune Diseases, Hospital Clinic, 

Barcelona, Spain, 14 CHU de Bordeaux, Pessac, France, 

15 

University Hospital of Limoges, Limoges, France, 

16 

Hôpital Hôtel Dieu, Paris, France, 17 Pitié-Salpêtrière 

University Hospital, Paris, France, 18 Haut Lévèque 

Hospital, Bordeaux, France, 19 MUHC, Montreal, 

QC, 20 St Louis Hospital, Paris, France, 21 Amsterdam 

Rheumatology Center, Amsterdam, Netherlands, 

22 

Rheumatology and Clinical Immunology, Spedali Civili 

and University of Brescia, Brescia, Italy, 23 University 

College of London Hospital, london, United Kingdom, 

24 

Internal Medicine Department, Limoges, France, 

25 

Pharmacological, Pitié Salpêtrière, Paris, France, 

26 

Internal Medicine Department, European Hospital 

Georges Pompidou, Paris, France, 27 Internal Medicine 

Department, University Hospital “Pitié-Salpêtrière”, 

“Pierre et Marie Curie Paris VI” University, Paris, 

France, 28 Johns Hopkins University School of Medicine, 

Baltimore, MD, 29 Centre for Rheumatology, Division of 

Medicine, University College London, London, United 

Kingdom 

3:15 pm 

2011. Enteric-Coated Mycophenolate Sodium Versus 

Azathioprine for Patients with Moderate/Severe 

Active Systemic Lupus Erythematosus: Results from 

a Phase 3, Randomized, Parallel, Multicentre Study 

Josefina Cortés-Hernández 1 , luis Sáez-Comet 2 , 

Mercedes Pérez-Conesa 2 , M Rubio Rivas 3 , Francesca 

Mitjavila 4 , A. Castro Salomó 5 , Sandra Parra 6 , J. Cuquet 

Pedragosa 7 , Vera Ortiz-Santamaría 8 , M. Mauri Plana 9 , 

Segundo Bujan-Rivas 10 , P Suñé Martin 11 , Xavier 

Vidal 11 and Josep Ordi-Ros 12 , 1 Vall d´Hebron Hospital, 

Barcelona, Spain, 2 Miguel Servet University Hospital, 

Zaragoza, Spain, 3 hopital Universitario Bellvitge, 

Barcelona, Spain, 4 Bellvitge University Hospital, 

Barcelona, Spain, 5 Hospital Universitari de Reus, Spain, 

Reus, Spain, 6 Sant Joan de Reus University Hospital, 

Reus, Spain, 7 Granollers University Hospital, Granollers, 

Spain, 8 Hospital General. Granollers., Granollers, 

Spain, 9 Mataró Hospital, Mataró, Spain, 10 Vall d’Hebron 

Hospital, Barcelona, Barcelona, Spain, 11 Vall d’Hebron 

Hospital, Barcelona, Spain, 12 Systemic Autoimmune 

disease Research Unit. Hospital Vall d’Hebron., 

Barcelona, Spain 


Monday 




3:30 pm 

2012. Utility of the Lupus Low Disease Activity State 

Definition in Discriminating Responders in the 

Phase IIb Muse Trial of Anifrolumab in Systemic 


E. Morand 1 , A. Berglind 2 , T. Sheytanova 2 , R. Tummala 3 

and G. Illei 3 , 1 Monash University, Melbourne, Australia, 

2 

AstraZeneca, Mölndal, Sweden, 3 MedImmune, 

Gaithersburg, MD 

3:45 pm 

2013. BIIB059, a Monoclonal Antibody Targeting 

BDCA2, Shows Evidence of Biological Activity and 

Early Clinical Proof of Concept in Subjects with 

Active Cutaneous SLE 

Richard Furie 1 , Victoria P. Werth 2 , Joseph Merola 3 , 

Wenting Wang 4 , Dania Rabah 4 , Catherine Barbey 4 , 

Cynthia Carrillo-Infante 4 , Taylor Reynolds 4 , Lauren 

Stevenson 4 , David Martin 4 and Nathalie Franchimont 4 , 

1 

Northwell Health, Great Neck, NY, 2 University of 

Pennsylvania School of Medicine, Philadelphia, 

PA, 3 Harvard Medical School, Boston, MA, 4 Biogen, 

Cambridge, MA 

145 A 


Raynaud’s – Clinical Aspects and Therapeutics II 

Moderators: Sindhu R. Johnson, MD, PhD; Jerry A. 

Molitor, MD, PhD 

2:30 pm 

2014. A Deep Insight into Causes and Predictors of 

Death in Systemic Sclerosis 

Muriel Elhai 1 , Christophe Meune 2 , Jerome Avouac 1 , 

Fazia Amrouche 1 , Eric Hachulla 3 , Alexandra Balbir- 

Gurman 4 , Gabriela Riemekasten 5 , Paolo Airò 6 , 

Patricia E. Carreira 7 , Yannick Allanore 8 and on behalf 

of EUSTAR co-authors, 1 Paris Descartes University, 

Cochin Hospital, Paris, France, 2 Paris XIII University, 

Bobigny, France, 3 CHU Lille, Lille, France, 4 B Shine 

Department of Rheumatology, Rambam Health Care 

Campus,. Rappaport Faculty of Medicine, Technion, 

Haifa, Israel, 5 University of Luebeck, Lübeck, Germany, 

6 

Rheumatology and Clinical immunology Unit, Spedali 

Civili of Brescia, Brescia, Italy, 7 Multidisciplinary 

Pulmonary Hypertension Unit. Hospital Universitario 

12 de Octubre, Madrid, Spain, 8 Cochin Institute, Paris, 

France 

2:45 pm 

2015. The Systemic Sclerosis Disease State 

Is Associated with Specific Alterations in 

Gastrointestinal Microbiota in Two Independent 

Cohorts 

Elizabeth R. Volkmann 1 , Anna-Maria Hoffmann-Vold 2 , 

Yu-Ling Chang 1 , Jonathan Jacobs 1 , Philip J. Clements 1 , 

Martin Kummen 2 , Johannes R. Hov 2 , Kirsten Tillisch 1 , 

Venu Lagishetty 1 , Oyvind Midtvedt 2 , Øyvind Molberg 2 

and Jonathan Braun 1 , 1 University of California, Los 

Angeles, David Geffen School of Medicine, Los Angeles, 

CA, 2 Oslo University Hospital, Oslo, Norway 

3:00 pm 

2016. Esophageal Disease in Systemic Sclerosis: 

Does Heritability Play a Role? 

Latifa Fakoya 1 , Kathryn Peterson 1 , Andrew Gawron 1 , 

Jathine Wong 2 , Mary Beth Scholand 1 , Allen D. Sawitzke 3 

and Tracy M. Frech 4 , 1 University of Utah, Salt Lake City, 

UT, 2 University of Utah, Salt Lake, UT, 3 Univ of Utah, Salt 

Lake City, UT, 4 Salt Lake City VAMC, Salt Lake, UT 

3:15 pm 

2017. Performance of Modified Rodnan Skin Score 

in Early Diffuse Cutaneous Scleroderma-Analysis 

from 4 International Cohorts 

Dinesh Khanna 1 , Susanna Proudman 2 , Tracy M. 

Frech 3 , Svetlana Nihtyanova 4 , Robyn T. Domsic 5 , 

Veronica J. Berrocal 1 , Wendy Stevens 6 , Mandana 

Nikpour 7 and Christopher P.Denton 8 , 1 University of 

Michigan, Ann Arbor, MI, 2 Royal Adelaide Hospital, 

Adelaide, Australia, 3 University of Utah Medical Ctr, 

Salt Lake City, UT, 4 University College London Medical 

School, Royal Free Hospital, London, United Kingdom, 

5 

University of Pittsburgh, Pittsburgh, PA, 6 St. Vincent’s 

Hospital, Melbourne, Australia, 7 Melbourne University, 

Melbourne, Australia, 8 University College London, 


3:30 pm 

2018. A Clinical Risk Prediction Model for Skin 

Thickness Progression in Early Diffuse Scleroderma 

Robyn T. Domsic 1 , Mary Lucas 2 , Virginia D. Steen 3 and 

Thomas A. Medsger Jr. 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 University of Pittsburgh Scleroderma 

Center, Pittsburgh, PA, 3 Georgetown University Medical 

Center, Washington, DC 


113


Monday 



3:45 pm 

2019. Faces in Motion: Clinical Subtyping in 

Scleroderma Using Changes in Forced Vital Capacity 

Colin Ligon 1 , Peter Schulam 2 , Suchi Saria 3 , Fredrick 

M. Wigley 4 , Robert Wise 4 and Laura K. Hummers 4 , 

1 

University of Pennsylvania School of Medicine, 

Philadelphia, PA, 2 Johns Hopkins University, Baltimore, 

MD, 3 Johns Hopkins Bloomberg School of Public Health, 



ARHP SESSIONS 

2:30 pm – 4:00 pm 

209 A 

How to Give a Fantastic Talk 


Speakers: Scott Litin, MD; Edward T. Creagan, MD 

201 

EULAR/ARHP Pain Management Trends 

Moderator: Christina H. Opava, Prof, PhD, RPT 

2:30 pm 

The Ongoing Shift of Paradigms within Pain 

Management 

Speaker: Karen Huisinga, MN, ARNP, FNP 

3:00 pm 

The Benefits of Prompt Pain Management in Arthritis 

Speaker: Cecile Overman, PhD 

3:30 pm 

Recommendations for Prompt Pain Management in 

Inflammatory Arthritis and Osteoarthritis 

Speaker: Rinie Geenen 

143 A 

The Power of Arthritis Advocacy 

Moderator: Nancy A. Baker, ScD, MPH, OTR/L 

2:30 pm 


Speaker: Janet Stevens, BA 

3:00 pm 


Speaker: Carole V. Dodge, OT, CHT 

206 

The Science Behind Exercise and Body 

Composition in Rheumatoid Arthritis 

Inflammation 

Moderators: Joshua Baker, MD, MSCE; Nadine M. Fisher, 

EdD 

2:30 pm 

Adiposity and Inflammation in Rheumatoid Arthritis 

Speaker: Jon T. Giles, MD, MPH 

3:00 pm 

Circadian Rhythms, Physical Activity, and Skeletal 

Muscle: Implications for Inflammatory Disorders 

Speaker: Karyn Esser, PhD 

3:30 pm 

Insulin Resistance, Adiposity, and Inactivity in 


Speaker: Kim Huffman, MD, PhD 

204 A 

Update: Skin Features of Rheumatological 

Diseases 

Moderator: Alexandru F. Kimel, MD 

2:30 pm 

Skin Features of Rheumatological Diseases – I 

Speaker: David Rosmarin, MD 

3:15 pm 

Skin Features of Rheumatological Diseases – II 

Speaker: Michael K. Lichtman, MD 


2:30 pm – 4:00 pm 

202 B 

ARHP III – Education and Community Programs 

Moderators: Susan J. Bartlett; Monica C. Richey, ANP, 

BC, BSN, MSN 


Monday 




2:30 pm 

2020. Making the Case for Self-Management 

Education: Marketing Lessons Learned from 

Qualitative Research 

Teresa J. Brady 1 , Bithiah Lafontant 2 , Tai Baker 1 and 

Rebecca Ledsky 2 , 1 Centers for Disease Control and 

Prevention, Atlanta, GA, 2 FHI 360, Washington, DC 

2:45 pm 

2021. Development of an Item Bank on Disease and 

Treatment Associated Knowledge of Rheumatoid 

Arthritis to Improve Patient Engagement in Care 

Marieke J. de Jonge 1 , Martijn A.H. Oude Voshaar 2 , 

Anita M.P. Huis 1 , Mart A.F.J. van de Laar 2 , Marlies E.J.L. 

Hulscher 1 and Piet L.C.M. van Riel 3 , 1 Radboud university 

medical center, Radboud Institute for Health Sciences, 

IQ healthcare, Nijmegen, Netherlands, 2 University 

of Twente, Department of Psychology, Health and 

Technology, Enschede, Netherlands, 3 Bernhoven, 

Department of Rheumatology, Uden, Netherlands 

3:00 pm 

2022. Developing a Gout Needs 

Assessment Incorporating Patient Perspective 

on Self-Management, Self-Efficacy, and Disease 

Specific Knowledge, to Inform a Patient Education 

Initiative 

Adam Rifaat, Adena Batterman, Roberta Horton and 

Theodore R. Fields, Hospital for Special Surgery, New 

York, NY 

3:15 pm 

2023. Patient Barriers to Osteoporosis Screening in 

a Medical Clinic: Why Underserved Patients 

Who Follow Recommendations for Colonoscopy and 

Mammography Fail to Get Their DXA Scans 

Suzana John 1 , Sonam Kiwalkar 2 , Hamdy Mohamed 

Abdelaziz Ahmed 1 and Walter Polashenski 3 , 1 Rochester 

General Hospital, Rochester, NY, 2 Rochester general 

hospital, Rochester, NY, 3 Rochester general hospital, 

rochester, NY 

3:30 pm 

2024. Effect of a Revised Counselor Training on 

Skills Development and Knowledge of Volunteers 

with Systemic Lupus Erythematosus 

Melissa T. Flores 1 , Jillian A. Rose 1 , Priscilla Toral 1 , 

Roberta Horton 1 and Janice Karbachinskiy 2 , 1 Hospital 

for Special Surgery, New York, NY, 2 New York- 

Presbyterian Hospital Weill Cornell, New York, NY 

3:45 pm 

2025. Lupus Education Advancement Project 

(LEAP): Rheumatology Fellows Serving as Educators 

Increased Knowledge and Efficiency in Lupus 

Recognition and Referral By Providers in Primary 

and Emergency Care 

Diane Gross 1 , Amy Caron 2 , Irene Blanco 3 , Alfred Denio 4 , 

Sheetal Desai 5 , Amanda Sammut 6 and Zoon Naqvi 7 , 

1 

S.L.E. Lupus Foundation/Lupus Research Institute, 

New York, NY, 2 Lupus Research Institute, Ny, NY, 

3 

Albert Einstein College of Medicine and Montefiore 

Medical Center, Bronx, NY, 4 Geisinger Medical Center, 

Danville, PA, 5 Unviersity of California, Irvine, Orange, 

CA, 6 Columbia University Medical Center and Harlem 

Hospital Center, New York, NY, 7 Albert Einstein College 

of Medicine, Bronx, NY 

WORKSHOPS 

4:00 pm – 6:00 pm 










144 B 

227 – Musculoskeletal Exam Skills: Regional 

Musculoskeletal Examination of the Shoulder 

and Knee PM PS E 

Speakers: George V. Lawry II, MD; Paul Utrie, MD 

144 C 

228 – Musculoskeletal Ultrasonography: Basic 

Clinical Practice 

Speakers: Gurjit S. Kaeley, MBBS, MRCP; Johannes Roth, 

MD, PhD, FRCPC, RhMSUS 

144 A 

229 – Nailfold Capillarscopy Made Easy for the 

Clinician 

Speaker: Maurizio Cutolo, MD 


115


Monday 



149 A 

230 – Osteoporosis: Interpreting Dual Energy 

X-Ray Absorptiometry and Clinical Risk Factors: 

The New Fracture Risk Assessment Algorithm 

Speaker: Stuart L. Silverman, MD 

ACR SESSION 

4:30 pm – 5:30 pm 

Hall D 

Treatment of Rheumatoid Arthritis When the 

Patient Is Not Well 

Moderator: Daniel E. Furst, MD 

Speaker: Iain B McInnes, MD, PhD, FRCP 

ARHP SESSION 

4:30 pm – 5:30 pm 

209 A 

Smart Office, Smart Home: Adaptations for 

Rheumatic Disease PM PS E 

Moderator: Nadine M. Fisher, EdD 

4:30 pm 

Person-Environment Fit to Support Assistive Device 

Selection for the Home and Office 

Speaker: Victor L. Paquet III, ScD 

5:00 pm 

Smart Technologies for the Home and Office 

Speaker: Victor L. Paquet III, ScD 


4:30 pm – 6:00 pm 










148 

051 – Antiphospholipid Syndrome 

Speaker: David P. D’Cruz, FRCP, MD 

153 

052 – Behçet’s Syndrome 

Speaker: Kenneth Calamia, MD 

154 A 


Gout 

PM PS E 

Speaker: John S. Sundy, MD, PhD 

154 B 

054 – Juvenile Dermatomyositis 

Speaker: Angela B. Robinson, MD, MPH 


155 

055 – Management of Difficult Raynaud’s and 

Digital Ischemia 

Speaker: Fredrick M. Wigley, MD 

158 A 

056 – Non-Surgical Treatments for 


Speaker: David T. Felson, MD, MPH 

158 B 

057 – Psoriatic Arthritis 

Speaker: Philip J Mease 

159 A 


Arthritis PM PS E 

Speaker: Eric M. Ruderman, MD 

159 B 

059 – Still’s Disease and Autoinflammatory 

Syndromes 

Speaker: Petros Efthimiou, MD 

160 

060 – Systemic Lupus Erythematosus: Difficult 

to Treat Systemic Lupus Erythematosus 

Speaker: Eliza Chakravarty, MD, MS 


Monday 



ACR SESSIONS 

4:30 pm – 6:00 pm 

Salon B 

Central Nervous System Vasculopathies and 

Antibody-Associated Syndromes 

Moderators: Grant Hughes, MD; Eli Miloslavsky, MD 

4:30 pm 

Central Nervous System (CNS) Vasculopathies: 

Challenging Mimickers of CNS Vasculitis 

Speaker: Tracey Cho, MD 

5:00 pm 

Neuromyelitis Optica Spectrum Disorders 

Speaker: Dean Wingerchuk, MD 

4:30 pm 

Podocyte Injury and Regeneration in Lupus Nephritis 

Speaker: Paola Romagnani, MD, PhD 

5:00 pm 

Podocyte Assessment in Management of Nephritis 

Speaker: Roger C. Wiggins, MB, BChir 

5:30 pm 

Transcriptome Analysis in Lupus Nephritis 

Speaker: Matthias Kretzler, MD 

143 A 

The Rheumatology Workforce: Present and 

Future PM Ed Pd PS PrM FIT 

Moderators: Seetha Monrad, MD; Anne R. Bass, MD 

5:30 pm 

Antibody-Mediated Disorders of the Synapse 

Speaker: Josep Obrador Dalmau, MD, PhD 

Ballroom A 

More than Skin Deep: Topics in 

Dermatomyositis 

Moderators: Gregory Gardner, MD, FACP; Siamak 

Moghadam-Kia, MD 

4:30 pm 

Cutaneous Manifestations of Dermatomyositis in All 

Their Variety 

Speaker: Victoria Werth, MD 

5:00 pm 

Treatment Approaches to Dermatomyositis 

Speaker: Chester V. Oddis, MD 

5:30 pm 

Malignancy in Dermatomyositis: How Hard Should I 

Look? 


151 A 

Intrinsic Renal Injury in Glomerulonephritis 

Moderators: Anne Davidson, MBBS; Maria Dall’Era, MD 

4:30 pm 

The Rheumatology Workforce: Present and Future 

Speaker: Daniel F. Battafarano, DO 

5:20 pm 

Challenges to the Rheumatology Workforce – Panel 

Discussion 

Speakers: V. Michael Holers, MD; Rodolfo Molina, MD; 

Lisa F. Imundo, MD; John FitzGerald, MD; Deborah 

Desir, MD; Kori Dewing, DNP 


4:30 pm – 6:00 pm 

147 A 

Genetics, Genomics, and Proteomics I 

Moderators: Timothy B. Niewold, MD; Patrick M. 

Gaffney, MD 

4:30 pm 

2032. Genome-Wide Association Analysis Reveals 

Novel Juvenile Idiopathic Arthritis Susceptibility 

Loci 

Laura A McIntosh 1 , Miranda C Marion 2 , Marc 

Sudman 1 , Mary E Comeau 2 , Sampath Prahalad 3 , John F 

Bohnsack 4 , Johannes P Haas 5 , Carol A Wallace 6 , Daniel 

J Lovell 7 , Thomas A Griffin 8 , Mara L Becker 9 , Peter A 

Nigrovic 10 , Marilynn Punaro 11 , Carlos D Rosé 12 , Carol A 



Monday 



Wise 11 , Halima Moncrieffe 1 , Timothy D Howard 2 , Carl D 

Langefeld 2 , Susan D Thompson 1 and Boston Children’s 

JIA Registry, JIA gene expression studies, NIAMS JIA 

genetic registry, TREAT study, Understanding TNF 

Therapy in JIA Project, 1 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 2 Wake Forest University 

School of Medicine, Winston-Salem, NC, 3 Emory 

Children’s Center, Atlanta, GA, 4 University of Utah, Salt 

Lake City, UT, 5 German Centre for Rheumatology in 

Children and Young People, Garmisch-Partenkirchen, 

Germany, 6 Seattle Children’s Hospital, Seattle, WA, 

7 

PRCSG Cincinnati Children’s Hospital Medical Center, 

Cinncinnati, OH, 8 Levine Children’s Hospital at 

Carolinas Medical Center, Charlotte, NC, 9 Children’s 

Mercy Hospitals and Clinics, Kansas City, MO, 

10 

Brigham and Women’s Hospital, Boston, MA, 11 Texas 

Scottish Rite Hospital for Children, Dallas, TX, 12 Division 

of Rheumatology, Nemours/A.I. duPont Hospital for 

Children, Thomas Jefferson University, Wilmington, DE 

4:45 pm 

2033. A Multi-Dimensional Genomic Map for 

Polyarticular Juvenile Idiopathic Arthritis 

James Jarvis 1 , Lisha Zhu 2 , Kaiyu Jiang 2 , Michael Buck 2 , 

Yanmin Chen 2 , Halima Moncrieffe 3 , Laura Brungs 3 , 

Tao Liu 2 and Ting Wang 4 , 1 SUNY Buffalo School of 

Medicine, Buffalo, NY, 2 University at Buffalo, Buffalo, 

NY, 3 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 4 Washington University School of 

Medicine, St. Louis, MO 

5:00 pm 

2034. Novel Susceptible Genes for Behçet’s Disease 

Identified By Dense Genotyping of Immune- 

Related Loci Implicate Host Responses to Microbial 

Exposure 

Masaki Takeuchi 1 , Nobuhisa Mizuki 2 , Akira Meguro 3 , 

Michael J. Ombrello 4 , Yohei Kirino 3 , Colleen Satorius 5 , 

Julie Le 1 , Mary Blake 6 , Burak Erer 7 , Tatsukata Kawagoe 3 , 

Duran Ustek 8 , Ilknur Tugal-tutkun 9 , Emire Seyahi 10 , 

Yilmaz Ozyazgan 11 , Inês Sousa 12 , Fereydoun Davatchi 13 , 

Vânia Francisco 12 , Farhad Shahram 14 , Bahar Abdollahi 15 , 

Abdolhadi Nadji 15 , Niloofar Shafiee 15 , Fahmida 

Ghaderibarmi 16 , Shigeaki Ohno 17 , Atsuhisa Ueda 3 , 

Yoshiaki Ishigatsubo 18 , Massimo G. Gadina 6 , Sofia 

Oliveira 12 , Ahmet Gul 7 , Daniel L. Kastner 1 and Elaine 

F. Remmers 19 , 1 National Human Genome Research 

Institute, Bethesda, MD, 2 Yokohama City University, 

Yokohama, Japan, 3 Yokohama City University Graduate 

School of Medicine, Yokohama, Japan, 4 Translational 

Genetics and Genomics Unit, NIAMS, NIH, Bethesda, 

MD, 5 NIAMS, N.I.H, Bethesda, MD, 6 National Institute 

of Arthritis and Musculoskeletal and Skin Diseases, 

National Institutes of Health, Bethesda, MD, 7 Istanbul 

University, Istanbul Faculty of Medicine, Istanbul, 

Turkey, 8 Istanbul University, Istanbul, Turkey, 

9 

Istanbul Faculty of Medicine, Istanbul University, 

Istanbul, Turkey, 10 Istanbul University, Cerrahpasa 

Medical Faculty, Department of Internal Medicine, 

Division of Rheumatology, Istanbul, Turkey, 11 Istanbul 

University, Cerrahpasa Medical Faculty, Department 

of Ophthalmology, Istanbul, Turkey, 12 Universidade 

de Lisboa, Lisboa, Portugal, 13 Rheumatology Research 

Ctr-Tehran Univ, Tehran, Iran, 14 Tehran University of 

Medical Sciences, Tehran, Iran (Islamic Republic of), 

15 

Tehran University of Medical Sciences, Teheran, Iran 

(Islamic Republic of), 16 Tehran University of Medical 

Sciences, Teheran, Portugal, 17 Hokkaido University 

Graduate School of Medicine, Hokkaido, Japan, 

18 

Yokohama City Grad Sch of Med, Yokohama, Japan, 

19 

National Human Genome Research Institute, National 

Institutes of Health, Bethesda, MD 

5:15 pm 

2035. Dosage Contribution of a Non-Classical HLA 

Gene, HLA-Doa, to the Risk of Rheumatoid Arthritis 

Yukinori Okada 1 , Akari Suzuki 2 , Katsunori Ikari 3 , 

Chikashi Terao 4 , Yuta Kochi 2 , Koichiro Ohmura 5 , 

Koichiro Higasa 5 , Masato Akiyama 2 , Kyoto Ashikawa 2 , 

Masahiro Kanai 2 , Jun Hirata 1 , Naomasa Suita 1 , Yik-Ying 

Teo 6 , Huji Xu 7 , Sang-Cheol Bae 8 , Yukihide Momozawa 2 , 

koichi Matsuda 9 , Shigeki Momohara 3 , Atsuo Taniguchi 3 , 

Ryo Yamada 5 , Tsuneyo Mimori 5 , Michiaki Kubo 2 , 

Matthew A. Brown 10 , Soumya Raychaudhuri 11 , Fumihiko 

Matsuda 5 , Hisashi Yamanaka 3 , Yoichiro Kamatani 2 

and Kazuhiko Yamamoto 9 , 1 Osaka University, Osaka, 

Japan, 2 Center for Integrative Medical Sciences, RIKEN, 

Yokohama, Japan, 3 Tokyo Women’s Medical University, 

Tokyo, Japan, 4 Brigham and Women’’s Hospital, 

Harvard Medical School, Boston, MA, 5 Kyoto University 

Graduate School of Medicine, Kyoto, Japan, 6 Genome 

Institute of Singapore, Agency for Science, Technology 

and Research, Singapore, Singapore, 7 The Second 

Military Medical University, Shanghai, Japan, 8 Hanyang 


Monday 




University Hospital for Rheumatic Diseases, Seoul, 

Korea, The Republic of, 9 The University of Tokyo, Tokyo, 

Japan, 10 The University of Queensland Diamantina 

Institute, Brisbane, Australia, 11 Brigham and Women’s 

Hospital, Boston, MA 

5:30 pm 

2036. Whole Exome Sequencing in Early Onset 


Ezgi Deniz Batu 1 , Can Kosukcu 1 , Ekim Z. Taskiran 1 , Sema 

Akman 2 , Kubra Ozturk 3 , Betul Sozeri 4 , Erbil Unsal 5 , 

Zelal Ekinci 3 , Yelda Bilginer 6 , Mehmet Alikasifoglu 1 and 

Seza Ozen 1 , 1 Hacettepe University Faculty of Medicine, 

ANKARA, Turkey, 2 Akdeniz University Faculty of 

Medicine, Antalya, Turkey, 3 Kocaeli University Faculty 

of Medicine, Kocaeli, Turkey, 4 Erciyes University Faculty 

of Medicine, Kayseri, Turkey, 5 Dokuz Eylul University, 

Izmir, Turkey, 6 Hacettepe University Faculty of 

Medicine, Ankara, Turkey 

5:45 pm 

2037. Proteostasis Dysregulation and 

Autoinflammation in Patients with TRNT1 

Deficiency 

Angeliki Giannelou 1 , Qing Zhou 2 , Hongying Wang 3 , 

Abu-Asab Mones 4 , Hong-Wei Sun 5 , Deborah L. Stone 6 , 

Amanda K. Ombrello 7 , Wanxia L. Tsai 8 , Stephen 

Brooks 9 , Jehad H. Edwan 5 , Kimberly Risma 10 , Lucie 

Sramkova 11 , Abdullah Al Sonbul 12 , Sarita Joshi 13 , Helen 

C. Su 14 , Karyl Barron 14 , Massimo G. Gadina 5 , Gustavo 

Gutierrez-Cruz 5 , Markus Hafner 5 , Ivona Aksentijevich 15 

and Daniel L. Kastner 15 , 1 National Human Genome 

Research Institute, National Institute of Arthritis and 


of Health, Bethesda, MD, 2 National Human Genome 


Inflammatory Disease Branch, Bethesda, MD, 3 National 

Human Genome Research Institute, Bethesda, MD, 

4 

National Eye Institute, National Institutes of Health, 



of Health, Bethesda, MD, 6 National Human Genome 


Bethesda, MD, 7 National Institutes of Health, Bethesda, 

MD, 8 National Institute of Arthritis and Musculoskeletal 

and Skin Diseases, Bethesda, MD, 9 NIAMS/NIH, 

Bethesda, MD, 10 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 11 Charles University 2nd Faculty 

of Medicine and UH Motol, Prague, Czech Republic, 

12 

King Faisal Specialist Hospital & Research Center, 

Riyadh, Saudi Arabia, 13 Nationwide Children’s Hospital, 

Columbus, OH, 14 National Institute of Allergy and 

Infectious Diseases, National Institutes of Health, 

Bethesda, MD, 15 National Human Genome Research 

Institute, National Institutes of Health, Inflammatory 

Disease Section, Bethesda, MD 

Salon G 

Quality Measures and Quality of Care I 

Moderators: Christie M. Bartels, MD, MS; E. Blair Solow, 

MD, MSCS 

4:30 pm 

2038. Pediatric Rheumatology Care and 

Outcomes Improvement Network Demonstrates 

Improvement on Quality Measures for Children 

with Juvenile Idiopathic Arthritis 

C. April Bingham 1 , Jesse Pratt 2 , Cagri Yildirim-Toruner 3 , 

Ronald Laxer 4 , Beth Gottlieb 5 , Jennifer E. Weiss 6 , 

Tzielan Lee 7 , Sheetal S. Vora 8 , Jon M. Burnham 9 , 

Julia Harris 10 , Judyann C. Olson 8 , Murray Passo 11 , 

Michelle Batthish 12 , Michael Shishov 13 , Kerry Ferraro 14 , 

Deborah M. Levy 4 , Christine O’Brien 4 , Kristi Whitney- 

Mahoney 4 , Nancy Griffin 2 , Anne Paul 2 and Esi Morgan 15 , 

1 

Penn State Health Children’s Hospital, Hershey, 

PA, 2 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 3 Nationwide Children’s Hospital, 

Columbus, OH, 4 The Hospital for Sick Children, 

Toronto, ON, 5 Cohen Children’s Medical Center, Lake 

Success, NY, 6 Hackensack Univ Med Ctr, Hackensack, 

NJ, 7 Stanford University School of Medicine, Palo 

Alto, CA, 8 Medical College of Wisconsin, Milwaukee, 

WI, 9 Children’s Hospital Philadelphia, Philadelphia, 

PA, 10 Children’s Mercy Kansas City, Kansas City, MO, 

11 

Medical University of South Carolina, Charleston, 

SC, 12 McMaster Children’s Hospital, Hamilton, ON, 

13 

Phoenix Children’s Hospital, Phoenix, AZ, 14 Pediatric 

Rheumatology Care and Outcomes Improvement 

Network, Cincinnati, OH, 15 Cincinnati Children’s 

Hospital, Cincinnati, OH 


119


Monday 



4:45 pm 

2039. Assessing Barriers to Uveitis Screening in 

Patients with JIA: A Qualitative Study 

Laura Ballenger 1 , Kyla Driest 1 and Stacy P. Ardoin 2 , 

1 

Nationwide Children’s Hospital, Columbus, OH, 2 Ohio 

State University, Columbus, OH 

5:00 pm 

2040. Responsiveness of Patient Reported 

Outcomes Measurement Information System 

Measures in RA Patients Starting or Switching a 

DMARD 

Alyssa Wohlfahrt 1 , Clifton Bingham III 2 , Zhi Zhang 1 , 

Marcy Bolster 3 , Larry W. Moreland 4 , Tuhina Neogi 5 , 

Kristine Phillips 6 and Yvonne C. Lee 7 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Johns Hopkins 

University, Baltimore, MD, 3 Massachusetts General 

Hospital, Boston, MA, 4 University of Pittsburgh, 

Pittsburgh, PA, 5 Boston University School of Medicine, 

Boston, MA, 6 University of Michigan, Ann Arbor, MI, 

7 


School, Boston, MA 

5:15 pm 

2041. Validity and Reliability of Patient Reported 

Outcomes Measurement Information System 

(PROMIS ® ) Global Health Short Form in Patients 

with SLE 

Shanthini Kasturi, Jayme C. Burket, Jessica Berman, 

Kyriakos A. Kirou, Alana B. Levine, Lisa R. Sammaritano 

and Lisa Mandl, Hospital for Special Surgery, New York, 

NY 

5:30 pm 

2042. Improving the Overall Pneumococcal 

Vaccination Rate in Lupus Patients at the 

Rheumatology Clinic 

Shivani Garg 1 , Aliza Lipson 2 and Katina Tsagaris 3 , 

1 

Emory University, Atlanta, GA, 2 EMORY UNIVERSITY, 

atlanta, GA, 3 EMORY UNIVERSITY, Atlanta, GA 

5:45 pm 

2043. Feasibility and Accuracy of Translating a 

Patient Safety Quality Measure into an Automated 

e-Measure 

Chris Tonner 1 , Gabriela Schmajuk 2 , Laura Trupin 1 

and Jinoos Yazdany 1 , 1 University of California, San 

Francisco, San Francisco, CA, 2 San Francisco VA Medical 

Center, University of California, San Francisco, San 

Francisco, CA 

150 A 

Reproductive Issues in Rheumatic Disorders 

Moderators: Jane E. Salmon, MD; Megan E. B. Clowse, 

MD, MPH 

4:30 pm 

2044. Effect of Pregnancy on Disease Flares in 

Patients with Systemic Lupus Erythematosus 

Amanda M. Eudy 1 , Anna Maria Siega-Riz 1 , Stephanie 

Engel 1 , Nora Franceschini 1 , Annie Green Howard 1 , 

Megan E. B. Clowse 2 and Michelle Petri 3 , 1 University of 

North Carolina at Chapel Hill, Chapel Hill, NC, 2 Duke 

University Medical Center, Durham, NC, 3 Johns Hopkins 

University School of Medicine, Baltimore, MD 

4:45 pm 

2045. Early Preeclampsia Risk in Lupus Pregnancy: 

A Swedish Population-Based Register Investigation 

Julia F Simard 1 , Elizabeth V. Arkema 2 , Cathina Nguyen 1 , 

Elisabet Svenungsson 2 , Anna-Karin Wikstrom 3 , Kristin 

Palmsten 4 and Jane E. Salmon 5 , 1 Stanford School 

of Medicine, Stanford, CA, 2 Karolinska Institutet, 

Stockholm, Sweden, 3 Karolinska Institute, Stockholm, 

Sweden, 4 University of California, San Diego, La 

Jolla, CA, 5 Hospital for Special Surgery, Weill Cornell 


5:00 pm 

2046. The Low-Dose Intravenous Cyclophosphamide 

Euro-Lupus Regimen Does Not Impact the Ovarian 

Reserve of Lupus Patients, As Measured By Serum 

Anti-Mullerian Hormone Levels 

Séverine Nieuwland 1 , Farah Tamirou 1 , Damien Gruson 2 , 

Frédéric Debiève 3 , Bernard R. Lauwerys 1 and Frédéric 

A. Houssiau 1 , 1 Rheumatology Department, Cliniques 

universitaires Saint-Luc, Brussels, Belgium, 2 Clinical 

Chemistry Department, Cliniques universitaires 

Saint-Luc, Brussels, Belgium, 3 Obstetrics Department, 

Cliniques universitaires Saint-Luc, Brussels, Belgium 

5:15 pm 

2047. Impact of in Utero Hydroxychloroquine 

Exposure on the Risk of Cutaneous Neonatal Lupus 

Erythematosus 

Julie Barsalou 1 , Nathalie Costedoat-Chalumeau 2 , Adey 

Berhanu 3 , Cesar Fors-Nieves 4 , Ummara Shah 5 , Patrick 

Brown 6 , Carl Laskin 7 , Nathalie Morel 8 , Kateri Levesque 9 , 

Jill P. Buyon 10 , Earl Silverman 6 and Peter M. Izmirly 11 , 


Monday 




1 

Hospital for Sick Children, Toronto, ON, 2 Cochin 

University Hospital, Paris, France, 3 NYU Langone 

Medical Center/NYU School of Medicine, New York, 

NY, 4 NYU School of Medicine, New York, NY, 5 Strong 

Memorial Hospital, University of Rochester, Rochester, 

NY, 6 University of Toronto, Toronto, ON, 7 University 

of Toronto and LifeQuest Centre for Reproductive 

Medicine, Toronto, ON, 8 Internal Medicine Department, 

Cochin Hospital, “René-Descartes Paris V” University, 

Paris, France, 9 CHU Ste-Justine, Montréal, QC, 10 Tisch 

Hospital, New York, NY, 11 New York University School of 


5:30 pm 

2048. Evaluating Transfer of Certolizumab Pegol 

into Breast Milk: Results from a Prospective, 

Postmarketing, Multicenter Pharmacokinetic Study 

Megan E. B. Clowse 1 , Frauke Förger 2 , Caroline Hwang 3 , 

John Thorp 4 , Radboud J. E. M. Dolhain 5 , Astrid van 

Tubergen 6 , Laura Shaughnessy 7 , Jeff Simpson 7 , Marie 

Teil 8 , Nathalie Toublanc 9 , Maggie Wang 7 and Thomas W. 

Hale 10 , 1 Duke University School of Medicine, Durham, 

NC, 2 Inselspital University Hospital of Bern, Bern, 

Switzerland, 3 Keck Hospital of USC, Los Angeles, CA, 

4 

University of North Carolina at Chapel Hill, Chapel Hill, 

NC, 5 University Medical Center Rotterdam, Rotterdam, 

Netherlands, 6 Maastricht University Medical Center, 

Maastricht, Netherlands, 7 UCB Pharma, Raleigh, NC, 

8 

UCB Pharma, Slough, United Kingdom, 9 UCB Pharma, 

Brussels, Belgium, 10 Texas Tech University School of 

Medicine, Amarillo, TX 

5:45 pm 

2049. Serious Infections in RA Offspring Exposed to 

Tumor Necrosis Factor Inhibitors 

Evelyne Vinet 1 , Cristiano S. Moura 2 , Jeffrey R. Curtis 3 , 

Christian A. Pineau 1 , Michal Abrahamowicz 2 and Sasha 

Bernatsky 2 , 1 McGill University Health Centre, Montreal, 

QC, 2 Research Institute of the McGill University Health 

Centre, Montreal, QC, 3 University of Alabama at 

Birmingham, Birmingham, AL 

Hall E 

Rheumatoid Arthritis – Clinical Aspects III: 

Prevention of Comorbidity 

Moderators: Jon T. Giles, MD, MPH; Cecilia P. Chung, 

MD, MPH 

4:30 pm 

2050. Screening for and Management of 

Comorbidities after a Nurse-Led Program: Results 

of a 3 Year Longitudinal Study in 776 Established RA 

Patients 

Laure Gossec 1 , Martin Soubrier 2 , Frantz Foissac 3 , Anna 

Molto 4 , Françoise Fayet 5 , Thomas Bardin 6 , Francis 

Berenbaum 7 , Alain Cantagrel 8 , Marie Hélène Cerato 9 , 

Gerard H. Chales 10 , Bernard Combe 11 , Emmanuelle 

Dernis Labous 12 , Isabelle Chary-Valckenaere 13 , Liana 

Euller-Ziegler 14 , Rene-Marc Flipo 15 , Philippe Gaudin 16 , 

Melanie Gilson 17 , Sandrine Guis 18 , Xavier Mariette 19 , 

Gaël Mouterde 20 , Sophie Pouplin 21 , Pascal Richette 6 , 

Alain Saraux 22 , Thierry Schaeverbeke 23 , Jean Sibilia 24 

and Maxime Dougados 4 , 1 Pitié Salpêtrière Hospital, 

Paris, France, 2 Department of Rheumatology, 

CHU Gabriel Montpied, Clermont-Ferrand, France, 

3 

COMEDRA working group, Paris, France, 4 Paris 

Descartes University, Paris, France, 5 CHU Gabriel- 

Montpied, Clermont-Ferrand, France, 6 Hôpital 

Lariboisière, Paris, France, 7 Rheumatology dept, APHP 

St-Antoine hospital, Univ Paris 06, Paris, France, Paris, 

France, 8 Purpan Hospital, Toulouse, France, 9 University 

Hospital, Toulouse, France, 10 CHU RENNES, Rennes, 

France, 11 Hôpital Lapeyronie, Montpellier, France, 

12 

Le Mans Hospital, Le Mans, France, 13 University 

Hospital, Nancy, France, 14 Rheumatology, Nice, 

France, 15 University Hospital, Lille, France, 16 Grenoble 

University Hospital, France, Grenoble, France, 17 Hopital 

Sud, Grenoble, France, 18 Aix-Marseille Université, 

AP-HM, CNRS, Marseilles, France, 19 Rheumatology 

department, Bicetre Hospital, Paris-Sud University, 

Le Kremlin Bicetre, France, 20 Hopital Lapeyronie, 

Montpellier, France, 21 Department of Rheumatology, 

Rouen University Hospital & Inserm 905, Institute 

for Biomedical Research, University of Rouen, 

Rouen, France, 22 CHU de la Cavale Blanche, Brest 

Cedex, France, 23 CHU Bordeaux, Bordeaux, France, 

24 

Department of Rheumatology, Strasbourg University 

Hospital, Strasbourg, France 

4:45 pm 

2051. Risk Factors for Cardiovascular Disease 

Predate the Onset of Symptoms of Rheumatoid 

Arthritis 

Heidi Kokkonen, Lisbeth Ärlestig and Solbritt Rantapää- 

Dahlqvist, Umeå University, Umeå, Sweden 


121


Monday 



5:00 pm 

2052. Preoperative Timing of Infliximab and Risk of 

Post-Operative Infection in a Medicare Cohort 

Michael D. George 1 , Joshua F. Baker 1 , Jesse Yenchih 

Hsu 1 , Qufei Wu 1 , Fenglong Xie 2 , Lang Chen 2 , Huifeng 

Yun 3 and Jeffrey Curtis 2 , 1 University of Pennsylvania, 

Philadelphia, PA, 2 University of Alabama at 

Birmingham, Birmingham, AL, 3 University of Alabama 

at Birmingham School of Public Health, Birmingham, 

AL 

5:15 pm 

2053. Prosthetic Joint Infection with Staphylococcus 

Aureus: Recurrence after Surgical Treatment in U.S. 

Veterans with and without Rheumatoid Arthritis 

Namrata Singh 1 , Rajeshwari Nair 2 , Michihiko Goto 3 , 

Elizabeth Field 2 , Petar Lenert 4 , Ryan Carnahan 5 , Marin 

Schweizer 2 and Eli Perencevich 2 , 1 University of Iowa 

Hospitals and Clinics and Iowa City VA, Iowa City, IA, 

2 

Iowa City VA, Iowa City, IA, 3 Iowa city VA and UIHC, 

Iowa City, IA, 4 University of Iowa, Iowa City, IA, 5 College 

of public health, UI, Iowa City, IA 

5:30 pm 

2054. Effect of Temporary Methotrexate 

Discontinuation on Efficacy of Seasonal Influenza 

Vaccination in Patients with Rheumatoid Arthritis: 

A Randomized Clinical Trial 

Jin Kyun Park 1 , Min Ah Lee Lee 2 , Kyung Hee Lee 2 , 

Eun Young Lee 1 , Yeong Wook Song 3 , Yunhee Choi 2 , 

Kevin L. Winthrop 4 and Eun Bong Lee 5 , 1 Division of 

Rheumatology, Department of Internal Medicine, 

Seoul National University, Seoul, South Korea, 2 Seoul 

National University College of Medicine, Seoul, Korea, 

The Republic of, 3 Department of Molecular Medicine 

and Biopharmaceutical Sciences, Graduate School of 

Convergence Science and Technology, Seoul National 

University, Seoul, South Korea, 4 Oregon Health and 

Sciences University, Portland, OR, 5 Seoul National 

University, Seoul, Korea, Republic of 

5:45 pm 

2055. Myocardial Abnormalities Are Associated 

with Corrected QT Interval in Patients with 

Rheumatoid Arthritis without Cardiac Symptoms 

Assessed Using Cardiac Magnetic Resonance 

Imaging 

Yasuyuki Kobayashi 1 , Hitomi Kobayashi 2 , Atsuma 

Nishiwaki 2 , Kaita Sugiyama 2 , Yosuke Nagasawa 2 , 

Takamasa Nozaki 2 , Noboru Kitamura 3 , Masami Takei 2 , 

Natsumi Ikumi 4 and Hirotake Inomata 2 , 1 St.Marianna 

University School of Medicine, Kawasaki, Japan, 2 Nihon 

University School of Medicine, Tokyo, Japan, 3 NIhon 

University School of Medicine, Tokyo, Japan, 4 Nihon 

University School of Medicine, Shinjuku, Japan 

140 A 

Systemic Lupus Erythematosus – Animal Models 

Moderators: Chaim Putterman, MD; Dwight H. Kono, 

MD 

4:30 pm 

2056. Choroid Plexus Infiltrates in Lupus Model 

(MRL/lpr) Mice Represent Tertiary Lymphoid 

Structures, Shedding Light on the Immunological 

Mechanisms of Neuropsychiatric Lupus 

Ariel Stock 1 , Sivan Gelb 2 , Ayal Ben-Zvi 2 and Chaim 

Putterman 1 , 1 Albert Einstein College of Medicine, 

Bronx, NY, 2 Hebrew University, Jerusalem, Israel 

4:45 pm 

2057. TLR-7-Mediated Lupus Nephritis Flares Are 

Independent of Type I Interferon Signaling 

Sonya Wolf 1 , Tamra J. Reed 2 , Chaim O. Jacob 3 and J. 

Michelle Kahlenberg 4 , 1 University of Michigan Medical 

School, Ann Arbor, MI, 2 University of Michigan, Ann 

Arbor, MI, 3 USC School of Medicine, Los Angeles, CA, 

4 

Division of Rheumatology, University of Michigan 

Medical Center, Ann Arbor, MI 

5:00 pm 

2058. Ectonucleotidase-Mediated Protection of 

Lupus Mice from Exaggerated Immune Responses 

and Arterial Vasculopathy 

Jason S Knight, Levi F Mazza, Srilakshmi Yalavarthi, 

Yogen Kanthi and David J Pinsky, University of 

Michigan, Ann Arbor, MI 

5:15 pm 

2059. Serine/Arginine-Rich Splicing Factor 1 (SRSF1) 

Is a Novel Factor in T Cell Homeostasis and Its 

Selective Loss in T Cells Causes Autoimmunity and 

Lupus-Like Nephritis 

Vaishali R. Moulton, Hao Li, Michael W. Mosho, Andrew 

R. Gillooly, Meghan L. Keane and George C. Tsokos, 

Beth Israel Deaconess Medical Center, Harvard Medical 



Monday 




5:30 pm 

2060. Bim Suppresses the Development of SLE By 

Limiting Macrophage Inflammatory Responses 

FuNien Tsai 1 , Carla Cuda 2 , Harris R. Perlman 2 , Philip 

J. Homan 2 , Salina Dominguez 2 , Alexander Shaffer 2 , 

George Kenneth Haines III 3 and Jack Hutcheson 4 , 

1 

Northwestern University-Feinberg School of Medicine, 

Chicago, IL, 2 Northwestern University, Chicago, IL, 

3 

Mount Sinai, New York, NY, 4 UT Southwestern, Dallas, 

TX 

5:45 pm 

2061. Successful Treatment of Murine Lupus 

Nephritis with Helminths Related Tuftsin- 

Phosphorylcholine Compound and Its Effect on the 

Microbiota 

Yehuda Shoenfeld 1 , Tomer Bashi 2 , Hadar Gershon 3 , Or 

Givol 4 , Alexander Volkov 5 , Iris Barshack 5 , Mati Fridkin 6 , 

Miri Blank 2 and Omry Koren 7 , 1 Zabludowicz Center for 

Autoimmune Diseases, Chaim Sheba Medical Center, 

Tel Hashomer, Israel Incumbent of the Laura Schwarz- 

Kipp Chair for Research of Autoimmune Diseases, 

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, 

Israel, 2 Sheba Medical Center, Zabludowicz Center for 

Autoimmune Diseases, affiliated to affiliated to Sackler 

Faculty of Medicine, Tel-Aviv University, Ramat Gan, 

Israel, 3 Bar-Ilan University, Sefat, Israel, 4 Zabludowicz 

Center for Autoimmune Diseases, Ramat Gan, Israel, 

5 

Sheba Medical Center, Institute of Pathology, affiliated 

to Sackler Faculty of Medicine, Tel-Aviv University, 

Ramat Gan, Israel, 6 Weizmann Institute for Sciences, 

Rehovot, Israel, 7 Bar-Ilan university, Sefat, Israel 

146 A 

Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis I 

Moderators: Mariana Kaplan, MD; Gary S. Gilkeson, MD 

4:30 pm 

2062. Increased Expression of Response Gene to 

Complement-32 in Kidney Biopsies from Patients 

with Lupus Nephritis 

Julie Yip 1 , Vinh Nguyen 1 , Alexandru Tatomir 1 , Armugam 

Mekala 1 , Dallas Boodhou 1 , Horea Rus 2 , Cinthia 

Drachenberg 1 and Violeta Rus 2 , 1 University of Maryland 

School of Medicine, Baltimore, MD, 2 Research Service, 

VAMHCS, Baltimore, MD 

4:45 pm 

2063. Identification of Microrna Predictive of 

Outcome in Lupus Nephritis 

Mohammad Hadavand 1 , Nada Binmadi 1 , Hua Zhou 1 , 

Mayank Tandon 2 , Sarfaraz Hasni 3 and Illias Alevizos 4 , 

1 


Bethesda, MD, 2 NIDCR/NIH, Bethesda, MD, 3 National 

Institute of Arthritis and Musculoskeletal and Skin 

Diseases, National Institutes of Health, Bethesda, MD, 

4 


National Institutes of Health, Bethesda, MD 

5:00 pm 

2064. Blood and Kidney Molecular Profiles 

Distinguish Subjects with Lupus Nephritis from 

Other Kidney Disorders 

Matteo Cesaroni 1 , Jarrat Jordan 1 , Marc Chevrier 2 , 

Alan Perlman 3 , James M. Chevalier 4 , Thomas Parker 3 , 

Daniel Levine 3 , Surya V. Seshan 5 , Anna Gong 6 , Takahiro 

Sato 1 and Jacqueline Benson 1 , 1 Estrela Lupus Venture, 

Janssen Research and Development, LLC., Spring 

House, PA, 2 Janssen Research and Development, 

LLC, Collegeville, PA, 3 The Rogosin Institute,New York 

Presbyterian Hospital-Weill Medical College of Cornell 

University, New York, NY, 4 The Rogosin Institute New 

York Presbyterian Hospital, Weill Cornell Medical 

Center, New York, NY, 5 Hospital for Special Surgery, 

New York, NY, 6 The Rogosin Institute,New York 

Presbyterian Hospital-Weill Medical College of Cornell 

University, New York, NY 

5:15 pm 

2065. Platelet FcγRIIa Polymorphism H131R 

Associates with Subclinical Atherosclerosis and 

Increased Platelet Activity in SLE 

Sara Rasmussen, Harmony Reynolds, Jill P. Buyon, 

Sokha Nhek, Jonathan Newman, Jeffrey Berger and 

Robert M Clancy, New York University School of 


5:30 pm 

2066. Anti-Ds-DNA Antibodies Regulate 

Atherothrombosis in Systemic Lupus 

Erythematosus Through the Induction of Netosis, 

the Prothrombotic and Proinflammatory Activities 

of Monocytes and the Endothelial Activation 

Carlos Perez-Sanchez 1 , Maria Ángeles Aguirre 

Zamorano 1 , María Galindo 2 , Patricia Ruiz-Limon 1 , Ivan 


123


Monday 



Arias de la Rosa 1 , Nuria Barbarroja 1 , Yolanda Jiménez- 

Gómez 1 , Pedro Segui 1 , Eduardo Collantes-Estévez 1 , 

Maria Jose Cuadrado 3 and Chary Lopez-Pedrera 1 , 

1 

IMIBIC/Reina Sofia Hospital/University of Cordoba, 

Cordoba, Spain, 2 Hospital 12 de Octubre, Madrid, 

Spain, 3 Lupus Research Unit, London, United Kingdom 

5:45 pm 

2067. Dermal Fibroblasts from Patients with Lupus 

Nephritis Express an Anti-Fibrotic Transcriptome 

Robert M Clancy 1 , Evan Der 2 , Kemal Akat 3 , Anna 

R. Broder 4 , H. Michael Belmont 1 , Peter M. Izmirly 1 , 

Beatrice Goilav 5 , Thomas Tuschl 3 , Chaim Putterman 5 

and Jill P. Buyon 1 , 1 New York University School of 

Medicine, New York, NY, 2 Albert Einstein College of 

Medicine, Bronx, NY, 3 Rockefeller University, New York, 

NY, 4 Division of Rheumatology, Albert Einstein College 

of Med, Bronx, NY, 5 Albert Einstein College of Medicine/ 

Montefiore Medical Center, New York, NY 

Ballroom B 


Raynaud’s – Pathogenesis, Animal Models and 

Genetics I 

Moderator: Sandeep Agarwal, MD, PhD 

4:30 pm 

2068. Type 2 Innate Lymphoid Cells – Cellular 

Source of Profibrotic Mediators Rapidly and 

Persistently Recruited in Experimental Fibrosis and 

Systemic Sclerosis 

Stefanie Weber 1 , Thomas Wohlfahrt 1 , Simon Rauber 1 , 

Markus Luber 1 , Matthias Englbrecht 2 , Clara Dees 2 , 

Christian Beyer 1 , Oliver Distler 3 , Georg Schett 2 , Joerg 

HW Distler 2 and Andreas Ramming 1 , 1 University of 

Erlangen-Nuremberg, Erlangen, Germany, 2 Friedrich- 

Alexander-University Erlangen-Nürnberg (FAU), 

Erlangen, Germany, 3 Department of Rheumatology, 

University Hospital Zurich, Zurich, Switzerland 

4:45 pm 

2069. Dipeptidyl-Peptidase-4 (DPP4) Positive 

Fibroblast Subpopulation Promotes Fibrosis and 

Are a Molecular Target for Treatment of Fibrosis 

Alina Soare 1 , Simon Rauber 2 , Thomas Wohlfahrt 3 , 

Clara Dees 4 , Ruifang Liang 4 , Yun Zhang 3 , Chih-Wei 

Chen 3 , Andreas Ramming 5 , Oliver Distler 6 , Carina 

Mihai 7 , Georg Schett 4 and Joerg HW Distler 4 , 1 Carol 

Davila University of Medicine and Pharmacy, Internal 

Medicine and Rheumatology Department, Cantacuzino 

Clinical Hospital, Bucharest, Romania, 2 University of 

Erlangen-Nuremberg, Erlangen, Germany, 3 Department 

of Internal Medicine 3 and Institute for Clinical 

Immunology, University of Erlangen-Nuremberg, 

Erlangen, Germany, 4 Friedrich-Alexander-University 

Erlangen-Nürnberg (FAU), Erlangen, Germany, 

5 

Department of Internal Medicine 3, Rheumatology 

and Immunology, University of Erlangen-Nuremberg, 

Erlangen, Germany, 6 Center of Experimental 

Rheumatology, University Hospital Zurich, Zurich, 

Switzerland, 7 Carol Davila University of Medicine and 

Pharmacy, Cantacuzino Hospital, Bucharest, Romania 

5:00 pm 

2070. Long Noncoding RNA H19X Is a Master 

Regulator of Extracellular Matrix Production in 

Systemic Sclerosis and Other Fibrotic Disease 

Elena Pachera 1 , Shervin Assassi 2 , Gloria Salazar 2 , Mojca 

Frank Bertoncelj 1 , Rucsandra Dobrota 3 , Matthias 

Brock 1 , Fina Kurreeman 4 , Jeska K. de Vries-Bouwstra 4 , 

Tobias Messemaker 4 , Carol Feghali-Bostwick 5 , Jeorg HW 

Distler 6 , Gabriela Kania 1 and Oliver Distler 3 , 1 University 

Hospital Zurich, Zurich, Switzerland, 2 University 

of Texas-McGovern Medical School, Houston, TX, 

3 

Department of Rheumatology, University Hospital 

Zurich, Zurich, Switzerland, 4 Leiden University Medical 

Center, Leiden, Netherlands, 5 Medical University of 

South Carolina, Charleston, SC, 6 University of Erlangen, 

Erlangen, Germany 

5:15 pm 

2071. Expression of Neuraminidase 1 (NEU1) Is 

Upregulated in the Lungs of Scleroderma Patients 

with Pulmonary Fibrosis, and Gene Delivery of 

NEU1 to Mouse Lungs Elicits Accumulation of CD8+ 

Lymphocytes and Collagen 

Irina G. Luzina 1 , Anne E. Wyman 2 , Virginia Lockatell 1 , 

Zahid Noor 1 , Nevins W. Todd 2 , Simeon E. Goldblum 2 

and Sergei P. Atamas 2 , 1 University of Maryland School 

of Medicine, Baltimore, MD, 2 Baltimore VA Medical 

Center, Baltimore, MD 


Monday 




5:30 pm 

2072. Fli1-Haploinsufficient Dermal Fibroblasts 

Promote Skin-Localized Transdifferentiation of Th2- 

and Th17-Like Regulatory T Cells 

Ryosuke Saigusa 1 , Yoshihide Asano 2 , Takuya 

Miyagawa 2 , Megumi Hirabayashi 2 , Kouki Nakamura 1 , 

Shunsuke Miura 2 , Takashi Yamashita 2 , Yohei Ichimura 1 , 

Takehiro Takahashi 1 , Tetsuo Toyama 2 , Takashi 

Taniguchi 1 , Ayumi Yoshizaki 2 , Maria Trojanowska 3 

and Shinichi Sato 1 , 1 The University of Tokyo Graduate 

School of Medicine, Tokyo, Japan, 2 University of Tokyo 

Graduate School of Medicine, Tokyo, Japan, 3 Boston 

University, Arthritis Center, Boston, MA 

5:45 pm 

2073. Jumonji Domain Containing Protein 3 (JMJD3) 

as a Novel Epigenetic Mechanism of Fibroblast 

Activation by Regulation of Fra-2 

Christina Bergmann 1 , Amelie Brandt 2 , Clara Dees 3 , 

Yun Zhang 1 , Neng-Yu Lin 4 , Chih-Wei Chen 1 , Tatjana 

Mallano 5 , Ruifang Liang 3 , Pui-See Kam 2 , Oliver Distler 6 , 

Georg Schett 3 and Joerg HW Distler 3 , 1 Department 

of Internal Medicine 3 and Institute for Clinical 

Immunology, University of Erlangen-Nuremberg, 

Erlangen, Germany, 2 University of Erlangen- 

Nuremberg, Erlangen, Germany, 3 Friedrich-Alexander- 


Germany, 4 Friedrich Alexander University, Erlangen, 

Germany, 5 Friedrich-Alexander-University Erlangen- 

Nuremberg (FAU), Erlangen, Germany, 6 Department 

of Rheumatology, University Hospital Zurich, Zurich, 

Switzerland 

Ballroom C 

Vasculitis II: Population Studies 

Moderators: Cornelia M. Weyand, MD, PhD; Alfred 

Mahr, MD, PhD 

4:30 pm 

2074. Herpes Zoster and the Risk of Incident Giant 

Cell Arteritis 

Bryant R. England 1 , Ted R. Mikuls 1 , Fenglong Xie 2 , Shuo 

Yang 2 , Lang Chen 2 and Jeffrey Curtis 2 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 University of 

Alabama at Birmingham, Birmingham, AL 

4:45 pm 

2075. No Detection of Varicella-Zoster Virus in 

Temporal Arteries of Patients with Giant Cell 

Arteritis 

Francesco Muratore 1 , Stefania Croci 2 , Ione Tamagnini 3 , 

Alessandro Zerbini 2 , Salvatore Bellafiore 4 , Lucia 

Belloni 2 , Luigi Boiardi 5 , Alessandra Bisagni 1 , Maria 

Parmeggiani 2 , Alberto Cavazza 2 and Carlo Salvarani 1 , 

1 

Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 

2 

Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 

3 

Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, 

Italy, 4 Arcispedale S Maria Nuova, Reggio Emilia, Italy, 

5 

Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy 

5:00 pm 

2076. Impact of Vasculitis on Employment and 

Income: An Online Survey of Participants in 

the Rare Diseases Clinical Research Network – 

Vasculitis Clinical Research Consortium Patient 

Contact Registry 

Lillian Barra 1 , Renee Borchin 2 , Cristina Burroughs 3 , 

Simon Carette 4 , George Casey 5 , Carol A McAlear 6 , 

Antoine Sreih 6 , Kalen Young 5 , Peter A. Merkel 7 , 

Christian Pagnoux 8 and Vasculitis Clinical Research 

Consortium and the Vasculitis Patient-Powered 

Research Network , 1 Schulich School of Medicine and 

Dentistry, Western University, London, ON, 2 University 

of South Florida, Tampa, FL, 3 Vasculitis center, 

Division of Rheumatology, University of Pennsylvania, 

Philadelphia, PA, 4 Mount Sinai Hospital, University of 

Toronto, Toronto, ON, 5 Vasculitis Foundation, Kansas 

city, MN, 6 University of Pennsylvania, Philadelphia, 

PA, 7 Univ of Pennsylvania; Perelman School of Med, 

Philadelphia, PA, 8 Division of Rheumatology, Mount 

Sinai Hospital, University Health Network, University of 

Toronto, Toronto, Canada, Toronto, ON 

5:15 pm 

2077. Impact of Diabetes, Angiotensin Converting 

Enzyme Inhibitor or Angiotensin II Receptor Blocker 

Use, and Statin Use on Presentation and Outcomes 

in Patients with Giant Cell Arteritis 

Jocelyn Ma 1 , Nader A. Khalidi 2 , Ola Wierzbicki 1 , Abdallah 

Al Qethami 3 , Simon Carette 4 and Christian Pagnoux 4 , 

1 

McMaster University, Hamilton, ON, 2 St. Joseph’s 

Health Care, McMaster University, Hamilton, ON, 

3 

University of Toronto, Toronto, ON, 4 Mount Sinai 

Hospital, University of Toronto, Toronto, ON 


125


Monday 



5:30 pm 

2078. Global Ethnic and Geographic Differences in 

the Clinical Features of ANCA-Associated Vasculitis 

Fiona Pearce 1 , Anthea Craven 2 , Peter A. Merkel 3 , 

Raashid Luqmani 4 and Richard A. Watts 5 , 1 University of 

Nottingham, Nottingham, United Kingdom, 2 University 

of Oxford, Oxford, United Kingdom, 3 University of 

Pennsylvania, Philadelphia, PA, 4 Nuffield Department 

of Orthopaedics Rheumatology and Musculoskeletal 

Sciences, Botnar Research Centre, University of Oxford, 

Oxford, United Kingdom, 5 Ipswich Hospital, Ipswich, 

Great Britain 

5:45 pm 

2079. Incidence and Risk of Pneumocystis 

Jiroveci Pneumonia Following Rituximab Treatment 

in Granulomatosis with Polyangiitis in the United 

States: An Analysis from a National Database 

Sirada Panupattanapong 1 , Anthony R. French 1 , Andrew 

J. White 1 , Margaret A. Olsen 2 , Maya Rendulic 2 and 

Mary E. Hartman 1 , 1 Washington University School of 

Medicine, St. Louis Children’s Hospital, St. Louis, MO, 

2 

Washington University School of Medicine, St. Louis, 

MO 

ARHP SESSIONS 

4:30 pm – 6:00 pm 

201 

Social Influences in Rheumatic Disease: An 

International Perspective 

Moderator: Marian T. Hannan, DSc, MPH 

4:30 pm 

The Intersection of Context and Consequences for 

Arthritis 

Speaker: Kristina A. Theis, PhD 

5:00 pm 

The Role of Socio-Economic Factors on the Impact of 

Musculoskeletal Conditions 

Speaker: Ross Wilkie, PhD 

5:30 pm 

Social Determinants and Outcomes in Osteoarthritis 

and Rheumatoid Arthritis 

Speaker: Leigh F. Callahan, PhD 

206 

Surgery and Therapy for the Elbow and Hand 

PM PS E 

Moderator: Susan Chrostowski, DNP, ANP-C 

4:30 pm 

Elbow and Hand Surgical Considerations 

Speaker: Richard W. Barth, ND 

5:15 pm 

Rehabilitation and Therapy for the Elbow and Hand 

Speaker: Sarah Wilson, MSOTR/L, CHT, CLT 

204 A 

Update: Emerging Systemic Lupus 

Erythematosus Treatments 

Moderator: Sara Monday, COO Metroplex Clinical 

Research Center 


ACR/ARHP COMBINED ABSTRACT SESSION 

4:30 pm – 6:00 pm 

145 A 

ACR/ARHP Combined Abstract Session: 

Epidemiology and Pubic Health 

Moderators: Kristine Phillips, MD, PhD; Alyssa B. Dufour, 

PhD 

4:30 pm 

2026. Are Adult Trajectories of Weight over a 

Lifetime Linked to Foot Problems Years Later? 

Alyssa B. Dufour 1 , Elena Losina 2 , Hylton B. Menz 3 , 

Michael P. Lavalley 4 and Marian T. Hannan 5 , 1 Hebrew 

SeniorLife, Harvard Medical School & Beth Israel 

Deaconess Medical Center, Boston, MA, 2 Brigham & 

Women’s Hospital, Boston, MA, 3 La Trobe University, 

Bundoora, Australia, 4 Boston University School of 

Public Health, Boston, MA, 5 Hebrew SL & Harvard Med 



Monday 



ACR/ARHP COMBINED ABSTRACT SESSION continued 

4:45 pm 

2027. The Association of Light and Moderateto-Vigorous 

Walking with Incident Poor Health 

Outcomes over Two Years in People with or at High 

Risk of Knee Osteoarthritis 

Sally Fenton 1 , Joan Duda 2 , Rainer Klocke 3 , Abishek 

Abishek 4 , Alison Rushton 2 , Michael Doherty 4 , Weiya 

Zhang 5 , George D. Kitas 6 , Tuhina Neogi 7 , Michael 

Nevitt 8 , Cora E Lewis 9 , James Torner 10 , Dorothy 

D. Dunlop 11 and Daniel White 12 , 1 University of 

Birmingham, Birmingham, United Kingdom, 2 University 

of Birmingham, UK, Birmingham, United Kingdom, 

3 

The Dudley Group of Hospitals NHS Foundation 

Trust, Dudley, United Kingdom, 4 University of 

Nottingham, Nottingham, United Kingdom, 5 Division 

of Rheumatology, Orthopaedics and Dermatology, 

School of Medicine, University of Nottingham, 

Nottingham, United Kingdom, 6 Russells Hall Hospital, 


Dudley, United Kingdom, 7 Boston University School 

of Medicine, Boston, MA, 8 University of California 

San Francisco School of Medicine, San Francisco, CA, 

9 


AL, 10 UIowa, Iowa City, IA, 11 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 12 University of 

Delaware, Newark, DE 

5:00 pm 

2028. Relationship of Limb Length Inequality 

and Incident and Progressive Knee and Hip 

Radiographic Osteoarthritis and Symptoms 

Yvonne M. Golightly 1 , Carolina Alvarez 1 , Kelli Allen 2 , 

Jordan B. Renner 1 and Joanne M. Jordan 1 , 1 University 

of North Carolina at Chapel Hill, Chapel Hill, NC, 

2 

University of North Carolina at Chapel Hill and 

Durham VA Medical Center, Chapel Hill, NC 

5:15 pm 

2029. Risk of Knee Pain, Radiographic 

Osteoarthritis, and Knee Arthroplasty in Retired 

Professional Footballers Compared to the General 

Population 

Gwen Fernandes 1 , Sanjay M Parekh 2 , Jonathan P 

Moses 2 , Colin Fuller 3 , Brigitte Scammell 4 , Mark Batt 4 , 

Weiya Zhang 4 and Michael Doherty 4 , 1 Arthritis Research 

UK Pain Centre, Nottingham, United Kingdom, 

2 

Arthritis Research UK Centre for Sports, Exercise 

and Osteoarthritis, Nottingham, United Kingdom, 

3 

Colin Fuller Consultancy Ltd, Nottingham, United 

Kingdom, 4 Division of Rheumatology, Orthopaedics 

and Dermatology, School of Medicine, University of 

Nottingham, Nottingham, United Kingdom 

5:30 pm 

2030. Difference in Risk Factor Profile Between 

Medial and Lateral Compartment Involvement in 

Tibiofemoral Knee Osteoarthritis 

Na Lu 1 , Jingbo Niu 1 , Hyon Choi 2 and Yuqing Zhang 1 , 

1 

Boston University School of Medicine, Boston, MA, 

2 

Massachusetts General Hospital, Harvard Medical 


5:45 pm 

2031. Dietary Patterns and Radiographic 

Progression of Knee Osteoarthritis: Data from the 

Osteoarthritis Initiative 

Bing Lu 1 , Jeffrey Driban 2 , Chang Xu 3 , Timothy E. 

McAlindon 2 and Charles B. Eaton 4 , 1 Brigham and 

Women’s Hospital, Harvard Medical School, Boston, 

MA, 2 Tufts Medical Center, Boston, MA, 3 Rutgers 

University, New Brunswick, NJ, 4 Alpert Medical School 

of Brown University, Pawtucket, RI 


4:30 pm - 6:00 pm 

202 B 

(#2080-2085) ARHP IV – Clinical Practice, Patient 

Care, and Health Services 

Moderators: Janine Shinn, MPAS, PA-C; Karen Huisinga, 

MN, ARNP, FNP 

4:30 pm 

2080. Three Simple Tests to Raise the Index of 

Suspicion for Fibromyalgia in Primary Care 

Amanda W. St. John, Jonathan H. Aebischer, Robert M. 

Bennett, Madeleine J. Sanford, Kaitlin Z. Haws and Kim 

D. Jones, Oregon Health & Science University, Portland, 

OR 


127


Tuesday 



4:45 pm 

2081. Dermal Temperature Is an Excelent 

Prognostic Indicator to Guide RA Therapy 

JoAnn Ball 1 and Maria Greenwald 2 , 1 Desert Medical 

Advances, Palm Deseret, CA, 2 Desert Medical Advances, 

Palm Desert, CA 

5:00 pm 

2082. Identification of Major Clinical Characteristics 

and Linear Correlations Among DAS28, HAQ and 

Morning Stiffness Time Using Smart System of 

Disease Management (SSDM) 

Jianlin Huang 1 , Hongzhi Wang 2 , Jing Yang 3 , Wenqiang 

Fan 4 , Hua Wei 5 , Rong Mu 6 , Xinwang Duan 7 , Xiangyuan 

Liu 8 , Fang He 9 , Zhenchun Zhang 10 , Fei Xiao 11 , Hui 

Xiao 11 , Yuhua Jia 11 , Yuan Liu 11 , Li Zhang 11 , Bing Wu 11 

and Xiaofeng Li 12 , 1 The Sixth Hospital Affiliated to 

Sun yat-sen University, Guangzhou, China, 2 The First 

Hospital of Jiaxing, Jiaxing, China, 3 Central Hospital of 

MianYang, Sichuan, Mian Yang, China, 4 Central Hospital 

of XinXiang, Henan, XinXiang, China, 5 Northern Jiangsu 

People’s Hospital, Yangzhou, China, 6 Peking University 

People’s Hospital, Beijing, China, 7 The Second Affiliated 

Hospital of Nanchang University, Nanchang, China, 

8 

Peking University Third hospital, Bei jing, China, 

9 

Central Hospital of Sui Ning, Sichuan, Suining, China, 

10 

People’s Hospital of Linyi, Shandong, Linyi, China, 

11 

Gothic Internet Technology Corporation, Shanghai, 

China, 12 The Second Affiliated Hospital of Shanxi 

Medical College, Taiyuan, China 

C. Allyson Jones 3 , Paul Adam 4 , Cheryl Koehn 5 , Alison 

Hoens 6 , Jasmina Geldman 1 , Charles Goldsmith 7 , Eric 

C. Sayre 1 and Nick Bansback 6 , 1 Arthritis Research 

Canada, Richmond, BC, 2 School of Interactive Arts 

and Technology, Simon Fraser University, Surrey, 

BC, 3 University of Alberta, Edmonton, AB, 4 Mary Pack 

Arthritis Program, Vancouver, BC, 5 Arthritis Consumer 

Experts, Vancouver, BC, 6 University of British Columbia, 

Vancouver, BC, 7 Simon Fraser University, Vancouver, 

BC 

5:45 pm 

2085. Minding the Gap: the Use of Nurse 

Practitioners and Physician Assistants in U.S. 

Rheumatology Practice to Affect Rheumatology 

Workforce Shortages 

Benjamin J Smith 1 , Marcy B. Bolster 2 , Marcia 

Ditmyer 3 , Karla B. Jones 4 , Seetha Monrad 5 and Daniel 

Battafarano 6 , 1 McIntosh Clinic, P.C., Thomasville, 

GA, 2 Massachusetts General Hospital, Boston, MA, 

3 

University of Nevada, Las Vegas, NV, 4 Nationwide 

Children’s, Columbus, OH, 5 University of Michigan, Ann 

Arbor, MI, 6 San Antonio Military Medical Center, San 

Antonio, TX 

TUESDAY 

NOVEMBER 15 

5:15 pm 

2083. Comparing the Electronic Patient Reported 

Outcome (ePro) Tool Versus the Paper Reported 

Outcome (pPro) Tool in Rheumatoid Arthritis 

Patients Treated with Certolizumab Pegol 

Charles Inderjeeth 1 , Warren Raymond 2 and Andrisha 

Inderjeeth 3 , 1 University of western Australia, North 

Metro Health Service, Perth WA, Australia, 2 Sir Charles 

Gairdner Hospital and University of Western Australia, 

Nedlands, Australia, 3 Sir Charles Gairdner Hospital, 

Perth, Australia 

5:30 pm 

2084. Effects of a Web-Based Patient Decision Aid 

on Biologics for Rheumatoid Arthritis: A Proof-of- 

Concept Study 

Linda Li 1 , Chris Shaw 2 , Diane Lacaille 1 , Elaine Yacyshyn 3 , 

ACR SESSIONS 

7:30 am – 8:30 am 

146 A 

Between the Sheets: Clinical Review of Sleep 

Disorders PM PS PME 

PS E 

Moderator: To Be Determined 

Speaker: Richard J. Schwab, MD, DABSM 

Salon G 

Immunology Update: Biologic Agents: From 

Nature, to Protein Engineering to Biosimilars 


Speaker: John D. Isaacs, MD, PhD, FRCP 


Tuesday 




140 A 

Legislative and Regulatory Update 2016 

Moderator: L. Douglas Graham, MD 

7:30 am 

ACR Legislative/Regulatory Update to the 

Membership 

Speaker: William F. Harvey, MD, MSc 

8:00 am 

View from the Hill: Top Issues Affecting Healthcare in 

2017 

Speaker: To Be Determined 

Hall E 

Rheumatology Research Foundation Memorial 

Lecture Honoring Dr. Ephraim Engelman: T Cell 

Receptor Signaling 

Moderator: David I. Daikh, MD, PhD 

Speaker: Arthur Weiss, MD, PhD 

ARHP SESSIONS 

7:30 am – 8:30 am 

151 A 

Immunology Boot Camp III: Applying Principles 

of Immunology to Treatment Decisions 

Moderators: Christine A. Stamatos, DNP, ANP-C; Kori 

Dewing, DNP 

7:30 am 

Applying Principles of Immunology to Treatment 

Decisions 


7:55 am 


Decisions 

Speaker: Sandro Perazzio, MD, PhD 

8:20 am 


Decisions – Case Studies 

Speaker: Kori Dewing, DNP 

204 A 

Long-Term Side Effects of Biologics 

Moderator: John Tesser, MD 

Speaker: John J. Cush, MD 

PM PS E 

201 

Nutrition for Rheumatic Disease: Diet and 

Supplements PM PS E 


Speaker: M. Kyla Shea, PhD 

143 A 

Statin-Induced Myopathy 

Moderators: Karen L. Smarr, PhD; Christine A. Stamatos, 

DNP, ANP-C 

Speaker: Lisa Christopher-Stine, MD, MPH 

ACR SESSIONS 

7:30 am – 9:00 am 

Ballroom A 

New Classification Criteria for ANCA- 

Associated Vasculitis: Implications for Clinical 

PM PS E 

Practice 

Moderators: Raashid Luqmani, B Med Sci, BM, BS, DM, 

FRCP, FRCPE; Peter A. Merkel, MD, MPH 

7:30 am 

New ACR-EULAR Classification Criteria for ANCA- 

Associated Vasculitis: Why and How? 

Speakers: Ravi Suppiah, BHB, MBChB (MD-equiv), 

PGDipSport Med, MD (PhD-equiv); Cristina Ponte, MD; 

Peter C. Grayson, MD 

8:00 am 

Comparisons Between the 2016 and 1990 

Classification Criteria for ANCA-Associated Vasculitis 

Speaker: Joanna C. Robson, MBBS, PhD, MRCP 

8:30 am 

Clinical Implications of the 2016 ACR-EULAR 

Classification Criteria for ANCA-Associated Vasculitis 

Speakers: Raashid Luqmani, B Med Sci, BM, BS, DM, 

FRCP, FRCPE; Peter A. Merkel, MD, MPH; Richard A. 

Watts, DM 


129


Tuesday 



152 A 

The Art of Asking Questions as a Gateway 

158 A 

066 -Fibromyalgia 2016: Update on Management 

to Effective Teaching and Feedback PM Ed Pd PS PrM FIT PM PS E 

Moderator: Eli Miloslavsky, MD 

Speaker: Daniel J. Clauw, MD 

Speakers: Dan Raemer, PhD; Brad Morrison, PhD; Laura 

Rock, MD 


7:45 am – 9:15 am 










148 


Speaker: Lianne S. Gensler, MD 

PM PS E 

158 B 

067 – Giant Cell Arteritis in 2016: Diagnosis and 

Management 


159 A 

068 – Myopathy: Issues in Diagnosis and 

Treatment 

Speaker: Mary E. Cronin, MD 

159 B 

069 – Systemic Lupus Erythematosus: Difficult 

to Treat Systemic Lupus Erythematosus 

Speaker: Eliza Chakravarty, MD, MS 

155 

070 – Vasculitis: Update 

Speaker: Carol A. Langford, MD, MHS 

153 

062 – Biomechanical Interventions for 

Managing Orthoarthritis 

Speaker: Kelly D. Krohn, MD 

154 A 

063 – Challenging Cases in Osteoporosis 

Management 

Speaker: Nancy Lane, MD 

154 B 

064 – Controversies with Vitamin D Use for 

Bone Health 

Speaker: Chad Deal, MD 

160 


Gout 

PM PS E 

Speaker: John S. Sundy, MD, PhD 

WORKSHOPS 

7:45 am – 9:45 am 










144 C 



Speakers: Jay B. Higgs, MD; Catherine Bakewell, MD 


Tuesday 




149 A 

232 – Histopathology of Vasculitis 

Speakers: Joseph Maleszewski, MD; Allen Burke, MD 

144 B 

233 – Joint Injections (Knee, Ankle, Shoulder, 

and Wrist) PM PS E 

Speakers: Jemima Albayda, MD; Pari Basharat, MD 

ACR SESSIONS 

8:30 am – 10:00 am 

Salon B 

Anatomy for the Clinician III: Knee Pain, Not 

from the Knee Joint 

PM PS E 


Speaker: P. Scott Pollock, MD 

150 A 

Digital Scholar Training Series: Engaging with 

Patients Online: The Dos and Don’ts, and What’s 

to Gain (Part 2 of 2 ) 

Moderator: Swamy Venuturupalli, MD 

Speaker: Katja Reuter, PhD 

Ballroom B 

New Insights into Mechanism of Fibrosis 

Moderators: Cong-Qiu Chu, MD; Pravitt Gourh, MD 

8:30 am 

Insights into Fibrosis in Scleroderma: Novel Fibrotic 

Pathways as Therapeutic Targets 

Speaker: John Varga, MD 

8:30 am 

Evaluation of the Child with Autoimmune Brain 

Disease: Diagnosis, Pathogenesis, and Therapeutic 

Decision-Making (AID) 

Speaker: Russell Dale, MD 

9:00 am 

Anti-NMDA Receptor Encephalitis 

Speaker: Josep Obrador Dalmau, MD, PhD 

9:30 am 

Update on Neuropsychiatric Systemic Lupus 

Erythematosus in Children: Diagnostics and Therapy 

Speaker: Hermine I. Brunner, MD, MSc 

Ballroom C 

Spondyloarthropathies: Advances in the Science 

and Management PM PS E 

Moderators: Petros Efthimiou, MD; Athanasios G. 

Tzioufas, MD, Professor 

8:30 am 

Relevance of the Gut/Joint Axis for the Management 

of Spondyloarthritis in Daily Clinical Practice 

Speaker: Dirk Elewaut, MD, PhD 

9:00 am 

Current Guidelines for the Treatment of 

Ankylosing Spondylitis and Non-Radiographic Axial 

Spondyloarthropathies 

Speaker: Michael Ward, MD, MPH 

9:30 am 

Emerging Therapies in Axial Spondyloarthritis (SpA) 

Speaker: Atul A. Deodhar, MD 

9:15 am 

New Insights into the Mechanisms and Prevention of 

Fibrotic Disease 

Speaker: Harry C. Dietz, MD 

207 B 

Pediatric Autoimmune Brain Disease PM PS 

Moderators: Eyal Muscal, MD, MS; Tania Cellucci, MD, 

FRCPC, MScCH 

Ed Pd PrM FIT 

ARHP SESSIONS 

8:30 am – 10:00 am 

206 

Comparative Effectiveness Trials in 

Rheumatology: Rationale, Design, and Analysis 

Moderator: Adam P. Goode, DPT, PhD 


131


Tuesday 



8:30 am 

Key Design Issues in Comparative Effectiveness Trials 

Speaker: Kelli Allen, PhD 

9:15 am 

Key Analytical Issues in Comparative Effectiveness 

Trials 

Speaker: Todd A. Schwartz, DrPH 

209 A 

Set the Teen Patient Up for Success in Adult 

Care PM Ed PM Pd PS PrM PS FIT E 

Moderator: Patience White, MD, MA 

8:30 am 

Caring for Adults with Juvenile Idiopathic Arthritis (JIA) 

and Childhood-Onset Systemic Lupus Erythematosus 

(SLE): What Every Adult Rheumatologist Should Know 

Speaker: Stacy P. Ardoin, MD, MS 

9:00 am 

Bridge the Gap: Guidelines and Tools to Implement a 

Transition Process in Your Clinic 

Speaker: Erica Lawson, MD 

9:30 am 

Empower the Patient: Resources Available Outside of 

the Clinic 

Speaker: Jennifer R. Horonjeff, PhD 

ACR SESSIONS 

9:00 am – 10:00 am 

201 

Autoimmunity and Tertiary Lymphoid Tissue 

Moderator: Theresa Lu, MD, PhD 

Speaker: Troy Randall, PhD 

Salon G 

Crystal-Related Arthropathies: Beyond Urate 

Moderator: Mathilde H. Pioro, MD 

Speaker: Geraldine M. McCarthy, MD 

ARHP SESSIONS 

9:00 am – 10:00 am 

140 A 

Fibromyalgia Symptom Clusters and Patterns 

of Symptom Change: An Individualized Study 

PM PS E 

Approach 

Moderators: Christine A. Stamatos, DNP, ANP-C; 

Gwynne Maloney-Saxon, RN, MS 

9:00 am 

Fibromyalgia Symptom Clusters: A Case Study 

Approach 

Speaker: Ann Vincent, MD 

9:30 am 

Understanding Symptom Stability and Change in 

Fibromyalgia 

Speaker: Loren L. Toussaint, PhD 

204 A 

The Future of Medicine Is in Your Smart Phone 


Speaker: Jonathan S. Hausmann, MD 

ACR POSTER SESSION C AND POSTER 

TOURS 

8:30 am – 4:00 pm 


(abstracts #2086-2981). Poster tours will be held 9:00 

– 9:45 am and 10:15 – 11:00 am. Morning snacks will be 

available at 8:30 am. 


Thieves’ Market Posters – ACR/ARHP Poster 

Sessions C 

Muscles in a Bind 

Delamo Bekele, MBBS 

Neurobehcet’s and Uhthoff’s Phenomenon 

Maryam Gul, MD 


Tuesday 



ACR POSTER SESSION C AND POSTER TOURS continued 

Not So Idiopathic 

Shivani Garg, MD 

Not Your Typical Pain in the Neck 

Ryan Weldon, MD 

Renal Mass in a Patient with Granulomatosis with 

Polyangitis 

Heena Bribal Jain, MD 

Sweet P? Or Three P? 

Minyoung Her, MD 

Systemic Lupus Erythematosus: Has a Lot of Nerves 

Nicola Berman, MD 

Unsuspecting Cause of Cardiomyopathy 

Megan Lynch, DO 

When a Good History Takes the Cake 

Talha Khawar, MD 






















headset is not returned within 15 minutes of the end of 

the tour. 

9:00 – 9:45 am 




10:15 – 11:00 am 




EXHIBITS 

10:00 am – 5:00 pm 










Theater A presentations will be held from 10:30 – 11:15 am 

and 12:30 – 1:15 pm. Innovation Theater B presentations 

will be held from 11:30 am – 12:15 pm and 1:30 – 2:15 pm. 

For a complete listing of Innovation Theater presentations, 

see page 194. 

WORKSHOPS 

10:30 am – 11:30 am 











133


Tuesday 



149 A 

234 – How to Be an Effective Advocate for 

Your Practice and Patients: Legislative Affairs, 

Advocacy, Social Media, and Technology (A 

Workshop) 

10:30 am 

Effective Advocacy: Learn from a Former U.S. Senator, 

and Hear Breaking News about the Results of the 

Election 

Speaker: Senator Tim Hutchinson 

11:00 am 

Advocacy in the 21st Century: Tips and Tools You Can 

Use 

Speaker: Kristen Burke 

WORKSHOPS 

10:30 am – 12:30 am 










144 C 

235 – Musculoskeletal Ultrasound 

Speakers: Eugene Y. Kissin, MD; Amy M. Evangelisto, MD 

144 B 

236 – The Rheumatologic Musculoskeletal 

Screening Exam, with Emphasis on Objective 

Disease-Specific Measurements PM PS E 

Speakers: Arthur M. Mandelin II, MD, PhD; Sharon 

Tymkiw, MSN, MBA, RN 

WORKSHOPS 

10:30 am – 3:30 pm 










144 A 

237 – Big Data Made Practical (ImmPort) 

10:30 am 

Open Clinical Trial Sharing Initiatives 

Speaker: Ravi Shankar, PhD 

11:00 am 

ImmPort: An Overview 

Speaker: Jeff Wiser, MD, PhD 

11:30 am 

Utilizing Open Clinical Trial Data: A Case Study Using 

the RAVE Trial 

Speaker: Mazen Nasrallah, MD, MSc 

12:30 pm 

Boxed Lunch 

1:15 pm 

Data Reuse, Reproducibility, and Reanalysis: 

Analytical Tools and Case Studies from ImmPort 

Speaker: Sanchita Bhattacharya, MSc, PhD 

1:30 pm 

Hands-on-Training: ImmPort Demo, Flow Cytometry 

Analysis Tools, and Rave Re-Analyses 

Speaker: Sanchita Bhattacharya, MSc, PhD; Ravi 

Shankar, PhD; Henry Schaefer, PhD; Cristel Thomas, 

PhD 


Tuesday 




3:00 pm 

Utilizing Open Clinical Trial Data: A Case Study Using 

the RAVE Trial 

Speaker: Mazen Nasrallah, MD, MSc 

ACR SESSIONS 

11:00 am – 12:00 pm 

207 B 

Advances in Clinical Care Through Whole Exome 

Sequencing PM Ed Pd PS PrM FIT 

Moderators: Megan A. Cooper, MD, PhD; Amanda K. 

Ombrello, MD 

11:00 am 

Whole Exome Sequencing: When to Order and How to 

Interpret and Utilize the Results 

Speaker: Alexei Grom, MD 

11:30 am 

Unbiased Genomic Approach to Pediatric 

Autoimmune and Autoinflammatory Patients 

Speaker: Jordan S. Orange, MD, PhD 

146 A 

Mining Big Data for Drug Repurposing 

Moderators: Nan Shen, MD; Patrick M. Gaffney, MD 

11:00 am 

Meta-Analysis of Gene Expression Data Sets to 

Identify Novel Molecular Pathways and Drug Targets 

in Systemic Lupus Erythematosus 

Speaker: Peter E. Lipsky, MD 

11:30 am 

Human Genetics for Drug Discovery and Repurposing 

Speaker: Robert Plenge, MD, PhD 

Ballroom B 

Polymyositis Mimics: A Weak Area for 

Rheumatologists: Recognizing Mimics of 

Polymyositis 

Moderators: Gregory Gardner, MD, FACP; James 

Andrews, MD 

Speaker: Michael Weiss, MD 

ACR SESSIONS 

11:00 am – 12:30 pm 

143 A 

Manuscript Peer Review: A Hands-On Session to 

Hone Skills and Provide Tools for Critical Review 

of Research Manuscripts 

Moderators: Marian T. Hannan, DSc, MPH; Richard 

Bucala, MD, PhD 

11:00 am 

Outline and Key Points of Conducting Manuscript 

Peer Review 

Speakers: Marian T. Hannan, DSc, MPH; Richard Bucala, 

MD, PhD 

11:20 am 

Hands-On Small-Group Experience in Conducting 

Manuscript Review 

Speakers: Marian T. Hannan, DSc, MPH; Richard Bucala, 

MD, PhD; Daniel H. Solomon, MD, MPH; Michael P. 

LaValley, PhD 

12:20 pm 

Wrap-Up and Question and Answer 


11:00 am – 12:30 pm 

Hall D 

ACR Plenary Session III: Discovery 2016 

Moderators: Victoria K. Shanmugam, MBBS, MRCP; 

Lindsey A. Criswell, Professor 

11:00 am 

2982. Tumor Necrosis Factor Inhibitors and the 

Risk of Malignancy in the Treatment of Juvenile 


Timothy Beukelman 1 , Fenglong Xie 1 , Lang Chen 1 , Daniel 

Horton 2 , James D. Lewis 3 , Ronac Mamtani 3 , Melissa 

Mannion 1 , Kenneth G. Saag 1 , Jie Zhang 1 and Jeffrey 

R. Curtis 1 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 Rutgers Robert Wood Johnson 

Medical School, New Brunswick, NJ, 3 University of 

Pennsylvania, Philadelphia, PA 


135


Tuesday 



11:15 am 

2983. Efficacy and Safety of Tofacitinib, an Oral 

Janus Kinase Inhibitor, or Adalimumab in Patients 

with Active Psoriatic Arthritis and an Inadequate 

Response to Conventional Synthetic Dmards: A 

Randomized, Placebo‐Controlled, Phase 3 Trial 

Philip J Mease 1 , Stephen Hall 2 , Oliver FitzGerald 3 , 

Désirée van der Heijde 4 , Joseph F Merola 5 , Francisco 

Avila-Zapata 6 , Dorata Cieślak 7 , Daniela Graham 8 , 

Cunshan Wang 9 , Sujatha Menon 9 , Thijs Hendrikx 8 and 

Keith Kanik 9 , 1 Swedish Medical Center and University of 

Washington, Seattle, WA, 2 Cabrini Health and Monash 

University, Melbourne, VIC, Australia, 3 St Vincent’s 

University Hospital and Conway Institute, University 

College, Dublin, Ireland, 4 Leiden University Medical 

Center, Leiden, Netherlands, 5 Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA, 6 Centro 

Multidisciplinario para el Desarrollo Especializado de 

la Investigacion Clinica en Yucatan S.C.P., Yucatán, 

Mexico, 7 Poznan University, Poznan, Poland, 8 Pfizer Inc, 

Collegeville, PA, 9 Pfizer Inc, Groton, CT 

11:30 am 

2984. Novel Anti-Malarial Drug Derivative Inhibited 

Type I Interferon Production and Autoimmune 

Inflammation through Inhibition of CGAS-Sting 

Pathway in Trex1-/- Mouse 

Jie An, Joshua Woodward, Mark Minie, Xizhang Sun, 

Lena Tanaka, Yufeng Peng, Jessica Snyder, Tomikazu 

Sasaki and Keith B. Elkon, University of Washington, 

Seattle, WA 

11:45 am 

2985. Practice-Level Variation in Quality of Care in 

the ACR’s Rheumatology Informatics System for 

Effectiveness (RISE) Registry 

Jinoos Yazdany 1 , Nick Bansback 2 , Megan E. B. Clowse 3 , 

Deborah Collier 4 , Karen Law 5 , Katherine Liao 6 , Kaleb 

Michaud 7 , Esi Morgan 8 , Jim Oates 9 , Catalina Orozco 10 , 

Andreas Reimold 11 , Julia F Simard 12 , Rachel Myslinski 13 , 

Tracy Johansson 14 and Salahuddin Kazi 15 , 1 University of 

California, San Francisco, San Francisco, CA, 2 University 

of British Columbia, Vancouver, BC, 3 Duke University 

School of Medicine, Durham, NC, 4 Massachusetts 

General Hospital, Harvard Medical School, Boston, 

MA, 5 Emory University School of Medicine, Atlanta, 

GA, 6 Brigham and Women’s Hospital, Boston, MA, 

7 

University of Nebraska Medical Center, Omaha, 

NE, 8 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 9 Medical University of South Carolina, 

Charleston, SC, 10 Rheumatology Associates, Dallas, 

TX, 11 Hospital of Southern Norway, Kristiansand, 

Norway, 12 Stanford School of Medicine, Stanford, 

CA, 13 Amer College of Rheumatology, Atlanta, GA, 

14 

American College of Rheumatology, Atlanta, GA, 15 UT 

Southwestern Medical Center, Dallas, TX 

12:00 pm 

2986. Trends and Determinants of Osteoporosis 

Prevention and Management in Patients with 

Rheumatoid Arthritis Compared to Osteoarthritis 

Gulsen Ozen 1 , Diane L. Kamen 2 , Ted R Mikuls 3 , 

Frederick Wolfe 4 and Kaleb Michaud 3 , 1 Marmara 

University Faculty of Medicine, Istanbul, Turkey, 

2 

Medical University of South Carolina, Charleston, SC, 

3 

University of Nebraska Medical Center, Omaha, NE, 

4 

National Data Bank for Rheumatic Diseases, Wichita, 

KS 

12:15 pm 

2987. Comparison of Certolizumab Pegol Versus 

Adalimumab: 2 Year Efficacy and Safety Results 

from a Superiority, Investigator-Blind, Head-to- 

Head Study 

Roy Fleischmann 1 , Gerd-Rüdiger Burmester 2 , Bernard 

Combe 3 , Jeffrey R. Curtis 4 , Stephen Hall 5 , Boulos 

Haraoui 6 , Ronald van Vollenhoven 7 , Christopher 

Cioffi 8 , Cécile Ecoffet 9 , Lucian Ionescu 9 , Leon Gervitz 9 , 

Luke Peterson 8 and Josef Smolen 10 , 1 University 

of Texas Southwestern Medical Center at Dallas 

Metroplex Clinical Research Center, Dallas, TX, 

2 

Charité – University Medicine Berlin, Berlin, Germany, 

3 

Montpellier University Hospital, Montpellier, France, 

4 


AL, 5 Cabrini Medical Centre, Monash University, 

Melbourne, Australia, 6 Centre Hospitalier de 

l’Université de Montréal, Montréal, QC, 7 Amsterdam 

Rheumatology and Immunology Center (ARC), 

Amsterdam, Netherlands, 8 UCB Pharma, Raleigh, NC, 

9 

UCB Pharma, Brussels, Belgium, 10 Medical University 

of Vienna and Hietzing Hospital, Vienna, Austria 


Tuesday 



ACR SESSIONS 

12:30 pm – 2:00 pm 

146 A 

2016 CARE: MOC Sessions 3 of 3: Miscellaneous 

Rheumatic Disorders (Conditions that Don’t Fit 

in a Box 


Speaker: Jason R. Kolfenbach, MD 


12:45 pm – 2:15 pm 










148 

071 – Ankylosing Spondylitis: Disease 

Modification 


153 

072 – Infections with Biologics PM PS E 


154 A 

073 – Management of Patients with Hepatitis C 

and Rheumatic Diseases 

Speaker: Timothy B. Niewold, MD 

154 B 

074 – Pediatric Systemic Lupus Erythematosus 


Speaker: Marisa S. Klein-Gitelman, MD, MPH 

155 

075 – Pulmonary Hypertension in the 


Speaker: Dinesh Khanna, MD, MS 

158 A 


Speaker: Stanley B. Cohen, MD 

158 B 

077 – Rheumatoid Arthritis: Challenging Cases 

Speaker: Daniel E. Furst, MD 

159 A 

078 – Scleroderma Mimics 

Speaker: Virginia D. Steen, MD 

159 B 


Nephritis PM PS E 

Speaker: Rosalind Ramsey-Goldman, MD, DrPH 

160 


Therapies 

Speaker: Jeffrey R. Curtis, MD, MS, MPH 

ACR SESSIONS 

1:00 pm – 2:00 pm 

150 A 

Innovative Educators, Novel Techniques: A 

Rheumatology Research Foundation Special 

Session PM Ed Pd PS PrM FIT 

Moderators: Deana M. Lazaro, MD; Lisa Criscione- 

Schrieber, MD, MEd 

1:00 pm 

Development of a Web-based Rheumatology 

Curriculum 

Speaker: Bernadette Siaton, MD 


137


Tuesday 



1:30 pm 

Clinician Educator Resources – ACR Website 

Speaker: Kenneth S. O’Rourke, MD 

1:45 pm 

The Rheumatology Research Foundation Clinician 

Scholar Educator Award: Fifteen Years Promoting 

Rheumatology Educators and Education 

Speaker: Jessica Berman, MD 

207 B 

Pediatric Rheumatology Year in Review (Town 

Hall Meeting) PM Ed Pd PS PrM FIT 

Moderator: Stacy P. Ardoin, MD, MS 

1:00 pm 

Clinical Review 

Speaker: Christian Hedrich, MD, PhD 

1:15 pm 

Basic Science Review 

Speaker: Rae S.M. Yeung, MD, PhD, FRCPC 

1:30 pm 

Pediatric Rheumatology Awards 

Speaker: Stacy P. Ardoin, MD, MS 

1:45 pm 

Translational Research Review 

Speaker: Randy Q. Cron 

Hall E 

Psoriatic Arthritis: Therapeutic Challenges 

PM PS E 

Moderators: Arthur Weinstein, MD; Dafna D. Gladman, 

MD, FRCPC 

Speaker: Laura C. Coates, PhD 

Ballroom A 

Visualizing Immune Cell Interactions 

Moderator: Marcus R. Clark, MD 

Speaker: Ronald Germain, MD, PhD 

Salon G 

What Determines Tissue Localization in Chronic 

Inflammation 

Moderator: Ru Liu Bryan, PhD 

Speaker: Christopher Buckley, FRCP, PhD 

STUDY GROUPS 

1:00 pm – 2:00 pm 

152 A 

Antiphospholipid Syndrome Task Forces Study 

Group 

Speakers: Doruk Erkan, MD; Roger A. Levy, MD; Ignasi 

Rodriquez-Pinto, MD; Danieli Andrade, MD, PhD; Tadej 

Avcin 

209 A 

Capillaroscopy: The New and Safest Diagnostic/ 

Prognostic Tool in Rheumatology? 

Speakers: Maurizio Cutolo, MD; Vanessa Smith; Alberto 

Sulli, MD; Ariane L. Herrick, MD, PhD 

145 A 

Developing, Implementing, and Assessing 

Effective Patient Education and Support 

Programs for People with Rheumatologic Illness 

Speakers: Adena Batterman, LCSW, MS; Roberta 

Horton, LCSW, ACSW; Jillian A. Rose, LCSW; Joan 

Westreich, MSW 

147 A 

Joint Hypermobility Study Group 

Speakers: Jaime F. Bravo; Eric Gall, MD; Antonio 

Bulbena-Vilarrasa, MD, PhD, MSc; Neuseli Marino 

Lamari, PhD; Josefa Lopez 

206 

Myositis Study Group: Exercise in Myositis 

Speakers: Ignacio Garcia-De La Torre, MD; Lesley Ann 

Saketkoo, MD, MPH; Marco van Brussel, PhD; Helene 

Alexanderson, RPT, PhD; Sue Mallard , MSc 


Tuesday 




202 B 

Pediatric Rheumatology Imaging Study Group 

Speaker: Nikolay Tzaribachev, MD; Andrea S. Doria, MD, 

PhD, MSc 

201 

Sexuality and Intimacy in Rheumatic Diseases 

Study Group 

Speaker: Mary L. Jurisson, MD; Leslie L. Barnard 

204 A 

Sjögren’s Syndrome: Development of 

Biomarkers Study Group 

Speakers: Athanasios G. Tzioufas, MD, Professor; 

Haralampos M. Moutsopoulos, FACP, FRCP, MD; Kathy 

L. Sivils, PhD 

140 A 

SPARTAN-Spondyloarthritis Study Group 

Speakers: Lianne S. Gensler, MD; Liron Caplan, MD, PhD 

151 A 

Veterans Affairs Study Group 

Speakers: Elizabeth Chang, MD; Amy Joseph, MD; Grant 

Cannon, MD; Laurence J. Meyer, MD, PhD; Brian Sauer, 

PhD, MS 

WORKSHOPS 

1:15 pm – 3:15 pm 










149 A 

238 – Complementary and Alternative 

Therapies in Rheumatic Disease 

PM PS E 

Speakers: Randy Horwitz, MD, PhD; Nisha J. Manek, MD 

144 B 

239 – Knee Braces, Foot Orthoses, and Shoe 

Gear for Managing Knee Osteoarthritis PM PS E 

PM PS E 

Speakers: Howard J. Hillstrom, PhD; Kelly D. Krohn, MD 

144 C 

240 – Musculoskeletal Ultrasonography: Basic 

Speakers: Gurjit S. Kaeley, MBBS, MRCP; Johannes Roth, 

MD, PhD, FRCPC, RhMSUS 

ACR SESSION 

1:30 pm – 2:00 pm 

143 A 

ACR Business Meeting 

Moderators: Joan Marie Von Feldt, MD, MSEd; Sharad 

Lakhanpal, MBBS, MD 

1:30 pm 

Report from Treasurer 

Speaker: Paula Marchetta, MD, MBA 

1:35 pm 

Report from Rheumatology Research Foundation 


1:45 pm 

Report from the ARHP 

Speaker: Elizabeth A. Schlenk, PhD, RN 

1:55 pm 

Report from Secretary on Membership 

Speaker: David I. Daikh, MD, PhD 

ARHP SESSION 

2:30 pm – 3:30 pm 

206 

The Business of Clinical Trials: Contracts and 

Budgets 



139


Tuesday 


ARHP SESSION continued 

2:30 pm 

Contract and Budget Negotiation of Clinical Trials in a 

Private Research Setting 

Speaker: Lisa M. Kastanek, RN, CCRC 

3:00 pm 

Contract and Budget Negotiation of Clinical Trials in a 

Academic Setting 

Speaker: Deborah McCloskey, BSN, RN 

ACR SESSIONS 

2:30 pm – 4:00 pm 

143 A 

ILAR Session: Innovative Solutions to Deliver 

Care 

Moderator: Carlo V. Caballero-Uribe Sr., MD 

2:30 pm 

A Look to Innovative Ideas to Deliver Care in Medicine 

in XXI Century 

Speaker: Rafael Grossman, MD, FACS 

3:00 pm 

Telerheumatology: An Idea Whose Time Has Come 

Speaker: Irwin Lim, MD 

3:30 pm 

Delivering Care for Rheumatic Patients in the XXI 

Century: The Patient’s Perspective 

Speaker: Seth D. Ginsberg 

201 

Mechanisms of Thrombosis: Interface Between 

Endothelium and Blood 

Moderators: Jane E. Salmon, MD; Danieli Andrade, MD, 

PhD 

2:30 pm 

Tissue Factor and Thrombosis in Anti-Phospholipid 

Syndrome 

Speaker: Nigel Mackman, PhD 

3:00 pm 

Protein Disulfide Isomerase as a Target to Prevent 

Thrombosis in a Mouse Model of Anti-Phospholipid 

Syndrome 

Speaker: Bruce Furie, MD 

3:30 pm 

Beta2 Glycoprotein I as a Bridge Between Coagulation 

Players and Anti-Phospholipid Antibodies 

Speaker: Pier Luigi Meroni 

Hall D 

Optimizing Care of Gout and Hyperuricemia 

with Personalized Medicine PM PS PME 

PS PME 

PS E 

Moderators: Jasvinder A. Singh, MD, MPH; Hyon K. Choi, 

MD, DrPH 

2:30 pm 

Personalized Education and Treat-to-Target Approach 

to Improve Gout Care 

Speaker: Michael Doherty, FRCP, MA, MD 

3:00 pm 

A Rheumatologist’s Perspective of the AHRQ Evidence 

Review for PCP Gout Care 

Speaker: John FitzGerald, MD, PhD 

3:30 pm 

Cardiovascular and Renal Effects of Serum Urate, 

Gout, and Gout Therapies: Chicken or Egg? 


Hall E 

Systemic Sclerosis: Assessment and Treatment 

of Gastrointestinal Manifestations PM PS E 

Moderators: Shervin Assassi, MD, MS; Ami A. Shah, MD, 

MHS 

2:30 pm 

Systemic Sclerosis Related Gastrointestinal 

Manifestations: Prevalence and Practical Tools for Its 

Assessment 

Speaker: Tracy M. Frech, MD, MS 


Tuesday 




3:00 pm 

Assessment and Treatment of Upper Gastrointestinal 

Manifestations in Systemic Sclerosis 

Speaker: Mark Pimentel, MD 

3:30 pm 

Assessment and Treatment of Lower Gastrointestinal 

Manifestations in Systemic Sclerosis 

Speaker: Navjyot Hansi, MD 

152 A 

Transforming the ABIM MOC Program and Its 

Impact on Rheumatologists 

Moderators: Carol Langford, MD, MHS; Joel A. Block, MD 

Speakers: Richard Battaglia, MD; Carol Langford, MD, 

MHS 


2:30 pm – 4:00 pm 

Ballroom A 

2016 Rheumatology Research Foundation 

Edmond L. Dubois, MD, Memorial Lectureship 

Moderators: Meenakshi Jolly, MD, MS; Eliza Chakravarty, 

MD, MS 

2:30 pm 

2988. Cigarette Smoking Increases the Risk of Anti- 

Double-Stranded DNA Positive SLE Among Women 

in the Nurses’ Health Studies 

Medha Barbhaiya, Sara Tedeschi, Bing Lu, Susan 

Malspeis, Jeffrey A. Sparks, Elizabeth W. Karlson and 

Karen H. Costenbader, Brigham and Women’s Hospital 

and Harvard Medical School, Boston, MA 

3:00 pm 

2989. Risk of Cardiovascular Disease Events Among 

Patients with Systemic Lupus Erythematosus 

Compared to Those with Diabetes Mellitus in a 

Nationwide Medicaid Cohort 

Medha Barbhaiya 1 , Candace H. Feldman 1 , Sarah K. 

Chen 2 , Hongshu Guan 1 , Tzu-Chieh Lin 1 , Michael A. 

Fischer 1 , Daniel H. Solomon 1 , Brendan M. Everett 1 

and Karen H. Costenbader 1 , 1 Brigham and Women’s 


2 

Beth Israel Deaconess Medical Center, Boston, MA 

3:15 pm 

2990. Cancer in Systemic Lupus Erythematosus: 

Results from the Systemic Lupus International 

Collaborating Clinics Inception Cohort 

Sasha Bernatsky 1 , Murray Urowitz 2 , John Hanly 3 , 

Ann E. Clarke 4 , Caroline Gordon 5 , Juanita Romero- 

Diaz 6 , Graciela S. Alarcon 7 , Sang-Cheol Bae 8 , Michelle 

Petri 9 , Joan T. Merrill 10 , Daniel J Wallace 11 , Paul R. 

Fortin 12 , Dafna D. Gladman 13 , David A. Isenberg 14 , 

Anisur Rahman 15 , Susan Manzi 16 , Ola Nived 17 , 

Gunnar K. Sturfelt 18 , Christine Peschken 19 , Jorge 

Sánchez-Guerrero 20 , Guillermo Ruiz-Irastorza 21 , 

Cynthia Aranow 22 , Ronald F. van Vollenhoven 23 , Asad 

Zoma 24 , Kristján Steinsson 25 , M Khamashta 26 , Ellen 

M. Ginzler 27 , Anca Askanase 28 , Kenneth C. Kalunian 29 , 

Mary Anne Dooley 30 , S. Sam Lim 31 , Diane L. Kamen 32 , 

Søren Jacobsen 33 , Manuel Ramos-Casals 34 , Murat 

Inanc 35 , Jeremy Labrecque 36 , Jennifer LF Lee 36 and 

Rosalind Ramsey-Goldman 37 , 1 McGill University Health 

Centre, Montreal, QC, 2 Toronto Western Hospital and 

University of Toronto, Toronto, ON, 3 Queen Elizabeth 

II Health Sciences Centre and Dalhousie University, 

Halifax, NS, 4 University of Calgary, Calgary, AB, 5 NIHR/ 

Wellcome Trust Clinical Research Facility, University 

Hospitals Birmingham NHS Foundation Trust, 

Birmingham, United Kingdom, 6 Instituto Nacional de 

Ciencias Médicas y Nutrición Salvador Zubirán, Mexico 

city, Mexico, 7 University of Alabama at Birmingham, 

Birmingham, AL, 8 Hanyang University Hospital for 

Rheumatic Diseases, Seoul, Korea, Republic of, 9 Johns 

Hopkins University School of Medicine, Baltimore, 

MD, 10 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 11 Cedars-Sinai Medical Center, 

Los Angeles, CA, 12 Université Laval, CHU de Québec, 

Québec, QC, 13 Centre for Prognosis Studies in the 

Rheumatic Diseases, Toronto Western Hospital 

and University of Toronto, Toronto, ON, 14 Centre 

for Rheumatology, Division of Medicine, University 

College London, London, United Kingdom, 15 Centre 

for Rheumatology Research, UCL Division of Medicine, 

London, United Kingdom, 16 West Penn Allegheny 

Health System, Pittsburgh, PA, 17 University Hospital, 

Lund, Sweden, 18 Univ Hospital Lund, Lund, Sweden, 

19 

University of Manitoba, Winnipeg, MB, 20 Immunology 

and Rheumatology, Instituto Nacional de Ciencias 

Médicas y Nutrición Salvador Zubirán, Mexico City, 


141


Tuesday 



Mexico, Mexico, 21 Hospital de Cruces, Bizkaia, Spain, 

22 

Feinstein Institute for Medical Research, Manhasset, 

NY, 23 Amsterdam Rheumatology and Immunology 

Center (ARC), Amsterdam, Netherlands, 24 Hairmyres 

Hospital, Scotland, United Kingdom, 25 Univ. Hospital, 

Reykjavik, Iceland, 26 Lupus Research Unit, The Rayne 

Institute, King’s College London School of Medicine, St 

Thomas’ Hospital, London, United Kingdom, 27 SUNY 

Downstate Medical Center, Brooklyn, NY, 28 NYU, 

Seligman Centre for Advanced Therapeutics, New York, 

NY, 29 UCSD School of Medicine Center for Innovative 

Therapy, La Jolla, CA, 30 Chapel Hill Doctors, Chapel Hill, 

NC, 31 Emory University School of Medicine, Atlanta, 

GA, 32 Medical University of South Carolina, Charleston, 

SC, 33 Rigshospitalet, Copenhagen University Hospital, 

Copenhagen, Denmark, 34 Sjögren Syndrome Research 

Group (AGAUR), Laboratory of Autoimmune Diseases 

Josep Font, Institut d’Investigacions Biomèdiques 

August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 35 Istanbul 

University, Istanbul, Turkey, 36 McGill UHC/RVH, Montreal, 

QC, 37 Northwestern University, Chicago, IL 

3:30 pm 

2991. A Molecular Signature Based on IFN Gene 

Signature and Serology Defines Two Populations of 

Patients with Different Baseline Disease Activity in 

a Large Multinational Phase 3 SLE Trial Population 

Michelle Petri 1 , Kenneth C. Kalunian 2 , Murray Urowitz 3 , 

David A. Isenberg 4 , Richard Furie 5 , MaryAnn Morgan- 

Cox 6 , Maria Silk 7 , Ernst R. Dow 8 , Richard Higgs 7 , Steven 

Watts 7 and Matthew D Linnik 9 , 1 Johns Hopkins University 

School of Medicine, Baltimore, MD, 2 UCSD School of 

Medicine Center for Innovative Therapy, La Jolla, CA, 

3 

Toronto Western Hospital and University of Toronto, 

Toronto, ON, 4 Centre for Rheumatology, Division of 

Medicine, University College London, London, United 

Kingdom, 5 North Shore University Hospital, Great Neck, 

NY, 6 Eli Lilly and Company, Indianapolis, IN, 7 Eli Lilly, 

Indianapolis, IN, 8 Lilly Research Laboratories, Eli Lilly and 

Company, Indianapolis, IN, 9 Lilly Biotechnology Center, 

San Diego, CA 

3:45 pm 

2992. In Systemic Lupus Erythematosus 

with Antiphospholipid Antibodies, 

Hypocomplementemia Associates with Thrombosis 

Laura Durcan 1 , Wei Fu 2 and Michelle Petri 3 , 1 University 

of Washington, Seattle, WA, 2 Division of Rheumatology, 

School of Medicine, Johns Hopkins University, 



150 A 

Biology and Pathology of Bone and Joint 

Moderator: Francisco J. Blanco, MD 

2:30 pm 

2993. Membrane-Type 1 Matrix Metalloproteinase 

Controls Osteo- and Chondrogenesis by a 

Proteolysis-Independent Mechanism Mediated By 

Its Cytoplasmic Tail 

Yang Qing 1 , Mukundan Attur 2 , Thorsten Kirsch 3 , You 

Jin Lee 3 , Shoshana Yakar 3 , Zhomgbo Liu 3 , Steven B. 

Abramson 4 and Paolo Mignatti 3 , 1 New York University 

School of Medicine, New York, NY, 2 NYU - Hospital for 

Joint Diseases, New York, NY, 3 New York University, 

New York, NY, 4 Hosp for Joint Diseases/NYU, New York, 

NY 

2:45 pm 

2994. Binding of Periostin to Discoidin Domain 

Receptor-1 (DDR1) Promotes Cartilage 

Degeneration by Inducing MMP-13 Expression 

Yang Qing 1 , Paolo Mignatti 2 , Austin Ramme 2 , Thorsten 

Kirsch 2 , Jyoti Patel 3 and Mukundan Attur 3 , 1 New York 

University School of Medicine, New York, NY, 2 New 

York University, New York, NY, 3 NYU - Hospital for Joint 

Diseases, New York, NY 

3:00 pm 

2995. WISP1/CCN4 Aggravates Experimental 

Osteoarthritis and Is Associated with Disease 

Progression in Early Osteoarthritis Patients 

Martijn H. van den Bosch 1 , Arjen B. Blom 1 , Azusa 

Maeda 2 , Tina Kilts 2 , Wim B. van den Berg 1 , Peter L. 

van Lent 1 , Marian F. Young 2 and Peter M. van der 

Kraan 1 , 1 Radboud university medical center, Nijmegen, 

Netherlands, 2 NIDCR/NIH, Bethesda, MD 

3:15 pm 

2996. High Fat Diet-Induced Osteoarthritis 

Progression Is Dependent on Toll-Like Receptor 4 

Mary Beth Humphrey 1 , Evangelia Kalaitzoglou 1 , Camille 

Herron 1 , Yanqing HU 1 , Yao Fu 2 , Erika Barboza Prado 

Lopes 2 , Elise Donovan 2 , Joanna Hudson 2 and Timothy 


Tuesday 




Griffin 2 , 1 University of Oklahoma Health Sciences 

Center, Oklahoma City, OK, 2 Oklahoma Medical 

Research Foundation, Oklahoma City, OK 

3:30 pm 

2997. Microrna-29a Curtails Synovitis in the 

Development of Knee Osteoarthritis By Disrupting 

VEGF 

Feng-Sheng Wang 1 , Yi-Chih Sun 1 , Yu-Shan Chen 1 

and Jih-Yang Ko 2 , 1 Core Facility for Phenomics & 

Diagnostics, Department of Medical Research, 

Kaohsiung Chang Gung Memorial Hospital, Taiwan, 

Kaohsiung, Taiwan, 2 Department of Orthopedic 

Surgery, Kaohsiung Chang Gung Memorial Hospital, 

Taiwan, Kaohsiung, Taiwan 

3:45 pm 

2998. Gut Microbiota Induce IGF-1 and Promote 

Bone Formation and Growth 

Jing Yan 1 , Jeremy Herzog 2 , Kelly Tsang 1 , R. Balfour 

Sartor 2 , Antonios Aliprantis 1 and Julia F. Charles 1 , 

1 

Brigham and Women’s Hospital, Boston, MA, 

2 

University of North Carolina at Chapel Hill, Chapel Hill, 

NC 

209 A 

Orthopedics, Low Back Pain, and Rehabilitation 

Moderators: Ora Singer, MD; Mariko Ishimori, MD 

2:30 pm 

2999. Autologous Osteoblastic Cells Versus 

Concentrated Bone Marrow Implantation in 

Osteonecrosis of the Femoral Head: A Randomized 

Controlled Single Blind Study 

Valérie Gangji 1 , Michel Toungouz 1 , Chantal Lechanteur 2 , 

Yves Beguin 2 , Etienne Baudoux 2 , Michel Malaise 2 , 

Viviane De maertelaer 3 , Sanjiva Pather 4 , Julia Ino 5 and 

Jean-Philippe Hauzeur 2 , 1 Hôpital Erasme, brussels, 

Belgium, 2 Sart Tilman, Liège, Belgium, 3 Université 

Libre de Bruxelles, brussels, Belgium, 4 Hopital Erasme, 

Brussels, Belgium, 5 Bone Therapeutics, Gosselies, 

Belgium 

2:45 pm 

3000. Safety of the Knee Needle Arthroscopy: A 

Review of 1136 Procedures in 919 Patients 

Alla ISHCHENKO 1 , Jean-cyr YOMBI 2 and Adrien 

Nzeusseu Toukap 3 , 1 Cliniques universitaires Saint- 

Luc, Brussels, Belgium, 2 IREC/Cliniques universitaires 

St-Luc/Faculté de médecine/Université Catholique 

de Louvain, Brussels, Belgium, 3 Institut de Recherche 

Expérimentale et Clinique, Université catholique de 

Louvain, Brussels, Belgium 

3:00 pm 

3001. Lumbar CT-Guided Steroid Infiltration on the 

Refractory Low Back Pain. Study of 258 Procedures 

in the Same Center 

Eva Galindez Agirregoikoa, Olaia Fernandez 

Berrizbeitia, M. Luz García Vivar, Esther Ruíz Lucea, 

Jose Francisco Garcia Llorente, Ignacio Torre Salaberri, 

Catalina Gómez Arango, Juan Maria Blanco Madrigal, 

Edurne Guerrero Basterretxea, Itziar Calvo Zorrilla, 

Natalia Garcia Rivera and Maria Jesus Allande Lopez 

Linares, Rheumatology Department, Basurto University 

Hospital, Bilbao, Spain 

3:15 pm 

3002. Does Morbid Obesity Negatively Affect 

Patient Reported Outcomes Following Total Knee 

Arthroplasty? 

Jamie E. Collins 1 , Heidi Y. Yang 1 , Ilana M. Usiskin 2 , 

Jeffrey N. Katz 3 and Elena Losina 1 , 1 Brigham & Women’s 

Hospital, Boston, MA, 2 Brigham and Women’s Hospital, 

Boston, MA, 3 Brigham and Women’s Hospital and 


3:30 pm 

3003. Impact of Preoperative Opioid Use on Total 

Knee Arthroplasty Outcomes 

Savannah R. Smith 1 , Heidi Y. Yang 2 , Jamie E. Collins 2 , 

Jeffrey N. Katz 3 and Elena Losina 2 , 1 Brigham and 

Women’s Hospital, Boston, MA, 2 Brigham & Women’s 

Hospital, Boston, MA, 3 Brigham and Women’s Hospital 


3:45 pm 

3004. The Choosing Wisely Initiative: Is It Complete? 

Navya Kuchipudi and Cathie-Ann Mancuso, Saint 

Peters University Hospital, New Brunswick, NJ 

146 A 

Pediatric Rheumatology – Clinical and 

Therapeutic Aspects II: Juvenile Arthritis 

Moderators: Jennifer L. Huggins, MD; Jay Mehta, MD, 

MS 


143


Tuesday 



2:30 pm 

3005. Development and Initial Validation of the “MH 

Score,” a New Diagnostic Tool That Differentiates 

Primary Hemophagocytic Lymphohistiocytosis 

from Macrophage Activation Syndrome 

Francesca Minoia 1 , AnnaCarin Horne 2 , Francesca Bovis 1 , 

Sergio Davì 1 , Laura Pagani 1 , Graciela Espada 3 , Gao Yi- 

Jin 4 , Antonella Insalaco 5 , Kai Lehmberg 6 , Helga Sanner 7 , 

Susan Shenoi 8 , Sheila Weitzman 9 , Nicolino Ruperto 1 , 

Alberto Martini 1 , Randy Q. Cron 10 and Angelo Ravelli 1 , 

1 

Istituto Giannina Gaslini, Genoa, Italy, 2 Karolinska 

University Hospital Solna, Stockholm, Sweden, 

3 

Hospital de Ninos Ricardo Gutierrez, Buenos Aires, 

Argentina, 4 Children’s Hospital of Fudan, Shanghai, 

China, 5 Ospedale Pediatrico Bambino Gesù, Rome, 

Italy, 6 University Medical Center, Hamburg, Germany, 

7 

Norwegian National Advisory Unit on Rheumatic 

Diseases in Children and Adolescents, Oslo University 

Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 

8 

Seattle Children’s Hospital, Seattle, WA, 9 The Hospital 

for Sick Children, Toronto, ON, 10 University of Alabama 

at Birmingham, Birmingham, AL 

2:45 pm 

3006. IFN-Gamma (IFNγ), IFNγ-Induced Chemokines, 

and Other Biomarkers in Macrophage Activation 

Syndrome (MAS) 

Claudia Bracaglia 1 , Denise Pires Marafon 2 , Ivan Caiello 2 , 

Kathy de Graaf 3 , Florence Guilhot 3 , Walter Ferlin 3 , 

Sergio Davì 4 , Grant Schulert 5 , Angelo Ravelli 4 , Alexei 

Grom 5 , Robert Nelson 3 , Cristina de Min 3 and Fabrizio 

De Benedetti 1 , 1 Division of Rheumatology, Ospedale 

Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, 

Italy, 2 Division of Rheumatology, Ospedale Pediatrico 

Bambino Gesù IRCCS, Rome, Italy, 3 NovImmune S.A., 

Geneva, Switzerland, 4 Istituto Giannina Gaslini, Genoa, 

Italy, 5 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH 

3:00 pm 

3007. Long-Term Efficacy and Safety of 

Canakinumab in Patients with Active Systemic 

Juvenile Idiopathic Arthritis (SJIA): Results from a 

PHASE III Extension Study 

Hermine I. Brunner 1 , Nicolino Ruperto 2 , Pierre 

Quartier 3 , Tamás Constantin 4 , Ekaterina Alexeeva 5 , 

Isabelle Koné-Paut 6 , Katherine Marzan 7 , Nico 

Wulffraat 5 , Rayfel Schneider 7 , Shai Padeh 5 , Vyacheslav 

Chasnyk 8 , Carine Wouters 5 , Jasmin B. Kuemmerle- 

Deschner 5 , Tilmann Kallinich 5 , Bernard Lauwerys 9 , 

Elie Haddad 7 , Evgeny L Nasonov 5 , Maria Trachana 5 , 

Olga Vougiouka 5 , Karolynn Leon 10 , Eleni Vritzali 11 , 

Karine Lheritier 11 , Alberto Martini 5 and Daniel J 

Lovell 12 , 1 Cincinnati Children’s Hospital Medical 

Center, Cincinnati, OH, 2 Istituto Giannina Gaslini, 

Genoa, Italy, 3 Hôpital Necker-Enfants Malades, Paris, 

France, 4 Paediatric Rheumatology International Trials 

Organization (PRINTO), Genova, Italy, 5 PRINTO-Istituto 

Gaslini, Genova, Italy, 6 Department of Paediatric 

Rheumatology, AP-HP Bicêtre Hospital, Le Kremlin 

Bicêtre, France, 7 PRCSG, Cincinnati, OH, 8 PRINTO- 

Istituto Gaslini, Genoa, Italy, 9 Cliniques Universitaires 

Saint-Luc and Université Catholique de Louvain, 

Brussels, Belgium, 10 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, 11 Novartis Pharma 

AG, Basel, Switzerland, 12 PRCSG Cincinnati Children’s 

Hospital Medical Center, Cinncinnati, OH 

3:15 pm 

3008. Clinical Factors Associated with Non- 

Response to Methotrexate in Children with Juvenile 

Idiopathic Arthritis: Results from the Childhood 

Arthritis Response to Treatment Consortium 

Sunil Sampath 1 , Jamie C Sergeant 2 , Sebastien 

Viatte 1 , Roberto Carrasco 2 , Joanna Cobb 1 , Samantha 

Smith 3 , Anne Hinks 1 , Lucy R Wedderburn 4 , Michael 

W. Beresford 5 , Kimme L. Hyrich 2 , Wendy Thomson 1 

and Childhood Arthritis Response to Medication 

Study,Childhood Arthritis Prospective Study, British 

Society for Paediatric and Adolescent Rheumatology 

Etanercept Cohort Study, Biologics for Children with 

Rheumatic Diseases Study, 1 Arthritis Research UK 

Centre for Genetics and Genomics,The University of 

Manchester, Manchester, United Kingdom, 2 Arthritis 

Research UK Centre for Epidemiology, The University 

of Manchester, Manchester, United Kingdom, 3 Arthritis 

Research UK Centre for Genetics and Genomics,The 

University of Manchester, Mancherster, United 

Kingdom, 4 UCL Institute of Child Health, London, 

United Kingdom, 5 Institute of Translational Medicine 

(Child Health), University of Liverpool, Liverpool, United 

Kingdom 


Tuesday 




3:30 pm 

3009. Safety and Effectiveness of 

Adalimumab±Methotrexate for the Treatment of 


Daniel J Lovell 1 , Nicola Ruperto 2 , Carol Wallace 1 , Mary 

Toth 1 , Ivan Foeldvari 2 , John Bohnsack 1 , Diana Milojevic 1 , 

C. Egla Rabinovich 1 , Daniel Kingsbury 1 , Katherine 

Marzan 1 , Pierre Quartier 3 , Kirsten Minden 2 , Elizabeth 

Chalom 1 , Gerd Horneff 2 , Rolf M. Kuester 2 , Jason Dare 1 , 

Miriam Heinrich 4 , Hartmut Kupper 4 , Jasmina Kalabic 4 , 

Hermine I. Brunner 1 , Alberto Martini 2 and on behalf of 

PRINTO and PRCSG, 1 PRCSG, Cincinnati, OH, 2 PRINTO- 

IRCCS, Genova, Italy, 3 Hopital Necker-Enfants Malades, 

Paris, France, 4 AbbVie Deutschland GmbH & Co. KG, 

Ludwigshafen, Germany 

3:45 pm 

3010. Improvement of Spinal Inflammation Induced 

by Etanercept in Enthesitis Related Arthritis JIA- 

Patients. Data of the Reminder-Study 

Gerd Horneff 1 , Ivan Foeldvari 2 , Kirsten Minden 3 , Hans- 

Iko Huppertz 4 and Ariane Klein 5 , 1 Centre of Pediatric 

Rheumatology, Sankt Augustin, Germany, 2 Hamburger 

Zentrum Kinder-und Jugendrheumatologie, Hamburg, 

Germany, 3 Children’s University Hospital Charite/ 

German Rheumatism Research Centre Berlin, Berlin, 

Germany, 4 Klinikum Bremen-Mitte, Prof.-Hess- 

Kinderklinik, Bremen, Germany, 5 Asklepios Clinic Sankt 

Augustin, Sankt Augustin, Germany 

Ballroom B 

Rheumatoid Arthritis – Clinical Aspects IV: 

Managing Patients in Remission 

Moderators: Kimme L. Hyrich, FRCP, PhD; Clifton 

Bingham III, MD 

2:30 pm 

3011. Long-Term Outcomes after Disease Activity 

Guided Tapering of Tumor Necrosis Factor 

Inhibition in Rheumatoid Arthritis: 3 Year Data of a 

Randomised Controlled Pragmatic Non Inferiority 

Strategy Study 

Alfons A. den Broeder 1 , Chantal A.M. Bouman 1 , 

Frank H.J. van den Hoogen 2 , Jaap Fransen 2 , Ronald 

F. van Vollenhoven 3 , Johannes W.J. Bijlsma 4 , Aatke 

van der Maas 1 and Noortje van Herwaarden 1 , 1 Sint 

Maartenskliniek, Nijmegen, Netherlands, 2 Radboud 

University Medical Center, Nijmegen, Netherlands, 

3 

Amsterdam Rheumatology and Immunology Center 

ARC, Amsterdam, Netherlands, 4 University Medical 

Center Utrecht, Utrecht, Netherlands 

2:45 pm 

3012. Clinical Predictors of TNF-Inhibitor Free 

Disease Control in Patients with Rheumatoid 

Arthritis after Stopping TNFi Treatment: Results 

from a Dutch Multicentre Pragmatic Open-Label 

Randomized Controlled Trial 

Marjan Ghiti Moghadam 1 , Harald E. Vonkeman 2 , 

Peter M. ten Klooster 1 , Femke Lamers-Karnebeek 3 , 

Janneke Tekstra 4 , Barbara van Schaeybroeck 5 , Ruth 

Klaasen 6 , Marieke van Onna 7 , Hein J. Bernelot Moens 8 , 

H. Visser 9 , Annemarie Schilder 10 , Mark R. Kok 11 , Robert 

Landewé 12 , Piet L.C.M. van Riel 13 , Mart A.F.J. van de 

Laar 14 and Tim Jansen 15 , 1 Arthritis Centre Twente, 

University of Twente and Medisch Spectrum Twente, 

Enschede, The Netherlands, Enschede, Netherlands, 

2 

Rheumatology Center Twente, Medisch Spectrum 

Twente & Twente University, Enschede, Netherlands, 

3 

RadboudUMC, Nijmegen, Netherlands, 4 University 

Medical Center Utrecht, Utrecht, Netherlands, 5 Albert 

Schweitzer MC, Dordrecht, Netherlands, 6 Meander 

MC, Amersfoort, Netherlands, 7 AMC medical centre, 

Amsterdam, Netherlands, 8 Ziekenhuisgroep Twente, 

Almelo, Netherlands, 9 Rijnstate Hospital Arnhem, 

Arnhem, Netherlands, 10 Medisch Centrum Leeuwarden, 

Leeuwarden, Netherlands, 11 Maaststadziekenhuis, 

Rotterdam, Netherlands, 12 University of Amsterdam, 

Amsterdam, Netherlands, 13 radboudUMC, Nijmegen, 

Netherlands, 14 Arthritis Centre Twente, University of 

Twente and Medisch Spectrum Twente, Enschede, 

Netherlands, 15 VieCuri Medical Center, Venlo, 

Netherlands 

3:00 pm 

3013. Dose Reduction or Discontinuation of 

Biological Therapy in Patients with Rheumatoid 

Arthritis in Remission – 1-Year Results of a 

Guideline-Directed Longitudinal Cohort Study 

Cecilie Heegaard Brahe 1 , Simon Krabbe 1 , Mikkel 

Østergaard 2 , Henrik Rogind 3 , Hanne Slott Jensen 2 , 

Annette Hansen 4 , Jesper Nørregaard 5 , Søren Jacobsen 3 , 

Lene Terslev 6 , Tuan K. Huynh 7 , Dorte Vendelbo 

Jensen 4 , Natalia Manilo 8 , Karsten Heller Asmussen 9 , 


145


Tuesday 



Per Brown-Frandsen 3 , Mikael Boesen 10 , Zoreh 

Rastiemadabadi 11 , Daniel Glinatsi 12 , Lone Morsel- 

Carlsen 13 , Jakob M. Møller 14 , Niels Steen Krogh 15 and 

Merete Lund Hetland 2 , 1 Copenhagen Center for 

Arthritis Research, Center for Rheumatology and Spine 

Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 

2 



Denmark, Copenhagen, Denmark, 3 Center for 

Rheumatology and Spine Diseases, Rigshospitalet 

- Glostrup, University of Copenhagen, Denmark, 

Glostrup, Denmark, 4 DANBIO, On behalf of Depts of 

Rheumatology, North, South, Central, Zealand and 

Capital Region, Copenhagen, Denmark, 5 Copenhagen 

Center for Arthritis Research, Center for Rheumatology 

and Spine Diseases, Rigshospitalet, Copenhagen, 

Denmark, 6 Copenhagen Center for Arthritis Research 

(COPECARE), Copenhagen, Denmark, 7 Department 

of Rheumatology, Copenhagen University Hospital 

at Nordsjælland, Denmark, Hillerød, Denmark, 8 The 

DANBIO registry and the Danish Departments of 

Rheumatology, Copenhagen, Denmark, 9 Department 

of Rheumatology, Copenhagen University Hospital at 

Frederiksberg-Bispebjerg, Denmark, Frederiksberg, 

Denmark, 10 Parker Institute, Frederiksberg, Denmark, 

11 

Frederiksberg Hospital, Frederiksberg, Denmark, 

12 

Copenhagen Center for Arthritis Research, 

Center for Rheumatology and Spine Diseases, 

Rigshospitalet, Copenhagen, Denmark, Glostrup, 

Denmark, 13 Department of Radiology, Rigshospitalet, 

Copenhagen, Denmark, 14 Department of Radiology, 

Copenhagen University Hospital Herlev and Gentofte, 

Herlev, Denmark, 15 Zitelab, Frederiksberg, Denmark 

3:15 pm 

3014. Tapering of Adalimumab Based on 

Therapeutic Drug Monitoring in Rheumatoid 

Arthritis 

Merel J. l’Ami 1 , Anneke F. Marsman 1 , Charlotte LM 

Krieckaert 1 , Mike T. Nurmohamed 2 , Jill Ruwaard 1 , Ingrid 

M. Visman 1 , Eva L. Kneepkens 1 and Gertjan Wolbink 1 , 

1 

Amsterdam Rheumatology and immunology Center, 

location Reade, Amsterdam, Netherlands, 2 Amsterdam 

Rheumatology and immunology Center, Location VU 

University Medical Center, Amsterdam, Netherlands, 


3:30 pm 

3015. The Good, the Bad, and the Ugly – Refractory 

Rheumatoid Arthritis in 2016 

Manuel Unger 1 , Farideh Alasti 1 , Gabriela Supp 1 , Josef 

S. Smolen 2 and Daniel Aletaha 3 , 1 Medical University 

Vienna, Vienna, Austria, 2 Medical University of Vienna, 

Vienna, Austria, 3 Department of Internal Medicine 3, 

Medical University of Vienna, Vienna, Austria 

3:45 pm 

3016. Validity of a 2-Component Disease Activity 

Score for Accurate Assessment of Synovitis in 


Elizabeth M.A. Hensor 1 , Paul McKeigue 2 , Philip G. 

Conaghan 3 , Maya H. Buch 3 , Jennifer H. Barrett 3 , Jackie 

L. Nam 1 , Marco Colombo 2 , Athina Spiliopoulou 4 , Felix 

Agakov 4 , Stephen Kelly 5 , Myles J. Lewis 5 , Costantino 

Pitzalis 5 , Paul Emery 3 , Ann W. Morgan 3 and IACON 

Consortium & PEAC Consortium, 1 Leeds Institute of 

Rheumatic and Musculoskeletal Medicine, University of 

Leeds, Leeds, United Kingdom, 2 Centre for Population 

Health Sciences, University of Edinburgh, Edinburgh, 

United Kingdom, 3 NIHR-Leeds Musculoskeletal 

Biomedical Research Unit, Leeds, United Kingdom, 

4 

Pharmatics Limited, Edinburgh, Edinburgh, United 

Kingdom, 5 Barts and the London School of Medicine 

and Dentistry, William Harvey Research Institute, 

Queen Mary University of London, London, United 

Kingdom 

145 A 

Rheumatoid Arthritis – Human Etiology and 

Pathogenesis I 

Moderators: Maripat Corr, MD; Douglas J. Veale, MD, 

FRCPI 

2:30 pm 

3017. Elevated Neutrophil Extracellular Trap Levels 

Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA 

Levels in the Sputum of Individuals at Risk for 

Future Rheumatoid Arthritis 

M. Kristen Demoruelle 1 , Monica Purmalek 2 , Heather 

Rothfuss 3 , Michael Weisman 4 , Lindsay Kelmenson 1 , 

Michael Mahler 5 , Jill M. Norris 6 , Brian Cherrington 3 , 

Mariana Kaplan 2 , V. Michael Holers 1 and Kevin D. 

Deane 1 , 1 University of Colorado Denver, Aurora, 

CO, 2 National Institutes of Health, Bethesda, MD, 


Tuesday 




3 

University of Wyoming, Laramie, WY, 4 Cedars-Sinai 

Medical Center, Los Angeles, CA, 5 Inova Diagnostics, 

San Diego, CA, 6 Colorado School of Public Health, 

Aurora, CO 

2:45 pm 

3018. The Analysis of Severity of Arthritis in the 

Intestinal Microbiota-Humanized Mice 

Yuichi Maeda 1 , Masato Matsushita 2 , Masashi Narazaki 1 , 

Yukihiko Saeki 3 , Atsushi Kumanogoh 1 and Kiyoshi 

Takeda 1 , 1 Osaka University Graduate School of 

Medicine, Suita, Japan, 2 Osaka Minami Medical Center, 

Osaka, Japan, 3 Osaka-Minami Medical Ctr, Osaka, Japan 

3:00 pm 

3019. Sputum Antibodies to Individual Citrullinated 

Protein/Peptide Antigens Are Elevated in Subjects 

at Risk of Future RA and Subjects with Established 

Disease 

Emily Bowers 1 , M. Kristen Demoruelle 1 , Michael 

Weisman 2 , Jill M. Norris 3 , William H. Robinson 4 , V. 

Michael Holers 1 and Kevin D. Deane 1 , 1 University of 

Colorado Denver, Aurora, CO, 2 Cedars-Sinai Medical 

Center, Los Angeles, CA, 3 Colorado School of Public 

Health, Aurora, CO, 4 Stanford University School of 

Medicine, Stanford, CA 

3:15 pm 

3020. Citrullination of Inhibitor of DNA Binding-1 

at Specific Locations Leads to Autoantigenicity in 


Ray A. Ohara 1 , Henriette A. Remmer 2 , Phillip L. 

Campbell 3 , David A. Fox 3 and Jeffrey H. Ruth 3 , 1 Division 

of Rheumatology, University of Michigan Medical 

Center, Ann Arbor, MI, 2 Department of Biological 

Chemistry, University of Michigan Medical School, Ann 

Arbor, MI, 3 Division of Rheumatology, University of 

Michigan Medical School, Ann Arbor, MI 

3:30 pm 

3021. Frequency of Arthralgia, Seropositivity, and 

Seropositive Arthralgia and Their Association with 

Development of Rheumatoid Arthritis in a Cohort 

of Indigenous North Americans with or without a 

First Degree Relative with Rheumatoid Arthritis 

Elizabeth Ferucci 1 , Carol Hitchon 2 , Irene Smolik 2 , David 

Robinson 2 and Hani El-Gabalawy 3 , 1 Alaska Native 

Tribal Health Consortium, Anchorage, AK, 2 University 

of Manitoba, Winnipeg, MB, 3 University of Manitoba 

Arthritis Center, Winnipeg, MB 

3:45 pm 

3022. Autoantibodies to Peptidylarginine Deiminase 

2 Protect Against Radiographic Progression in 

Patients with Rheumatoid Arthritis 

Erika Darrah 1 , Jon T. Giles 2 , Ryan Davis 1 , Pooja Naik 1 , 

Maximilian Konig 1 and Felipe Andrade 1 , 1 The Johns 

Hopkins University, Division of Rheumatology, 

Baltimore, MD, 2 Columbia University, College of 

Physicians and Surgeons, Division of Rheumatology, 

New York, NY 

Ballroom C 


Biologics, and Gene Therapy III: Small Molecules 

and Early Intervention 

Moderators: J. Steuart Richards, MBBS; Ernest H. Choy 

2:30 pm 

3023. Lipid Profile and Effect of Statin Treatment in 

Pooled Phase 2 and Phase 3 Baricitinib Studies 

Iain B. McInnes 1 , Joel Kremer 2 , Paul Emery 3 , Steven 

H. Zuckerman 4 , Giacomo Ruotolo 4 , Chadi Saifan 4 , Lei 

Chen 4 , Shayami Thanabalasundrum 4 , Sarah Witt 4 and 

William Macias 4 , 1 University of Glasgow, Glasgow, Great 

Britain, 2 Albany Medical College, Albany, NY, 3 University 

of Leeds, Midlothian, United Kingdom, 4 Eli Lilly and 

Company, Indianapolis, IN 

2:45 pm 

3024. Major Adverse Cardiovascular Events: Risk 

Factors in Patients with RA Treated with Tofacitinib 

Christina Charles-Schoeman 1 , Hernan Valdez 2 , Koshika 

Soma 2 , Lie-Ju Hwang 2 , Ryan DeMasi 2 , Mary Boy 3 and 

Iain B McInnes 4 , 1 University of California, Los Angeles, 

Los Angeles, CA, 2 Pfizer Inc, New York, NY, 3 Pfizer Inc, 

Groton, CT, 4 Glasgow Biomedical Research Centre, 

University of Glasgow, Glasgow, United Kingdom 

3:00 pm 

3025. The Effect of Filgotinib (GLPG0634), an Oral 

JAK1 Selective Inhibitor on Patient-Reported 

Outcomes: Results from Two 24-Week Phase 2B 

Dose Ranging Studies 

Mark C. Genovese 1 , R Westhovens 2 , Arthur Kavanaugh 3 , 

Luc Meuleners 4 , Annegret Van der Aa 4 , Pille Harrison 4 

and Chantal Tasset 4 , 1 Stanford University Medical 

Center, Palo Alto, CA, 2 University Hospitals Leuven, 

Leuven, Belgium, 3 University of California San Diego, La 

Jolla, CA, 4 Galapagos NV, Mechelen, Belgium 


147


Tuesday 



3:15 pm 

3026. The Efficacy and Safety of Low Dose IL-2 

Therapy in Over-Treated Patients with Rheumatoid 

Arthritis: A Preliminary Study 

Sheng-Xiao Zhang, Miao Miao, Xiao-Qing Liu, Xiao-Wen 

Ma, Xiao-Yan Wu and Xiao-Feng Li, The Second Hospital 

of Shanxi Medical University, Taiyuan, China 

3:30 pm 

3027. Herpes Zoster in Patients with Moderate 

to Severe Rheumatoid Arthritis Treated with 

Baricitinib 

Kevin L. Winthrop 1 , Stephen Lindsey 2 , Michael 

Weinblatt 3 , Tsutomu Takeuchi 4 , David Hyslop 5 , 

Maher Issa 5 , Lei Chen 5 , John Bradley 5 , Christina 

Dickson 5 and Roy Fleischmann 6 , 1 Oregon Health and 

Sciences University, Portland, OR, 2 Ochsner Medical 

Center, Baton Rouge, LA, 3 Harvard Medical School, 

Brigham and Women’s Hospital, Boston, MA, 4 Keio 

University School of Medicine, Tokyo, Japan, 5 Eli Lilly 

and Company, Indianapolis, IN, 6 Metroplex Clinical 

Research Center and University of Texas Southwestern 

Medical Center, Dallas, TX 

3:45 pm 

3028. A Single Infusion of Rituximab Delays the 

Onset of Arthritis in Subjects at High Risk of 

Developing RA 

Danielle M. Gerlag 1 , Mary Safy 2 , Karen I. Maijer 3 , Sander 

W. Tas 4 , Mirian Starmans-kool 5 , A. van Tubergen 6 , 

M. Janssen 7 and Paul P. Tak 8 , 1 Current address: 

GSK,Clinical Unit Cambridge,R&D Projects Clinical 

Platforms & Sciences, Cambridge, United Kingdom, 

2 

Amsterdam Rheumatology and Immunology Center, 

Amsterdam, Netherlands, 3 Academic Medical Center 

/ University of Amsterdam, Amsterdam, Netherlands, 

4 

Academic Medical Center/University of Amsterdam, 

Amsterdam, Netherlands, 5 Orbis Medical Center, 

Geleen-Sittard, Netherlands, 6 Department of Internal 

Medicine, Rheumatology, Maastricht University Medical 

Center, Maastricht, Netherlands, 7 Rijnstate Hospital, 

Arnhem, Netherlands, 8 currently: , Ghent University, 

Ghent, Belgium, Ghent, Belgium 

151 A 

Sjögren’s Syndrome I: Clinical Insights 

Moderator: Arthur Bookman, FRCPC 

2:30 pm 

3029. Ultrasonography of Major Salivary Glands 

in Patients Suspected with Primary Sjögren’s 

Syndrome: Comparison with Salivary Gland Biopsy 

and Classification Criteria 

Esther Mossel 1 , Konstantina Delli 1 , Jolien F. van 

Nimwegen 1 , Alja J. Stel 1 , Erlin A. Haacke 1 , Fred K.L. 

Spijkervet 1 , Frans G.M. Kroese 1 , Arjan Vissink 1 , 

Hendrika Bootsma 2 and Suzanne Arends 1 , 1 University 

of Groningen, University Medical Center Groningen, 

Groningen, Netherlands, 2 Rheumatology and Clinical 


Medical Center Groningen, The Netherlands, 

Groningen, Netherlands 

2:45 pm 

3030. Evidence of Inflammasome Activation in the 

Peripheral Blood and Salivary Gland Tissues of 

Primary Sjögren’s Syndrome Patients: Correlation 

with Clinical Indices of Severe Disease and 

Lymphoma Development 

Aglaia G Vakrakou, Sorina Boiu and Menelaos N 

Manoussakis, Hellenic Pasteur Institute, Athens, 

Greece, Athens, Greece 

3:00 pm 

3031. Rethinking Primary Sjögren’s Syndrome: 

Stratification by Clinical Phenotypes to Improve 

Understanding of Disease Pathogenesis, Trial 

Design, Clinical Management, and Prospective 

Health Gains? 

Dennis Lendrem 1 , Nadia Howard Tripp 2 , Xavier 

Mariette 3 , Svein Joar A. Johnsen 4 , Jessica Tarn 5 , Katie 

Hackett 5 , Bridget Griffiths 6 , Sheryl Mitchell 7 , Alain 

Saraux 8 , Valerie Devauchelle 9 , Katrine Norheim 4 , 

John D. Isaacs 10 , Peter McMeekin 11 , Simon Bowman 12 , 

Roald Omdal 13 , Jacques-Eric Gottenberg 14 and Wan- 

Fai Ng 1 , 1 Newcastle University, Newcastle upon Tyne, 

United Kingdom, 2 Newcastle-upon-Tyne Hospitals 

NHS Foundation Trust, Newcastle-upon-Tyne, United 

Kingdom, 3 Université Paris-Sud, AP-HP, Hôpitaux 

Universitaires Paris-Sud, Paris, France, 4 Stavanger 

University Hospital, Stavanger, Norway, 5 Newcastle 

University, Newcastle-upon-Tyne, United Kingdom, 

6 

Freeman Hospital, Newcastle Upon Tyne, United 

Kingdom, 7 Freeman Hospital, Newcastle upon Tyne, 

United Kingdom, 8 CHU de la Cavale Blanche, Brest 


Tuesday 




Cedex, France, 9 Department of Rheumatology, Brest 

University Hospital, Brest, France, Brest, France, 

10 

Newcastle University and the Freeman Hospital, 

Newcastle-upon-Tyne, United Kingdom, 11 Northumbria 

University, Newcastle-upon-Tyne, United Kingdom, 

12 

Department of Rheumatology, University Hospitals 

Birmingham NHS Foundation Trust, Birmingham, 

United Kingdom, 13 University of Bergen, Bergen, 

Norway, 14 Department of Rheumatology, Strasbourg 

University Hospital, Strasbourg, France 

3:15 pm 

3032. Abnormalities in the Biological or 

Haematological Domain of the Essdai Predict an 

Increase in Systemic Disease Activity the Year 

after: 5-Year Data from the Prospective Multicenter 

Assess Cohort 

Jacques-Eric Gottenberg 1 , Raphaele Seror 2 , Alain 

Saraux 3 , Valerie Devauchelle 4 , Emmanuelle Dernis 5 , 

Philippe Dieudé 6 , Jean-Jacques Dubost 7 , Anne Laure 

Fauchais 8 , Vincent Goeb 9 , Claire Larroche 10 , Véronique 

Le-Guern 11 , Eric Hachulla 12 , Pierre Yves Hatron 13 , 

Jacques Morel 14 , Aleth Perdriger 15 , Stephanie Rist 

Bouillon 16 , Damien Sène 17 , Olivier Vittecoq 18 , Jean 

Sibilia 19 , Philippe Ravaud 20 and Xavier Mariette 21 , 

1 

Department of Rheumatology, Strasbourg University 

Hospital, Strasbourg, France, 2 Assistance Publique– 

Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, 

Le Kremlin Bicêtre, France, 3 Brest University Hospital, 

Brest, France, 4 Department of Rheumatology, Brest 

University Hospital, Brest, France, Brest, France, 

5 

Centre Hospitalier, Le Mans, France, 6 Hôpital 

Bichat, Paris, France, 7 Rheumatology department 

CHU Clermont-Ferrand, Clermont-Ferrand, France, 

8 

Rheumatology, Limoges, France, 9 CHU Amiens, 

Amiens, France, 10 Internal Medicine, Paris, France, 

11 

Department of Internal Medicine, Referral Center 

for Rare Autoimmune and Systemic Diseases, 

Hôpital Cochin, AP–HP, Université Paris Descartes, 

Paris, France, 12 Lille University Hospital, Lille, France, 

13 

Internal Medicine, Lille, France, 14 Department of 

Rheumatology, Montpellier University Hospital, 

Montpellier, France, 15 C.H.R. Hôpital Sud, Rennes, 

France, 16 Hopital La Source, La Source, France, 

17 

Department of Internal Medicine, Pitié-Salpêtrière 

Hospital, Paris, France, 18 Rouen University Hospital 

&INSERM U905, Rouen, France, 19 Department of 

Rheumatology, Strasbourg University Hospital, 

Strasbourg, France, 20 Epidemiologist, PARIS, France, 

21 

Rheumatology department, Bicetre Hospital, Paris- 

Sud University, Le Kremlin Bicetre, France 

3:30 pm 

3033. Safety and Efficacy of Single Dose 

VAY736 (anti-BAFF-R mAb) in Patients with 

Primary Sjögren’s Syndrome (pSS) 

Thomas Doerner 1 , Maximilian Posch 2 , Frank Wagner 2 , 

Andreas Hueser 2 , Thomas Fischer 3 , Louise Mooney 4 , 

Olivier Petricoul 4 , Paul Maguire 4 , Parasar Pal 5 , Julie 

Doucet 4 , Maciej Cabanski 4 , Esther Kamphausen 4 , 

Remi Kazma 4 and Stephen Oliver 4 , 1 Charité – 

Universitätsmedizin, Berlin, Germany, 2 Charité 

Research Organisation GmbH, Berlin, Germany, 

3 

Charité - Universitätsmedizin, Berlin, Germany, 

4 

Novartis Pharma AG, Basel, Switzerland, 5 Novartis 

Pharma AG, Hyderabad, India 

3:45 pm 

3034. A Selective JAK1 Inhibitor, Filgotinib 

Suppresses Lymphocytic Infiltration in Salivary 

Gland of Non Obese Diabetic Mice Via Suppression 

of BAFF and Chemokine Production of Salivary 

Gland Epithelial Cells 

Jennifer Lee 1 , Seo Hwa Kim 2 , Haneul Kim 2 , Seung-Ki 

Kwok 3 , Ji Hyeon Ju 3 and Sung-Hwan Park 3 , 1 Division 

of Rheumatology, Department of Internal Medicine, 

College of Medicine, The Catholic University of Korea, 

Seoul, Korea, Republic of, 2 Division of Rheumatology, 

Department of Internal Medicine, College of Medicine, 

The Catholic University of Korea, Seoul, Korea, The 

Republic of, 3 Division of Rheumatology, Department 

of Internal Medicine, College of Medicine, The Catholic 

University of Korea, Seoul, South Korea 

147 A 

Spondylarthropathies Psoriatic Arthritis – 

Pathogenesis, Etiology I 

Moderators: Oliver FitzGerald; Christopher T. Ritchlin, 

MD, MPH 


149


Tuesday 



2:30 pm 

3035. Characterization of DC-STAMP+ T Cells, 

a CD3+CD4+ T Cell Subset Uniquely Present in 

Patients with Psoriatic Disease 

Yahui Grace Chiu 1 , Edward Schwarz 2 , Richard Bell 2 , 

Dongge Li 2 , Nelson Huertas 2 , Cristy Bell 2 , Sharon 

Moorehead 2 , Debbie Campbell 2 , Changyong Feng 2 

and Christopher T. Ritchlin 1 , 1 University of Rochester 

Medical Center, Rochester, NY, 2 University of 

Rochester, Rochester, NY 

2:45 pm 

3036. IL-22 Is Dysregulated in Psoriatic Arthritis 

and Acts to Limit IFN-γ Driven Inflammatory 

Chemokine Production 

Amara Ezeonyeji 1 , Helen Baldwin 2 , Milica Vukmanovic- 

Stejic 3 and Michael R. Ehrenstein 1 , 1 University College 

London, London, United Kingdom, 2 Centre for 

Rheumatology Research, University College London, 

london, United Kingdom, 3 University College London, 

london, United Kingdom 

3:00 pm 

3037. Calprotectin Is Highly Upregulated in 

Inflamed Axial Entheses in SKG Mice 

Zheni Stavre, Yukiko Maeda and Ellen M. Gravallese, 

University of Massachusetts Medical School, Worcester, 

MA 

3:15 pm 

3038. Enumeration and Preliminary 

Characterisation of Peri-Entheseal Bone Type 3 

Innate Lymphoid Cells 

Richard Cuthbert 1 , Yasser El-Sherbiny 1 , Evangelos M. 

Fragkakis 1 , Robert Dunsmuir 2 , Helena Marzo-Ortega 3 , 

Elena Jones 1 and Dennis McGonagle 1 , 1 University 

of Leeds, Leeds, United Kingdom, 2 National Health 

Service, Leeds, United Kingdom, 3 NIHR Leeds 

Musculoskeletal Biomedical Research Unit, Leeds 

Teaching Hospitals and University of Leeds, Leeds, 


3:30 pm 

3039. Anti-IL-17A, but Not Anti-TNF, Can Halt 

Pathological New Bone Formation in Experimental 


Melissa van Tok 1 , Leonie van Duivenvoorde 1 , Ina 

Kramer 2 , Peter Ingold 2 , Veronique Knaup 1 , Joel Taurog 3 , 

Frank Kolbinger 4 and Dominique Baeten 5 , 1 Academic 

Medical Center, Amsterdam, Netherlands, 2 Novartis 

Institutes for Biomedical Research, Basel, Switzerland, 

3 

University of Texas Southwestern Medical Center, 

Dallas, TX, 4 Novartis Institutes for BioMedical Research, 

Novartis Pharma AG, Basel, Switzerland, 5 Amsterdam 

Rheumatology and immunology Center, Amsterdam, 

Netherlands 

3:45 pm 

3040. Th17 Migration into the Synovial Fluid of 

Patients with Active Psoriatic Arthritis Is Enhanced 

By Regulatory T Cells 

Helen Baldwin, Amara Ezeonyeji, Mohammed Rohan 

Butt and Michael R. Ehrenstein, University College 

London, London, United Kingdom 

Salon B 

Vasculitis III: Pathogenic Mechanisms 

Moderators: Stuart Levine, MD; Paul A. Monach, MD, 

PhD 

2:30 pm 

3041. Age-Related Defects in the Immune System of 

Patients with GCA 

Zhenke Wen 1 , Yasuhiro Shimojima 2 , Gerald Berry 1 , 

Ebru Hosgur 1 , Joyce Liao 3 , Lindsy Forbess 4 , Michael 

Weisman 5 , Jorg Goronzy 1 and Cornelia M. Weyand 1 , 

1 


2 

Shinshu University School of Medicine, Matsumoto, 

Japan, 3 Stanford University, Palo Alto, CA, 4 Cedars-Sinai, 

Los Angeles, CA, 5 Cedars-Sinai Medical Center, Los 

Angeles, CA 

2:45 pm 

3042. PD-1–Expressing T Cells in GCA Fail to Promote 

Immune Tolerance Functions 

Ryu Watanabe, Hui Zhang, Ebru Hosgur, Gerald Berry, 

Jorg Goronzy and Cornelia M. Weyand, Stanford 

University School of Medicine, Stanford, CA 

3:00 pm 

3043. Dense Genotyping of Immune Related Loci in 

a Multi-Ethnic Behçet’s Disease Cohort Identifies 

Genetic Associations in a Long Noncoding RNA 

Near QSOX2, RASIP1/FUT2, and IL12A-AS1 

Paul Renauer 1 , Patrick Coit 1 , Travis Hughes 2 , Mikhail 

Ognenovski 1 , Adam Adler 3 , Lourdes Ortiz-Fernández 4 , 


Tuesday 




Vuslat Yilmaz 5 , Kenan Aksu 6 , Nursen Duzgun 7 , Gokhan 

Keser 6 , Ayse Cefle 8 , Ayten Yazici 9 , Andac Ergen 10 , Erkan 

Alpsoy 11 , Carlo Salvarani 12 , Bruno Casali 13 , Ina Koetter 14 , 

Alexandra Zhernakova 15 , Cisca Wijmenga 16 , Fujio 

Takeuchi 17 , Shinji Harihara 18 , Toshikatsu Kaburaki 19 , 

Yeong Wook Song 20 , Francisco David Carmona 21 , Marta 

E. Alarcon Riquelme 22 , Javier Martín 21 , Güher Saruhan- 

Direskeneli 23 , María Francisca Gonzalez Escribano 24 , 

Haner Direskeneli 25 and Amr H Sawalha 1 , 1 Division 

of Rheumatology, University of Michigan, Ann Arbor, 

MI, 2 Division of Health Sciences and Technology, 

Harvard Medical School, Boston, MA, 3 Oklahoma 

Medical Research Foundation, OK, OK, 4 Immunology 

department, Hospital Universitario Virgen del Rocío, 

Sevilla, Spain, 5 Istanbul University, Istanbul Faculty 

of Medicine, Department of Physiology, Istanbul, 

Turkey, 6 Ege University Medical Faculty, Izmir, Turkey, 

7 

Ankara University School of Medicine, Ankara, Turkey, 

8 

Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 

9 

Kocaeli University School of Medicine, Kocaeli, Turkey, 

10 

Okmeydaný Research and Education Hospital, 

Istanbul, Turkey, 11 Department of Dermatology, 

Akdeniz University School of Medicine, Antalya, Turkey, 

12 

Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura 

a Carattere Scientifico, Reggio Emilia, Italy, 13 Molecular 

Biology Laboratory, Azienda Ospedaliera Arcispedale 

Santa Maria Nuova, Istituto di Ricovero e Cura a 

Carattere Scientifico, Reggio Emilia, Italy, 14 Asklepios 

Klinik Altona, Hamburg, Germany, 15 University of 

Groningen, University Medical Center, Groningen, 

Netherlands, 16 University Medical Hospital Groningen, 

University of Groningen, Groningen, Netherlands, 

17 

Faculty of Medicine, University of Toyko, Tokyo, Japan, 

18 

The University of Tokyo Graduate School of Science, 

Tokyo, Japan, 19 The University of Tokyo School of 

Medicine, Bunkyo-ku, Japan, 20 Department of Molecular 

Medicine and Biopharmaceutical Sciences, Graduate 

School of Convergence Science and Technology, 

Seoul National University, Seoul, South Korea, 

21 

Instituto de Parasitología y Biomedicina López-Neyra, 

IPBLN-CSIC, PTS-Granada, Granada, Spain, 22 Pfizer- 

University of Granada-Junta de Andalucía, Granada, 

Spain, 23 Department of Physiology, Istanbul Faculty 

of Medicine, Istanbul University, Istanbul, Turkey, 

24 

Hospital Universitario Virgen del Rocío (IBiS,CSIC,US), 

Sevilla, Spain, 25 Marmara University, School of 

Medicine, Istanbul, Turkey 

3:15 pm 

3044. Endothelin 1 Induces a Myofibroblastic 

Phenotype in Vascular Smooth Muscle Cells. A 

Mechanism Potentially Contributing to Vascular 

Remodeling and Intimal Hyperplasia in Giant Cell 

Arteritis 

Ester Planas-Rigol 1 , Nekane Terrades-Garcia 1 , Marc 

Corbera-Bellalta 1 , Ester Lozano 1 , Marco Antonio Alba 1 , 

Georgina Espígol-Frigolé 1 , Sergio Prieto-González 1 , 

Marta Segarra 1 , Jose Hernández-Rodríguez 1 , Sara 

Preciado 2 , Rodolfo Lavilla 2 and Maria C. Cid 1 , 1 Hospital 

Clínic. University of Barcelona. IDIBAPS, Barcelona, 

Spain, 2 Faculty of Pharmacy. Barcelona Science Park, 


3:30 pm 

3045. Immunometabolism in ANCA-Associated 

Glomerulonephritis 

Peter C. Grayson 1 , Sean Eddy 2 , Viji Nair 2 , Hemang 

Parikh 3 , Maja Lindenmeyer 4 , Laura Mariani 2 , Huateng 

Huang 2 , Wenjun Ju 3 , Casey Greene 5 , Clemens Cohen 4 , 

Jeffrey Krischer 3 , Matthias Kretzler 2 , Peter A. Merkel 5 

and Felix H. Eichinger 2 , 1 National Institute of Arthritis 

and Musculoskeletal and Skin Diseases, National 

Institutes of Health, Bethesda, MD, 2 University of 

Michigan, Ann Arbor, MI, 3 University of South Florida, 

Tampa, FL, 4 University of Munich, Munich, Germany, 

5 

University of Pennsylvania, Philadelphia, PA 

3:45 pm 

3046. Inflammatory Pathways as Shared Molecular 

Targets Across ANCA-Associated Vasculitis and 

Nephrotic Syndrome 

Sean Eddy 1 , Viji Nair 1 , Hemang Parikh 2 , Maja 

Lindenmeyer 3 , Laura Mariani 1 , Felix H. Eichinger 1 , 

Huateng Huang 1 , Wenjun Ju 2 , Casey Greene 4 , Peter C. 

Grayson 5 , Clemens Cohen 3 , Jeffrey Krischer 2 , Peter A. 

Merkel 4 and Matthias Kretzler 1 , 1 University of Michigan, 

Ann Arbor, MI, 2 University of South Florida, Tampa, FL, 

3 

University of Munich, Munich, Germany, 4 University 

of Pennsylvania, Philadelphia, PA, 5 National Institute 

of Arthritis and Musculoskeletal and Skin Diseases, 

National Institutes of Health, Bethesda, MD 

ARHP SESSIONS 

2:30 pm – 4:00 pm 


151


Tuesday 



204 A 

Connective Tissue Disorders: Not-So-Benign 

Joint Hypermobility and Pain PM 

PS 

E 

Moderator: Janine Shinn, MPAS, PA-C 

Ed Pd PrM FIT 

2:30 pm 

Connective Tissue Disorders: Not-So-Benign Joint 

Hypermobility and Pain 

Speaker: Katherine Marzan 

3:00 pm 

Ehlers-Danlos Syndromes and Heritable Connective 

Tissues Disorders 

Speaker: Pragya Singh, MD 

3:30 pm 

Rehabilitation Considerations for the Management of 

Joint Hypermobility 

Speaker: Yvonne M. Golightly, PT, MS, PhD 

140 A 

Factors to Consider with Non-Pharmacologic 

Therapies for Osteoarthritis 

PM PS E 

Moderator: Cindy Cabrera, RN, MSN, BA 

2:30 pm 

Ask Not How Osteoarthritis Impacts Work, but How 

Work Impacts Osteoarthritis 

Speaker: Monique A.M. Gignac, PhD 

3:00 pm 

Ethnic and Sex Differences in Knee Osteoarthritis (OA) 

Pain: New Biological and Psychosocial Contributors 

Speaker: Laurence Bradley, PhD 

3:30 pm 

Biomechanical Factors that Impact Movement in 


Speaker: Najia Shakoor, MD, MS 


2:30 pm – 4:00 pm 

202 B 

ARHP V – Epidemiology and Public Health 

Moderators: Jung-Hwa Lee; Kamil E. Barbour, PhD 

2:30 pm 

3047. Diabetes and BMI Modify the Association 

Between Painful Hip OA and All-Cause Mortality 

Rebecca Cleveland, Todd A. Schwartz, Jordan B. Renner, 

Leigh F. Callahan and Joanne M. Jordan, University of 

North Carolina at Chapel Hill, Chapel Hill, NC 

2:45 pm 

3048. Pain Severity as a Mediator of the Effect of 

Depressive Symptoms on Physical Performance in 

Knee Osteoarthritis 

Alan Rathbun 1 , Michelle Shardell 2 , Michelle S. Yau 3 , 

Mona Baumgarten 1 , Elizabeth Stuart 4 and Marc 

Hochberg 1 , 1 University of Maryland School of Medicine, 

Baltimore, MD, 2 National Institute on Aging, Baltimore, 

MD, 3 Boston University School of Medicine, Boston, 

MA, 4 Johns Hopkins Bloomberg School of Public Health, 

Baltimore, MD 

3:00 pm 

3049. Prevalence of Doctor-Diagnosed Arthritis 

Among Adults with Clinically Measured Pre- 

Diabetes— United States, 2009–2014 

Kamil E. Barbour 1 , Michael Boring 1 , Charles Hemlick 1 , 

Jennifer M. Hootman 2 , Louise Murphy 1 and Giuseppina 

Imperatore 3 , 1 Centers for Disease Control and 

Prevention, Atlanta, GA, 2 Centers for Disease Control 

and Prevention, Kennesaw, GA, 3 Division of Diabetes 

Translation, National Center for Chronic Disease 

Prevention and Health Promotion, Atlanta, GA 

3:15 pm 

3050. Post-Partum Complications and Depression in 

New Mothers with Juvenile Arthritis 

Debbie Ehrmann Feldman 1 , Evelyne Vinet 2 , Marie- 

Pierre Sylvestre 1 , Elizabeth Hazel 3 , Ciarán M. Duffy 4 , 

Anick Bérard 5 , Garbis Meshefedjian 6 and Sasha 

Bernatsky 2 , 1 Université de Montréal, Montreal, QC, 

2 

McGill University Health Centre, Montreal, QC, 3 McGill 

University Health Centre, Pointe-Claire, QC, 4 Children’s 

Hospital of Eastern Ontario and University of Ottawa, 

Ottawa, ON, 5 Université de Montréal, Montréal, QC, 

6 

Public Health Department of Montreal, Montreal, QC 


Tuesday 




3:30 pm 

3051. Is Frailty a Relevant Concept in Systemic 

Lupus Erythematosus (SLE)? 

Patricia P. Katz 1 , James Andrews 2 , Edward H. Yelin 1 

and Jinoos Yazdany 1 , 1 University of California, San 

Francisco, San Francisco, CA, 2 University of Washington, 

Seattle, WA 

3:45 pm 

3052. Causes of Death for Patients with 


Jessica Widdifield 1 , Michael Paterson 2 , Anjie Huang 3 , 

Bindee Kuriya 4 , Carter Thorne 5 , Janet E. Pope 6 , Claire 

Bombardier 7 and Sasha Bernatsky 8 , 1 McGill University, 

Toronto, ON, 2 Institute of Clinical Evaluative Sciences, 

Toronto, ON, 3 Institute for Clinical Evaluative Sciences, 

Toronto, ON, 4 Mount Sinai Hospital, University of 

Toronto, Toronto, ON, 5 University of Toronto and 

Southlake Regional Health Centre, Newmarket, ON, 

6 

University of Western Ontario, St Joseph’s Health 

Care, London, ON, 7 University of Toronto, Toronto, ON, 

8 

McGill University Health Centre, Montreal, QC 

WORKSHOPS 

4:00 pm – 6:00 pm 










144 C 

243 – Systemic Sclerosis: How to Perform Skin 

Scores PM PS E 

Speaker: Daniel E. Furst, MD 

144 A 

244 – When Is Muscle Biopsy Helpful in the 

Evaluation and Management of Myopathy? 

Speaker: David Lacomis, MD 

ACR SESSION 

4:30 pm – 5:30 pm 

209 A 

Mechanical Cues Determine Mesenchymal Stem 

Cell Fate: Can Exercise Improve Osteoporosis? 

Moderator: Teresa K. Tarrant, MD 

Speaker: Janet Rubin, MD 


4:30 pm – 6:00 pm 










144 B 

241 – Evaluation and Management of Shoulder 

Pain PM Ed PM Pd PS PrM PS FITE 

Speaker: Michael J. Battistone, MD; Andrea M. Barker, 

MPAS, PA-C 

149 A 

242 – MDHAQ/RAPID3 and RHEUMDOC: 

Quantitative, Standard, Scientific Summaries 

of Patient History and Physical Exam, Toward 

Better Clinical Decisions and Outcomes 

Speaker: Theodore Pincus, MD 

PM PS E 

148 

081 – Antiphospholipid Syndrome 

Speaker: David P. D’Cruz, FRCP, MD 

153 

082 – Behçet’s Syndrome 

Speaker: Kenneth Calamia, MD 

154 A 

083 – Hypermobility 

Speaker: Rodney Grahame, MD, FRCP, FACP 


153


Tuesday 



154 B 

084 – IgG4-Related Disease 

Speaker: John H. Stone, MD, MPH 

155 

085 – Immunodeficiency Syndromes 

Speaker: Leonard H. Calabrese, DO 

158 A 

086 – Pediatrics: Difficult to Treat Juvenile 

Idiopathic Arthritis PM Ed Pd PS PrM FIT 

Speaker: Jennifer E. Weiss, MD 

158 B 

087 – Reactive Arthritis: An Update 

Speaker: Siba P. Raychaudhuri, MD 

159 A 

088 – Systemic Lupus Erythematosus: Central 

Nervous System 

Speaker: Jorge Sanchez-Guerrero, MD, MSc 

159 B 


Patterns 

Speaker: Kenneth J. Warrington, MD 

160 

090 – What Is Not Central Nervous Angiitis: 

Making the Right Diagnosis 

Speaker: Rula A Hajj-Ali, MD 

ACR SESSIONS 

4:30 pm – 6:00 pm 

Ballroom A 

Clinical Conundrums in Sjögren’s Syndrome 

Moderators: Peter A. Valen, MD, FACP; Petros Efthimiou, 

MD 

4:30 pm 

How Do I Evaluate My Patient with Salivary and 

Lacrimal Gland Enlargement? 

Speaker: Alan N. Baer, MD 

5:00 pm 

How Do I Assess My Sjögren’s Patient with Numbness 

and Tingling? 

Speaker: Julius Birnbaum, MD, MHS 

5:30 pm 

Should I Treat My Sjögren’s Patient with Biologic 

Therapy? 

Speaker: Eugene William St.Clair, MD 

143 A 

Is Your Patient Googling You? How the Sunshine 

Act and Public Websites Allow Patients to Learn 

about Their Doctors PM PSPM Ed PM Ed Pd PS E Pd PS 

PrM PrM FIT FIT 

Moderators: Robert Shmerling, MD; Karen Onel, MD 

4:30 pm 

The Sunshine Act: What It Is and Why We Need It 

Speaker: Shantanu Agrawal, MD 

5:00 pm 

The Implications of The Sunshine Act for Funding 

Institutions and Pharma 

Speaker: Kelly N. (Nikki) Reeves, JD, MPA 

5:30 pm 

Making the Grade: How Patients Use Online 

Resources to Evaluate Their Doctors 

Speaker: Jane Kang, MD 

Hall E 

Rheumatoid Arthritis in Real Life: How Do You 

Treat to Target in 2016? PM PS E 

Moderators: Irene Tan, MD; Cynthia Aranow, MD 

4:30 pm 

When and How to Treat Preclinical or Very Early 


Speaker: Hani S. El-Gabalawy, MD 

5:00 pm 

Incorporating Treat-to-Target for Rheumatoid 

Arthritis in Clinical Practice 

Speaker: Daniel H. Solomon, MD, MPH 


Tuesday 




5:30 pm 

Cardiovascular Outcomes in Rheumatoid Arthritis 

Speaker: Sherine E. Gabriel, MD, MSc 


4:30 pm – 6:00 pm 

202 B 

Education 

Moderators: Deana M. Lazaro, MD; Mathilde H Pioro, 

MD 

4:30 pm 

3059. Impact of a Musculoskeletal Training Program 

on Residents’ Evaluation, Diagnosis, and Treatment 

of Osteoporosis 

Michael J. Battistone 1 , Richard Nelson 1 , Junjie Ma 2 , 

Karla L. Miller 1 , Phillip Lawrence 3 , Joanne Lafleur 4 , 

Marissa Grotzke 1 , Andrea M. Barker 1 and Grant W. 

Cannon 1 , 1 Veterans Affairs Salt Lake City Health Care 

System and University of Utah School of Medicine, 

Salt Lake City, UT, 2 Veterans Affairs Salt Lake City 

Health Care System and University of Utah College of 

Pharmacy, Salt Lake City, UT, 3 Salt Lake City VA Medical 

Center and Roseman University of Health Sciences, 

Salt Lake City, UT, 4 University of Utah Department of 

Pharmacotherapy and Salt Lake City VA Medical Center, 

Salt Lake City, UT 

4:45 pm 

3060. Development and Implementation of a 

Question-Based Tool Promoting Learning of 

Relevant Epidemiology and Biostatistics in 

Rheumatology: The Critical Literature Assessment 

Skills Support - Rheumatology (CLASS-Rheum) Pilot 

Juliet Aizer 1 , Julie Schell 2 , Christopher Collins 3 , Lisa 

Criscione-Schrieber 4 , Pascale Schwab 5 , Karina Marianne 

D. Torralba 6 , Anne R. Bass 1 , Jessica Berman 1 , Alexa 

Adams 1 , Stephen A. Paget 1 , Rima Abhyankar 7 , Kelly 

McHugh 7 and Lisa Mandl 1 , 1 Hospital for Special Surgery 

Weill Cornell Medical College, New York, NY, 2 University 

of Texas, Austin, TX, 3 MedStar Washington Hospital 

Center/ Georgetown University Medical Center, 

Washington, DC, 4 Duke University Medical Center, 

Durham, NC, 5 Oregon Health and Science University, 

Portland, OR, 6 Loma Linda University, Loma Linda, CA, 

7 

Hospital for Special Surgery, New York, NY 

5:00 pm 

3061. Future Challenges in Pediatric Rheumatology: 

The Role of Graduate Medical Education (GME) 

Lisa Imundo 1 , Marcy B. Bolster 2 , Seetha Monrad 3 , 

Daniel Battafarano 4 , Marisa Klein-Gitelman 5 , Jonathan 

S. Hausmann 6 and Marcia Ditmyer 7 , 1 Columbia 

University, New York, NY, 2 Massachusetts General 

Hospital, Boston, MA, 3 University of Michigan, Ann 

Arbor, MI, 4 San Antonio Military Medical Center, San 

Antonio, TX, 5 Northwestern University, Chicago, IL, 

6 

Beth Israel Deaconess Medical Center, Boston, MA, 

7 

Academy for Academic Research, Las Vegas, NV 

5:15 pm 

3062. Use of Script Concordance Testing to Evaluate 

the Efficacy of a Web-Based Module on Gout: Three 

Years of Experience 

Bernadette C. Siaton 1 , Elizabeth Clayton 2 , Alexandra 

M. Kueider 3 and Matthew Rietschel 4 , 1 University of 

Maryland School of Medicine, Baltimore, MD, 2 Edmund 

J. MacLaughlin, M.D., L.L.C., Easton, MD, 3 National 

Institute on Aging, Baltimore, MD, 4 University of 

Maryland School of Nursing, Baltimore, MD 

5:30 pm 

3063. Learning Rheumatology through Fellow- 

Generated Questions: The Rheumatology Image of 

the Week Project 

Jonathan S. Hausmann, Beth Israel Deaconess Medical 

Center, Boston, MA 

5:45 pm 

3064. From Art to Science: A Mobile App for 

Point-of-Care Relevance Determination for the 

Musculoskeletal Exam 

Joy-Ann Tabanor, Joongheum Park, Heidi-Anne Hanson 

and Hnin Hnin Oo, Englewood Hospital and Medical 

Center, Englewood, NJ 

146 A 

Epidemiology and Public Health II: Obesity, 

Cancer, and Mortality 

Moderators: Kaleb Michaud, PhD; Julia F. Simard, ScD 


155


Tuesday 



4:30 pm 

3065. Mortality in Patients with Rheumatoid 

Arthritis and Interstitial Lung Disease Treated with 

First Line TNFi or Rituximab Therapies 

Katie Druce 1 , Kundan Iqbal 2 , Kath Watson 1 , Deborah 

P.M. Symmons 1 , Kimme L. Hyrich 1 and Clive Kelly 3 , 

1 

Arthritis Research UK Centre for Epidemiology, 

The University of Manchester, Manchester, United 

Kingdom, 2 Newcastle University, Newcastle, United 

Kingdom, 3 Queen Elizabeth Hospital, Gateshead, 


4:45 pm 

3066. Risk of Incident Cancer with Biologic and 

Tofacitinib Therapy in Rheumatoid Arthritis 

Bryant R. England 1 , Sofia Pedro 2 , Ted R Mikuls 3 and 

Kaleb Michaud 1 , 1 University of Nebraska Medical 

Center, Omaha, NE, 2 National Data Bank for Rheumatic 

Diseases, Wichita, KS, 3 Veteran Affairs Nebraska- 

Western Iowa Health Care System and University of 

Nebraska Medical Center, Omaha, NE 

5:00 pm 

3067. Treatment Decisions Following Diagnosis of 

Cancer during TNFi Inhibitor Treatment in Patients 

with Rheumatoid Arthritis: Results from the BSRBR- 

RA 

Katie Druce 1 , Diederik Decock 2 , Kath Watson 1 , Deborah 

P.M. Symmons 1 and Kimme L. Hyrich 1 , 1 Arthritis 

Research UK Centre for Epidemiology, The University 

of Manchester, Manchester, United Kingdom, 2 Skeletal 

Biology and Engineering Research Center, Leuven, 

Belgium 

5:15 pm 

3068. Smoking and Excess Weight Attenuate Rate of 

Improvement over First 3 Years in Early RA 

Susan J. Bartlett 1 , Orit Schieir 2 , Kathleen Andersen 3 , 

Gilles Boire 4 , Boulos Haraoui 5 , Carol Hitchon 6 , Edward 

Keystone 2 , Janet E. Pope 7 , J Carter Thorne 8 , Diane Tin 8 , 

Vivian P. Bykerk 9 and Canadian Early Arthritis Cohort 

(CATCH) Investigators, 1 McGill University, Montreal, 

QC, 2 University of Toronto, Toronto, ON, 3 Hospital for 

Special Surgery, New York, NY, 4 CHUS - Sherbrooke 

University, Sherbrooke, QC, 5 Institut de Recherche 

en Rhumatologie de Montréal (IRRM), Montreal, QC, 

6 

University of Manitoba, Winnipeg, MB, 7 University of 

Western Ontario, St Joseph’s Health Care, London, ON, 

8 

Southlake Regional Health Centre, Newmarket, ON, 

9 

Divison of Rheumatology, Hospital for Special Surgery, 

New York, NY 

5:30 pm 

3069. Weight Loss in the Early Rheumatoid Arthritis 

Period Is Associated with Subsequent Increased 

Mortality in RA Patients and Matched Comparators: 

Evidence Against an RA-Specific Obesity Paradox 

Jeffrey A. Sparks 1 , Shun-Chiao Chang 1 , Uyen Sa D.T. 

Nguyen 2 , Medha Barbhaiya 1 , Sara K. Tedeschi 1 , Bing 

Lu 1 , Karen H. Costenbader 1 , Yuqing Zhang 3 , Hyon 

K. Choi 4 and Elizabeth W. Karlson 1 , 1 Brigham and 

Women’s Hospital and Harvard Medical School, Boston, 

MA, 2 University of Massachusetts Medical School, 

Worcester, MA, 3 Boston University School of Medicine, 

Boston, MA, 4 Massachusetts General Hospital and 


5:45 pm 

3070. Effect of Sarcopenia, Subcutaneous Adipose 

Tissue, and Abdominal Visceral Fat on Mortality 

Risk of Community-Dwelling Older Adults: A 

Population-Based Prospective Cohort Study 

Felipe M Santana 1 , Michel A Gonçalves 1 , Diogo S 

Domiciano 1 , Luana G Machado 1 , Jaqueline B Lopes 1 , 

Camille P Figueiredo 1 , Valéria Caparbo 1 , Liliam 

Takayama 1 and Rosa M R Pereira 2 , 1 Faculdade de 

Medicina da Universidade de São Paulo, São Paulo, 

Brazil, 2 Rheumatology Division, Faculdade de Medicina 

da USP, São Paulo, Brazil 

145 A 

Metabolic and Crystal Arthropathies I: 

Mechanisms of Disease 

Moderators: Robert T. Keenan, MD, MPH; Theodore R. 

Fields, MD 

4:30 pm 

3071. Recombinant Human Proteoglycan-4 

(rhPRG4) Inhibits Monosodium Urate (MSU) 

Crystal Phagocytosis By Human Macrophages and 

Resultant Inflammatory Response 

Marwa Qadri 1 , Tannin Schmidt 2 , Khaled Elsaid 3 and 

Gregory Jay 4 , 1 Massachusetts College of Pharmacy and 

Health Sciences University, Boston, MA, 2 University of 

Calgary, Calgary, AB, 3 Chapman University, Irvine, CA, 

4 

Brown University, Providence, RI 


Tuesday 




4:45 pm 

3072. Increased Platelet Reactivity in Gout: 

Relationship to Tophus Burden and Colchicine Use 

Richard Conway 1 , Claire-Louise Murphy 2 , Anne 

Madigan 3 , Patricia Kavanagh 4 , Liz Geraghty 3 , Niamh 

Redmond 5 , Laura Helbert 6 , John J. Carey 7 , Eimear 

Dunne 8 , Dermot Kenny 8 and Geraldine M. McCarthy 6 , 

1 

CARD Newman Research Fellow, University College 

Dublin, Dublin, Ireland, 2 Centre for Rheumatology 

Research, UCL Division of Medicine, London, United 

Kingdom, 3 Mater Misericordiae University Hospital, 

Dublin 7, Ireland, 4 Mater Public Hospital, Dublin 7, 

Ireland, 5 UCD Clinical Research Centre, Dublin, Ireland, 

6 

Mater Misericordiae University Hospital, Dublin, 

Ireland, 7 Galway University Hospitals, Galway, Ireland, 

8 

RCSI, Dublin 2, Ireland 

5:00 pm 

3073. Non-Additive Interaction of the Glucokinase 

Regulatory Protein and APOBEC1 Complementation 

Factor Loci with Alcohol Consumption to Influence 

the Risk of Gout 

Humaira Rasheed 1 , Lisa K. Stamp 2 , Nicola Dalbeth 3 

and Tony R. Merriman 4 , 1 University of Engineering and 

Technology, Lahore, Pakistan, 2 University of Otago, 

Christchurch, New Zealand, 3 University of Auckland, 

Auckland, New Zealand, 4 University of Otago, Dunedin, 

New Zealand 

5:15 pm 

3074. Population-Specific Association Between 

ABCG2 Variants and Tophaceous Disease in People 

with Gout 

Wendy He 1 , Amanda Phipps-Green 2 , Lisa K. Stamp 3 , 

Tony R. Merriman 2 and Nicola Dalbeth 1 , 1 University 

of Auckland, Auckland, New Zealand, 2 University of 

Otago, Dunedin, New Zealand, 3 University of Otago, 

Christchurch, New Zealand 

5:30 pm 

3075. Mitochondrial Genetic Variation, Copy 

Number, and Susceptibility to Gout in the New 

Zealand Polynesian Population 

Tony R. Merriman 1 , James Boocock 1 , Nicola Dalbeth 2 , 

Lisa K. Stamp 3 , Eli A. Stahl 4 , Hyon K. Choi 5 , Elizabeth 

Matisoo-Smith 1 and Anna Gosling 1 , 1 University of 

Otago, Dunedin, New Zealand, 2 University of Auckland, 

Auckland, New Zealand, 3 University of Otago, 

Christchurch, New Zealand, 4 Brigham and Women’s 

Hospital, Boston, MA, 5 Massachusetts General Hospital 


5:45 pm 

3076. Development of a Matrix-Binding Interlukin-1 

Receptor Antagonist Fusion Protein for Extended 

Retention in the Joint Tissues 

James Pancoast 1 , Richard Lee 2 and Parth Patwari 1 , 

1 

ProteoThera, Inc., Newton, MA, 2 Harvard University, 

Cambridge, MA 

147 A 

Miscellaneous Rheumatic and Inflammatory 

Diseases II 

Moderators: Andy Abril, MD; Lee S. Shapiro, MD 

4:30 pm 

3077. Quiescence in Active and Inactive Non- 

Infectious, Intermediate, Posterior, or Panuveitis in 

Patients Treated with Adalimumab 

Robert Landewé 1 , Irene van der Horst-Bruinsma 2 , 

Samir Tari 3 , Stefan Florentinus 3 , Alexandra P. 

Song 3 , Martina Kron 4 , Sophia Pathai 5 and James T. 

Rosenbaum 6 , 1 University of Amsterdam, Amsterdam, 

Netherlands, 2 VU University Medical Center, 

Amsterdam, Netherlands, 3 AbbVie Inc., North Chicago, 

IL, 4 Abbvie Deutschland GmbH & Co KG, Ludwigshafen, 

Germany, 5 AbbVie Ltd, Maidenhead, United Kingdom, 

6 

Oregon Health & Science University, Portland, OR 

4:45 pm 

3078. Diffuse Idiopathic Skeletal Hyperostosis and 

Diabetes – Using Genetic Risk Scores to Explore the 

Association 

Melissa Wang 1 , Mariko Ishimori 2 , Greg Kinney 3 , Irina 

Ianculsecu 1 , Elizabeth Regan 4 , Michael Weisman 5 

and Mark Goodarzi 1 , 1 Cedars-Sinai Medical Center, 

Los Angeles, CA, 2 Cedars-Sinai Medical Center, LA, 

CA, 3 Colorado School of Public Health, Aurora, CO, 

4 

National Jewish Health, Denver, CO, 5 Cedars-Sinai 

Medical Center, West Hollywood, CA 

5:00 pm 

3079. The Characteristic Features of the Patients 

with Deficiency of Adenosine Deaminase 2 (DADA2) 

Abdulsamet Erden 1 , Ezgi Deniz Batu 1 , Ekim Z. Taskiran 2 , 

Hafize Emine Sonmez 1 , Alper Sari 1 , Berkan Armagan 1 , 


157


Tuesday 



Levent Kilic 1 , Zehra Serap Arıcı 1 , Yelda Bilginer 1 , Ali 

Akdogan 1 , Omer Karadag 1 , Umut Kalyoncu 1 and Seza 

Ozen 1 , 1 Hacettepe University Faculty of Medicine, 

Ankara, Turkey, 2 Hacettepe University Faculty of 

Medicine, ANKARA, Turkey 

5:15 pm 

3080. Rheumatologic Consequences of 

Immunotherapy to Treat Malignancies: The Tip of 

an Iceberg 

Laura Cappelli 1 , Anna Kristina Gutierrez 1 , Alan N. 

Baer 1 , Jemima Albayda 1 , Rebecca L. Manno 1 , Uzma 

Haque 1 , Ami A. Shah 1 , Evan Lipson 1 , Karen Bleich 1 , Julie 

Brahmer 1 , Patrick Forde 1 , Dung Le 1 , Jarushka Naidoo 1 

and Clifton Bingham III 2 , 1 Johns Hopkins University 

School of Medicine, Baltimore, MD, 2 Johns Hopkins 

University, Baltimore, MD 

5:30 pm 

3081. Prognostic Factors of Death in a Cohort of 116 

Adults with Hemophagocytic Syndrome: Impact of 

Underlying Disease and Laboratory Parameters 

Pilar Brito-Zerón 1 , Pedro Moral Moral 2 , Belchin 

Kostov 3 , Luis Caminal-Montero 4 , Guadalupe Fraile 5 , 

Eva Fonseca 6 , Patricia Pérez Guerrero 7 , Angel Robles 8 , 

Antonio J. Chamorro 9 , María Andrés Calvo 10 , José 

Ramón Larrañaga 11 , Maria José Forner 12 , Mónica 

Rodriguez Carballeira 13 , Manuel Ruiz Muñoz 14 , Roberto 

Hurtado García 15 , Luis Fernando Viejo Llorente 16 , 

Sergio Prieto-González 17 , Pedro Castro 18 , Aleida 

Martínez Zapico 4 , María Vaquero Herrero 9 , Angela 

Ruiz de Temiño de la Peña 10 , Soledad Retamozo 19 , 

Manuel Ramos-Casals 20 and REGHEM-GEAS-SEMI 

Spanish Cohort, 1 Laboratory of Systemic Autoimmune 

Diseases “Josep Font”, CELLEX, Institut d’Investigacions 

Biomèdiques August Pi i Sunyer (IDIBAPS), Department 

of Systemic Autoimmune Diseases, ICMID, Hospital 

Clinic, Barcelona, Barcelona, Spain, 2 Department of 

Internal Medicine, Hospital La Fé, Valencia, Valencia, 

Spain, 3 Research Group in Primary Care, IDIBAPS, 

ABS Les Corts, CAPSE, Barcelona, Spain, 4 Department 

of Internal Medicine, Hospital Universitario Central 

de Asturias, Oviedo, Spain, 5 Department of Internal 

Medicine, Hospital Ramón y Cajal, Madrid, Spain, 

Madrid, Spain, 6 Department of Internal Medicine, 

Hospital de Cabueñes, Gijón, Gijón, Spain, 7 Department 

of Internal Medicine, Hospital Universitario Puerta 

del Mar, Cádiz, Cadiz, Spain, 8 Department of Internal 

Medicine, Hospital La Paz, Madrid, Madrid, Spain, 

9 

Department of Internal Medicine, Complejo Asistencial 

Universitario de Salamanca, Salamanca, Spain, 

10 

Department of Internal Medicine, Hospital Rio 

Hortega, Valladolid, Valladolid, Spain, 11 Department 

of Internal Medicine, Hospital Xeral, Vigo, Vigo, 

Spain, 12 Department of Internal Medicine, Hospital 

Clínico de Valencia, Valencia, Spain, 13 Department 

of Internal Medicine, Hospital Mutua de Terrasa, 

Terrasa, Spain, 14 Department of Internal Medicine, 

Hospital Universitario Fundacion Alcorcón, Madrid, 

Spain, 15 Department of Internal Medicine, Hospital 

Vega Baja, Orihuela, Orihuela, Spain, 16 Department of 

Internal Medicine, Hospital Virgen de la Salud, Toledo, 

Toledo, Spain, 17 Department of Autoimmune Diseases, 

ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, 

18 

Medical Intensive Care Unit, ICMiD, Hospital Clínic, 

Barcelona, Barcelona, Spain, 19 Rheumatology Unit, 

Hospital Privado Centro Médico de Córdoba, Argentina, 

Córdoba, Argentina, 20 Laboratory of Systemic 

Autoimmune Diseases “Josep Font”, CELLEX, Institut 

d’Investigacions Biomèdiques August Pi i Sunyer 

(IDIBAPS), Department of Systemic Autoimmune 

Diseases, ICMID, Hospital Clinic, Barcelona, Spain, 


5:45 pm 

3082. Macrophage Activation Syndrome Is 

Identified By Coagulopathy, Hyperferritinemia, 

Fever, and Cytopenia in Hospitalized Patients, 

Resulting in Poor Outcome 

Bita Shakoory 1 , Negin Mohtasham 2 , Matthew Mullen 3 , 

Richard Amdur 4 and W. Winn Chatham 3 , 1 None, 

MCLEAN, VA, 2 Tehran University of Medical Sciences, 

Tehran, Iran (Islamic Republic of), 3 University of 

Alabama at Birmingham, Birmingham, AL, 4 George 

Washington University, Washington, DC 

Salon B 

Rheumatoid Arthritis – Clinical Aspects V: 

Challenges in the Assessment and Management 

of Established RA 

Moderators: Elizabeth R. Wahl, MD; Iris Navarro-Millán 


Tuesday 




4:30 pm 

3083. Utility of Patient-Reported Outcomes 

Measurement Information System (PROMIS) 29 

Short Form for Understanding Interplay Between 

Patient-Reported Outcome Measures and Physician 

Driven Disease Activity Measures 

Yong Gil Hwang 1 , Juan (June) Feng 2 , Heather Eng 2 , 

Jason Lyons 2 , Anthony Fabio 2 and Larry W. Moreland 1 , 

1 

University of Pittsburgh, Pittsburgh, PA, 2 University of 

Pittsburgh, School of Public Health, Pittsburgh, PA 

4:45 pm 

3084. The Impact of Mental Health on Indicators 

of Disease Severity Among Patients with 

Inflammatory Arthritis: A Cross-Sectional and 

Longitudinal Investigation 

Renee El-Gabalawy, Mathew Bernstein, Cory 

Mackenzie, Jitender Sareen and Carol Hitchon, 

University of Manitoba, Winnipeg, MB 

5:00 pm 

3085. Do Depression and Anxiety Reduce the 

Chance of Remission in Rheumatoid Arthritis and 

Psoriatic Arthritis? 

Brigitte Michelsen 1 , Karen M Fagerli 2 , Elisabeth Lie 2 , 

Hilde Berner Hammer 2 , Glenn Haugeberg 3 , Eirik K 

Kristianslund 2 and Tore K. Kvien 2 , 1 Hospital of Southern 

Norway Trust, Kristiansand, Norway, 2 Diakonhjemmet 

Hospital, Oslo, Norway, 3 The Norwegian University of 

Science and Technology, Trondheim, Norway 

5:15 pm 

3086. Changing Patterns over Time in Opiate Use in 

U.S. Rheumatoid Arthritis Patients 

Jeffrey Curtis 1 , Fenglong Xie 1 , Kenneth Saag 1 , Lang 

Chen 1 , Timothy Beukelman 2 , Melissa Mannion 1 and 

Huifeng Yun 3 , 1 University of Alabama at Birmingham, 

Birmingham, AL, 2 University of Alabama-Birmingham, 

Birmingham, AL, 3 University of Alabama at Birmingham 

School of Public Health, Birmingham, AL 

5:30 pm 

3087. Association of Weight Loss with Improved 

Disease Activity in Patients with Rheumatoid 

Arthritis 

David J. Kreps, Florencia Halperin, Sonali P. Desai, Zhi 

Zhang, Elena Losina, Elizabeth W. Karlson, Bonnie L. 

Bermas and Jeffrey A. Sparks, Brigham and Women’s 

Hospital and Harvard Medical School, Boston, MA 

5:45 pm 

3088. Predictors of Non-Adherence with Anti- 

Rheumatic Medication in Rheumatoid Arthritis 

Patients: Data from a Rheumatoid Arthritis Cohort 

Vandana Ahluwalia 1 , Mohammad Movahedi 2 , 

Emmanouil Rampakakis 3 , Angela Cesta 2 , Xiuying Li 2 , 

John S. Sampalis 4 and Claire Bombardier 5 , 1 Brampton 

Civic Hospital, Brampton, ON, 2 Toronto General 

Hospital Research Institute, University Health Network, 

Toronto, ON, 3 JSS Medical Research, St-Laurent, QC, 

4 

McGill University, Montreal, QC, 5 University of Toronto, 

Toronto, ON 

Ballroom C 


Biologics, and Gene Therapy IV: Biomarkers 

Moderators: Peter C. Taylor, MA, PhD, FRCP; Angelo L. 

Gaffo, MD, MSPH 

4:30 pm 

3089. Predicting the Response to TNF Inhibition or 

B Cell Depletion Therapy from Peripheral Whole 

Blood Gene Expression Profiles in Patients with 


Duncan Porter 1 , C. S. Goodyear 1 , J. S. Nijjar 1 , Martina 

Messow 1 , Stefan Siebert 1 , Manikhandan Mudaliar 1 

and Iain B. McInnes 2 , 1 University of Glasgow, Glasgow, 

United Kingdom, 2 University of Glasgow, Glasgow, 

Great Britain 

4:45 pm 

3090. Inflammation Detected with Modern 

Sensitive MRI Analysis Demonstrates That 

Therapeutic Response as Early as One Month 

Predicts 12-Month Radiographic Progression: Data 

from a Study Using Tofacitinib and Methotrexate in 

Early RA 

Philip G. Conaghan 1 , Michael A Bowes 2 , Mikkel 

Østergaard 3 , Gwenael Guillard 2 , Douglass Chapman 4 , 

Amy Stein 5 , John Andrews 4 , Zhiyong Xie 6 , Andrew 

Koenig 7 , Koshika Soma 4 and Bethanie Wilkinson 6 , 

1 

Leeds Institute of Rheumatic and Musculoskeletal 

Medicine, University of Leeds, Leeds, United 

Kingdom, 2 Imorphics Ltd, Manchester, United 

Kingdom, 3 Copenhagen Center for Arthritis Research, 

Copenhagen, Denmark, 4 Pfizer Inc, New York, NY, 

5 

Biostatistics, Quintiles, Morrisville, NC, 6 Pfizer Inc, 

Groton, CT, 7 Pfizer Inc, Collegeville, PA 


159


Tuesday 



5:00 pm 

3091. Effect of Sarilumab on Circulating Biomarkers 

of Bone and Joint Destruction in Patients with 

Rheumatoid Arthritis with Inadequate Response to 

Methotrexate 

Cem Gabay 1 , Jérôme Msihid 2 , Nikki Daskalakis 3 , Neil 

Graham 4 , Anne Barbot 2 , Moshe Zilberstein 3 and Anita 

Boyapati 4 , 1 University Hospitals of Geneva/SCQM 

Registry, Geneva, Switzerland, Geneva, Switzerland, 

2 

Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France, 

3 

Sanofi Genzyme, Bridgewater, NJ, 4 Regeneron 

Pharmaceuticals, Inc., Tarrytown, NY 

5:15 pm 

3092. Predictive Factors for Better Outcome of 

Switching of Biologics for Patients with Rheumatoid 

Arthritis in Daily Clinical Practice 

Kazuyoshi Saito 1 , Kazuhisa Nakano 1 , Shingo 

Nakayamada 1 , Satoshi Kubo 1 , Ippei Miyagawa 1 , Shigeru 

Iwata 1 and Yoshiya Tanaka 2 , 1 University of Occupational 

and Environmental Health, Japan, Kitakyushu, Japan, 

2 

University of Occupational and Environmental Health, 

Kitakyushu, Japan 

5:30 pm 

3093. Comparison of Changes in Cardiovascular 

Risk-Associated Biomarkers in RA Patients Treated 

with Anti-TNF or Other Biological Agents: A 

Metabolic Study from a Randomized Trial 

Alexandre Virone 1 , Jean-Philippe Bastard 2 , Soraya 

Fellahi 2 , Jacqueline Capeau 2 , Stéphanie Rouanet 3 , Jean 

Sibilia 4 , Philippe Ravaud 5 , Francis Berenbaum 1 , Jacques- 

Eric Gottenberg 6 and Jeremie Sellam 1 , 1 Rheumatology 

dept, APHP St-Antoine hospital, Univ Paris 06, Paris, 

France, Paris, France, 2 APHP Hôpital Tenon, Sorbonne 

Universités, UPMC Univ Paris-6, Inserm UMR_S938, 

ICAN, DHU i2B, Paris, France, 3 StatEthic, Levallois- 

Perret, France, 4 Department of Rheumatology, 

Strasbourg University Hospital, Strasbourg, France, 

5 

Hôpital Hôtel Dieu, Paris, France, 6 Department 


Strasbourg, France 

5:45 pm 

3094. Factors Associated with Initial or Subsequent 

Choice of Biologic Disease Modifying Antirheumatic 

Drugs for the Treatment of Rheumatoid Arthritis 

Yinzhu Jin 1 , Rishi J. Desai 1 , Jun Liu 1 , Nam-Kyong Choi 1 

and Seoyoung Kim 2 , 1 Brigham and Women’s Hospital, 

Boston, MA, 2 Brigham and Women’s Hospita and, 

Harvard Medical School,, Boston, MA 

Salon G 


– Clinical Aspects and Treatment IV: Psoriatic 

Arthritis – Clinical 

Moderators: Alexis Ogdie, MD; Philip J Mease 

4:30 pm 

3095. What Should Be the Primary Target of ‘Treat 

to Target’ in PsA? 

Laura C. Coates 1 , Paul Emery 2 , Philip G. Conaghan 1 

and Philip S. Helliwell 3 , 1 Leeds Institute of Rheumatic 

and Musculoskeletal Medicine, University of Leeds, 

Leeds, United Kingdom, 2 NIHR-Leeds Musculoskeletal 

Biomedical Research Unit and Leeds Institute of 

Rheumatic and Musculoskeletal Medicine, University 

of Leeds, Leeds, United Kingdom, 3 University of Leeds, 

Leeds, United Kingdom 

4:45 pm 

3096. Association Between Smoking and Psoriatic 

Arthritis Among Psoriasis Patients and the General 

Population: Data from National Inpatient Sample 

Paras Karmacharya 1 , Dilli Poudel 1 , Rashmi Dhital 2 

and Pragya Shrestha 3 , 1 Reading Health System, WEST 

READING, PA, 2 MBBS, Kathmandu, Nepal, 3 Reading 

Health System, West Reading, PA 

5:00 pm 

3097. Osteoclast Precursor Frequency and Imaging 

Findings Associated with Arthritis Onset in a 

Psoriasis Longitudinal Cohort 

Ralf G. Thiele 1 , Yahui Grace Chiu 1 , Francisco Tausk 2 , 

Bethany A. Marston 1 , Changyong Feng 2 , Gregory 

Dieudonne 2 , Vaseem Chengazi 2 , Sharon Moorehead 2 , 

Debbie Campbell 2 and Christopher T. Ritchlin 1 , 

1 

University of Rochester Medical Center, Rochester, NY, 

2 

University of Rochester, Rochester, NY 

5:15 pm 

3098. The Occurrence of Peripheral Arthritis 

Mutilans in Psoriatic Arthritis Is Associated with 

Certain Major Histocompatibility Class I Alleles 

Jon T. Giles 1 , Deepak R. Jadon 2 , Muhammad Haroon 3 , 

Jing Bi 1 , Eleanor Korendowych 2 , William Tillett 2 , Oliver 


Tuesday 




FitzGerald 4 , Robert Winchester 1 and Neil J. McHugh 2 , 

1 

Columbia University, College of Physicians & Surgeons, 

New York, NY, 2 Royal National Hospital for Rheumatic 

Diseases, Bath, United Kingdom, 3 St. Vincent’s 

University Hospital, Department of Rheumatology, 

Dublin, Ireland, 4 St. Vincent’s University Hospital, 

Department of Rheumatology. UCD Conway Institute 

of Biomolecular and Biomedical Research, University 

College Dublin, Dublin, Ireland 

5:30 pm 

3099. Higher Prevalence and Severity of Coronary 

Atherosclerosis in Psa Patients 

Lydia Ho Pui TAM 1 , Tsz Ho CHENG 1 , Ho Man LAM 1 , Ka 

Tat WONG 2 , Qing SHANG 1 , Edmund LI 1 , Wang Kit LI 1 , 

Man Fei CHEUNG 1 , Uen-Lam MING 1 , Tin-Long LUI 1 , 

Wing-Lam TAO 1 , SY TSANG 1 and Lai-Shan TAM 3 , 1 The 

Chinese University of Hong Kong, Hong Kong, Hong 

Kong, 2 Prince of Wales Hospital, Hong Kong, Hong 

Kong, 3 The Chinese University of Hong Kong, Hong 

Kong, China 

5:45 pm 

3100. Can Achieving Sustained Minimal Disease 

Activity (MDA) Prevent Progression of Subclinical 

Atherosclerosis? A Prospective Cohort Study in 

Psoriatic Arthritis 

Tsz Ho CHENG 1 , Qing SHANG 1 , PW Alex LEE 1 , Priscilla 

WONG 1 , Tracy Y. ZHU 2 , Chun-Kwok WONG 1 , JW Jack 

LEE 1 , M Mimi CHANG 3 , Edmund LI 1 and Lai-Shan TAM 2 , 

1 

The Chinese University of Hong Kong, Hong Kong, 

Hong Kong, 2 The Chinese University of Hong Kong, 

Hong Kong, China, 3 Prince of Wales Hospital, Hong 

Kong, Hong Kong 

Ballroom B 


Aspects and Treatment IV: Biomarkers 

Moderators: Peter M. Izmirly, MD; Anca Askanase, MD, 

MPH 

4:30 pm 

3101. Lipoprotein Profile and Serum Glycoprotein 

Acetylation as Markers of Cardiovascular Risk in 


Simantini Sakhardande 1 , Monica Purmalek 1 , Yenealem 

Temesgen-Oyelakin 1 , Maureen Sampson 1 , Aditya 

Joshi 1 , Alice Fike 1 , Michael Davis 2 , Taufiq Salahuddin 1 , 

Balaji Natarajan 1 , Joseph Lerman 1 , Zerai G. Manna 3 , 

Amit Dey 1 , Marcus Chen 1 , Sarfaraz Hasni 3 , Nehal N. 

Mehta 1 , Alan Remaley 1 and Mariana Kaplan 4 , 1 National 

Institutes of Health, Bethesda, MD, 2 NIH, Bethesda, MD, 

3 

National Institute of Arthritis and Musculoskeletal and 

Skin Diseases, National Institutes of Health, Bethesda, 

MD, 4 NIAMS/NIH, Bethesda, MD 

4:45 pm 

3102. Neutrophil Subsets, Arterial Inflammation, 

and Vascular Stiffness in Patients with Systemic 


Monica Purmalek 1 , Simantini Sakhardande 1 , 

Yenealem Temesgen-Oyelakin 1 , Aditya Joshi 2 , Joseph 

Lerman 2 , Michael Davis 2 , Alice Fike 3 , Amit Dey 1 , Taufiq 

Salahuddin 1 , Balaji Natarajan 2 , Martin P. Playford 4 , 

Heather Teague 2 , Zerai G. Manna 3 , Marcus Chen 2 , 

Sarfaraz Hasni 3 , Nehal N. Mehta 1 and Mariana Kaplan 1 , 

1 

National Institutes of Health, Bethesda, MD, 2 NIH, 



of Health, Bethesda, MD, 4 NHLBI, National Institutes of 

Health, Bethesda, MD 

5:00 pm 

3103. Apolipoprotein L1 Risk Variants Associate 

with Prevalent Cardiovascular Disease in African 

American Systemic Lupus Erythematous Patients 

Ashira Blazer 1 , Robert M Clancy 2 , H. Michael Belmont 2 , 

Peter M. Izmirly 2 , Androo Markham 2 and Jill P. Buyon 2 , 

1 

NYU School of Medicine, New York, NY, 2 New York 

University School of Medicine, New York, NY 

5:15 pm 

3104. Early Proteinuria Response in Real Life 

Situation Predicts Long-Term Lupus Renal Outcome 

in Ethnically Diverse Group with Biopsy-Proven 

Nephritis 

Michelle Lopes 1 , Luciana Seguro 1 , Maite Castro 2 , 

Danielle Daffre 3 , Eduardo Ferreira Borba 2 and Eloisa 

Bonfa 2 , 1 Hospital das Clínicas da Faculdade de 

Medicina da Universidade de São Paulo, São Paulo, 

Brazil, 2 Hospital das Clinicas, Faculdade de Medicina, 

University of São Paulo, São Paulo, Brazil, 3 São Paulo 

University, São Paulo, Brazil 


161


Tuesday 



5:30 pm 

3105. Relationships Between a Serum Biomarker of 

B Cell Differentiation and B Cell Activating Factor 

Suggest Possible Distinct Pathways of Response 

to Rituximab in Patients with Systemic Lupus 

Erythematosus 

Ricardo Marques 1 , Laura Heretiu 2 , David A. Isenberg 2 , 

Maria J. Leandro 2 and Geraldine Cambridge 2 , 1 Serviço 

de Medicina Interna B, Centro Hospitalar Universitário 

de Coimbra, Coimbra, Portugal, 2 Centre for 

Rheumatology, Division of Medicine, University College 


5:45 pm 

3106. A Simple Test for Assessing and Monitoring 

SLE Disease Activity Status 

Chaim Putterman 1 , Michael Rowe 2 , Joseph Barten 

Legutki 2 , Theodore M. Tarasow 2 and Kathryn Sykes 2 , 

1 

Albert Einstein College of Medicine/Montefiore 

Medical Center, New York, NY, 2 HealthTell, Inc, san 

ramon, CA 

150 A 

T Cell Biology and Targets in Autoimmune 

Disease 

Moderators: Ralph Budd, MD; Alessandra B. Pernis, MD 

4:30 pm 

3107. Switching from Anabolic to Catabolic 

Metabolism – A Novel Immunomodulatory Therapy 

in RA 

Zhen Yang 1 , Yi Shen 1 , Eric L. Matteson 2 , Ebru Hosgur 1 , 

Jison Hong 3 , Jorg Goronzy 1 and Cornelia M. Weyand 1 , 

1 


2 

Mayo Clinic, Rochester, MN, 3 Stanford University, Palo 

Alto, CA 

4:45 pm 

3108. Citrullinated Aggrecan Peptides Are Targets 

of Auto-Reactive CD4+ T-Cells in Rheumatoid 

Arthritis 

Hannes Uchtenhagen, Cliff Rims, Eddie James and Jane 

H. Buckner, Benaroya Research Institute at Virginia 

Mason, Seattle, WA 

5:00 pm 

3109. Regulatory T Cells Deficient in Protein 

Phosphatase 2A Lose Suppressive Function and 

Convert to an Effector Phenotype 

Isaac R. Kasper 1 , Hao Li 1 , Sokratis Apostolidis 1 , Maria G. 

Tsokos 2 and George C. Tsokos 3 , 1 Beth Israel Deaconess 

Medical Center/Harvard Medical School, Boston, MA, 

2 

Beth Israel Deaconess Medical Center, Boston, MA, 

3 

Harvard Medical School Beth Israel, Boston, MA 

5:15 pm 

3110. Rab4A Is Required for Development of Tregs, 

Restricts Antiphospholipid Antibody Production 

and Pro-Inflammatory Expansion of Macrophages 

and Neutrophils, and Blocks Pristane-Induced 

Intra-Alveolar Hemorrhage in a Mouse Model of SLE 

Zachary Oaks 1 , Thomas Winans 1 , Nick Huang 1 , Sarah 

Blair 1 , Miguel Beckford 1 , Katalin Banki 2 and Andras 

Perl 3 , 1 SUNY, Syracuse, NY, 2 SUNY Upstate Medical 

University, Syracuse, NY, 3 Upstate Medical University, 

Syracuse, NY 

5:30 pm 

3111. Pathogenic T Cell Responses in Systemic 

Sclerosis Is Shaped By Novel Cytokine Axis in the 

Microenvironment: A Multidimensional, High 

Throughput Analysis 

Hari Balaji 1 , Andrea HL Low 2 , Chieh Hwee Ang 3 , 

Raymond Ong Jr. 3 , Juntao Li 4 , Camillus Chua 3 , Liyun 

Lai 3 , Suzan Saidin 3 and Salvatore Albani 3 , 1 SingHealth 

Translational Immunology and Inflammation Centre, 

Singapore, Singapore, 2 -, Singapore, Singapore, 

3 

Singapore Health Services Pte Ltd, Singapore, 

Singapore, 4 Duke-National University of Singapore 

Graduate Medical School, Singapore, Singapore 

5:45 pm 

3112. DOCK8 Associates with STAT5 and Promotes 

Regulatory T Cell Function 

Erin Janssen, Mira Tohme, Sumana Ullas and Raif Geha, 

Boston Children’s Hospital, Boston, MA 

ACR CONCURRENT ABSTRACT SESSION 

4:30 pm – 6:00 pm 

Hall D 

ACR Late-Breaking Abstract Session 

Moderators: Richard F. Loeser, MD; David Pisetsky, MD, 

PhD; Victoria K. Shanmugam, MBBS, MRCP 


Tuesday 



ARHP SESSIONS 

4:30 pm – 6:00 pm 

201 

4:30 pm 

A Historical Perspective of Occupational and Physical 

Therapy in Rheumatology 

Speaker: Talitha Cox, MA, OTR/L 

Pd PS PrM FIT 

Be a Better Leader, Manager, or Mentor PM Ed Pd PS PrM FIT 


4:30 pm 

Be a Better Leader, Manager, or Mentor: Part I 

Speaker: James Udell, MD 

5:00 pm 

Be a Better Leader, Manager, or Mentor: Part II 

Speaker: Marian T. Hannan, DSc, MPH 

5:30 pm 

Be a Better Leader, Manager, or Mentor: Part III 

Speaker: Janet L. Poole, OTR, PhD 

206 

Pediatric Amplified Pain: A Comprehensive 

Treatment Approach PM Ed Pd PS PrM FIT 

Moderator: Cara M. Hoffart, DO 

4:30 pm 

Pediatric Amplified Pain, Including Complex Regional 

Pain Syndrome and Fibromyalgia, Characteristics, 

Treatment, and Outcome 

Speaker: David D. Sherry, MD 

5:00 pm 

Exercise Therapy for Amplified Pain: How and What 

We Do 

Speaker: Lori Kile, PTA 

5:00 pm 

Current Practices and New Directions in Pediatric 

Occupational and Physical Therapy 

Speaker: Jill R. Blitz, PT, DPT 

5:30 pm 

Evolution of Occupational Therapy Practice in Adult 

Rheumatology, Past, Present, and Future 

Speaker: Carole V. Dodge, OT, CHT 

151 A 

Update Small Vessel Vasculitis PM 


4:30 pm 

Small Vessel Vasculitides – I 

Speaker: Jason Springer, MD MS 

5:15 pm 

Small Vessel Vasculitides – II 

Speaker: Alexandra Villa-Forte, MD, MPH 

Ed Pd PS PrM FIT 


4:30 pm – 6:00 pm 

204 A 

ACR/ARHP Combined Abstract Session: 

Rehabilitation 

Moderators: M. Elaine Husni; Marie Westby, PT, PhD 

5:30 pm 

Psychological Factors to Consider in the Treatment of 

Patients with Pediatric Amplified Pain 

Speaker: Jennifer Sherker, PsyD 

140 A 

Physical and Occupational Therapies Through 

the Lifespan in the Biologic Era 


4:30 pm 

3053. Cartilage Loss Primarily Occurs in the Most 

Affected Tibiofemoral Compartment with No 

Evidence of a Ceiling Effect Among Advanced-Stage 

Disease: A Two-Year Longitudinal Study of Data 

from the Osteoarthritis 

Ming Zhang 1 , Lori Lyn Price 1 , Amanda R. Canavatchel 1 , 

Jeffrey B. Driban 1 , Puwei Yuan 2 , Grace H. Lo 3 and 

Timothy E. McAlindon 1 , 1 Tufts Medical Center, Boston, 

MA, 2 Shaanxi University of Chinese Medicine, Xian 


163


Tuesday 



Yang, China, 3 Baylor College of Medicine, Houston, TX 

4:45 pm 

3054. The Impact of Obesity on Knee Osteoarthritis 

Symptoms and Related Biomarker Profiles in a 

Bariatric Surgery Cohort 

Thayer Mukherjee 1 , Fernando Bomfim 1 , Evan Wilder 1 , 

Lauren Browne 2 , Kayleigh Toth 3 , Shira Aharon 3 , Janice 

Lin 3 , Renata La Rocca Vieira 1 , Christine Ren-Fielding 4 , 

Manish Parikh 1 , Steven B. Abramson 1 , Mukundan 

Attur 5 and Jonathan Samuels 1 , 1 NYU Langone Medical 

Center, New York, NY, 2 NYU Langone Medical Center, 

Rheumat, New York, NY, 3 NYU Langone Medical Center, 

Rheumatology, New York, NY, 4 New York University 

School of Medicine, New York, NY, 5 NYU - Hospital for 

Joint Diseases, New York, NY 

5:00 pm 

3055. Ultrasound Features of the First 

Metatarsophalangeal Joint in Gout and 

Asymptomatic Hyperuricaemia: Comparison with 

Normouricaemic Individuals 

Sarah Stewart 1 , Nicola Dalbeth 2 , Alain Vandal 3 , Bruce 

Allen 4 , Rhian Miranda 5 and Keith Rome 6 , 1 Auckland 

University of Technology, Auckland, New Zealand, 

2 

Auckland District Health Board, Auckland, New 

Zealand, 3 Counties Manukau District Health Board, 

Auckland, New Zealand, 4 Horizon Radiology, Auckland, 

New Zealand, 5 Auckland City Hospital Radiology, 

Auckland, New Zealand, 6 AUT University, Auckland, 

New Zealand 

5:15 pm 

3056. Efficacy of a Work Disability Prevention 

Program for People with Rheumatic and 

Musculoskeletal Conditions: A Randomized 

Controlled Trial 

Julie J. Keysor 1 , Michael P. LaValley 2 , Carrie Brown 2 , 

David T. Felson 1 , Rawan AlHeresh 3 , Molly Vaughan 4 , 

Robert A. Yood 5 , John Reed 6 and Saralynn Allaire 7 , 

1 


2 

Boston University School of Public Health, Boston, 

MA, 3 King Faisal Specialist Hospital & Research Center, 

Riyadh, Saudi Arabia, 4 Boston University College 

of Health & Rehabilitation Sciences, Boston, MA, 

5 

Fallon Clinic, Worcester, MA, 6 Reliant Medical Group, 

Worcester, MA, 7 Clinical Epidemiology, BUSM, Boston, 

MA 

5:30 pm 

3057. Objectively Measured Physical Activity and 

Risk of Knee Osteoarthritis: The Osteoarthritis 

Initiative 

Jin Qin 1 , Kamil E. Barbour 1 , Michael C. Nevitt 2 , Charles 

Hemlick 1 , Jennifer M. Hootman 1 , Louise Murphy 1 , 

Jane A. Cauley 3 and Dorothy D. Dunlop 4 , 1 Centers 

for Disease Control and Prevention, Atlanta, GA, 

2 


CA, 3 Univ of Pittsburgh, Pittsburgh, PA, 4 Northwestern 

University Feinberg School of Medicine, Chicago, IL 

5:45 pm 

3058. Varus Thrust and Incident and Progressive 

Knee Osteoarthritis 

Leena Sharma 1 , Alison H. Chang 1 , Charles Eaton 2 , Marc 

Hochberg 3 , Rebecca D. Jackson 4 , C. Kent Kwoh 5 , Michael 

C. Nevitt 6 , Orit Almagor 1 , Kirsten C. Moisio 1 and Joan S. 

Chmiel 1 , 1 Northwestern University, Chicago, IL, 2 Brown 

University, Providence, RI, 3 University of Maryland, 

Baltimore, MD, 4 Ohio State University, Columbus, OH, 

5 

University of Arizona, College of Medicine, Tucson, AZ, 

6 


CA 

INDUSTRY-SUPPORTED SYMPOSIA 

6:30 – 9:30 pm 

These symposia are both CME-accredited and non- 

CME company-directed programs. For CME-accredited 

symposia, the sponsoring organization is responsible 

for planning and providing CME credit. All non-CME 

programsare wholly sponsored and supported by 

commercial entities. Please visit the organization’s 

exhibit booth or the industry-supported symposia booth 

or download the ACR Annual Meeting App for more 

information on each symposium. 


Wednesday 



WEDNESDAY 

NOVEMBER 16 

ACR SESSIONS 

7:30 am – 8:30 am 

143 A 

Emerging Biosimilars in Therapeutic 

Management PM PS E 

Moderator: Gwenesta Melton, MD 

Speaker: Candida Fratazzi, MD 

146 A 

Innovative Research in Inflammatory Arthritis: 

A Rheumatology Research Foundation Special 

Session 

Moderator: Timothy B. Niewold, MD 

7:30 am 

Targeting T Cell Adhesion in Rheumatoid 

Arthritis 

Speaker: Adam Mor, MD, PhD 

7:50 am 

The Role of Non-Classical Monocytes and Resident 

Synovial Macrophages in Rheumatoid Arthritis 

Speaker: Harris R. Perlman, PhD 

8:10 am 

Aberrant Immunoglobulin G (IgG) Glycosylation in 

Juvenile Idiopathic Arthritis 

Speaker: Peter A. Nigrovic, MD 

Hall D 

Rheumatology Roundup: Highlights from the 

2016 Annual Meeting 

Moderator: Richard F. Loeser, MD 

7:30 am 


Annual Meeting 

Speaker: John J. Cush, MD 

8:00 am 


Annual Meeting 


ARHP SESSION 

7:30 am – 8:30 am 

201 

Mental Health in the Transition to Adulthood: 

Patient Stories PM Ed PM Pd PS PrM PS FIT E 

Moderator: Kiana Johnson, PhD, MPH 

7:30 am 

Understanding Patient Perspectives on Mental Health 

During the Transition to Adulthood 

Speaker: Courtney Wells, MPH, MSW, PhD 

8:00 am 

Engaging Meaningfully with Patients about Mental 

Health 

Speaker: David M. Wells, PhD, LP 

ARHP SESSION 

9:00 am – 10:00 am 

204 A 

Update: Sarcopenia in Rheumatic Disease 

Moderator: Michael P. LaValley, PhD 

Speaker: Robert R. McLean, DSc, MPH 

ACR SESSIONS 

9:00 am – 10:30 am 

Ballroom A 

Fibromyalgia 

PM PS E 

Moderators: Lan Chen, MD, PhD; Robert S. Katz, MD 

9:00 am 

Fibromyalgia: Central or Peripheral? Primary and 

Secondary? 

Speaker: Daniel J. Clauw, MD 


165


Wednesday 



10:00 am 

What Are the Options to Treat Fibromyalgia Patients? 

Speaker: Carmen E. Gota, MD 

140 A 

Novel Pathways in Muscle Diseases 

Moderators: Lisa Christopher-Stine, MD, MPH 

9:00 am 

Type I Interferon in Myositis 

Speaker: Steven A. Greenberg, MD 

9:30 am 

Speaker: Novel Autoantibodies in Inflammatory 

Myopathy 

Ingrid E. Lundberg, MD, PhD 

10:00 am 

Myostatin in Muscle Disease and as Therapeutic 

Target 

Speaker: Kathryn Wagner, MD, PhD 

206 

Relevance of the National Institutes of Health 

(NIH) Research Strategic Plan : Roadmap from 

Concept to Successful Grant Application 

Moderator: Alexis Ogdie, MD 

9:00 am 

Introduction: Relevance of the NIH Strategic Plan 

Speaker: Stephen I. Katz, MD, PhD 

9:20 am 

Introduction to Grants: Career Development and 

Project Grants for Young Investigators 

Speaker: Jeffrey A. Sparks, MD, MMSc 

9:35 am 

Round Table Discussions 

Moderator: Gwenesta Melton, MD 

Speakers: Marie Mancini, PhD; Su-Yau Mao; Yan Wang, 

PhD; James P. Witter, MD, PhD; Timothy B. Niewold, MD; 

Michael Siegel, PhD; Amy Hewitt; Joyce Kullman; David 

A. Fox, MD; Tuhina Neogi, MD, PhD, FRCPC; Hermine I. 

Brunner; John Peyman, PhD; David Johnson, PhD, Gayle 

Lester, PhD 


9:00 am – 10:30 am 

146 A 

Genetics, Genomics, and Proteomics II 

Moderators: Amr H. Sawalha, MD; Soumya 

Raychaudhuri, MD, PhD 

9:00 am 

3119. Complete Whole Genome Transcriptome, 

DNA Methylation, and Histone Mark Analysis 

of Rheumatoid Arthritis (RA) Fibroblast-Like 

Synoviocytes (FLS) Reveals a Distinctive Epigenetic 

Landscape and Critical Pathogenic Pathways 

Rizi Ai 1 , Deepa Hammaker 2 , David L. Boyle 3 , Andre 

‎ Wildberg 4 , Keisuke Maeshima 2 , Emmanuele 

Palescandolo 5 , Vinod Krishna 5 , Bryan Linggi 6 , Radu 

Dobrin 5 , John W. Whitaker 7 , Wei Wang 3 and Gary 

Firestein 8 , 1 UC San Diego, La Jolla, CA, 2 UCSD School 

of Medicine, La Jolla, CA, 3 University of California, San 

Diego, La Jolla, CA, 4 UNIVERSITY OF CALIFORNIA SAN 

DIEGO, LA JOLLA, CA, 5 Janssen Pharmaceuticals, Spring 

House, PA, 6 janssen Pharmaceuticals, Spring House, 

PA, 7 Janssen Pharmaceuticals, La Jolla, CA, 8 UCSD, La 

Jolla, CA 

9:15 am 

3120. RA Net: A Systems Biology Approach to 

Identify Genes Regulating Pathogenic Pathways 

in Rheumatoid Arthritis (RA) Fibroblast-Like 

Synoviocytes (FLS) 

Wei Wang 1 , RIchard Ainsworth 2 , Richard Stein 2 , Rizi Ai 2 

and Gary Firestein 3 , 1 University of California, San Diego, 

La Jolla, CA, 2 UC San Diego, La Jolla, CA, 3 UCSD, La Jolla, 

CA 

9:30 am 

3121. Specific Antibody Subphenotypes in 

Rheumatoid Arthritis Are Associated with Unique 

HLA-DRB1 Residues at Position 11 

Chikashi Terao 1 , Boel Brynedal 2 , Zuomei Chen 3 , Xia 

Jiang 3 , Helga Westerlind 3 , Monika Hansson 4 , Linda 

Mathsson-Alm 5 , Per Johan Jakobsson 6 , Karl Skriner 7 , 

Guy Serre 8 , Johan Rönnelid 5 , Leonid Padyukov 6 , Jane 

Worthington 9 , Lars Alfredsson 3 , Lars Klareskog 6 and 

Soumya Raychaudhuri 9 , 1 Brigham and Women’’s 

Hospital, Harvard Medical School, Boston, MA, 


Wednesday 




2 

Section of Epidemiology, Institute of Environmental 

Medicine, Karolinska Institutet, Karolinska, Sweden, 

3 

Section of Epidemiology, Institute of Environmental 

Medicine, Karolinska Institutet, Stockholm, Sweden, 

4 

Rheumatology Unit, Department of Medicine, 

Karolinska Institute, Karolinska University Hospital, 

Stockholm, Sweden, 5 Department of Immunology 

Genetics and Pathology,Uppsala University, Uppsala, 

Sweden, 6 Unit of Rheumatology, Department of 

Medicine, Karolinska Institutet and Karolinska 

University Hospital, Stockholm, Sweden, 7 Humboldt 

University of Berlin, Berlin, Germany, 8 Unité 

Différenciation Épidermique et Autoimmunité 

Rhumatoïde, Unité Mixte de Recherche, INSERM, 

Toulouse, France, 9 Arthritis Research UK Centre for 

Genetics and Genomics, Centre for Musculoskeletal 

Research, Faculty of Biology, Medicine and Health, 

Manchester Academic Health Science Centre, The 

University of Manchester, Manchester, United Kingdom 

9:45 am 

3122. Genome-Wide DNA Methylation Association 

Study of Hand Osteoarthritis 

Michelle S. Yau 1 , Roby Joehanes 1 , Yi-Hsiang Hsu 1 , 

Douglas P. Kiel 2 and David T. Felson 3 , 1 Hebrew 

SeniorLife, Harvard Medical School, Boston, MA, 

2 

Institute for Aging Research, Hebrew Senior Life, 

Harvard Medical School, Boston, MA, USA, Boston, 

MA, 3 University of Manchester, Manchester, United 

Kingdom 

10:00 am 

3123. Rare Mediterranean Fever (MEFV) Gene 

Polymorphisms Are Associated with Ankylosing 

Spondylitis in Turkish and Iranian Population 

Zhixiu Li 1 , Servet Akar 2 , Handan Yarkan 3 , Pinar Cetin 3 , 

Gerçek Can 3 , Gökce Kenar 3 , Omer Nuri Pamuk 4 , Yavuz 

Pehlivan 5 , Katie Cremin 6 , Erika De Guzman 1 , Jessica 

Harris 1 , Ahmad Reza Jamshidi 7 , Mahdi Vojdanian 7 , 

Nooshin Ahmadzadeh 7 , Mahdi Mahmoudi 7 , Matthew A. 

Brown 1 and Nurullah Akkoc 3 , 1 Translational Genomics 

Group, Institute of Health and Biomedical Innovation, 

Queensland University of Technology, Translational 

Research Institute, Brisbane, Australia, Brisbane, 

Australia, 2 Department of Rheumatology, İzmir Katip 

Çelebi University, School of Medicine, İzmir, Turkey, 

İzmir, Turkey, 3 Department of Rheumatology, Dokuz 

Eylul University, Faculty of Medicine, İzmir, Turkey, 

İzmir, Turkey, 4 Department of Rheumatology, Trakya 

University Medical Faculty, Edirne, Turkey, Edirne, 

Turkey, 5 Department of Rheumatology, Uludag 

University Medical Faculty, Bursa, Turkey, Bursa, 

Turkey, 6 The University of Queensland Diamantina 

Institute, Translational Research Institute, Brisbane, 

Australia, Brisbane, Australia, 7 Rheumatology Research 

Center, Tehran University of Medical Sciences, Tehran, 

Iran, Tehran, Iran (Islamic Republic of) 

10:15 am 

3124. Huntingtin Interacting Protein 1 (Hip1) Is a 

New Arthritis Severity Gene 

Teresina Laragione 1 , Percio Gulko 1 and Max Brenner 2 , 

1 

Icahn School of Medicine at Mount Sinai, New 

York, NY, 2 Feinstein Institute for Medical Research, 

Manhasset, NY 

202 B 

Metabolic and Crystal Arthropathies II: Clinical 

Practice 

Moderators: Geraldine M. McCarthy, MD; Nicola 

Dalbeth, MD 

9:00 am 

3125. Secular Trend of Premature Mortality in Gout: 

A Contrast from Rheumatoid Arthritis 

Sharan K. Rai 1 , Leo Lu 2 , Yuqing Zhang 3 and Hyon K. 

Choi 2 , 1 Arthritis Research Canada, Vancouver, BC, 

2 


School, Boston, MA, 3 Boston University School of 

Medicine, Boston, MA 

9:15 am 

3126. Computational Polarizing Microscopy: A 

Novel Method to Detect Birefringent Crystals Using 

Lens-Free on-Chip Microscopy 

Seung Yoon Lee 1 , Yibo Zhang 2 , Daniel E. Furst 1 , Ann 

Rosenthal 3 , Ralph Schumacher 4 , John FitzGerald 1 

and Aydogan Ozcan 2 , 1 University of California Los 


CA, 2 University of California Los Angeles, School of 

Engineering, Los Angeles, CA, 3 Medical College of 

Wisconsin, Milwaukee, WI, 4 University of Pennsylvania, 

Perelman School of Medicine, Philadelphia, PA 


167


Wednesday 



9:30 am 

3127. Ultrasound Evaluation of the Achilles Tendon 

in Tophaceous Gout: A Case-Control Study 

Matthew Carroll 1 , Nicola Dalbeth 2 , Mark Boocock 1 and 

Keith Rome 1 , 1 AUT University, Auckland, New Zealand, 

2 

University of Auckland, Auckland, New Zealand 

9:45 am 

3128. A Longitudinal Dual Energy Computed 

Tomography Study on the Effect of Urate Lowering 

Therapies on the Reduction of Tophus Burden in 

Patients with Chronic Gout 

Hanna Ellmann 1 , Sara Bayat 1 , Isabelle Oliveira 1 , 

Matthias Englbrecht 1 , Elizabeth Araujo 1 , Alexander 

Cavallaro 2 , Silvana Mendonca 3 , Michael Lell 2 , 

Bernhard Manger 1 , Georg Schett 1 and Juergen Rech 1 , 

1 

Friedrich-Alexander-University Erlangen-Nürnberg 

(FAU), Erlangen, Germany, 2 University of Erlangen- 

Nuremberg, Department of Radiology, Erlangen, 

Germany, 3 Americas Medical City, Rio de Janeiro, Brazil 

10:00 am 

3129. The Pharmacokinetics of Oxypurinol in 

Patients Treated with Hemodialysis and Allopurinol 

Matthew Doogue 1 , Dan Wright 2 , Nick Cross 3 , John 

Irvine 3 , Peter T. Chapman 3 , Murray Barclay 1 and Lisa 

K. Stamp 1 , 1 University of Otago, Christchurch, New 

Zealand, 2 University of Otago, Dunedin, New Zealand, 

3 

Christchurch Hospital, Christchurch, New Zealand 

10:15 am 

3130. Development and Pilot Testing of an Online 

Educational Tool for Gout Patients — Mygoutcare® 

Puja Khanna, Aaron Rankin, Veronica Berrocal, Larry An 

and Dinesh Khanna, University of Michigan, Ann Arbor, 

MI 

Salon G 

Osteoarthritis – Clinical Aspect II: Treatment 

and Imaging 

3131. Pregabalin Is More Effective in Treating Hand 

Osteoarthritis Pain Than Duloxetine or Placebo: A 

Double-Blind Randomized Controlled Trial 

Nidhi Sofat 1 , Abiola Harrison 2 , Salma Ayis 3 , Patrick 

Kiely 4 , Thomas Richard Barrick 2 and Franklyn Howe 2 , 

1 

St. George’s, University of London, London, United 

Kingdom, 2 St George’s, University of London, London, 

United Kingdom, 3 Division of Health & Social Care 

Research, Guy’s Campus, King’s College London, 

London, United Kingdom, 4 St Georges Hospital, 

London, Great Britain 

9:15 am 

3132. Protective Effects of Replacing Sedentary 

Time with Light and Moderate to Vigorous Physical 

Activity on Functional Limitation in Knee OA 

Daniel White, University of Delaware, Newark, DE 

9:30 am 

3133. Association Between Quantitatively 

Measured Infrapatellar Fat Pad High Signal 

Intensity Alteration and Knee Structural and 

Symptomatic Abnormalities in Patients with 

Symptomatic Knee Osteoarthritis 

WEIYU HAN, Graeme Jones and Changhai Ding, 

Menzies Institute for Medical Research, University of 

Tasmania, Hobart, Australia 

9:45 am 

3134. Hydroxychloroquine Is Not Effective in 

Reducing Symptoms of Hand Osteoarthritis: 

Results from a Placebo-Controlled Randomised 

Trial 

Sarah R. Kingsbury 1 , Puvan Tharmanathan 2 , Ada 

Keding 2 , Sarah Ronaldson 2 , Andrew Grainger 3 , Richard 

J. Wakefield 3 , Catherine Arundel 2 , Fraser Birrell 4 , 

Michael Doherty 5 , Tonia Vincent 6 , Fiona E Watt 7 , Krysia 

Dziedzic 8 , Terence W. O’Neill 9 , Nigel K Arden 10 , David 

L Scott 11 , John Dickson 12 , Toby Garrood 13 , Michael 

Green 14 , Ajit Menon 15 , Tom Sheeran 16 , David Torgerson 2 

and Philip G. Conaghan 17 , 1 Section of Musculoskeletal 

Disease, Leeds Institute of Molecular Medicine, 

Leeds, United Kingdom, 2 University of York, York, 

United Kingdom, 3 University of Leeds, Leeds, United 

Kingdom, 4 Newcastle University, Newcastle upon 

Tyne, United Kingdom, 5 University of Nottingham, 

Nottingham, Great Britain, 6 University of Oxford, 

London, Great Britain, 7 University of Oxford, Oxford, 

United Kingdom, 8 Keele University, Staffordshire, 

United Kingdom, 9 The University of Manchester, Centre 

for Musculoskeletal Research, Manchester, United 

Kingdom, 10 Oxford NIHR Musculoskeletal Biomedical 

Research Unit, University of Oxford, Oxford, United 

Kingdom, 11 King’s College London, London, United 

Kingdom, 12 South Tees Hospitals NHS Foundation 


Wednesday 




Trust, Middlesbrough, United Kingdom, 13 Guy’s and 

St. Thomas’ NHS Foundation Trust, London, United 

Kingdom, 14 Harrogate and District NHS Foundation 

Trust, Harrogate, United Kingdom, 15 Haywood Hospital, 

Stoke-On-Trent, United Kingdom, 16 Cannock Chase 

Hospital, Cannock, United Kingdom, 17 Leeds Institute of 

Rheumatic and Musculoskeletal Medicine, University of 

Leeds, Leeds, United Kingdom 

10:00 am 

3135. Influence of Baseline Magnetic Resonance 

Imaging Features on Outcomes of Operative and 

Non-Operative Treatment of Meniscal Tear in 

Patients ≥ 45 

Lindsey MacFarlane 1 , Heidi Y. Yang 1 , Jamie E. Collins 1 , 

Ali Guermazi 2 , Morgan Jones 3 , Amelia Winter 1 , Elena 

Losina 1 and Jeffrey N. Katz 1 , 1 Brigham & Women’s 

Hospital, Boston, MA, 2 Boston University School of 

Medicine, Boston, MA, 3 Cleveland Clinic, Cleveland, OH 

10:15 am 

3136. Impact of Novel Smartphone Application 

on Pain and Mobility in Osteoarthritis Patients 

Treated with Hylan G-F 20 

Nebojsa Skrepnik 1 , Andrew Spitzer 2 , Roy Altman 3 , 

John A. Hoekstra 4 , John Stewart 5 and Richard Toselli 6 , 

1 

Tucson Orthopaedic Institute, Tucson, AZ, 2 Cedars- 

Sinai Orthopedic Center, Los Angeles, CA, 3 UCLA 

Medical Center, Los Angeles, CA, 4 National Clinical 

Research–Richmond, Richmond, VA, 5 Sanofi, Laval, QC, 

6 

Sanofi, Cambridge, MA 

Ballroom B 

Quality Measures and Quality of Care II 

Moderator: Eric Newman, MD 

9:00 am 

3137. Assessing System-Level Performance 

Measures for Early Rheumatoid Arthritis in a Large 

Multicenter Cross-Country Prospective 8-Year 

Observational Cohort Study 

Claire E H Barber 1 , Cheryl Barnabe 1 , Glen Hazlewood 1 , 

Orit Schieir 2 , Lyne Nadeau 3 , J Carter Thorne 4 , Vandana 

Ahluwalia 5 , Susan J. Bartlett 6 , Gilles Boire 7 , Boulos 

Haraoui 8 , Carol Hitchon 9 , Edward Keystone 2 , Diane Tin 4 , 

Janet E. Pope 10 , Lisa Denning 11 , Vivian P. Bykerk 12 and 

Canadian early Arthritis Cohort (CATCH) Investigators, 

1 

University of Calgary, Calgary, AB, 2 University of 

Toronto, Toronto, ON, 3 McGill University, Qubec, 

QC, 4 Southlake Regional Health Centre, Newmarket, 

ON, 5 Ontario Rheumatology Association, Brampton, 

ON, 6 Johns Hopkins University School of Medicine, 

Baltimore, MD, 7 CHUS - Sherbrooke University, 

Sherbrooke, QC, 8 Institute de Rheumatologie, 

Montreal, QC, 9 University of Manitoba, Winnipeg, MB, 

10 

University of Western Ontario, St Joseph’s Health 

Care, London, ON, 11 William Osler Health System, 

Brampton, ON, 12 Divison of Rheumatology, Hospital for 

Special Surgery, New York, NY 

9:15 am 

3138. Sustained Improvement in Follow-Up of 

Hypertension in Rheumatology Patients: Results of 

an Intervention Sustainability Assessment 

Edmond Ramly 1 , Daniel Panyard 2 , Diane Lauver 3 , 

Emmanuel Sampene 2 , Zhanhai Li 2 , Heather Johnson 2 , 

Patrick McBride 2 , Kristin Steffen Lewicki 2 and Christie 

M. Bartels 2 , 1 University of Wisconsin-Madison College 

of Engineering, Madison, WI, 2 University of Wisconsin 

School of Medicine and Public Health, Madison, WI, 

3 

University of Wisconsin-Madison School of Nursing, 

Madison, WI 

9:30 am 

3139. Breaking the Cycle: Analyzing Preventable 

Hospital Admissions Due to Gout 

Pieusha Malhotra, Nikky Keer and Robert Yood, 

Department of Medicine, Division of Rheumatic 

Diseases and Musculoskeletal Medicine, Saint Vincent 

Hospital, Worcester, MA 

9:45 am 

3140. Assessment of American College of 

Rheumatology Gout Quality Measures at a 

University Practice Plan 

Soo Choi, John FitzGerald, Robin Clarke and Andrew 

Hackbarth, UCLA, Los Angeles, CA 

10:00 am 

3141. Development of a Glucocorticoid Toxicity 

Index Using Multi-Criteria Decision Analysis 

Eli Miloslavsky 1 , Raymond P. Naden 2 , Johannes WJ 

Bijlsma 3 , Paul Brogan 4 , Sherwood Brown 5 , Paul 

Brunetta 6 , Frank Buttgereit 7 , Hyon K. Choi 1 , Jean- 

Francois Dicaire 8 , Jeffrey Gelfand 9 , Liam Heaney 10 , 

Liz Lightstone 11 , Leo Lu 1 , Dedee Murrell 12 , Michelle 


169


Wednesday 



Petri 13 , James T. Rosenbaum 14 , Kenneth Saag 15 , 

Murray Urowitz 16 , Kevin L Winthrop 17 and John H. 

Stone 18 , 1 Massachusetts General Hospital, Harvard 

Medical School, Boston, MA, 2 New Zealand Ministry 

of Health, Auckland, New Zealand, 3 ARC, Amsterdam, 

Netherlands, 4 UCL Institute of Child Health and 

Great Ormond Street Hospital NHS Foundation 

Trust, London, United Kingdom, 5 UT Southwestern 

Medical Center, Dallas, TX, 6 Genentech, Inc., South San 

Francisco, CA, 7 Charité - University Medicine Berlin, 

Berlin, Germany, 8 Pinnacle Inc., Quebec, QC, 9 University 

of California San Francisco, San Francisco, CA, 

10 

Queen’s University Belfast, Belfast, Ireland, 11 Imperial 

College London, London, England, 12 University of 

New South Wales, Sydney, Australia, 13 Johns Hopkins 

University School of Medicine, Baltimore, MD, 14 Oregon 

Health & Science University, Portland, OR, 15 University 

of Alabama Birmingham School of Medicine, 

Birmingham, AL, 16 Toronto Western Hospital and 

University of Toronto, Toronto, ON, 17 Oregon Health 

and Sciences University, Portland, OR, 18 Massachusetts 

General Hospital Rheumatology Unit, Harvard Medical 


10:15 am 

3142. Improving Counseling, Documentation, and 

Adherence to Highly Effective Birth Control in 

Women on Teratogenic Medications at a Rural 

Medical Center: A Quality Improvement Initiative 

Sonal Bhalla, John Mecchella and Alicia Zbehlik, 

Dartmouth-Hitchcock Medical Center, Lebanon, NH 

147 A 

Rheumatoid Arthritis – Animal Models II 

Moderators: Harris Perlman; Chris Buckley, Prof 

9:00 am 

3143. The Caspase 8/RIPK3 Signaling Axis in 

Dendritic Cells Controls Joint Homeostasis Under 

Steady-State and Arthritic Conditions 

Salina Dominguez, Harris R. Perlman and Carla Cuda, 

Northwestern University, Chicago, IL 

9:15 am 

3144. Role of the Gut Microbiome in Modulating 

Arthritis Progression in Mice 

Xiao fei Liu, Qing hua Zou, Bing Zhong and Yong fei 

Fang, Southwest Hospital, Third Military Medical 

University, chongqing, China 

9:30 am 

3146. Selective Deletion of a Pathogenic 

Subset Synovial Fibroblasts Attenuates Synovial 

Inflammation 

Adam Paul Croft, Joana Campos, Andrew Filer, 

Francesca Barone and Chris Buckley, University of 

Birmingham, Birmingham, United Kingdom 

9:45 am 

3147. Remote Inflammation Triggers Autoimmune 

Arthritis through Th17 Distribution 

Nina Chevalier 1 , Jian Tan 2 , Linda Mason 2 , Remy 

Robert 2 , Craig McKenzie 2 , Seth Masters 3 and Charles 

Mackay 2 , 1 University Freiburg Medical Center, Freiburg, 

Germany, 2 Monash University, Melbourne, Australia, 

3 

WEHI, Melbourne, Australia 

10:00 am 

3148. Peptidylarginine Deiminase 2 Is Required for 

Tumor Necrosis Factor Alpha Induced Citrullination 

and Arthritis, but Not Neutrophil Extracellular Trap 

Formation 

Mandar Bawadekar 1 , Daeun Shim 1 , Ryan Rebernick 1 , 

Chloe Peyton 1 , Chad J. Johnson 1 , Thomas F. Warner 1 , 

Dres Damgaard 2 , Claus Henrik Nielsen 3 , Anthony P. 

Nicholas 4 , Ger JM Pruijn 5 , Jeniel E. Nett 1 and Miriam A. 

Shelef 6 , 1 University of Wisconsin-Madison, Madison, 

WI, 2 Institute for Inflammation Research, Center for 

Rheumatology and Spine Diseases, Copenhagen 

University Hospital, Rigshospitalet, Copenhagen, 

Denmark, 3 Danish Rheumatologic Biobank and 

DANBIO registry, Rigshospitalet, Glostrup, Gentofte 

and Herlev University Hospital, Copenhagen, Denmark, 

4 

University of Alabama at Birmingham and Birmingham 

VA Medical Center, Birmingham, AL, 5 Institute for 

Molecules and Materials and Radboud Institute for 

Molecular Life Sciences, Radboud University, Nijmegen, 

Netherlands, 6 William S. Middleton Memorial Veterans 

Hospital, Madison, WI 

Hall E 

Rheumatoid Arthritis – Clinical Aspects VI: 

Management of Early Rheumatoid Arthritis 

Moderators: Grant W. Cannon, MD; Bindee Kuriya 

9:00 am 

3149. “Early Use of Subcutaneous MTX 

Monotherapy vs. MTX Oral or Combination Therapy 


Wednesday 




Significantly Delays Time to Initiating Biologics in 

Early RA 

Stephanie Gottheil 1 , J Carter Thorne 2 , Orit Schieir 3 , 

Gilles Boire 4 , Boulos Haraoui 5 , Carol Hitchon 6 , Diane 

Tin 2 , Cheryl Barnabe 7 , Glen Hazlewood 7 , Edward 

Keystone 8 , Vivian P. Bykerk 9 , Janet E. Pope 10 , Susan 

J. Bartlett 11 and Canadian Early Arthritis Cohort, 

1 

University of Western Ontario, LONDON, ON, 

2 

Southlake Regional Health Centre, Newmarket, 

ON, 3 McGill University, Montreal, ON, 4 CHUS - 

Sherbrooke University, Sherbrooke, QC, 5 Institute de 

Rheumatologie, Montreal, QC, 6 University of Manitoba, 

Winnipeg, MB, 7 University of Calgary, Calgary, AB, 

8 

University of Toronto, Toronto, ON, 9 Divison of 

Rheumatology, Hospital for Special Surgery, New York, 

NY, 10 University of Western Ontario, St Joseph’s Health 

Care, London, ON, 11 McGill University, Montreal, QC 

9:15 am 

3150. The Initial Dose of Methotrexate per Weight 

Is Determinant of Disease Activity and Early DAS28 

Remission in DMARD-Naive Early Rheumatoid 

Arthritis Patients Receiving Usual Care 

Tuomas Rannio 1 , Juha Asikainen 2 , Pekka Hannonen 2 , 

Timo Yli-Kerttula 3 , Päivi Ekman 3 , Laura Kuusalo 4 , Laura 

Pirilä 5 , Markku Mali 4 , Marja Puurtinen-Vilkki 4 , Satu 

Kortelainen 4 , Johanna Paltta 5 , Kirsi Taimen 4 , Markku J. 

Kauppi 6 , Kari Laiho 6 , Satu Nyrhinen 6 , Heidi Mäkinen 7 , 

Pia Isomäki 7 , Terhi Uotila 7 , Kalle Aaltonen 8 , Hannu 

Kautiainen 9 and Tuulikki Sokka-Isler 1 , 1 Jyvaskyla Central 

Hospital, Jyvaskyla, Finland, 2 Jyvaskyla Central Hospital, 

Jyväskylä, Finland, 3 Satakunta Central Hospital, Rauma, 

Finland, 4 Turku University Central Hospital, Turku, 

Finland, 5 Turku University Hospital, Turku, Finland, 

6 

Päijät-Häme Central Hospital, Lahti, Finland, 7 Tampere 

University Hospital, Tampere, Finland, 8 Helsinki 

University, Helsinki, Finland, 9 Unit of Primary Health 

Care, University of Helsinki and Helsinki University 

Hospital, Helsinki, Finland 

9:30 am 

3151. The Diagnostic and Predictive Value of Anti- 

Acetylated Peptide Antibodies in RA Patients 

Starting Methotrexate Treatment 

Paul Studenic 1 , Stephan Blüml 2 , Holger Bang 3 , Manuel 

Unger 1 , Karim Raza 4 , Daniel Aletaha 5 , Josef S. Smolen 6 

and Günter Steiner 1 , 1 Medical University Vienna, 

Vienna, Austria, 2 Medical University of Vienna, Vienna, 

Austria, 3 Orgentec Diagnostika GmbH, Mainz, Germany, 

4 

University of Birmingham, Rheumatology Research 

Group, Institute of Inflammation and Ageing, United 

Kingdom, Birmingham, United Kingdom, 5 Division of 

Rheumatology, Medical University of Vienna, Vienna, 

Austria, 6 Hietzing Hospital, Vienna, Austria 

9:45 am 

3152. Rheumatoid Arthritis (RA): Premature Use of 

Biologics Accelerating in United States (US) 

James R. O’Dell 1 , Stanley B. Cohen 2 , J Carter Thorne 3 

and Ted R Mikuls 1 , 1 University of Nebraska Medical 

Center, Omaha, NE, 2 Metroplex Clinical Research 

Center, Dallas, TX, 3 Southlake Regional Health Centre, 

Newmarket, ON 

10:00 am 

3153. Automated Cell Phone Monitoring of Disease 

Activity and Medication Adherence in Early 


Laura Kuusalo 1 , Hannu Kautiainen 2 , Tuulikki Sokka- 

Isler 3 , Toini Uutela 4 , Laura Pirilä 5 , Timo Yli-Kerttula 6 , 

Markku J Kauppi 7 , Tuomas Rannio 8 , Kirsi Paalanen 3 , 

Arto Kokko 8 , Juha Asikainen 8 , Jelena Borodina 3 , 

Johanna Paltta 5 , Kari Laiho 9 , Andrus Mullanmaa 10 , Kari 

Puolakka 10 and SandRA Study Group, 1 University of 

Turku, Turku, Finland, 2 Unit of Primary Health Care, 

University of Helsinki and Helsinki University Hospital, 

Helsinki, Finland, 3 Jyvaskyla Central Hospital, Jyvaskyla, 

Finland, 4 Lapland Central Hospital, Rovaniemi, Finland, 

5 

Turku University Hospital, Turku, Finland, 6 Satakunta 

Central Hospital, Rauma, Finland, 7 School of Medicine, 

University of Tampere, Tampere, Finland, 8 Jyvaskyla 

Central Hospital, Jyväskylä, Finland, 9 Päijät-Häme 

Central Hospital, Lahti, Finland, 10 South Karelia Central 

Hospital, Lappeenranta, Finland 

10:15 am 

3154. Assessing Bone Erosions in the 

Metatarsophalangeal Joints of Patients with Early 

Rheumatoid Arthritis: A Comparison Between MRI 

and Ultrasound 

Karen A. Beattie 1 , Sydney Scheffler 1 , George Ioannidis 2 , 

Edward Schreyer 3 , Saara Totterman 4 and Maggie 

Larche 1 , 1 McMaster University, Hamilton, ON, 2 St 

Joseph’s Healthcare Hamilton, Hamilton, ON, 3 QMetrics 

Technologies, Rochester, NY, 4 VirtualScopics Inc., 

Rochester, NY 


171


Wednesday 



Salon B 


– Clinical Aspects and Treatment V: Imaging of 


Moderators: Michael Weisman, MD; Xenofon 

Baraliakos, MD, PhD 

9:00 am 

3155. Zygapophyseal Joint Fusion in Ankylosing 

Spondylitis Assessed Using Computed Tomography: 

Associations with Syndesmophytes and Spinal 

Motion 

Sovira Tan 1 , Jianhua Yao 2 , Lawrence Yao 3 , John Flynn 4 

and Michael Ward 1 , 1 NIAMS/NIH, Bethesda, MD, 2 NIH 

Clinical Center, Bethesda, MD, 3 NIH, Bethesda, MD, 

4 

Johns Hopkins University, Baltimore, MD 

9:15 am 

3156. Adding MRI of the Spine to the ASAS 

Classification Criteria for Axial Spondyloarthritis, 

Redundant or Beneficial? Results from the 

Spondyloarthritis Caught Early (SPACE)-Cohort 

Zineb Ez-Zaitouni 1 , Pauline Bakker 1 , Miranda van 

Lunteren 1 , Rosaline van den Berg 2 , M. Reijnierse 1 , 

Karen M Fagerli 3 , Roberta Ramonda 4 , Robert Landewé 5 , 

Lennart T.H. Jacobsson 6 , Floris van Gaalen 1 and Désirée 

van der Heijde 1 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Department of Rheumatology, 


3 

Diakonhjemmet Hospital, Oslo, Norway, 4 University 

of Padova, Padova, Italy, 5 Amsterdam Rheumatology 

Center, Amsterdam, Netherlands, 6 Sahlgrenska 

Academy at Gothenburg University, Gothenburg, 

Sweden 

9:30 am 

3157. The Association Between Sonographic 

Enthesitis and Radiographic Damage in Psoriatic 

Arthritis 

Ari Polachek 1 , Dafna D Gladman 1 , Richard J. Cook 2 , 

Vinod Chandran 3 and Lihi Eder 4 , 1 University of Toronto, 

Toronto Western Hospital, Toronto, ON, 2 University 

of Waterloo, Waterloo, ON, 3 University of Toronto, 

Toronto, ON, 4 University of Toronto, Women’s College 

Hospital, Toronto, ON 

9:45 am 

3158. What Predicts Absence of Spinal Damage in 

Patients with Spondyloarthritis after Prolonged 

Follow up? 

Walter Maksymowych 1 , Stephanie Wichuk 1 , Praveena 

Chiowchanwisawakit 2 , Robert G Lambert 1 and Susanne 

J Pedersen 3 , 1 University of Alberta, Edmonton, AB, 

2 

Mahidol University, Bangkok, Thailand, 3 Copenhagen 

University Hospitals, Copenhagen, Denmark 

10:00 am 

3159. Validation of MRI Structural Lesions Using 

Computed Tomography in Patients with Axial 


Robert G. Lambert 1 , Damien Loeuille 2 , Marie Raynal 3 , 

Jean Melchior 2 , Maria Antonietta D’Agostino 4 , Joel 

Paschke 5 and Walter Maksymowych 1 , 1 University 

of Alberta, Edmonton, AB, 2 CHRU Vandoeuvre les 

Nancy, Nancy, France, 3 CHRU Nancy, Nancy, France, 

4 

Versailles-Saint Quentin en Yvelines University, 

Boulogne-Billancourt, France, 5 CaRE Arthritis, 

Edmonton, AB 

10:15 am 

3160. Scoring Syndesmophytes on CT Spine 

Images of Patients with Radiographic Axial 

Spondyloarthritis from the Sensitive Imaging of 

Axial Spondyloarthritis (SIAS) Cohort 

F. de Bruin 1 , R van den Berg 1 , Xenofon Baraliakos 2 , 

Monique Reijnierse 3 and Désirée van der Heijde 1 , 

1 


2 

Rheumazentrum Ruhrgebiet Herne, Ruhr-University 

Bochum, Herne, Germany, 3 Department of Radiology, 

Leiden University Medical Center, Leiden, Netherlands 

145 A 

Spondylarthropathies and Psoriatic Arthritis – 

Pathogenesis, Etiology II 

Moderator: Robert Winchester, MD 

9:00 am 

3161. The Association Between HLA Genetic 

Susceptibility Markers and Sonographic Enthesitis 

in Psoriatic Arthritis 

Ari Polachek 1 , Richard J. Cook 2 , Vinod Chandran 1 , 

Fatima Abji 1 , Dafna D Gladman 1 and Lihi Eder 3 , 

1 

University of Toronto, Toronto Western Hospital, 

Toronto, ON, 2 University of Waterloo, Waterloo, ON, 

3 

University of Toronto, Women’s College Hospital, 

Toronto, ON 


Wednesday 




9:15 am 

3162. Symmetric and Asymmetric Sacroiliitis Are 

Associated with Different Major Histocompatibility 

Class I Alleles in Psoriatic Arthritis 

Jon T. Giles 1 , Muhammad Haroon 2 , Deepak R. 

Jadon 3 , Raj Sengupta 4 , Alison L Nightingale 5 , Eleanor 

Korendowych 3 , Jing Bi 1 , Neil J. McHugh 3 , Oliver 

FitzGerald 6 and Robert Winchester 1 , 1 Columbia 

University, College of Physicians & Surgeons, New York, 

NY, 2 Kerry General Hospital, Co Kerry, Ireland, 3 Royal 

National Hospital for Rheumatic Diseases, Bath, United 

Kingdom, 4 Royal National Hospital for Rheumatic 

Diseases,, Bath, United Kingdom, 5 University of 

Bath, Bath, United Kingdom, 6 St. Vincent’s University 

Hospital, Department of Rheumatology, Dublin, Ireland 

9:30 am 

3163. SEC16A and Intracellular Trafficking 

Abnormalities in Axial Spondyloarthritis 

Fanxing Zeng 1 , Zhenbo Zhang 1 , Vidya Ranganathan 2 , 

Darren Orielly 3 , Proton Rahman 4 and Nigil Haroon 5 , 

1 

Krembil research institute, Toronto, ON, 2 University 

Health Network, Toronto, ON, 3 Faculty of Medicine, 

Memorial University of Newfoundland, St. John’s, 

NF, 4 St Claires Mercy Hospital, St Johns, NF, 5 Toronto 

Western Hospital, University of Toronto, Spondylitis 

Clinic, Toronto, ON 

9:45 am 

3164. Spondyloarthritis Pathogenesis Involves 

Interplay Between Gut Microbiota and Genetic 

Background 

Tejpal Gill 1 , Mark Asquith 2 , Stephen Brooks 3 , James 

T. Rosenbaum 2 and Robert A. Colbert 4 , 1 National 

Institutes of Health, Bethesda, MD, 2 Oregon Health 

& Science University, Portland, OR, 3 NIAMS/NIH, 



of Health, Bethesda, MD 

10:00 am 

3165. HLA-B27 Expression Is Accompanied by a 

Profoundly Altered IgA Response to the Intestinal 

Microbiota and Microbial Translocation to the Joint 

Mark Asquith, Sean Davin, Patrick Stauffer, Claire 

Mitchell and James T. Rosenbaum, Oregon Health & 

Science University, Portland, OR 

10:15 am 

3166. HLA-B27 and Ankylosing Spondylitis Have 

Shared Effects on the Gut Microbiome 

Mary-Ellen Costello 1 , Mark Asquith 2 , Kim-Anh Lê 

Cao 3 , Tammy Martin 4 , Sarah Diamond 2 , Michelle 

Beaumont 5 , Timothy D. Spector 5 , James T. Rosenbaum 2 

and Matthew A. Brown 1 , 1 Translational Genomics 

Group, Institute of Health and Biomedical Innovation, 

Queensland University of Technology, Brisbane, 

Australia, 2 Oregon Health & Science University, 

Portland, OR, 3 The University of Queensland 

Diamantina Institute, Brisbane, Australia, 4 Oregon 

Health & Science Univ, Portland, OR, 5 Dept of Twin 

Research and Genetic Epidemiology, King’s College 


Hall D 


Aspects and Treatment V: Damage and 

Morbidity 

Moderators: Eliza Chakravarty, MD, MS; Diane L. 

Kamen, MD, MSCR 

9:00 am 

3167. Total and Glucocorticoid-Related Damage 

Accrual in the Systemic Lupus International 

Collaborating Clinics Inception Cohort 

Jayne Little 1 , Mark Lunt 2 , Benjamin Parker 1 , Ian 

N. Bruce 2 and The Systemic Lupus International 

Collaborating Clinics (SLICC) Group, 1 NIHR Manchester 

Musculoskeletal Biomedical Research Unit, Central 

Manchester University Hospitals NHS Foundation 

Trust, Manchester, United Kingdom, 2 Arthritis Research 

UK Epidemiology Unit, The University of Manchester, 

Manchester Academic Health Sciences Centre, 

Manchester, United Kingdom 

9:15 am 

3168. Economic Evaluation of Damage Accrual in an 

International SLE Inception Cohort 

Megan Barber 1 , Ian N. Bruce 2 , Murray Urowitz 3 , John 

G. Hanly 4 , Li Su 4 , Juanita Romero-Diaz 5 , Caroline 

Gordon 6 , Sang-Cheol Bae 7 , Sasha Bernatsky 8 , Daniel J 

Wallace 9 , Joan T. Merrill 10 , David A. Isenberg 11 , Anisur 

Rahman 12 , Ellen M. Ginzler 13 , Michelle Petri 14 , Mary 

Anne Dooley 15 , Paul R. Fortin 16 , Dafna D. Gladman 17 , 

Jorge Sanchez-Guerrero 18 , Kristján Steinsson 19 , 


173


Wednesday 



Rosalind Ramsey-Goldman 20 , M Khamashta 21 , Cynthia 

Aranow 22 , Graciela S. Alarcon 23 , Barri J. Fessler 24 , Susan 

Manzi 25 , Ola Nived 26 , Andreas Jönsen 27 , Asad Zoma 28 , 

Ronald F. van Vollenhoven 29 , Manuel Ramos-Casals 30 , 

Guillermo Ruiz-Irastorza 31 , S. Sam Lim 32 , Kenneth C. 

Kalunian 33 , Murat Inanc 34 , Diane L. Kamen 35 , Christine 

A. Peschken 36 , Søren Jacobsen 37 , Anca Askanase 38 , Jill P. 

Buyon 39 , Chris Theriault 40 , Vernon Farewell 4 and Ann E. 

Clarke 41 , 1 University of Calgary, Caglary, AB, 2 Arthritis 

Research UK Epidemiology Unit, The University of 

Manchester, Manchester Academic Health Sciences 

Centre, Manchester, United Kingdom, 3 Toronto 

Western Hospital and University of Toronto, Toronto, 

ON, 4 Division of Rheumatology, Capital Health and 

Dalhousie University, Halifax, NS, 5 Instituto Nacional 

de Ciencias Médicas y Nutrición Salvador Zubirán, 

Mexico city, Mexico, 6 NIHR/Wellcome Trust Clinical 

Research Facility, University Hospitals Birmingham 

NHS Foundation Trust, Birmingham, United Kingdom, 

7 

Hanyang University Hospital for Rheumatic 

Diseases, Seoul, Korea, Republic of, 8 McGill University 

Health Centre, Montreal, QC, 9 Cedars-Sinai Medical 

Center, West Hollywood, CA, 10 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 11 Centre 

for Rheumatology, Division of Medicine, University 

College London, London, United Kingdom, 12 Centre 

for Rheumatology Research, UCL Division of Medicine, 

London, United Kingdom, 13 SUNY Downstate Medical 

Center, Brooklyn, NY, 14 Johns Hopkins University 

School of Medicine, Baltimore, MD, 15 Chapel Hill 

Doctors, Chapel Hill, NC, 16 University of Laval, Quebec, 

QC, 17 Centre for Prognosis Studies in the Rheumatic 

Diseases, Toronto Western Hospital and University 

of Toronto, Toronto, ON, 18 Toronto Western Hospital, 

Toronto, ON, 19 Univ. Hospital, Reykjavik, Iceland, 

20 

Northwestern University, Chicago, IL, 21 Lupus 

Research Unit, The Rayne Institute, King’s College 

London School of Medicine, St Thomas’ Hospital, 

London, United Kingdom, 22 Hofstra Northwell School 

of Medicine, Hempstead, NY, 23 University of Alabama 

at Birmingham, Birmingham, AL, 24 Department of 

Medicine, University of Alabama at Birmingham, 

Birmingham, AL, 25 West Penn Allegheny Health 

System, Pittsburgh, PA, 26 University Hospital, Lund, 

Sweden, 27 Lund University, Department of Clinical 

Sciences, Rheumatology, Lund, Sweden, 28 Hairmyres 

Hospital, East Kilbride, Great Britain, 29 Amsterdam 

174 For the most up-to-date meeting content, download the 2016 ACR/ARHP Annual Meeting App from the App Store or Google Play. 

Rheumatology and Immunology Center (ARC), 

Amsterdam, Netherlands, 30 Sjögren Syndrome 

Research Group (AGAUR), Laboratory of Autoimmune 

Diseases Josep Font, Institut d’Investigacions 

Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 

Spain, 31 Hospital de Cruces, Bizkaia, Spain, 32 Emory 

University School of Medicine, Atlanta, GA, 33 UCSD 

School of Medicine Center for Innovative Therapy, 

La Jolla, CA, 34 Istanbul University, Istanbul Faculty of 

Medicine, Istanbul, Turkey, 35 Medical University of 

South Carolina, Charleston, SC, 36 Univ of Manitoba, 

Winnipeg, MB, 37 Rigshospitalet, Copenhagen University 

Hospital, Copenhagen, Denmark, 38 Columbia University 

Medical Center, New York, NY, 39 New York University 

School of Medicine, New York, NY, 40 Queen Elizabeth 

II Health Sciences Centre and Dalhousie University, 

Halifax, NS, 41 University of Calgary, Calgary, AB 

9:30 am 

3169. Mortality Trends in Systemic Lupus 

Erythematosus: A General Population-Based Cohort 

Study 

April Jorge 1 , Na Lu 1 , Sharan K. Rai 2 and Hyon Choi 1 , 

1 


School, Boston, MA, 2 Arthritis Research Canada, 

Vancouver, BC 

9:45 am 

3170. Association Between Insulin Resistance, 

Subclinical Artheriosclerosis and Activity/Damage 

Status in Systemic Lupus Erythematosus Patients 

Hiurma Sanchez-Perez 1 , Beatriz Tejera 2 and Ivan 

Ferraz-Amaro 3 , 1 Rheumatology Division, Hospital 

Universitario de Canarias, La Laguna, Spain, 

2 

Rheumatology Division, Hospital Universitario de 

Canarias, Santa Cruz de Tenerife, Spain, 3 Rheumatology 

Division, Hospital Universitario de Canarias, Tenerife, 

Spain 

10:00 am 

3171. The Impact of Statin Use on Mortality in 

Systemic Autoimmune Rheumatic Diseases 

April Jorge, Na Lu and Hyon K. Choi, Massachusetts 

General Hospital, Harvard Medical School, Boston, MA

Wednesday 




10:15 am 

3172. Temporal Trends in SLE Mortality According 

to Sex, Race, Ethnicity, and Geographic Region in 

the United States over the Past Five Decades 

Eric Yen 1 , Magda Shaheen 2 , Jennifer MP Woo 1 , Neil 

Mercer 1 , Lewei Duan 1 , Ning Li 1 , Arun Karlamangla 1 , 

Deborah K. McCurdy 1 and Ram R. Singh 1 , 1 UCLA, Los 

Angeles, CA, 2 Charles R. Drew University of Medicine 

and Science, Los Angeles, CO 

151 A 


Raynaud’s – Pathogenesis, Animal Models, and 

Genetics II 

Moderators: Jessica K. Gordon, MD; Robert Lafyatis, 

MD 

9:00 am 

3173. Pan-PPAR Agonist IVA337 Is Effective in the 

Prevention of Experimental Lung Fibrosis and 

Related Pulmonary Hypertension 

Jerome Avouac 1 , Irena Konstantinova 2 , Christophe 

Guignabert 3 , Sonia Pezet 4 , Anne Cauvet 1 , Jeremy 

Sadoine 5 , Thomas Guilbert 4 , Jean-Michel Luccarini 6 , 

Jean-Louis Junien 6 , Pierre Broqua 6 and Yannick 

Allanore 7 , 1 Paris Descartes University, Cochin Hospital, 

Paris, France, 2 Inventiva, Daix, France, 3 Inserm UMR_S 

999, Hôpital Marie Lannelongue, Le Plessis Robinson, 

France, 4 INSERM U1016, Paris, France, 5 Equipe d’Accueil 

(EA) 2496 Pathologie, Imagerie et Biothérapies 

Orofaciales, Faculty of Odontology, Paris Descartes 

University, Montrouge, France, 6 Inventiva, DAIX, France, 

7 

Paris Descartes University, Paris, France 

9:15 am 

3174. Apremilast Attenuates the Fibrogenic 

Phenotype of Dermal Fibroblasts from Patients 

with Systemic Sclerosis, Contributing to the 

Prevention of the Progression of Experimental 

Dermal Fibrosis 

Tomoaki Higuchi 1 , Yasushi Kawaguchi 1 , Kae Takagi 2 , 

Akiko Tochimoto 1 , Yuki Ichimura 1 , Yasuhiro Katsumata 1 , 

Hisae Ichida 1 , Hidenaga Kawasumi 1 , Hirokazu Nishina 1 , 

Mari Tochihara 1 , Akira Nishino 1 , Shinya Hirahara 1 , Rina 

Moriyama 1 and Hisashi Yamanaka 1 , 1 Tokyo Women’s 

Medical University, Tokyo, Japan, 2 Tokyo Women’s 

Medical University medical Center East, Tokyo, Japan 

9:30 am 

3175. Longitudinal Analysis of MMF Clinical, 

Molecular, and Immunohistochemistry (IHC) 

Responses Shows SSc Patients Lose Their 

Inflammatory Signature and Rebound upon 

Treatment Cessation 

Diana Toledo 1 , Monique Hinchcliff 2 , Jaclyn Taroni 1 , 

Tammara A. Wood 1 , Jennifer Franks 1 , Sanjiv Shah 3 , Rishi 

Agrawal 3 , Lauren Beussink-Nelson 3 , Mary A. Carns 3 , 

Sofia Podlusky 3 , Patricia Pioli 1 and Michael Whitfield 1 , 

1 

Geisel School of Medicine at Dartmouth, Hanover, NH, 

2 

Northwestern University, Feinberg School of Medicine 

Scleroderma Program, Chicago, IL, 3 Northwestern 

University, Chicago, IL 

9:45 am 

3176. Meta-Analysis of SSc Clinical Trials with 

Molecular Gene Expression Data Suggests Potential 

Combination Therapies 

Jaclyn N. Taroni, Viktor Martyanov and Michael L. 

Whitfield, Geisel School of Medicine at Dartmouth, 

Hanover, NH 

10:00 am 

3177. Targeted Nuclear Imaging for the Early 

Detection of Lung Involvement in Systemic 

Sclerosis 

Janine Schniering 1 , Stephanie Haller 2 , Zhongning 

Guo 1 , Martina Benesova 3 , Carol A. Feghali-Bostwick 4 , 

Roger Schibli 3 , Oliver Distler 5 , Cristina Müller 3 

and Britta Maurer 5 , 1 University Hospital Zurich, 

Schlieren, Switzerland, 2 Paul Scherrer Institute, 

Villigen PSI, Switzerland, 3 Swiss Federal Institute of 

Technology, Zurich, Switzerland, 4 Medical University 

of South Carolina, Charleston, SC, 5 Department of 

Rheumatology, University Hospital Zurich, Zurich, 

Switzerland 

10:15 am 

3178. Heart Dysfunction in Systemic Sclerosis: 

Involvement of a Novel Fibrogenic Stromal Cell 

Subset 

Mara Stellato 1 , Michal Rudnik 1 , Florian Renoux 2 , Elena 

Pachera 1 , Karl Sotlar 3 , Karin Klingel 4 , Joerg C. Henes 4 , 

Przemyslaw Blyszczuk 5 , Oliver Distler 6 and Gabriela 

Kania 1 , 1 University Hospital Zurich, Zurich, Switzerland, 

2 

University Hospital Zurich, Schlieren, Switzerland, 

3 

Ludwig Maximilians University, Munich, Germany, 


175


Wednesday 



4 

University Hospital Tuebingen, Tuebingen, Germany, 

5 

University of Zurich, 8952 Schlieren, Switzerland, 

6 

Department of Rheumatology, University Hospital 

Zurich, Zurich, Switzerland 

Ballroom C 

Vasculitis IV: Diagnosis and Assessment 

of Disease Activity 

Moderators: Peter C. Grayson, MD; Rebecca L. Manno, 

MD, MHS 

9:00 am 

3179. Scale Structure and Measurement 

Properties of a Disease Specific Patient-Reported 

Outcome for Anti-Neutrophil Cytoplasmic 

Antibody-Associated Vasculitis 

Joanna C. Robson 1 , Jill Dawson 2 , Judy A. Shea 3 , Helen 

Doll 4 , Susan Ashdown 5 , Renee Borchin 6 , Ebony 

Easley 7 , John T. Farrar 3 , Don Gebhart 8 , Katherine 

Kellom 9 , Georgia Lanier 10 , Raashid Luqmani 11 , Carol A 

McAlear 3 , John Mills 12 , Nataliya Milman 13 , Jacqueline 

Peck 5 , Gunnar Tomasson 14 , Peter F. Cronholm 7 and 

Peter A. Merkel 3 , 1 University of Bristol, Bristol, United 

Kingdom, 2 University of Oxford, Oxford, United 

Kingdom, 3 University of Pennsylvania, Philadelphia, PA, 

4 

University of East Anglia, Norwich, United Kingdom, 

5 

Oxford, Oxford, United Kingdom, 6 University of South 

Florida, Tampa, FL, 7 The University of Pennsylvania, 

Philadelphia, PA, 8 Columbus, Columbus, OH, 9 Children’s 

Hospital of Philadelphia, Philadelphia, United Kingdom, 

10 

NONE, Framingham, MA, 11 Nuffield Department of 

Orthopaedics Rheumatology and Musculoskeletal 

Sciences, Botnar Research Centre, University of Oxford, 

Oxford, United Kingdom, 12 Vasculitis UK, Sheffield, 

United Kingdom, 13 Ottawa Hospital Research Institute, 

Ottawa, ON, 14 University of Iceland, Reykjavik, IS 

9:15 am 

3180. Utility of Measurements of Urinary Soluble 

CD163 & MCP-1 in the Identification of Subtle Renal 

Flares in ANCA-Associated Vasculitis 

Sarah M Moran 1 , Michelle Ryan 1 , Paul A. Monach 2 , 

David Cuthbertson 3 , Simon Carette 4 , Jean Dunne 5 , 

Gary S. Hoffman 6 , Nader A. Khalidi 7 , Curry L. Koening 8 , 

Carol A. Langford 6 , Carol A. McAlear 9 , Larry W. 

Moreland 10 , Christian Pagnoux 4 , Philip Seo 11 , Ulrich 

Specks 12 , Antoine G. Sreih 13 , Steven R. Ytterberg 12 , 

Lina Zgaga 14 , Peter A. Merkel 9 , Mark A. Little 14 and the 

Vasculitis Clinical Research Consortium, 1 Trinity Health 

Kidney Centre, Dublin, Ireland, 2 Boston University 

School of Medicine, Boston, MA, 3 University of South 

Florida, Tampa, FL, 4 Mount Sinai Hospital, University 

of Toronto, Toronto, ON, 5 St James’s Hospital, Dublin, 

Ireland, 6 Cleveland Clinic, Cleveland, OH, 7 McMaster 

University, St Joseph’s Healthcare Hamilton, Hamilton, 

ON, 8 University of Utah, Salt Lake City, UT, 9 University 

of Pennsylvania, Philadelphia, PA, 10 University of 

Pittsburgh, Pittsburgh, PA, 11 Johns Hopkins University, 

Baltimore, MD, 12 Mayo Clinic, Rochester, MN, 13 The 

University of Pennsylvania, Philadelphia, PA, 14 Trinity 

College Dublin, Dublin, Ireland 

9:30 am 

3181. The Utility of Urinalysis in Determining the 

Risk of Renal Relapse in ANCA-Associated Vasculitis 

Rennie L. Rhee 1 , John C. Davis 2 , Linna Ding 3 , Fernando 

Fervenza 4 , Gary S. Hoffman 5 , Cees G.M. Kallenberg 6 , 

Carol A. Langford 5 , W Joseph McCune 7 , Paul A. 

Monach 8 , Philip Seo 9 , Robert F. Spiera 10 , Eugene William 

St.Clair 11 , Ulrich Specks 4 , John H. Stone 12 and Peter A. 

Merkel 13 , 1 University of Pennsylvania, Philadelphia, PA, 

2 

Baxalta, Cambridge, MA, 3 NIH, Bethesda, MD, 4 Mayo 

Clinic, Rochester, MN, 5 Cleveland Clinic, Cleveland, OH, 

6 

University of Groningen, University Medical Center 

Groningen, Groningen, Netherlands, 7 University of 

Michigan, Ann Arbor, MI, 8 Boston University School 

of Medicine, Boston, MA, 9 Johns Hopkins University, 

Baltimore, MD, 10 Hospital for Special Surgery, Cornell, 

New York, NY, 11 Duke University, Durham, NC, 

12 

Massachusetts General Hospital Rheumatology 

Unit, Harvard Medical School, Boston, MA, 13 Univ of 

Pennsylvania; Perelman School of Med, Philadelphia, 

PA 

9:45 am 

3182. Attenuation of Fluorine-18- 

Fluorodeoxyglucose Uptake in Large Vessel Giant 

Cell Arteritis after Short-Term High-Dose Steroid 

Treatment – A Diagnostic Window of Opportunity 

Berit Dalsgaard Nielsen 1 , Ib Tønder Hansen 2 , Kresten 

Krarup Keller 2 , Philip Therkildsen 3 , Ellen-Margrethe 

Hauge 2 and Lars Christian Gormsen 4 , 1 Department 

of Rheumatology, Aarhus University Hospital, Århus 

C, Denmark, 2 Department of Rheumatology, Aarhus 


Wednesday 




University Hospital, Aarhus, Denmark, 3 Department of 

Rheumatology, Aarhus University Hospital, Aarhus C, 

Denmark, 4 Department of Nuclear Medicine and PET 

Center, Aarhus University Hospital, Århus C, Denmark 

10:00 am 

3183. Tocilizumab for the Treatment of Giant Cell 

Arteritis – MR-Angiography Results from the First 

Randomized Placebo-Controlled Trial 

Stephan Reichenbach 1 , Sabine Adler 2 , Jennifer 

Cullmann 2 , Harald Bonel 2 , Stefan Kuchen 1 , Felix 

Wermelinger 2 , Diana Dan 2 , Michael Seitz 2 and Peter 

M. Villiger 2 , 1 University of Bern, Bern, Switzerland, 

2 

University Hospital Bern, Bern, Switzerland 

10:15 am 

3184. Antiphospoholipid Antibodies in Giant Cell 

Arteritis. What Can They Tell Us? 

Alojzija Hocevar, Rok Jese, Ziga Rotar, Polona Žigon, 

Sašša Čučnik and Matija Tomšič, University Medical 

Centre Ljubljana, Ljubljana, Slovenia 


9:00 am - 10:30 am 

207 B 

ACR/ARHP Combined Abstract Session: Pediatric 

Rheumatology 

Moderators: Paula Melson, DPT, MMS; Lisa F. Imundo, 

MD 

9:00 am 

3113. Evaluation of a Clinical Transition Pathway 

for Adolescents with Autoimmune Diseases 

Margot Walter 1 , Sylvia S.M. Kamphuis 2 , Philomine 

A. van Pelt 3 , A. Vroed de 4 and Johanna M.W. Hazes 5 , 

1 

Erasmus MC - University Medical Center, Rotterdam, 

Netherlands, 2 Erasmus Medical Center, Rotterdam, 

Netherlands, 3 Erasmus MC, Rotterdam, Netherlands, 

4 

ErasmusMC, Rotterdam, Netherlands, 5 Erasmus 

University Medical Centre, Rotterdam, Netherlands 

9:15 am 

3114. Cardiorespiratory Fitness in Children 

with Juvenile Idiopathic Arthritis Treated in the 

Biological Era Is Comparable with Controls – A 

Cross-Sectional Study 

Kristine Risum 1 , Elisabeth Edvardsen 2 , Anne Marit 

Selvaag 3 , Oyvind Molberg 3 , Hanne Dagfinrud 4 and 

Helga Sanner 5 , 1 Department of Rehabilitation, Division 

of Orthopeadic Surgery, Oslo University Hospital, Oslo, 

Norway, Oslo, Norway, 2 Department of Pulmonary 

Medicine, Oslo University Hospital, Oslo, Norway, 

Oslo, Norway, 3 Department of Rheumatology, Oslo 

University Hospital, Oslo, Norway, Oslo, Norway, 

4 

Department of Rheumatology, Diakonhjemmet 

Hospital, Oslo, Norway, Oslo, Norway, 5 Norwegian 

National Advisory Unit on Rheumatic Diseases in 

Children and Adolescents, Oslo University Hospital, 

Oslo, Norway, Oslo, Norway 

9:30 am 

3115. Reconsidering the Juvenile Idiopathic 

Arthritis Core Set: How Patients and Caregivers 

Define Disease Activity 

Jennifer R. Horonjeff 1 , Susan Thornhill 2 , Daniel B. 

Horton 3 , Jennifer N. Stinson 4 , Anjali Fortna 1 , Stephanie 

Luca 4 , Arlene Vinci 5 , Laura C. Marrow 5 , Emily L. Creek 5 , 

Meredith Riebschleger 6 , Alessandro Consolaro 7 , Jane 

Munro 8 , Vibeke Strand 9 , Clifton Bingham III 10 and Esi 

Morgan 11 , 1 Columbia University Medical Center, New 

York, NY, 2 Thornhill Associates, Hermosa Beach, CA, 

3 

Division of Pediatric Rheumatology, Rutgers Robert 

Wood Johnson Medical School, Rutgers Biomedical 

and Health Sciences, New Brunswick, NJ, 4 The Hospital 

for Sick Children, Toronto, ON, 5 Arthritis Foundation, 

Atlanta, GA, 6 University of Michigan, Ann Arbor, MI, 

7 

Istituto Giannina Gaslini, Genoa, Italy, 8 Royal Children’s 

Hospital, Parkville, Australia, 9 Stanford University 

School of Medicine, Palo Alto, CA, 10 Johns Hopkins 

University, Baltimore, MD, 11 Cincinnati Children’s 

Hospital, Cincinnati, OH 

9:45 am 

3116. Risk of Infections in Juvenile Idiopathic 

Arthritis Patients Treated with Biologic Agentsand/ 

or Methotrexate: Results from Pharmachild 

Registry 

Gabriella Giancane 1 , Joost Swart 1 , Francesca Bovis 1 , Elio 

Castagnola 1 , Andreas Groll 1 , Gerd Horneff 1 , Hans-Iko 

Huppertz 1 , Daniel J. Lovell 1 , Tom Wolfs 1 , Michaël Hofer 1 , 

Ekaterina Alexeeva 1 , Violeta Vladislava Panaviene 1 , 

Susan Nielsen 1 , Jordi Anton 1 , Florence Uettwiller 1 , Valda 

Stanevicha 1 , Maria Trachana 1 , Denise Pires Marafon 2 , 


177


Wednesday 



Constantin Ailioaie 1 , Elena Tsitsami 1 , Sylvia S.M. 

Kamphuis 1 , Troels Herlin 1 , Pavla Dolezalová 2 , Gordana 

Susic 1 , Berit Flato 1 , Flavio Sztajnbok 1 , Angela Pistorio 1 , 

Alberto Martini 1 , Nico Wulffraat 1 and Nicolino Ruperto 1 , 

1 

Istituto Giannina Gaslini, Genoa, Italy, 2 Istituto 

Giannina Gaslini, genoa, Italy 

10:00 am 

3117. Development of Autoimmune Diseases and 

Genetic Predisposition in Children with Neonatal 

Lupus and Their Unaffected Siblings 

Aaron Garza Romero 1 , Peter M. Izmirly 2 , Hannah C. 

Ainsworth 3 , Miranda Marion 3 , Carl Langefeld 3 , Robert 

Clancy 2 , Jill P. Buyon 2 and Amit Saxena 2 , 1 NYU School of 

Medicine, New York, NY, 2 New York University School 

of Medicine, New York, NY, 3 Wake Forest School of 

Medicine, Winston-Salem, NC 

10:15 am 

3118. Differences in Disease Phenotype, 

Management and Outcomes of Children with 

Juvenile Idiopathic Arthritis throughout the 

World – Analysis of 8,325 Patients Enrolled in the 

Epoca Study 

Alessandro Consolaro 1 , Nicolino Ruperto 2 , Pieter van 

Dijkhuizen 3 , Marco Garrone 4 , Mariangela Rinaldi 4 , 

Jaime De Inocencio 5 , Erkan Demirkaya 6 , Stella Maris 

Garay 7 , Dirk Föll 8 , Daniel J Lovell 9 , Calin Lazar 10 , Susan 

Nielsen 11 , Berit Flatø 12 , Alberto Martini 1 , Angelo Ravelli 1 

and Pediatric Rheumatology International Trials 

Organization and EPOCA Study Group, 1 University 

of Genova, Genova, Italy, 2 Paediatric Rheumatology 

International Trials Organization (PRINTO), Istituto 

Giannina Gaslini, Genoa, Italy, 3 Istituto Giannina 

Gaslini, Genova, Italy, 4 PRINTO - Istituto Giannina 

Gaslini, Genova, Italy, 5 Hospital 12 de Octubre, Madrid, 

Spain, 6 Gulhane Military Medical Faculty, Ankara, 

Turkey, 7 Hospital de Ninos, La Plata, Argentina, 

8 

University Hospital Muenster, Muenster, Germany, 

9 

PRCSG Cincinnati Children’s Hospital Medical Center, 

Cinncinnati, OH, 10 Clinica Pediatrie I, Cluj-Napoca, 

Romania, 11 Rigshospitalet, Copenhagen, Denmark, 

12 

Oslo University Hospital-Rikshospitalet, Oslo, Norway 

ARHP SESSION 

9:00 am – 10:30 am 

201 

Move More, Sit Less: We All Need to Say the 

Same Thing PM PS E 

Moderator: Marie Westby, PT, PhD 

9:00 am 

Sizing the Inactivity Problem in Arthritis and 

Strategies for Activating the Inactive 

Speaker: Teresa J. Brady, PhD 

9:30 am 

Consistent, Credible, and Compelling Messaging 

about Physical Activity 

Speaker: Alison Hoens, BSc(PT), MSc 

10:00 am 

Exercise Is Medicine: The New Science of Sneaker 

Power 

Speaker: Pam Peeke, MD, MPH, FACP, FACSM 

ACR SESSIONS 

11:00 am – 12:30 pm 

140 A 

Single Cell Analysis: Promises and Challenges 

Moderators: Marta Alarcón-Riquelme, MD, PhD; Laura 

T. Donlin, PhD 

11:00 am 

An Immune Cell Atlas Based on Single Cell Data 

Speaker: Nir Hacohen, PhD 

11:30 am 

Seeking Insight from the RNA of Kidney and Skin to 

Inform Lupus Nephritis: A Classy Act? 


12:00 pm 

CyTOF and Beyond: New Tools for Autoimmune 

Disease Interrogation 

Speaker: Paul J. Utz, MD, Prof 


Wednesday 




Ballroom B 

Tuberculosis Update PM PS E 

Moderators: Aman Sharma, MD; Petros Efthimiou, MD 

11:00 am 

Diagnosis of Typical and Atypical Manifestations of 

Tuberculosis 

Speaker: Anand Malaviya, MD 

11:30 am 

Treatment of Latent and Active Tuberculosis 

Speaker: Jerrold Ellner, MD 

12:00 pm 

Atypical Mycobacteria: Diagnosis and What to Do 

about It 

Speaker: Kevin L. Winthrop 


11:00 am – 12:30 pm 

Ballroom C 

Epidemiology and Public Health III: Psoriatic 

Arthritis and More 

Moderators: Jasvinder A. Singh, MD, MPH; Alexis Ogdie, 

MD 

11:00 am 

3185. Sensitivity Analysis for the Smoking Paradox 

in the Development of Psoriatic Arthritis Among 

Psoriasis Patients 

Uyen-Sa D.T. Nguyen 1 , Yuqing Zhang 2 , David T. Felson 2 , 

Michael P. Lavalley 3 and Hyon K. Choi 4 , 1 University 

of Massachusetts Medical School, Worcester, MA, 

2 


3 

Boston University School of Public Health, Boston, 

MA, 4 Massachusetts General Hospital, Harvard Medical 


11:15 am 

3186. Determinants of Patient-Physician 

Discordance in Global Assessment in Psoriatic 

Arthritis and Levels of Discordance According to 

Disease Activity: A Multicenter European Study 

Carole Desthieux 1 , Benjamin Granger 1 , Andra Rodica 

Balanescu 2 , P Balint 3 , Jürgen Braun 4 , Juan Canete 5 , 

Turid Heiberg 6 , Philip S. Helliwell 7 , Umut Kalyoncu 8 , 

Tore K Kvien 9 , Uta Kiltz 4 , Dora Niedermayer 10 , Kati 

Otsa 11 , Rossana Scrivo 12 , Josef Smolen 13 , Tanja A. 

Stamm 14 , Douglas J. Veale 15 , Kurt de Vlam 16 , Maarten 

de Wit 17 and Laure Gossec 1 , 1 Pitié Salpêtrière Hospital, 

Paris, France, 2 Department of Internal Medicine 

and Rheumatology “Sf. Maria” Hospital, Bucharest, 

Romania, 3 National Institute of Rheumatology and 

Physiotherapy, Budapest, Hungary, 4 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 5 Hospital Clínic and 

IDIBAPS, Barcelona, Spain, 6 Oslo University Hospital, 

Oslo, Norway, 7 NIHR-Leeds Musculoskeletal Biomedical 

Research Unit, Leeds Institute of Rheumatic and 

Musculoskeletal Medicine, University of Leeds, Leeds, 

United Kingdom, 8 Hacettepe University, Ankara, 

Turkey, 9 Diakonhjemmet Hospital, Oslo, Norway, 

10 

PsAID taskforce, EULAR, Zurich, Switzerland, 11 Tallinn 

Central Hospital, Tallinn, EE, 12 Department of Internal 

Medicine and Medical Specialties, Sapienza University, 

Rome, Italy, 13 Medical University of Vienna and Hietzing 

Hospital, Vienna, Austria, 14 Vienna Medical University, 

Vienna, Austria, 15 Centre for Arthritis and Rheumatic 

Disease, St. Vincent’s University Hospital and University 

College Dublin, Dublin 4, Ireland, 16 Katholieke 

Universiteit Leuven, Leuven, Belgium, 17 VU Medical 

Centre, Amsterdam, Netherlands 

11:30 am 

3187. Societal Costs and Patients’ Experience of 

Health Inequities from Psoriatic Arthritis: A Danish 

Cohort Study 

Lars Erik Kristensen 1 , Tanja S Jørgensen 2 , Robin 

Christensen 3 , Henrik Gudbergsen 4 , Lene Dreyer 5 , 

Christine Ballegaard 6 , Lennart T.H. Jacobsson 7 , 

Vibeke Strand 8 , Philip J Mease 9 and Jakob Kjellberg 10 , 

1 

Copenhagen University Hospital, Bispebjerg and 

Frederiksberg, Copenhagen, Denmark, 2 The Parker 

Institute, Copenhagen, Denmark, 3 Musculoskeletal 

Statistics Unit, The Parker Institute, Copenhagen 

University Hospital, Bispebjerg and Frederiksberg, 

Copenhagen, Denmark, 4 Knowledge Centre for 

Telemedicine and Departments of Rheumatology, 

Copenhagen University Hospitals, Glostrup, 

Frederiksberg and Bispebjerg, Frederiksberg, 

Denmark, 5 Copenhagen University Hospital at 

Gentofte, Copenhagen, Denmark, 6 The Parker institute, 


179


Wednesday 



Copenhagen, Denmark, 7 Sahlgrenska Academy 

at Gothenburg University, Gothenburg, Sweden, 

8 

Stanford University School of Medicine, Palo Alto, CA, 

9 

University of Leeds, Leeds, United Kingdom, 10 Danish 

Institute for Local and Regional Government Research, 

Copenhagen, Denmark, Copenhagen, Denmark 

11:45 am 

3188. Association of Gout with Risk of Advanced 

Chronic Kidney Disease 

Austin Stack 1 , Betina Blak 2 , Michelle Johnson 3 , Victoria 

Parsons 3 , Andrew Maguire 3 , Alyssa B Klein 4 , John 

Ferguson 5 and Robert Morlock 6 , 1 University Hospital 

Limerick & Health Research Institute,University of 

Limerick, Limerick, Ireland, 2 AstraZeneca,, Luton, 

United Kingdom, 3 Oxon Epidemiology Ltd, London, 

United Kingdom, 4 AstraZeneca, Gaithersburg, MD, 

5 

University of Limerick, Limerick, Ireland, 6 Ardea 

Biosciences, Inc., San Diego, CA 

12:00 pm 

3189. Patient Perceptions of Glucocorticoid Side 

Effects: A Survey of Users in an Online Health 

Community 

Ruth Costello, Rikesh Patel, Jennifer Humphreys, John 

McBeth and William G Dixon, Arthritis Research UK 

Centre for Epidemiology, The University of Manchester, 

Manchester, United Kingdom 

12:15 pm 

3190. Epidemiology of Polymyalgia Rheumatica 

2000-2014: A Population Based Study 

Shafay Raheel, Cynthia S. Crowson and Eric L. 

Matteson, Mayo Clinic, Rochester, MN 

202 B 

Health Services Research II 

Moderators: Candace Feldman, MD, ScD; Jessica 

Widdifield, PhD 

11:00 am 

3191. Coronary Revascularization Procedure Rates 

and Risks Among Patients with Systemic Lupus 

Erythematosus Compared to Those with Diabetes 

Mellitus in a Nationwide Medicaid Cohort 

Medha Barbhaiya 1 , Candace H. Feldman 1 , Sarah K. 

Chen 2 , Hongshu Guan 1 , Tzu-Chieh Lin 1 , Michael A. 

Fischer 1 , Daniel H. Solomon 1 , Brendan M. Everett 1 

and Karen H. Costenbader 1 , 1 Brigham and Women’s 


2 

Beth Israel Deaconess Medical Center, Boston, MA 

11:15 am 

3192. Influence of Temperature and Humidity on 

Disease Activity in Rheumatoid Arthritis 

Peter Mandl 1 , Farideh Alasti 1 , Rainer Kaltenberger 2 , 

Thomas Krennert 2 , Gabriela Supp 1 , Uriel Landesmann 1 , 

Josef S. Smolen 3 and Daniel Aletaha 4 , 1 Medical 

University Vienna, Vienna, Austria, 2 Central Institute 

for Meteorology and Geodynamics, Vienna, Austria, 

3 

Medical University of Vienna, Vienna, Austria, 

4 

Department of Internal Medicine 3, Medical University 

of Vienna, Vienna, Austria 

11:30 am 

3193. Is an Intensive Diet and Exercise Regimen 

Cost-Effective for Obese and Overweight Patients 

with Symptomatic Knee OA? 

Elena Losina 1 , Karen C. Smith 2 , A. David Paltiel 3 , Lisa 

Gale Suter 3 , Jeffrey N. Katz 1 and Stephen P. Messier 4 , 

1 


School, Boston, MA, 2 Brigham and Women’s Hospital, 

Boston, MA, 3 Yale University, New Haven, CT, 4 Wake 

Forest University, Winston-Salem, NC 

11:45 am 

3194. Factors Related to Physicians’ Prescriptions 

for Rheumatoid Arthritis Drugs Never Filled or 

Subsequently Discontinued By Patients 

Hong J. Kan 1 , Kirill Dyagilev 1 , Peter Schulam 2 , Suchi 

Saria 1 , Charles Molta 3 and Jeffrey Curtis 4 , 1 John Hopkins 

University, Baltimore, MD, 2 Johns Hopkins University, 

Baltimore, MD, 3 Sun Pharmaceutical, Cranbury, NJ, 

4 

University of Alabama at Birmingham, Birmingham, AL 

12:00 pm 

3195. Patterns and Predictors of 

Hydroxychloroquine Nonadherence in a 

Nationwide Cohort of Medicaid Beneficiaries with 


Candace H. Feldman 1 , Jamie E. Collins 2 , Zhi Zhang 3 , 

Daniel H. Solomon 4 , Karen H. Costenbader 1 and Ichiro 

Kawachi 5 , 1 Division of Rheumatology, Immunology 

and Allergy, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA, 2 Brigham & Women’s 

Hospital, Boston, MA, 3 Brigham and Women’s Hospital 


Wednesday 




and Harvard Medical School, Boston, MA, 4 Brigham and 

Women’s Hospital and Harvard Medical School, Boston, 

MA, 5 Harvard T. H. Chan School of Public Health, 

Boston, MA 

12:15 pm 

3196. A Natural Language Processing System Can 

Capture Rheumatoid Arthritis Disease Activity 

Measures in US Veterans Across Multiple Sites 

Grant W. Cannon 1 , Shobhit Mehortra 2 , Brett South 2 , 

Ted R Mikuls 3 , Andreas M. Reimold 4 and Brian C Sauer 2 , 

1 

Veterans Affairs Salt Lake City Health Care System 

and University of Utah School of Medicine, Salt Lake 

City, UT, 2 Salt Lake City VA and University of Utah, Salt 

Lake City, UT, 3 Omaha VA and University of Nebraska 

Medical Center, Omaha, NE, USA, Omaha, NE, 4 Dallas 

VA and University of Texas Southwestern, Dallas, TX 

Salon B 

Imaging of Rheumatic Diseases III: Crystal 

Arthritis, Osteoarthritis, Connective Tissue 

Disease, and Vasculitis 

Moderators: Wolfgang A. Schmidt, MD; Gurjit S. Kaeley, 

MBBS, MRCP 

11:00 am 

3197. Ultrasound Definitions for Cranial and Large 

Vessel Giant Cell Arteritis: Results of a Reliability 

Exercise on Images and Videos of the Omeract 

Ultrasound Large Vessel Vasculitis Task Force 

Stavros Chrysidis 1 , Christina Duftner 2 , Christian 

Dejaco 3 , Cristina Ponte 4 , Annamaria Iagnocco 5 , Bhaskar 

Dasgupta 6 , Maria Antonietta D’Agostino 7 , Eugenio 

De Miguel 8 , Ulrich Fredberg 9 , Wolfgang Hartung 10 , 

Alojzija Hocevar 11 , Tanaz A. Kermani 12 , Matthew J. 

Koster 13 , Tove Lorenzen 14 , Pierluigi Macchioni 15 , Marcin 

Milchert 16 , Naina Rastalsky 17 , Chetan Mukhtyar 18 , 

Valentin S. Schaefer 19 , Kenneth J. Warrington 20 , Lene 

Terslev 21 , George A. W. Bruyn 22 , Petra Hanova 23 , Uffe 

Møller Døhn 24 , Esperanza Naredo 25 , Carlo Alberto 

Scirè 26 , Greta Carrara 27 , Sofia Ramiro 28 , Andreas 

P Diamantopoulos 29 and Wolfgang A. Schmidt 19 , 

1 

Department of Rheumatology, Hospital of Southwest 

Denmark, Esbjerg, Denmark, 2 Medical University 

Innsbruck, Innsbruck, Austria, 3 Medical University Graz, 

Graz, Austria, 4 Lisbon Academic Medical Centre, Lisbon, 

Portugal, 5 Sapienza Università Di Roma,, Roma, Italy, 

6 

Southend University Hospital NHS Foundation Trust, 

Westcliff-on-Sea, United Kingdom, 7 Versailles-Saint 

Quentin en Yvelines University, Boulogne-Billancourt, 

France, 8 Hospital Universitario La Paz, Madrid, 

Spain, 9 Diagnostic Centre Region Hospital Silkeborg 

Denmark, 8600 Silkeborg, Denmark, 10 Department 

of Rheumatology/Clinical Immunology, Asklepios 

Medical Center, 93077 Bad Abbach, Germany, 

11 

University Medical Centre Ljubljana, Ljubljana, 

Slovenia, 12 University of California Los Angeles, Santa 

Monica, CA, 13 University of California Los Angeles, CA, 

USA Mayo Clinic, Rochester, MN, 14 Region Hospital 

Silkeborg, Silkeborg, Denmark, 15 Arcispedale Santa 

Maria Nuova, Reggio Emilia,, Reggio Emilia, Italy, 

16 

Pomeranian Medical University, Szczecin,, Szczecin, 

Poland, 17 St. Elizabeth’s Medical Center, Boston, MA, 

Boston, MA, 18 Norfolk and Norwich University Hospital, 

Norwich, United Kingdom, 19 Immanuel Krankenhaus 

Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, 

Germany, 20 University of California Los Angeles, CA, 

USA Mayo, Rochester, MN, 21 Copenhagen Center 

for Arthritis Research (COPECARE), Copenhagen, 

Denmark, 22 MC Groep, Loenga, Netherlands, 23 Institute 

of Rheumatology and Department of Rheumatology, 

1st Faculty of Medicine, Charles University in Prague, 

Prague, Czech Republic, 24 Copenhagen Center for 

Arthritis Research (COPECARE), Glostrup, Denmark, 

25 

Hospital General Universitario Gregorio Marañón 

and Universidad Complutense, Madrid, Spain, 

26 

Epidemiology Unit – Italian Society for Rheumatology 

(SIR), Milano, Italy, 27 Italian Society for Rheumatology, 

Milano, Italy, 28 Leiden University Medical Center, 

Leiden, Netherlands, 29 Haugesund Sanitetsforenings 

Revmatismesykehus, Haugesund, Norway 

11:15 am 

3198. Inter-Reader and Intra-Reader Reliability of 

the New Omeract Ultrasonographic Criteria for the 

Diagnosis of Calcium Pyrophosphate Deposition 

Disease 

Georgios Filippou 1 , Carlo Alberto Scirè 2 , Nemanja 

Damjanov 3 , Antonella Adinolfi 4 , Greta Carrara 5 , 

Valentina Picerno 1 , Carmela Toscano 1 , George A. W. 

Bruyn 6 , Maria Antonietta D’Agostino 7 , Andrea Delle 

Sedie 8 , Emilio Filippucci 9 , Marwin Gutierrez 10 , Mihaela 

Cosmina Micu 11 , Ingrid Moller 12 , Esperanza Naredo 13 , 

Pascal Zufferey 14 , Carlos Pineda 15 , francesco Porta 16 , 


181


Wednesday 



Wolfgang A. Schmidt 17 , Lene Terslev 18 , Violeta Vlad 19 , 

Bruno Frediani 1 , Annamaria Iagnocco 20 and OMERACT 

working group “US in CPPD”, 1 University of Siena, 

Siena, Italy, 2 Epidemiology Unit – Italian Society 

for Rheumatology (SIR), Milano, Italy, 3 Institute of 

Rheumatology, University of Belgrade Medical School, 

Belgrade, Serbia, 4 Policlinico le Scotte, Siena, Italy, 

5 

Italian Society for Rheumatology, Milano, Italy, 6 MC 

Groep, Loenga, Netherlands, 7 University of Paris, 

Paris, France, 8 University of Pisa, Pisa, Italy, 9 Università 

Politecnica delle Marche, Jesi, Italy, 10 Instituto Nacional 

de Rehabilitación, Mexico, Mexico, 11 Division of 

Rheumatology, Department of Rehabilitation II, Clinical 

Rehabilitation Hospital, Cluj Napoca, Romania, 12 Poal 

Institute of Rheumatology, Corbera de Llobregat, Spain, 

13 

Hospital General Universitario Gregorio Marañón and 

Universidad Complutense, Madrid, Spain, 14 University 

Hospital Lausanne, Lausanne, Switzerland, 15 Instituto 

Nacional de Rehabilitation, Mexico, Mexico, 16 Hospital 

of Pistoia, Pistoia, Italy, 17 Immanuel Krankenhaus 

Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, 

Germany, 18 Copenhagen Center for Arthritis Research 

(COPECARE), Copenhagen, Denmark, 19 RCRD Research 

Center, Bucharest, Romania, 20 Sapienza Università di 

Roma, Roma, Italy 

11:30 am 

3199. Urate Crystal Deposition and Bone Erosion 

in Gout: Inside-Out or Outside-In? a Dual Energy 

Computed Tomography Study 

Patapong Towiwat 1 , Anthony Doyle 1 , Gregory Gamble 1 , 

Paul Tan 1 , Opetaia Aati 1 , Anne Horne 1 , Lisa K. Stamp 2 

and Nicola Dalbeth 1 , 1 University of Auckland, Auckland, 

New Zealand, 2 University of Otago, Christchurch, New 

Zealand 

11:45 am 

3200. Immunoscintigraphic Detection of Tumor 

Necrosis Factor by Radiolabeled Certolizumab 

Pegol in Patients with Erosive Hand Osteoarthritis 

in Relation to Disease Activity: A Proof of Concept 

Study 

Ruth Wittoek 1 , Philippe Carron 1 , Bieke Lambert 2 , 

Paulien Meersseman 1 , Gust Verbruggen 1 , Filip van Den 

Bosch 1 and Dirk Elewaut 3 , 1 Ghent University Hospital, 

Ghent, Belgium, 2 Department of Nuclear Medicine 

Ghent University Hospital, Ghent, Belgium, 3 VIB, Ghent 

University and Ghent University Hospital, Ghent, 

Belgium 

12:00 pm 

3201. Diagnostic Value of Quantitative 

Sialoscintigraphy Compared to Labial Salivary 

Gland Biopsy in Patients with Suspected Sjögren’s 

Syndrome 

Maria Garcia-Gonzalez, Maria Jesus Gonzalez-Soto, Ivan 

Ferraz-Amaro, Hiurma Sanchez, Vanesa Hernandez, 

Maria Angeles Gomez and Sagrario Bustabad, Hospital 

Universitario de Canarias, La Laguna, Tenerife, Spain 

12:15 pm 

3202. Clinical and Ultrasonographic Evaluation 

of Joint Involvement in Patients with Systemic 

Sclerosis 

María Victoria Martire 1 , Priscila Marcaida 2 , Santiago 

Scarafia 3 , Gloria Crespo 2 , Anastasia Secco 1 , Lida 

Santiago 2 and Marta Mamani 2 , 1 Hospital Bernardino 

Rivadavia, Buenos Aires, Argentina, 2 Hospital 

Bernardino Rivadavia, Ciudad Autónoma de Buenos 

Aires, Argentina, 3 Hospital Bernardino Rivadavia, CABA, 

Argentina 

207 B 

Pediatric Rheumatology – Clinical and 

Therapeutic Aspects III: Autoinflammatory 

Diseases and Juvenile Dermatomyositis 

Moderators: Stacy P. Ardoin, MD, MS; Natasha M. Ruth, 

MD, MS 

11:00 am 

3203. Analysis of Efficacy and Safety of 

Cyclophosphamide in Juvenile Dermatomyositis 

Using a Large National UK Cohort 

Claire Deakin 1 , Raquel Campanilho-Marques 2 , Stefania 

Simou 1 , Elena Moraitis 1 , Eleanor Pullenayegum 3 , Lucy 

R Wedderburn 1 , Clarissa Pilkington 4 and Juvenile 

Dermatomyositis Research Group (JDRG), 1 UCL 

Institute of Child Health, London, United Kingdom, 

2 

UCL Institute of Child Health, London, Portugal, 

3 

McMaster University, Hamilton, ON, 4 Great Ormond 

Street Hospital for Children NHS Trust, London, United 

Kingdom 


Wednesday 




11:15 am 

3204. Body Composition and Adipose Tissue 

Distribution in Juvenile Dermatomyositis and 

Associations with Cardiac Function 

Birgit Nomeland Witczak 1 , Kristin Godang 2 , Thomas 

Schwartz 3 , Nicoleta Cristina Olarescu 2 , Berit Flatø 4 , 

Jens Bollerslev 2 , Ivar Sjaastad 4 and Helga Sanner 5 , 

1 

Institute for Experimental Medical Research, Oslo 

University Hospital, Oslo, Norway, Oslo, Norway, 

2 

Section of Specialised Endocrinology, Department of 

Endocrinology, Oslo University Hospital, Rikshospitalet, 

Oslo, Norway, Oslo, Norway, 3 Department of Infectious 

Diseases, Oslo University Hospital, Oslo, Norway, Oslo, 

Norway, 4 Institute for Clinical Medicine, University of 

Oslo, Oslo, Norway, Oslo, Norway, 5 Department of 

Rheumatology, Oslo University Hospital, Rikshospitalet, 

Oslo, Norway, Oslo, Norway 

11:30 am 

3205. Efficacy and Safety of Canakinumab 

in Patients with Periodic Fever Syndromes 

(Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): 

Results from a Phase 3, Pivotal, Umbrella Trial 

Fabrizio De Benedetti 1 , Jordi Anton 2 , Eldad Ben- 

Chetrit 3 , Inmaculada Calvo 4 , Joost Frenkel 5 , Marco 

Gattorno 6 , Hal M. Hoffman 7 , Ozgur Kasapcopur 8 , 

Isabelle Koné-Paut 9 , Helen Lachmann 10 , Michel 

Moutschen 11 , Seza Ozen 12 , Pierre Quartier 13 , Anna 

Simon 14 , Andrew Zeft 15 , Karine Lheritier 16 , Antonio 

Speziale 16 and Guido Junge 16 , 1 IRCCS Ospedale 

Pediatrico Bambino Gesú, Rome, Italy, 2 Hospital 

Sant Joan de Déu, Barcelona, Spain, 3 Rheumatology 

Unit, Hadassah—Hebrew University Medical Center, 

Jerusalem, Israel, 4 Hospital Universitario y Piltecnico La 

Fe, Valencia, Spain, 5 University Medical Center Utrecht, 

Utrecht, Netherlands, 6 Pediatric Rheumatology, G. 

Gaslini Institute, Genoa, Italy, 7 University of California 

at San Diego, San Diego, CA, 8 Istanbul University, 

Cerrahpasa Medical School, Department of Pediatric 

Rheumatology, Istanbul, Turkey, 9 Hopital Kremlin 

Bicetre, University of Paris SUD, Paris, France, 10 UK 

National Amyloidosis Centre, University College 

London Medical School, London, United Kingdom, 

11 

C.H.U. Sart-Tilman, Liege, Belgium, 12 Hacettepe 

University Faculty of Medicine, Ankara, Turkey, 

13 

Hôpital Necker-Enfants Malades, Paris, France, 

14 

Radboud University Nijmegen Medical Centre, 

Nijmegen, Netherlands, 15 Pediatrics Rheumatology, 

Cleveland Clinic, Cleveland, OH, 16 Novartis Pharma AG, 

Basel, Switzerland 

11:45 am 

3206. Effectiveness of Childhood Vaccinations in 

CAPS Patients Treated with Canakinumab: Results 

from an Open-Label Phase III Extension Study 

Paul Brogan 1 , Michaël Hofer 2 , Jasmin B. Kuemmerle- 

Deschner 3 , Bernard Lauwerys 4 , Antonio Speziale 5 , 

Xiaoling Wei 6 and Ronald Laxer 7 , 1 University College 

London (UCL), London, United Kingdom, 2 Unité 

Romande de Rhumatologie Pédiatrique, Hospitalier 

Universitaire Vaudois, Lausanne, Switzerland, 

3 

University Hospital Tuebingen, Tuebingen, Germany, 

4 

Cliniques Universitaires Saint-Luc and Université 

Catholique de Louvain, Brussels, Belgium, 5 Novartis 

Pharma AG, Basel, Switzerland, 6 Shanghai Novartis 

Trading Limited, Shanghai, China, 7 The Hospital for Sick 

Children, University of Toronto, Toronto, ON 

12:00 pm 

3207. The Deficiency of Adenosine Deaminase Type 

2 (DADA2)—Results of Anti-TNF Treatment in a 

Cohort of Patients with a History of Stroke 

Amanda K. Ombrello 1 , Karyl Barron 2 , Patrycja 

Hoffmann 1 , Camilo Toro 1 , Deborah L. Stone 1 , Gineth 

Pinto-Patarroyo 1 , Anne Jones 1 , Tina Romeo 1 , Ariane 

Soldatos 3 , Qing Zhou 1 , Natalie Deuitch 1 , Jing Qin 2 , 

Ivona Aksentijevich 1 and Daniel L. Kastner 1 , 1 National 

Human Genome Research Institute, National Institutes 

of Health, Bethesda, MD, 2 National Institute of Allergy 

and Infectious Diseases, National Institutes of Health, 

Bethesda, MD, 3 National Institute of Neurological 

Disorders and Stroke, National Institutes of Health, 

Bethesda, MD 

12:15 pm 

3208. Preliminary Response to JAK1/2 Inhibition 

with Baricitinib in “Candle,” “Savi,” and “Candle- 

Like” Diseases. A New Therapeutic Approach for 

Type I IFN Mediated Autoinflammatory Diseases 

Gina A. Montealegre Sanchez 1 , Adam Reinhardt 2 , 

Paul Brogan 3 , Dawn C. Chapelle 4 , Hanna Kim 4 , 

Samantha Judd 4 , Bahar Kost 4 , Michelle O’Brien 4 , Wendy 

Goodspeed 4 , Robert A. Colbert 4 , Meryl Waldman 5 , 

Deborah L. Stone 6 , Ling Gao 7 , JA Dare 7 , Susanne 

Schalm 8 , Thomas L. Klausmeier 9 , Sara Murias 10 , Yackov 


183


Wednesday 



Berkun 11 , Diane Brown 12 , John D. Carter 13 , Fehime K 

Eroglu 14 , A. Zlotogorski 11 , Philip Hashkes 15 , Helmut 

Wittkowski 16 , Suzanne Ramsey 17 , Seza Ozen 18 , Adriana 

Almeida de Jesus 19 and Raphaela Goldbach-Mansky 19 , 

1 

NIAID/NIH, Bethesda, MD, 2 Children’s Hosp of Omaha/ 

UNMC, Omaha, NE, 3 UCL Institute of Child Health and 

Great Ormond Street Hospital NHS Foundation Trust, 

London, United Kingdom, 4 NIAMS/NIH, Bethesda, 

MD, 5 NIDDK/NIH, Bethesda, MD, 6 NHGRI/NIH, 

Bethesda, MD, 7 University of Arkansas for Medical 

Sciences, Little Rock, AR, 8 LMU Munich, Munich, 

Germany, 9 Riley Hospital for Children, Indianapolis, IN, 

10 

Hospital Infantil La Paz, Madrid, Spain, 11 Hadassah- 

Hebrew University Medical Center, Jerusalem, Israel, 

12 

Children’s Hospital Los Angeles, Los Angeles, CA, 

13 

University of South Florida, Tampa, FL, 14 Hacettepe 

University Hospitals, Ankara, Turkey, 15 Shaare Zedek 

Medical Center, Jerusalem, Israel, 16 University of 

Muenster, Muenster, Germany, 17 IWK Health Centre, 

Halifax, NS, 18 Hacettepe University Faculty of Medicine, 

Ankara, Turkey, 19 National Institute of Allergy and 

Infectious Diseases (NIAID), NIH, Bethesda, MD 

Ballroom A 

Rheumatoid Arthritis – Clinical Aspects VII: The 

Impact of Treating to Target 

Moderator: Elizabeth R. Wahl, MD 

11:00 am 

3209. Clinical and Radiological Outcomes of 5 Years’ 

Remission Steered Treatment in Early Rheumatoid 

and Undifferentiated Arthritis Patients 

Gülsah Akdemir 1 , L. Heimans 2 , R.J. Goekoop 3 , Maikel 

van Oosterhout 4 , J.B. Harbers 5 , C. Bijkerk 6 , G.M. 

Steup-Beekman 7 , L.R. Lard 8 , P.B.J. de Sonnaville 9 , 

B.A.M. Grillet 10 , TWJ Huizinga 11 and Cornelia F. Allaart 2 , 

1 

Department of Rheumatology, Leiden University 

Medical Center, Leiden, Netherlands, 2 Leiden University 

Medical Center, Leiden, Netherlands, 3 Haga Hospital, 

The Hague, Netherlands, 4 Groene Hart Hospital, 

Gouda, Netherlands, 5 Department of Rheumatology, 

Franciscus Hospital, Roosendaal, Netherlands, 6 Reinier 

de Graaf Gasthuis, Delft, Netherlands, 7 Bronovo 

Hospital, The Hague, Netherlands, 8 MCH Antoniushove 

Hospital, Leidschendam, Netherlands, 9 ADRZ, Goes, 

Netherlands, 10 Zorgsaam, Terneuzen, Netherlands, 

11 

Leiden University Medical Centre, Leiden, 

Netherlands 

11:15 am 

3210. 10+ Years’ Follow-Up of a Danish 2-Year Treatto-Target 

RCT in Patients with Early Rheumatoid 

Arthritis: Baseline Predictors of Functional and 

Radiographic Outcomes 

Merete Lund Hetland 1 , Kristian Stengaard-Pedersen 2 , 

Peter Junker 1 , Hanne Lindegaard 1 , Torkell Ellingsen 1 , 

Jan Pødenphant 2 , Henrik Skjødt 1 , Aage Vestergaard 2 , 

Bo Jannik Ejbjerg 1 , Søren Jacobsen 1 , Niels Steen 

Krogh 1 , Mikkel Ostergaard 1 and Kim Hørslev-Petersen 2 , 

1 

DANBIO Registry and Departments of Rheumatology, 

Glostrup, Denmark, 2 DANBIO Registry and 

Departments of Rheumatology, Copenhagen, Denmark 

11:30 am 

3211. Early Radiological Progression in Rheumatoid 

Arthritis Leads to More Long-Term Joint Damage 

in Daily Clinical Practice; Six Year Radiological 

Outcomes of a Strict Treat-to-Target Cohort in the 

Netherlands 

Letty G.A. Versteeg 1 , Laura M.M. Steunebrink 1 , 

Ina H. Kuper 1 , Harald E. Vonkeman 1 , Peter M. ten 

Klooster 2 , Arie E. van der Bijl 3 and Mart A.F.J. van de 

Laar 4 , 1 Medisch Spectrum Twente - Arthritis Center 

Twente, Enschede, Netherlands, 2 University of Twente, 

Enschede, Netherlands, 3 Isala Klinieken, Zwolle, 

Netherlands, 4 Arthritis Centre Twente, Medisch 

Spectrum Twente and University Twente, Enschede, 

Netherlands 

11:45 am 

3212. Treat-to-Target in RA: Does Early Simplified 

Disease Activity Index (SDAI) Remission Lead to 

Better 5-Year Functional Outcomes than SDAI Low 

Disease Activity? 

Vibeke Norvang, Elisabeth Lie, Inge C Olsen, 

Eirik K Kristianslund, Tore K Kvien and Till Uhlig, 

Diakonhjemmet Hospital, Oslo, Norway 

12:00 pm 

3213. Assessment of Two Different DAS Treatment 

Targets in Early Active Rheumatoid Arthritis 

Patients 

Gülsah Akdemir 1 , Iris M. Markusse 2 , Yvonne P. 

Goekoop-Ruiterman 3 , J.B. Harbers 4 , Maikel van 

Oosterhout 5 , Pit J.S.M. Kerstens 6 , Willem F. Lems 7 , 

TWJ Huizinga 8 and Cornelia F. Allaart 2 , 1 Department 

of Rheumatology, Leiden University Medical Center, 


Wednesday 




Leiden, Netherlands, 2 LUMC, Leiden, Netherlands, 

3 

HAGA hospital, The Hague, Netherlands, 4 Department 

of Rheumatology, Franciscus Hospital, Roosendaal, 

Netherlands, 5 Groene Hart Hospital, Gouda, 

Netherlands, 6 Department of Rheumatology, Reade, 


and immunology Center, VU University medical center, 

Amsterdam, Netherlands, 8 Leiden University Medical 

Centre, Leiden, Netherlands 

12:15 pm 

3214. Implementation of Treat to Target in 

Rheumatoid Arthritis through a Learning 

Collaborative 

Daniel H. Solomon 1 , Bing Lu 2 , Elena Losina 3 , Jen 

Agosti 4 , Agnes Zak 5 , Cassandra Corrigan 5 , Zhi Yu 5 , 

Sara Lee 5 , Asaf Bitton 5 , LR Harrold 6 , Theodore Pincus 7 , 

Helga Radner 8 , Josef Smolen 9 , Liana Fraenkel 10 and 

Jeffrey N. Katz 11 , 1 Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 2 Brigham & 

Women’s Hospital and Harvard Medical School, 

Boston, MA, 3 Brigham and Women’s Hospital and 

Harvard Medical School, Boston, MA, 4 JRA Consulting, 

Andover, MA, 5 Brigham and Women’s Hospital, Boston, 

MA, 6 University of Massachusetts Medical School, 

Worcester, MA, 7 Rush University Medical Center, 

Chicago, IL, 8 Medical University of Vienna, Vienna, 

Austria, 9 Division of Rheumatology, Medical University 

of Vienna and Hietzing Hospital, Vienna, Austria, 

10 

Yale University School of Medicine, New Haven, CT, 

11 

Brigham & Women’s Hospital, Boston, MA 

151 A 

Rheumatoid Arthritis – Human Etiology and 

Pathogenesis II 

Moderators: John D. Isaacs, PhD, MB BS, FRCP; Juan J. 

Gomez-Reino, MD, PhD 

11:00 am 

3215. ASK1 Is Regulated by IL-1β and TNF and 

Modulates Key Rheumatoid Arthritis (RA) 

Fibroblast-Like Synoviocyte Functions (FLS) 

Gyrid Nygaard 1 , Deepa Hammaker 2 , David L. Boyle 3 , 

Astrid Clarke 4 , Li Li 5 , Julie Dipaolo 6 and Gary Firestein 7 , 

1 

UC San Diego, La Jolla, CA, 2 UCSD School of Medicine, 

La Jolla, CA, 3 University of California, San Diego, La Jolla, 

CA, 4 GIlead, South San Francisco, CA, 5 Gilead Sciences, 

South San Francisco, CA, 6 Gilead, South San Francisco, 

CA, 7 UCSD, La Jolla, CA 

11:15 am 

3216. Integrated High-Dimensional Analyses Reveal 

a Pathologically Expanded ‘Peripheral’ B Cell-Helper 

T Cell Population in Rheumatoid Arthritis 

Deepak Rao 1 , Michael Gurish 1 , Kamil Slowikowski 1 , 

Chamith Fonseka 1 , Jennifer Marshall 2 , Yanyan Liu 1 , 

Laura T. Donlin 3 , Lauren Henderson 4 , Fumitaka 

Mizoguchi 5 , Nikola Teslovich 6 , Michael Weinblatt 1 , 

Elena Massarotti 1 , Jonathan Coblyn 1 , Simon M. 

Helfgott 1 , Yvonne C. Lee 1 , Derrick J. Todd 1 , Vivian P. 

Bykerk 7 , Susan M. Goodman 3 , Alessandra B. Pernis 3 , 

Lionel Ivashkiv 3 , Elizabeth W. Karlson 1 , Peter Nigrovic 6 , 

Andrew Filer 2 , Christopher Buckley 2 , James Lederer 1 , 

Soumya Raychaudhuri 8 and Michael Brenner 1 , 

1 


School, Boston, MA, 2 University of Birmingham, 

Birmingham, United Kingdom, 3 Hospital for Special 

Surgery, New York, NY, 4 Boston Children’s Hospital, 

Harvard Medical School, Boston, MA, 5 Graduate School 

of Medical and Dental Sciences, Tokyo Medical and 

Dental University, Tokyo, Japan, 6 Brigham and Women’s 

Hospital and Harvard Medical School, Cambridge, MA, 

7 

Divison of Rheumatology, Hospital for Special Surgery, 

New York, NY, 8 Brigham and Women’s Hospital, 

Boston, MA 

11:30 am 

3217. Broad-Based Interrogation of the Serum 

Proteome Suggests That RA Onset Is Associated 

with Activation of the Intrinsic Coagulation 

Cascade 

Liam O’Neil 1 , Xiaobo Meng 1 , Irene Smolik 1 , Carol 

Hitchon 1 and Hani El-Gabalawy 2 , 1 University of 

Manitoba, Winnipeg, MB, 2 University of Manitoba 

Arthritis Center, Winnipeg, MB 

11:45 am 

3218. Synovial Mast Cells Associate with High 

Disease Activity and Predict Radiographic 

Progression at 12 Months in Patients with Early 


Felice Rivellese 1 , Frances Humby 1 , Stephen Kelly 1 , 

Amato de Paulis 2 , Gianni Marone 2 and Costantino 

Pitzalis 1 , 1 Centre for Experimental Medicine and 

Rheumatology, William Harvey Research Institute, 

Barts and The London, School of Medicine and 

Dentistry, Queen Mary University of London, London, 


185


Wednesday 



United Kingdom, 2 Department of Translational Medical 

Sciences and Center for Basic and Clinical Immunology 

Research (CISI), University of Naples Federico II, Naples, 

Italy 

12:00 pm 

3219. Altered microRNA Expression Pattern in 

Synovial and Blood Neutrophils in Rheumatoid 

Arthritis Reveals the Pathogenic Profile of These 

Cells. Effect of Biological Therapies 

Nuria Barbarroja 1 , Ivan Arias de la Rosa 1 , Carlos 

Perez-Sanchez 1 , Yolanda Jiménez-Gómez 1 , Maria 

Carmen Abalos-Aguilera 1 , Miguel Angel Caracuel-Ruiz 2 , 

Jerusalem Calvo-Gutierrez 1 , Rafaela Ortega-Castro 1 , 

Eduardo Collantes-Estévez 1 , Alejandro Escudero- 

Contreras 1 , Chary Lopez-Pedrera 1 and Patricia Ruiz- 

Limon 1 , 1 IMIBIC/Reina Sofia Hospital/University of 

Cordoba, Cordoba, Spain, 2 IMIBIC/Reina Sofia Hospital/ 

University of Cordoba, Córdoba, Spain 

12:15 pm 

3220. Distinct Single Cell Gene Expression 

Signatures of Monocyte Subsets Differentiate 

Between TNF-Alpha Inhibitor Treatment Response 

Groups in Rheumatoid Arthritis 

Theresa L. Wampler Muskardin 1 , Wei Fan 1 , Zhongbo 

Jin 1 , Mark A. Jensen 1 , Jessica M. Dorschner 1 , Yogita 

Ghodke-Puranik 1 , Kerry Wright 1 , John M. Davis III 1 , 

Eric L. Matteson 1 , Clement Michet Jr. 1 , Thomas G. 

Mason II 2 , Scott T. Persellin 2 , Daniel Schaffer 1 , Betty 

Dicke 1 , Danielle Vsetecka 1 and Timothy B. Niewold 1 , 

1 

Mayo Clinic, Rochester, MN, 2 Mayo Clinic Rochester, 

Rochester, MN 

Hall E 


Biologics, and Gene Therapy V: New Biologics 

and Remission Induction 

Moderators: Mark C. Genovese, MD; Allan Gibofsky, 

MD, JD, MACR 

11:00 am 

3221. Efficacy and Safety of Sarilumab Versus 

Adalimumab in a Phase 3, Randomized, Double- 

Blind, Monotherapy Study in Patients with 

Active Rheumatoid Arthritis with Intolerance or 

Inadequate Response to Methotrexate 

Gerd Burmester 1 , Yong Lin 2 , Rahul Patel 2 , Janet van 

Adelsberg 3 , Erin Mangan 3 , Hubert van Hoogstraten 2 , 

Deborah Bauer 2 , Juan Ignacio Vargas 4 and Eun Bong 

Lee 5 , 1 Charit, Berlin, Germany, 2 Sanofi Genzyme, 

Bridgewater, NJ, 3 Regeneron Pharmaceuticals, Inc., 

Tarrytown, NY, 4 Quantum Research, Puerto Varas, 

Chile, 5 Seoul National University, Seoul, Korea, Republic 

of 

11:15 am 

3222. Efficacy and Safety of Monotherapy with 

Sirukumab, an Anti–IL-6 Cytokine Monoclonal 

Antibody, Compared with Adalimumab 

Monotherapy in Biologic-Naive Patients with 

Active Rheumatoid Arthritis: Results of a Global, 

Randomized, Double-Blind, Parallel-Group, Phase 3 

Study 

Peter C. Taylor 1 , Michael Schiff 2 , Qingmin Wang 3 , 

Yusang Jiang 3 , Regina Kurrasch 4 , Shruti Daga 5 , Ravi 

Rao 6 , Benjamin Hsu 3 and Paul P. Tak 7 , 1 Kennedy 

Institute of Rheumatology, NDORMs, University 

of Oxford, Oxford, United Kingdom, 2 University of 

Colorado, School of Medicine, Denver, CO, 3 Janssen 

Research & Development, LLC, Spring House, PA, 

4 

GlaxoSmithKline, Collegeville, PA, 5 GlaxoSmithKline, 

Uxbridge, United Kingdom, 6 GSK Medicines Research 

Centre, Stevenage, Hertfordshire, United Kingdom, 

7 

GlaxoSmithKline, Stevenage, Hertfordshire, United 

Kingdom 

11:30 am 

3223. Efficacy and Safety of Sirukumab, an Anti– 

IL-6 Cytokine Monoclonal Antibody, in Patients 

with Active Rheumatoid Arthritis Despite Anti-TNF 

Therapy: Results from a Randomized, Double-Blind, 

Placebo-Controlled, Global, Phase 3 Study 

Daniel Aletaha 1 , Clifton Bingham III 2 , Yoshiya Tanaka 3 , 

Prasheen Agarwal 4 , Regina Kurrasch 5 , Paul P. Tak 6 and 

Sharon Popik 4 , 1 Division of Rheumatology, Medical 

University of Vienna, Vienna, Austria, 2 Division of 

Rheumatology, Johns Hopkins University School of 

Medicine, Baltimore, MD, 3 University of Occupational 

and Environmental Health, Kitakyushu, Japan, 4 Janssen 

Research & Development, LLC, Spring House, PA, 

5 

GlaxoSmithKline, Collegeville, PA, 6 GlaxoSmithKline, 

Stevenage, Hertfordshire, United Kingdom 


Wednesday 




11:45 am 

3224. Efficacy of Sirukumab, an Anti–IL-6 Cytokine 

Monoclonal Antibody, Based upon Prior Use of 

Non-Anti-TNF Biologics in Patients with Active 

Rheumatoid Arthritis Despite Anti-TNF Therapy: 

Results from a Global Phase 3 Study 

Yoshiya Tanaka 1 , Daniel Aletaha 2 , Clifton Bingham 

III 3 , Prasheen Agarwal 4 , Regina Kurrasch 5 and Sharon 

Popik 4 , 1 University of Occupational and Environmental 

Health, Kitakyushu, Japan, 2 Division of Rheumatology, 

Medical University of Vienna, Vienna, Austria, 3 Division 

of Rheumatology, Johns Hopkins University School 

of Medicine, Baltimore, MD, 4 Janssen Research & 

Development, LLC, Spring House, PA, 5 GlaxoSmithKline, 

King of Prussia, PA 

12:00 pm 

3225. Dual Cytokine Inhibition with ABT-122, a 

Tnf– and IL-17–Targeted Dual Variable Domain 

Immunoglobulin (DVD-Ig): Results from a 24- 

Week Open-Label Extension Study in Patients with 


Mark C. Genovese 1 , Michael Weinblatt 2 , Heikki T. 

Mansikka 3 , Paul M. Peloso 3 , Kun Chen 3 , Yihan Li 3 , John 

Liu 3 and Robert J. Padley 3 , 1 Stanford University Medical 

Center, Palo Alto, CA, 2 Brigham and Women’s Hospital, 

Boston, MA, 3 AbbVie Inc., North Chicago, IL 

12:15 pm 

3226. Maintenance of Clinical Remission and 

Radiographic Non-Progression with MTX after 

Completion of 1 Year Initial Treatment with 

Certolizumab Pegol in Japanese Patients with Early 


Yoshiya Tanaka 1 , Tatsuya Atsumi 2 , Kazuhiko 

Yamamoto 3 , Tsutomu Takeuchi 4 , Hisashi Yamanaka 5 , 

Naoki Ishiguro 6 , Katsumi Eguchi 7 , Akira Watanabe 8 , 

Hideki Origasa 9 , Toshiharu Shoji 10 , Pauline Ralston 11 , 

Désirée van der Heijde 12 , Nobuyuki Miyasaka 13 

and Takao Koike 14 , 1 University of Occupational and 

Environmental Health, Kitakyushu, Japan, 2 Hokkaido 

University Graduate School of Medicine, Sapporo, 

Japan, 3 The University of Tokyo, Tokyo, Japan, 4 Division 

of Rheumatology, Keio University School of Medicine, 

Tokyo, Japan, 5 Tokyo Women’s Medical University, 

Tokyo, Japan, 6 Nagoya University, Nagoya, Japan, 

7 

Sasebo Chuo Hospital, Sasebo, Japan, 8 Tohoku 

University, Sendai, Japan, 9 University of Toyama 

School of Medicine, Toyama, Japan, 10 UCB Pharma, 

Tokyo, Japan, 11 Hays Pharma, London, United 

Kingdom, 12 Leiden University Medical Center, Leiden, 

Netherlands, 13 Tokyo Medical and Dental University, 

Tokyo, Japan, 14 Sapporo Medical Center NTT EC, 

Sapporo, Japan 

145 A 

Sjögren’s Syndrome II: Basic Insights 

Moderators: Simon Bowman, PhD, FRCP; R. Hal 

Scofield, MD 

11:00 am 

3227. Modelling Primary Sjögren’s Syndrome Using 

Salivary Gland Stem Cells 

Sarah Pringle 1 , Hendrika Bootsma 2 , Arjan Vissink 3 , 

Fred K.L. Spijkervet 3 , Robert Coppes 1 and Frans G.M. 

Kroese 3 , 1 University Medical Centrum Groningen, 

Groningen, Netherlands, 2 Rheumatology and Clinical 


Medical Center Groningen, The Netherlands, 

Groningen, Netherlands, 3 University of Groningen, 

University Medical Center Groningen, Groningen, 

Netherlands 

11:15 am 

3228. Specific T Cell and B Cell Distributions 

Characterize Subgroups of Patients with Primary 

Sjögren’s Syndrome and Are Associated with 

Disease Activity and Pro-Inflammatory Cytokine 

Expression 

Lucas Le Lann 1 , Quentin Simon 1 , Christophe Jamin 1 , 

Maria Orietta Borghi 2 , Lorenzo Beretta 3 , Ricard 

Cervera 4 , Alain Saraux 5 , Divi Cornec 1 , Rik Lories 6 , Carlo 

Chizzolini 7 , Marta E. Alarcon Riquelme 8 , Jacques-Olivier 

Pers 1 and on behalf of the PRECISESADS Consortium, 

1 

INSERM ERI29, EA2216, Université de Brest, Labex 

IGO, CHRU Morvan, Brest, France, 2 University of 

Milan, IRCCS Istituto Auxologico Italiano, Milan, 

Italy, 3 Rheumatology, Milan, Italy, 4 Department of 

Autoimmune Diseases, Institut Clínic de Medicina i 

Dermatologia, Hospital Clínic de Barcelona, Barcelona, 

Spain, 5 CHU de la Cavale Blanche, Brest Cedex, France, 

6 

KU Leuven and University Hospitals Leuven., Leuven, 

Belgium, 7 University hospital of Geneva, Geneva, 

Switzerland, 8 Pfizer-University of Granada-Junta de 

Andalucía, Granada, Spain 


187


Wednesday 



11:30 am 

3229. Bone Morphogenetic Protein 6 Receptor 

Inhibition Restores Salivary Gland Function in a 

Mouse Model of Primary Sjögren’s Syndrome 

Hongen Yin 1 , Lovika Kalra 1 , Arif Karim 1 , Zhennan Lai 1 , 

Maria Guimaro 1 , Lauren Aber 1 , Bill Swaim 1 , Sandra 

Afione 1 , Alexandria Voigt 2 , Cuong Nguyen 3 , Paul 

Yu 4 , Donald Bloch 5 and John A. Chiorini 1 , 1 Molecular 

Physiology and Therapeutics Branch, National 

Institute of Dental and Craniofacial Research, National 

Institutes of Health, Bethesda, MD, 2 Department 

of Pathology and Infectious Diseases, University of 

Florida, Gainesville, FL, 3 Department of Pathology and 

Infectious Diseases, University of Florida, Bethesda, 

MD, 4 Cardiovascular Division, Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA, 5 Center 

for Immunology and Inflammatory Diseases and the 

Division of Rheumatology, Allergy, and Immunology of 

the Department of Medicine, Massachusetts General 

Hospital, Harvard Medical School, Boston, MA 

11:45 am 

3230. Genome-Wide Association Study Identifies 

Novel Sjögren’s Syndrome Risk Loci in the Regions 

of NAB1, TYK2, and PTTG1-mir146a 

Christopher J. Lessard 1 , Indra Adrianto 1 , John Ice 1 , 

Astrid Rasmussen 2 , Kiely Grundahl 3 , Jennifer A. 

Kelly 1 , R. Hal Scofield 1 , Simon Bowman 4 , Susan 

Lester 5 , Per Eriksson 6 , Maija-Leena Eloranta 7 , Johan 

G. Brun 8 , Lasse G. Goransson 9 , Erna Harboe 9 , Marika 

Kvarnström 10 , Michael T. Brennan 11 , James Chodosh 12 , 

Raj Gopalakrishnan 13 , Andrew J.W. Huang 14 , Pamela 

Hughes 13 , David M. Lewis 15 , Michael D. Rohrer 13 , 

Donald U. Stone 16 , Nelson L. Rhodus 13 , Barbara 

M. Segal 17 , Lida Radfar 15 , A. Darise Farris 18 , Joel M. 

Guthridge 1 , Patrick M. Gaffney 1 , Judith A. James 1 , 

John B. Harley 19 , Lars Rönnblom 7 , Juan-Manuel 

Anaya 20 , Deborah S. Cunninghame-Graham 21 , 

Timothy J. Vyse 22 , Ilias Alevizos 23 , Xavier Mariette 24 , 

Roald Omdal 9 , Marie Wahren-Herlenius 25 , Torsten 

Witte 26 , Roland Jonsson 27 , Maureen Rischmueller 28 , 

Lindsey A. Criswell 29 , Courtney G. Montgomery 1 , 

Wan-Fai Ng 30 , Gunnel Nordmark 31 and Kathy L. 

Sivils 1 , 1 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 2 Arthritis and Clinical Immunology 

Research Program, Oklahoma Medical Research 

Foundation, USA, Oklahoma City, OK, 3 Oklahoma 

Medical Research Foundation, Oklahoma CIty, OK, 

4 

Department of Rheumatology, University Hospitals 

Birmingham NHS Foundation Trust, Birmingham, 

United Kingdom, 5 Queen Elizabeth Hospital, University 

of Adelaide, Adelaide, Australia, 6 Rheumatology clinic, 

Linköping, Sweden, 7 Uppsala University, Department 

of Medical Sciences, Rheumatology and Science 

for Life Laboratory, Uppsala, Sweden, 8 Haukeland 

University Hospital, Bergen, Norway, 9 Stavanger 

University Hospital, Stavanger, Norway, 10 Karolinska 

Institutet, Stockholm, Sweden, 11 Carolinas Medical 

Center, Charlotte, NC, 12 University of Oklahoma Health 

Sciences Center, Oklahoma City, OK, 13 University of 

Minnesota School of Dentistry, Minneapolis, MN, 

14 

Washington University,, St Louis, MO, 15 University 

of Oklahoma College of Dentistry, Oklahoma City, 

OK, 16 Dean McGee Eye Institute, Oklahoma City, OK, 

17 

University of Minnesota Medical School, Minneapolis, 

MN, 18 Oklahoma Medical Research Foun, Oklahoma 

City, OK, 19 Cincinnati Childrens Hospital, Cincinnati, 

OH, 20 Center for Autoimmune Diseases Research 

(CREA). School of Medicine and Health Sciences, 

Universidad del Rosario, Bogotá, Colombia., Bogotá, 

Colombia, 21 King’s College London, London, United 

Kingdom, 22 King’s College London, London, United 

Kingdom, 23 National Institute of Dental and Craniofacial 

Research, Bethesda, MD, 24 Université Paris-Sud, AP- 

HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 

25 

Department of Medicine, Solna, Unit of Experimental 

Rheumatology, Karolinska Institutet, and Karolinska 

University Hospital, Stockholm, Sweden, Stockholm, 

Sweden, 26 Hannover Medical School, Hannover, 

Germany, 27 University of Bergen, Bergen, Norway, 

28 

University of Adelaide, Adelaide, Australia, 29 UCSF, San 

Francisco, CA, 30 Newcastle University, Newcastle upon 

Tyne, United Kingdom, 31 Rheumatology, Department of 

Medical Sciences, Uppsala University, Sweden, Uppsala, 

Sweden 

12:00 pm 

3231. miR200b-5p Expression in Minor Salivary 

Glands (MSG): A Possible Predictor of Lymphoma 

Development in Sjögren’s Syndrome (SS)? 

Efstathia K. Kapsogeorgou 1 , Aristea Papageorgiou 1 , 

Michael Voulgarelis 1 and Athanasios G. Tzioufas 2 , 

1 

School of Medicine, National and Kapodistrian 

University of Athens, Athens, Greece, 2 School of 


Wednesday 




Medicine, Pathophysiology Department, National and 

Kapodistrian University of Athens, Athens, Greece 

12:15 pm 

3232. Decreased Expression of Micro-RNA 130a 

and Micro-RNA 708 in Type-1 Classical Dendritic 

Cells of Patients with Primary SS Indicates Their 

Dysregulation 

Maarten R. Hillen, Sofie L.M. Blokland, Elena Chouri, 

Ana Lopes, Aike A. Kruize, Marzia Rossato, Timothy 

R.D.J. Radstake and Joel A.G. van Roon, UMC Utrecht, 

Utrecht, Netherlands 

Hall D 


Aspects and Treatment VI: Quality of Life 

Moderators: Meenakshi Jolly, MD, MS; Swamy 

Venuturupalli, MD 

11:00 am 

3233. Determinants of Pain, Fatigue, Physical 

Function, and Social Participation in SLE Patients, 

Measured with Patient Reported Outcomes 

Measurement Information System (PROMIS®) 

Computerized Adaptive Tests 

Shanthini Kasturi, Jayme C. Burket, Jessica Berman, 

Kyriakos A. Kirou, Alana B. Levine, Lisa R. Sammaritano 

and Lisa Mandl, Hospital for Special Surgery, New York, 

NY 

11:15 am 

3234. Prevalence and Metric of Depression and 

Anxiety in Lupus: A Systematic Review and Meta- 

Analys 

Ahmed Moustafa 1 , Mohamed Hassanein 2 , Lihi Eder 3 , 

Joan E. Wither 4 , William Fung 5 , Panayiotis Lambiris 6 

and Zahi Touma 4 , 1 Western University, London, ON, 

2 

Michigan State University, East Lansing, MI, 3 University 

of Toronto, Women’s College Hospital, Toronto, ON, 

4 


Toronto, ON, 5 University of Toronto, Toronto, ON, 

6 

University Health Network, Toronto, ON 

11:30 am 

3235. Long-Term Impact of Belimumab on Health- 

Related Quality of Life and Fatigue in Patients with 

Systemic Lupus Erythematosus: Up to 7 Years of 

Treatment Exposure 

Vibeke Strand 1 , Pam Berry 2 , Sulabha Ramachandran 2 

and James Fettiplace 3 , 1 Stanford University School of 

Medicine, Palo Alto, CA, 2 GSK, Philadelphia, PA, 3 GSK, 

Uxbridge, Middlesex, United Kingdom 

11:45 am 

3236. Socio-Demographic and Clinical Factors 

Influencing Generic and Disease-Specific 

Quality of Life in Patients with Systemic Lupus 

Erythematosus: Results of a Prospective 

Multicenter Study 

Hervé Devilliers 1 , Jean-François Besancenot 1 , Sylvain 

Audia 2 , Bernard Bonnotte 3 , Francois Maurier 4 , 

Christiane Broussolle 5 , Nadine Magy-Bertrand 6 , Denis 

Wahl 7 , Jean-Loup Pennaforte 8 , Thierry Martin 9 , Olivier 

Aumaître 10 , Gilles Blaison 11 , Geraldine Muller 1 , Alexis 

Mathian 12 , Christine Binquet 13 and Zahir Amoura 12 , 

1 

Department of Internal Medicine and Systemic 

Diseases, Hôpital François Mitterrand, CHU de Dijon, 

Dijon, France, 2 Department of Internal Medicine and 

Clinical Immunology, Hôpital François Mitterrand, 

CHU de Dijon; INSERM, UMR1098, University of 

Bourgogne Franche-Comté, FHU INCREASE, Dijon, 

France, 3 Department of Internal Medicine and Clinical 

Immunology, Hôpital François Mitterrand, CHU de 

Dijon, Dijon, France, 4 Department of Internal Medicine, 

HP Metz Belle Isle Hospital, Metz, France, 5 Internal 

medicine department, Hôpital de la Croix-Rousse, 

Hospices Civils de Lyon, Lyon, France, 6 CHU Jean- 

Minjoz, Service de médecine interne et immunologie 

clinique, Besançon, France, 7 CHU de Nancy, Vascular 

Medicine Division and Regional Competence Centre 

For Rare Vascular And Systemic Autoimmune 

Diseases; and UMR_S U1116 Research Unit, Nancy, 

France, 8 Internal medicine departement, CHU de 

Reims, Reims, France, 9 Internal medicine and clinical 

immunology departement, Strasbourg University 

Hospital, Strasbourg, France, 10 CHU Pitié-Salpêtrière - 

Department of Internal Medicine 2. Referal center for 

SLE/APS, Paris, France, 11 Internal medicine 


189


Wednesday 



departement, Colmar Hospital, Colmar, France, 

12 

Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 

06 & French National Reference Center For Systemic 

Lupus and Antiphospholipid Syndrome, Paris, France, 

13 

INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital 

François Mitterrand, CHU de Dijon, Dijon, France 

12:00 pm 

3237. Responsiveness and Its Magnitude in the 

36-Item Short Form Health Survey and the Lupus 

Quality of Life Questionnaire in Patients with 

Active Disease 

Stephanie Nantes 1 , Jiandong Su 2 and Zahi Touma 1 , 

1 


Toronto, ON, 2 Toronto Western Hospital and University 

of Toronto, Toronto, ON 

Uppsala, Sweden, 3 Department of Medicine, Solna, Unit 

of Experimental Rheumatology, Karolinska Institutet, 

and Karolinska University Hospital, Stockholm, Sweden, 

Stockholm, Sweden 

11:15 am 

3240. Interferon Kappa Is a Novel Type I IFN That 

Drives Cutaneous Inflammation in Systemic Lupus 

Jasmine Stannard 1 , Tamra J. Reed 1 , Emily Myers 2 , 

Lori Lowe 1 , Mrinal Sarkar 1 , Xianying Xing 1 , Celine 

C. Berthier 3 , Johann Gudjonsson 1 and J. Michelle 

Kahlenberg 4 , 1 University of Michigan, Ann Arbor, MI, 

2 

Georgetown University, Washington, DC, 3 Division of 

Nephrology, University of Michigan Medical Center, 

Ann Arbor, MI, 4 Division of Rheumatology, University of 

Michigan Medical Center, Ann Arbor, MI 

12:15 pm 

3238. Depression Symptoms Throughout the 

Lifespan in a Low-Income, Minority Cohort of Lupus 

Patients: Who Is at Risk? 

Tamar Rubinstein 1 , Noa Schwartz 2 , Nicole Jordan 3 , 

Rebecca Lois 1 , Dawn Wahezi 4 , Ruth E K Stein 5 and 

Chaim Putterman 2 , 1 Albert Einstein College of Medicine, 

Children’s Hospital at Montefiore, Bronx, NY, 2 Albert 

Einstein College of Medicine, Bronx, NY, 3 Montefiore 

Medical Center, New York, NY, 4 The Children’s Hospital 

at Montefiore, Bronx, NY, 5 Children’s Hospital at 

Montefiore, Bronx, NY 

147 A 

Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis II 

Moderator: Susan A. Boackle, MD 

11:00 am 

3239. Expression of IFN-Regulated Genes in 

Autoantibody Exposed Babies in Utero 

Malin Hedlund 1 , Gudny-Ella Thorlacius 1 , Margarita 

Ivanchenko 1 , Vijole Ottosson 1 , Amina Ossoinak 1 , 

Linda Lagnefeldt 1 , Joanna Tingstrom 1 , Alexander 

Espinosa 1 , Lars Rönnblom 2 , Maija-Leena Eloranta 2 , 

Sven-Erik Sonesson 1 and Marie Wahren-Herlenius 3 , 

1 

Department of Medicine, Solna, Unit of Experimental 

Rheumatology, Karolinska Institutet, and Karolinska 

University Hospital, Stockholm, Stockholm, Sweden, 

2 

Uppsala University, Department of Medical Sciences, 

Rheumatology and Science for Life Laboratory, 

11:30 am 

3241. Genetic Variation and Tobacco Smoke 

Exposure in Systemic Lupus Erythematosus: A Case 

Control Study Among African Americans 

Bethany Wolf, Paula S. Ramos, Paul Nietert, J. Madison 

Hyer, Viswanathan Ramakrishnan, Gary S. Gilkeson, 

Gerard Hardiman and Diane L. Kamen, Medical 

University of South Carolina, Charleston, SC 

11:45 am 

3242. Identification and Functional 

Characterization of TNIP1 Causal Variants 

Associated with Systemic Lupus Erythematosus 

Satish Pasula 1 , Mandi Wiley 1 , Ying-yu Wu 1 , Ajay Nair 1 , 

Jaanam Gopalakrishnan 2 and Patrick M. Gaffney 1 , 

1 

Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 2 University of Oklahoma Health Sciences 

Center, Oklahoma City, OK 

12:00 pm 

3243. Intestinal Microbial Dysbiosis in SLE Is Linked 

to Elevated IgA and Induction of Autoimmunity 

Doua F. Azzouz 1 , Lelise Getu 2 , Celine Anquetil 1 , Jill 

P. Buyon 2 and Gregg J. Silverman 2 , 1 NYU School of 

Medicine, New York, NY, 2 New York University School of 



Wednesday 




12:15 pm 

3244. Observations of Early and Late B Cell 

Alterations During Belimumab Treatment in 

Patients with Systemic Lupus Erythematosus Using 

Mass Cytometry (CyTOF) 

Ioannis Parodis, Daniel Ramsköld, Petter Brodin, 

Agneta Zickert, Lakshmikanth Tadepally, Yang Chen, 

Jaromir Mikes, Adnane Achour, Iva Gunnarsson and 

Vivianne Malmström, Karolinska Institutet, Karolinska 

University Hospital, Stockholm, Sweden 

146 A 


Raynaud’s – Clinical Aspects and Therapeutics 

III 

Moderators: Laura K. Hummers, MD, ScM; Janet E. 

Pope, MD, MPH, FRCPC 

11:00 am 

3245. Surfactant Protein D and Krebs Von Den 

Lungen-6 Predict Severity of Systemic Sclerosis- 

Related Interstitial Lung Disease in Two 

Independent Cohorts 

Elizabeth R. Volkmann 1 , Donald P. Tashkin 2 , Faye 

N. Hant 3 , Galina S. Bogatkevich 3 , Michael Roth 1 , 

Kim Hyun 1 , Jonathan Goldin 1 , Tanjina Akter 3 , Holly 

Wilhalme 1 , Chi-hong Tseng 1 , Shervin Assassi 4 , Dinesh 

Khanna 5 , Philip J. Clements 1 , Daniel E. Furst 1 , Robert 

Elashoff 2 and Richard Silver 3 , 1 University of California, 

Los Angeles, David Geffen School of Medicine, Los 

Angeles, CA, 2 University of California, Los Angeles, Los 

Angeles, CA, 3 Medical University of South Carolina, 

Charleston, SC, 4 University of Texas-McGovern Medical 

School, Houston, TX, 5 University of Michigan, Ann 

Arbor, MI 

11:15 am 

3246. Predictors of Long-Term Outcomes in 

Systemic Sclerosis Associated Pulmonary Arterial 

Hypertension from the Pulmonary Hypertension 

Assessment and Recognition of Outcomes in 

Scleroderma Registry 

Kathleen Kolstad 1 , Shufeng Li 2 , Virginia D. Steen 3 

and Lorinda Chung 4 , 1 Stanford Univeristy, Stanford, 

CA, 2 Stanford University, Stanford, CA, 3 Georgetown 

University Medical Center, Washington, DC, 4 Stanford 

University Medical Center, Palo Alto, CA 

11:30 am 

3247. Safety and Efficacy of Belimumab with 

Background Mycophenolate for Early Diffuse 

Cutaneous Systemic Sclerosis: A Randomized, 

Placebo Controlled, Pilot Trial 

Jessica K. Gordon 1 , Eliza Pelrine 1 , Yuo-Yu Lee 1 , Cynthia 

Magro 2 , Elana J. Bernstein 3 , Horatio F. Wildman 2 and 

Robert F. Spiera 1 , 1 Hospital for Special Surgery, New 

York, NY, 2 Weill Cornell Medical College, New York, NY, 

3 

Columbia University, New York, NY 

11:45 am 

3248. Efficacy of Mycophenolate Mofetil and Oral 

Cyclophosphamide on Skin Thickness: Post-Hoc 

Analyses from the Scleroderma Lung Study I and II 

Rajaie Namas 1 , Donald P. Tashkin 2 , Holly Wilhalme 3 , 

Daniel E. Furst 4 , Chi-hong Tseng 3 , Michael Roth 3 , 

Suzanne Kafaja 5 , Elizabeth R. Volkmann 3 , Philip 

J. Clements 3 and Dinesh Khanna 1 , 1 University of 

Michigan, Ann Arbor, MI, 2 University of California, Los 

Angeles, Los Angeles, CA, 3 University of California, Los 


CA, 4 UCLA, Los Angeles, CA, 5 University of California Los 


CA 

12:00 pm 

3249. Improvement in Cough and Cough-Related 

Quality of Life in Participants Undergoing 

Treatment for Systemic Sclerosis-Related 

Interstitial Lung Disease 

Elizabeth R. Volkmann 1 , Dinesh Khanna 2 , Chi-hong 

Tseng 1 , Robert Elashoff 3 , Bingling Wang 3 , Michael Roth 1 , 

Philip J. Clements 1 , Daniel E. Furst 1 , Arthur Theodore 4 

and Donald P. Tashkin 3 , 1 University of California, Los 


CA, 2 University of Michigan, Ann Arbor, MI, 3 University 

of California, Los Angeles, Los Angeles, CA, 4 Boston 

University, Boston, MA 

12:15 pm 

3250. Serum MCP-1 Levels Predict Long-Term 

Progression of Interstitial Lung Disease in Systemic 

Sclerosis 

Minghua Wu 1 , Murray Baron 2 , Marie Hudson 3 , 

Marvin J. Fritzler 4 , Claudia Pedroza 1 , Jun Ying 1 , Gloria 

Salazar 1 , Julio Charles 1 , Maureen D Mayes 1 and 

Shervin Assassi 1 , 1 University of Texas-McGovern 


191


Wednesday 



Medical School, Houston, TX, 2 McGill University, Jewish 

General Hospital, Montreal, QC, 3 Lady David Institute 

for Medical Research and Jewish General Hospital, 

Montreal, QC, 4 University of Calgary, Calgary, AB 

ARHP SESSION 

11:00 am – 12:30 pm 

201 

Spondyloarthopathies: Beyond Medications 

PM PS PME 

PS E 

Moderator: Laura Cappelli, MD 

11:00 pm 

Complementary Medicine In the Management of Axial 

Spondyloarthritis: Is There Any Scientific Evidence? 


11:30 am 

Exercise and Physiotherapy In the Management of 

Patients with Axial Spondyloarthritis 

Speaker: Salih Ozgocmen, MD 

12:00 pm 

We Got Your Back! Empowering Patients with Axial 

Spondyloarthritis Through Education 

Speaker: Laura A. Passalent, BSc(PT), MHSc, ACPAC 


11:00 am – 12:30 pm 

Salon G 

ARHP VI – Rehabilitation Sciences 

Moderator: Paula Melson, DPT, MMS 

11:00 am 

3251. Sleep and Physical Activity: A Nationwide 

Survey Among People with Rheumatic Disease in 

Ireland 

Sean McKenna 1 , Alan Donnelly 1 , Sandy Fraser 2 and 

Norelee Kennedy 1 , 1 University of Limerick, Ireland, 

Limerick, Ireland, 2 University Hospitals Limerick, 

Ireland, Limerick, Ireland 

11:15 am 

3252. Content Analysis of Ergonomic 

Recommendations Using the Ergonomic 

Assessment Tool for Arthritis 

Lisa Allyn 1 , Lisa Zoller 1 , Catherine L. Backman 2 and 

Diane Lacaille 3 , 1 The University of British Columbia, 

Vancouver, BC, 2 Arthritis Research Canada, Richmond, 

BC, 3 University of British Columbia, Vancouver, BC 

11:30 am 

3253. Minimum Physical Function Needed to Walk 

6000 Steps/Day in People with Knee Osteoarthritis 

Hiral Master, Louise Thoma, Meredith Christiansen, 

Emily Polakowski, Laura Schmitt and Daniel White, 

University of Delaware, Newark, DE 

11:45 am 

3254. Use of the Short Valued Life Activities Scale in 

People with Systemic Sclerosis 

Janet L. Poole 1 and Betty Skipper 2 , 1 1 University of New 

Mexico, Albuquerque, NM, 2 University of New Mexico, 

Albuquerque, NM 

12:00 pm 

3255. A Randomized Trial of Automated Telephone- 

Linked Communication to Improve Exercise 

Adherence for a Progressive Resistance Training 

Program in People with Knee Osteoarthritis 

Kristin Baker 1 , Aileen Ledingham 1 , Carrie Brown 2 , Kelly 

Pesanelli 1 , Faye Cochrane 1 , Robert Friedman 3 , Michael 

P. LaValley 2 , David T. Felson 3 and Julie J. Keysor 3 , 

1 

Boston University Sargent College, Boston, MA, 

2 

Boston University School of Public Health, Boston, MA, 

3 

Boston University School of Medicine, Boston, MA 

12:15 pm 

3256. Functional Ability ‘to Rise’ and Autonomy 

Support for Physical Activity: Implications for Light 

Physical Activity Engagement and Psychological 

Wellbeing in People Living with Rheumatoid 

Arthritis 

Sally Fenton 1 , Jet Veldhuijzen van Zanten 2 , George 

Metsios 2 , Peter Rouse 3 , Chen-an Yu 1 , George D. 

Kitas 1 and Joan Duda 1 , 1 University of Birmingham, 

Birmingham, United Kingdom, 2 Russells Hall Hospital, 


Dudley, United Kingdom, 3 University of Bath, Bath, 



Wednesday 



INDUSTRY-SUPPORTED POST-MEETING 

SYMPOSIA 

1:00 pm – 4:00 pm 

For CME-accredited symposia, the sponsoring organization 

is responsible for planning and providing CME credit. 

Please visit the organization’s exhibit booth or the industrysupported 

symposia booth or download the ACR Annual 

Meeting App for more information on each symposium. 


193


These non-CME-accredited presentations have been planned and will be implemented with the requirements of the 

FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. 

Innovation Theater A & B Located in Hall A 


Innovation Theater A 

10:30 – 11:15 am 

Tocilizumab: Lessons Learned from a Decade of 

Clinical Study Experience 

Presented by Genentech 

12:30 – 1:15 pm 

Understanding the Clinical Profile of a 

Rheumatoid Arthritis Treatment 

Including an analysis of the effects of glucocorticoid 

use on its efficacy and safety profiles 

Presented by Pfizer, Inc. 

2:30 – 3:15 pm 

Spotlight on Erosive Disease: Biomarkers in 


Presented by Bristol-Myers Squibb 

Innovation Theater B 

11:30 am – 12:15 pm 

A new therapy in combination with a xanthine 

oxidase inhibitor: the benefits of addressing 

overproduction and inefficient excretion of uric 

acid in gout 

Presented by Ironwood Pharmaceuticals 

1:30 – 2:15 pm 

The Role of the JAK-STAT Pathway in Rheumatoid 

Arthritis (RA) 

Presented by Eli Lilly & Company 

3:30 – 4:15 pm 

Targeting Wnt: A New Pathway for Potential 

Disease Modification in Knee Osteoarthritis 

Presented by Samumed 



10:30 – 11:15 am 

COSENTYX ® (secukinumab) Innovation Theater 

Presented by Novartis Pharmaceuticals 

12:30 – 1:15 pm 

Integrating Wellness into Rheumatic Disease 

Management: An approach to improving 

population health in the US healthcare landscape 

Presented by UCB, Inc. 

2:30 – 3:15 pm 

Psoriatic Arthritis and Psoriasis: Two Interrelated 

Diseases, One Treatment 

Presented by Celgene Corporation 


11:30 am – 12:15 pm 

Initiating Biologic Therapy in Moderate to Severe 

RA: Options in Disease Management 

Presented by Amgen, Inc. 

1:30 – 2:15 pm 

New Perspectives on IL-6 and Rheumatoid 

Arthritis 

Presented by Sanofi, Genzyme, & Regeneron 

3:30 – 4:15 pm 

Intra-Articular Hyaluronic Acid for Management 

of Osteoarthritis Knee Pain 

Presented by Ferring Pharmaceuticals 


2 0 1 6 


tracker 


These non-CME-accredited presentations have been planned and will be implemented with the requirements of the 

FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. 

Innovation Theater A & B Located in Hall A 



10:30 – 11:15 am 

Multi-Specialty Perspectives on a Biologic with a 

Unique Mechanism of Action 

Presented by Janssen Biotech, Inc. 

12:30 – 1:15 pm 

From Pathway to Practice: Evaluating the 

Evidence for Biosimilars 




11:30 – 12:15 pm 

Managing Clinical and Practice Implications in the 

Era of Biosimilars 

Presented by Janssen Biotech, Inc. 

1:30 – 2:15 pm 

Complexities in Diagnosing and Treating Psoriatic 

Arthritis—How Can Specialists Work Together? 



195


INDUSTRY-SUPPORTED SYMPOSIA LISTING 

Non-CME Symposia 

The non-CME Programs are wholly sponsored and 

supported by the commercial entities listed. By holding 

the Programs, the commercial entities have represented 

that the Programs have been developed and will be 

implemented in accordance with the requirements of 

the FDA and applicable standards of the PhRMA Code on 

Interactions with Healthcare Professionals. The commercial 

entities are to observe all guidelines established by 

federal and state regulatory agencies regarding non-CME 

educational or promotional presentations throughout the 

duration of the Program. The content and views expressed 

during the Program are those of the commercial entities 

and presenters. The ACR by making this venue available 

does not guarantee, warrant or endorse the content of the 

Program nor the products discussed and reviewed during 

the Program. 

Clinical and Patient Perspectives: A “Joint” Approach 

for Improving the Management of Psoriatic Arthritis 

Non-CME Symposium 

Marriott Marquis Washington, DC, Liberty Ballroom 

LMNOP 

Developed and offered by Pfizer, Inc. 

Vision for the Future: Combining Forces with 

Ophthalmologists for the Treatment of Non- 

Infectious Uveitis 


Marriott Marquis Washington, DC, Marquis 

Ballroom 7, 8, 9, 10 

Developed and offered by AbbVie 

CME-Accredited Symposia 

For CME-accredited symposia, the sponsoring organization 

is responsible for planning and providing CME credit. 

SUNDAY, NOVEMBER 13 

A 3D View of Targeted Therapy for the Patient with 

Rheumatoid Arthritis: Changing the Treatment 

Paradigm by Inhibiting Key Intracellular Pathways 

CME-Accredited Symposium 

Marriott Marquis Washington, DC, Independence 

Ballroom ABCD 

Supported by an educational grant from Lilly USA, LLC 

TUESDAY, NOVEMBER 15 

Expert Insights on the Uses of COSENTYX® 

(secukinumab) 



Ballroom ABCD 

Developed and offered by Novartis Pharmaceuticals 

Emerging Steroid-Sparing Biologics for the 

Treatment of Giant Cell Arteritis 



Ballroom 7, 8, 9, 10 

Supported by an educational grant from Genentech 


2 0 1 6 


tracker 


INDUSTRY-SUPPORTED SYMPOSIA LISTING 

WEDNESDAY, NOVEMBER 16 

What’s New in Psoriatic Arthritis—Clinical 

Considerations When Targeting Specific Pathways 



Ballroom ABC 

Supported by an educational grant from Lilly USA, LLC 

Uncharted Territory: Management of Rheumatoid 

Arthritis and Comorbidities 



NOP 

Supported by an educational grant from Pfizer, Inc. 

Are You Up-to-Date on Individualizing SLE 

Treatment Strategies? An Innovative, Patient- 

Focused Learning Experience 



IJK 

Supported by an educational grant from GlaxoSmithKline 

Incorporating Biosimilars into the Rheumatic 

Disease Treatment Armamentarium 



Ballroom FGH 

Supported by an educational grant from Sandoz, Inc. 

SPARTAN-GRAPPA-ASAS Educational Symposium 

on Axial Spondyloarthritis (axSpA) and Psoriatic 

Arthritis (PsA) 



Ballroom 9 & 10 

Supported by an educational grant from AbbVie 


197


ACKNOWLEDGEMENTS 

The ACR and ARHP wish to thank the following organizations for providing support 

for the 2016 ACR/ARHP Annual Meeting. 

AbbVie 

Exhibit Hall Networking Lounges 

Exhibit Hall Column Wrap 

Exhibit Hall Escalator Clings 

Middle Building Escalator Clings 

Amgen, Inc. 

Grand Lobby Pre-Function Wall Banners 

Grand Lobby Rotunda Banners 

Session Tracker Plus 

Technology Kiosks 

ARHP Networking Forum 

Bristol-Myers Squibb Company 

Exhibit Hall Hanging Aisle Signs 

Celgene Corporation 

Exhibit Hall Floor Decals 

Conference Shuttle Buses 

Grand Lobby Column Cling 

EMD Serono 

Digital Signs 

Gilead 

Digital Signs 

Horizon Pharma 

Grand Lobby Banner 

Genentech, a Member of the Roche Group 

Hotel Key Cards 

Novartis Pharmaceuticals 

Exhibit Hall WiFi Way 

Digital Signs 

Grand Lobby Column Clings 

Pfizer, Inc. 

Concourse A/B Middle Rotunda Wall Banners 

Digital Signs 

L Street Bridge Banners 

Reata Pharmaceuticals 

Attendee Lounge 

Sanofi Genzyme and Regeneron Pharmaceuticals 

Charging Stations 

Digital Signs 

Grand Lobby Banners 

198 For the most up-to-date meeting content, download the 2016 ACR/ARHP Annual Meeting app from the App Store or Google Play.

Corporate Roundtable 

The Rheumatology Research 

Foundation is making great 

strides in its mission to advance 

research and training and 

improve the health of people 

with rheumatic diseases by 

increasing fundingfor research 

and training, thanks in large 

part to the generosity of the 

Corporate Roundtable. 

Participation in the Corporate 

Roundtable is a direct investment 

in the Foundation’s efforts 

to develop the next generation 

of rheumatology professionals 

who will provide high-quality 

care for patients, as well as 

accelerate research that will 

lead to advances in treatments 

and, one day, cures. 

leadership $7,500,000+ 

pinnacle $5,000,000+ 

principal $2,500,000+ 

partner $1,000,000+ 

executive $100,000+ 

GlaxoSmithKline


YEAR – ROUND SUPPORT LISTING 

In addition to the support provided for the 2016 ACR/ARHP Annual Meeting, the ACR, the ARHP, and the Foundation 

wish to thank the following organizations for providing support for activities and programs throughout the year. 

AbbVie 

Corporate Roundtable, Leadership 

Level 

Fellows Education Fund 

Annual Meeting Corporate 

Roundtable Symposium 

Annual Meeting Industry-Supported 

Post-Conference Symposium 

Amgen, Inc. 


Level 

Amgen Fellowship Training Awards 


Winter Rheumatology Symposium 

Maintenance of Certification Course 

Program Directors’ Meeting 

Division Directors’ Meeting 

State-of-the-Art Clinical Symposium 

CARE 2016 

Musculoskeletal Ultrasound Course 

for Rheumatologists 

Pediatric Visiting Professorship 

Program 

Pediatric Research Award 

AstraZeneca 

Corporate Roundtable, Principal 

Level 

Bristol-Myers Squibb Company 

Corporate Roundtable, Partner 

Level 

Celgene Corporation 


Level 






CARE 2016 



Genentech, a Member of the 

Roche Group 

Corporate Roundtable, Pinnacle 

Level 



GlaxoSmithKline 

Corporate Roundtable, Executive 

Level 



Janssen Biotech, Inc. 


Level 


Lilly USA, LLC 


Level 






CARE 2016 







Mallinckrodt Pharmaceuticals 


Novartis Pharmaceuticals 


Level 



Pfizer, Inc. 


Level 







Regeneron Healthcare Solutions 


Level 






CARE 2016 



Sanofi US 


Level 






CARE 2016 



UCB, Inc. 


Level 

200 For the most up-to-date meeting content, download the 2016 ACR/ARHP Annual Meeting app from the App Store or Google Play.

Notes

Notes

Enbrel ® (etanercept) Brief Summary 

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION 

WARNINGS 

SERIOUS INFECTIONS AND MALIGNANCIES 

Patients treated with Enbrel are at increased risk for developing serious infections 

that may lead to hospitalization or death [see Warnings and Precautions and Adverse 

Reactions]. Most patients who developed these infections were taking concomitant 

immunosuppressants such as methotrexate or corticosteroids. 

Enbrel should be discontinued if a patient develops a serious infection or sepsis. 

Reported infections include: 

• Active tuberculosis, including reactivation of latent tuberculosis. Patients with 

tuberculosis have frequently presented with disseminated or extrapulmonary 

disease. Patients should be tested for latent tuberculosis before Enbrel use and 

during therapy. Treatment for latent infection should be initiated prior to Enbrel use. 

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, 

candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with 

histoplasmosis or other invasive fungal infections may present with 

disseminated, rather than localized, disease. Antigen and antibody testing for 

histoplasmosis may be negative in some patients with active infection. Empiric 

anti-fungal therapy should be considered in patients at risk for invasive fungal 

infections who develop severe systemic illness. 

• Bacterial, viral, and other infections due to opportunistic pathogens, including 

Legionella and Listeria. 

The risks and benefits of treatment with Enbrel should be carefully considered prior 

to initiating therapy in patients with chronic or recurrent infection. 

Patients should be closely monitored for the development of signs and symptoms of 

infection during and after treatment with Enbrel, including the possible 

development of tuberculosis in patients who tested negative for latent tuberculosis 

infection prior to initiating therapy. 

MALIGNANCIES 

Lymphoma and other malignancies, some fatal, have been reported in children and 

adolescent patients treated with TNF blockers, including Enbrel. 

INDICATIONS AND USAGE 


Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, 

inhibiting the progression of structural damage, and improving physical function in 

patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be 

initiated in combination with methotrexate (MTX) or used alone. 


Enbrel is indicated for reducing signs and symptoms of moderately to severely active 

polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. 

Psoriatic Arthritis 

Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of 

structural damage of active arthritis, and improving physical function in patients with 

psoriatic arthritis (PsA). Enbrel can be used with or without MTX. 

Ankylosing Spondylitis 

Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing 

spondylitis (AS). 

Plaque Psoriasis 

Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic 

moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy 

or phototherapy. 

CONTRAINDICATIONS 

Enbrel should not be administered to patients with sepsis. 

WARNINGS AND PRECAUTIONS 

Serious Infections 

Patients treated with Enbrel are at increased risk for developing serious infections 

involving various organ systems and sites that may lead to hospitalization or death. 

Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, 

or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, 

coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and 

tuberculosis have been reported with TNF blockers. Patients have frequently presented 

with disseminated rather than localized disease. 

Treatment with Enbrel should not be initiated in patients with an active infection, 

including clinically important localized infections. Patients greater than 65 years of age, 

patients with co-morbid conditions, and/or patients taking concomitant 

immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk 

of infection. The risks and benefits of treatment should be considered prior to initiating 

therapy in patients: with chronic or recurrent infection; who have been exposed to 

tuberculosis; with a history of an opportunistic infection; who have resided or traveled 

in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, 

coccidioidomycosis, or blastomycosis; or with underlying conditions that may 

predispose them to infection, such as advanced or poorly controlled diabetes [see 

Adverse Reactions]. 

Patients should be closely monitored for the development of signs and symptoms 

of infection during and after treatment with Enbrel. 

Enbrel should be discontinued if a patient develops a serious infection or sepsis. 

A patient who develops a new infection during treatment with Enbrel should be 

closely monitored, undergo a prompt and complete diagnostic workup appropriate 

for an immunocompromised patient, and appropriate antimicrobial therapy should 

be initiated. 

Tuberculosis 

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed 

in patients receiving Enbrel, including patients who have previously received treatment 

for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest 

that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with 

TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of 

tuberculosis reactivation have been reported for TNF blockers, including Enbrel. 

Tuberculosis has developed in patients who tested negative for latent tuberculosis prior 

to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and 

tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests 

for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. 

Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has 

been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 

5 mm or greater with tuberculin skin testing should be considered a positive test result 

when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, 

even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). 

Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients 

with a past history of latent or active tuberculosis in whom an adequate course of 

treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis 

but having risk factors for tuberculosis infection. Consultation with a physician with 

expertise in the treatment of tuberculosis is recommended to aid in the decision whether 

initiating anti-tuberculosis therapy is appropriate for an individual patient. 

Tuberculosis should be strongly considered in patients who develop a new infection 

during Enbrel treatment, especially in patients who have previously or recently traveled 

to countries with a high prevalence of tuberculosis, or who have had close contact with 

a person with active tuberculosis. 

Invasive Fungal Infections 

Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have 

been reported with TNF blockers, including Enbrel. For patients who reside or travel in 

regions where mycoses are endemic, invasive fungal infection should be suspected if 

they develop a serious systemic illness. Appropriate empiric antifungal therapy should 

be considered while a diagnostic workup is being performed. Antigen and antibody 

testing for histoplasmosis may be negative in some patients with active infection. When 

feasible, the decision to administer empiric antifungal therapy in these patients should 

be made in consultation with a physician with expertise in the diagnosis and treatment 

of invasive fungal infections and should take into account both the risk for severe fungal 

infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort 

studies in all approved indications representing 27,169 patient-years of exposure 

(17,696 patients) from the United States and Canada, no histoplasmosis infections were 

reported among patients treated with Enbrel. 

Neurologic Events 

Treatment with TNF-blocking agents, including Enbrel, has been associated with rare 

(< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating 

disorders, some presenting with mental status changes and some associated with 

permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, 

Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset 

or exacerbation of seizure disorders have been reported in postmarketing experience 

with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel 

in patients with preexisting or recent-onset central or peripheral nervous system 

demyelinating disorders [see Adverse Reactions]. 

Malignancies 

Lymphomas 

In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma 

have been observed among patients receiving a TNF blocker compared to control patients. 

During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 

2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 

1521 control patients (duration of controlled treatment ranged from 3 to 36 months). 

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled 

and uncontrolled portions of clinical trials, representing approximately 12,845 patientyears 

of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. 

This was 3-fold higher than the rate of lymphoma expected in the general US population 

based on the Surveillance, Epidemiology, and End Results (SEER) Database. An 

increased rate of lymphoma up to several-fold has been reported in the RA patient 

population, and may be further increased in patients with more severe disease activity. 

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, 

representing approximately 4278 patient-years of therapy, the observed rate of 

lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the 

general population. No cases were observed in Enbrel- or placebo-treated patients 

during the controlled portions of these trials. 

Leukemia 

Cases of acute and chronic leukemia have been reported in association with 

postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in 

the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher 

risk (approximately 2-fold) than the general population for the development of leukemia. 

During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 

5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 

(0%) control patients (duration of controlled treatment ranged from 3 to 48 months). 

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical 

trials representing approximately 23,325 patient-years of therapy, the observed rate of 

leukemia was 0.03 cases per 100 patient-years. 

Other Malignancies 

Information is available from 10,953 adult patients with 17,123 patient-years and 696 

pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. 

For malignancies other than lymphoma and non-melanoma skin cancer, there was no 

difference in exposure-adjusted rates between the Enbrel and control arms in the 

controlled portions of clinical studies for all indications. Analysis of the malignancy rate in 

combined controlled and uncontrolled portions of studies has demonstrated that types and 

rates are similar to what is expected in the general US population based on the SEER 

database and suggests no increase in rates over time. Whether treatment with Enbrel might 

influence the development and course of malignancies in adults is unknown. 

Melanoma and Non-melanoma skin cancer (NMSC) 

Melanoma and non-melanoma skin cancer has been reported in patients treated with 

TNF antagonists including etanercept. 

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical 

trials representing approximately 23,325 patient-years of therapy, the observed rate of 

melanoma was 0.043 cases per 100 patient-years. 

Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled 

clinical trials representing approximately 2669 patient-years of therapy, the observed rate of 

NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 

control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients 

treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of 

therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 

100 patient-years among 720 control-treated patients representing 156 patient-years. 

Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in 

patients treated with Enbrel. 

Periodic skin examinations should be considered for all patients at increased risk for 

skin cancer. 

Pediatric Patients 

Malignancies, some fatal, have been reported among children, adolescents, and young 

adults who received treatment with TNF-blocking agents (initiation of therapy at 

≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, 

including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a 

variety of different malignancies and included rare malignancies usually associated 

with immunosuppression and malignancies that are not usually observed in children 

and adolescents. The malignancies occurred after a median of 30 months of therapy 

(range 1 to 84 months). Most of the patients were receiving concomitant 

immunosuppressants. These cases were reported postmarketing and are derived from 

a variety of sources, including registries and spontaneous postmarketing reports. 

In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, 

no malignancies, including lymphoma or NMSC, have been reported. 

Postmarketing Use 

In global postmarketing adult and pediatric use, lymphoma and other malignancies have 

been reported. 

Patients With Heart Failure 

Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were 

terminated early due to lack of efficacy. One of these studies suggested higher mortality 

in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have 

been postmarketing reports of worsening of congestive heart failure (CHF), with and 

without identifiable precipitating factors, in patients taking Enbrel. There have also been 

rare (< 0.1%) reports of new onset CHF, including CHF in patients without known 

preexisting cardiovascular disease. Some of these patients have been under 50 years of 

age. Physicians should exercise caution when using Enbrel in patients who also have 

heart failure, and monitor patients carefully. 

Hematologic Events 

Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic 

anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. 

The causal relationship to Enbrel therapy remains unclear. Although no high-risk group 

has been identified, caution should be exercised in patients being treated with Enbrel 

who have a previous history of significant hematologic abnormalities. All patients 

should be advised to seek immediate medical attention if they develop signs and 

symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, 

bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be 

considered in patients with confirmed significant hematologic abnormalities. 

Two percent of patients treated concurrently with Enbrel and anakinra developed 

neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient developed cellulitis that 

resolved with antibiotic therapy. 

Hepatitis B Reactivation 

Reactivation of hepatitis B in patients who were previously infected with the hepatitis B 

virus (HBV) and had received concomitant TNF-blocking agents, including very rare 

cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B 

reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The 

majority of these reports have occurred in patients concomitantly receiving other 

medications that suppress the immune system, which may also contribute to hepatitis 

B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence 

of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise 

caution in prescribing TNF blockers in patients previously infected with HBV. Adequate 

data are not available on the safety or efficacy of treating patients who are carriers of 

HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV 

reactivation. Patients previously infected with HBV and require treatment with Enbrel 

should be closely monitored for clinical and laboratory signs of active HBV infection 

throughout therapy and for several months following termination of therapy. In patients 

who develop HBV reactivation, consideration should be given to stopping Enbrel and 

initiating anti-viral therapy with appropriate supportive treatment. The safety of 

resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, 

prescribers should weigh the risks and benefits when considering resumption of 

therapy in this situation. 

Allergic Reactions 

Allergic reactions associated with administration of Enbrel during clinical trials have 

been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic 

reaction occurs, administration of Enbrel should be discontinued immediately and 

appropriate therapy initiated. 

Caution: The following components contain dry natural rubber (a derivative of latex), 

which may cause allergic reactions in individuals sensitive to latex: the needle cover of 

the prefilled syringe and the needle cover within the needle cap of the SureClick ® 

autoinjector. 

Immunizations 

Live vaccines should not be given concurrently with Enbrel. It is recommended that 

pediatric patients, if possible, be brought up-to-date with all immunizations in 

agreement with current immunization guidelines prior to initiating Enbrel therapy [see 

Drug Interactions]. 

Autoimmunity 

Treatment with Enbrel may result in the formation of autoantibodies [see Adverse 

Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or 

autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal 

of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like 

syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should 

be discontinued and the patient should be carefully evaluated. 

Immunosuppression 

TNF mediates inflammation and modulates cellular immune responses. TNF-blocking 

agents, including Enbrel, affect host defenses against infections. The effect of TNF 

inhibition on the development and course of malignancies is not fully understood. In a 

study of 49 patients with RA treated with Enbrel, there was no evidence of depression 

of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in 

enumeration of effector cell populations [see Adverse Reactions]. 

Use in Wegener’s Granulomatosis Patients 

The use of Enbrel in patients with Wegener’s granulomatosis receiving 

immunosuppressive agents is not recommended. In a study of patients with Wegener’s 

granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) 

was associated with a higher incidence of non cutaneous solid malignancies and was 

not associated with improved clinical outcomes when compared with standard therapy 

alone [see Drug Interactions].

Use with Anakinra or Abatacept 

Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions]. 

Use in Patients with Moderate to Severe Alcoholic Hepatitis 

In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to 

severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar 

to patients treated with placebo at 1 month but significantly higher after 6 months. 

Physicians should use caution when using Enbrel in patients with moderate to severe 

alcoholic hepatitis. 

ADVERSE REACTIONS 

Across clinical studies and postmarketing experience, the most serious adverse 

reactions with Enbrel were infections, neurologic events, CHF, and hematologic events 

[see Warnings and Precautions]. The most common adverse reactions with Enbrel were 

infections and injection site reactions. 

Clinical Studies Experience 

Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, 

Ankylosing Spondylitis, or Plaque Psoriasis 

The data described below reflect exposure to Enbrel in 2219 adult patients with RA 

followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients 

with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. 

In controlled trials, the proportion of Enbrel-treated patients who discontinued 

treatment due to adverse events was approximately 4% in the indications studied. 

Because clinical trials are conducted under widely varying conditions, adverse 

reactions rates observed in the clinical trials of a drug cannot be directly compared to 

rates in the clinical trials of another drug and may not predict the rates observed in 

clinical practice. 

Infections 

Infections, including viral, bacterial, and fungal infections, have been observed in 

adult and pediatric patients. Infections have been noted in all body systems and have 

been reported in patients receiving Enbrel alone or in combination with other 

immunosuppressive agents. 

In controlled portions of trials, the types and severity of infection were similar between 

Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, 

PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in 

Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory 

tract infection, sinusitis and influenza. 

In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection 

were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated 

groups). In clinical trials in rheumatologic indications, serious infections experienced by 

patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, 

bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical 

trials in PsO, serious infections experienced by patients have included, but are not 

limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of 

serious infections was not increased in open-label extension trials and was similar to 

that observed in Enbrel- and placebo-treated patients from controlled trials. 

In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), 

tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients 

(27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US 

and Canada, tuberculosis was observed in approximately 0.006% of patients. These 

studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings 

and Precautions]. 

Injection Site Reactions 

In placebo-controlled trials in rheumatologic indications, approximately 37% of patients 

treated with Enbrel developed injection site reactions. In controlled trials in patients 

with PsO, 15% of patients treated with Enbrel developed injection site reactions during 

the first 3 months of treatment. All injection site reactions were described as mild to 

moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not 

necessitate drug discontinuation. Injection site reactions generally occurred in the first 

month and subsequently decreased in frequency. The mean duration of injection site 

reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous 

injection site when subsequent injections were given. 

Immunogenicity 

Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to 

etanercept. Antibodies to the TNF receptor portion or other protein components of the 

Enbrel drug product were detected at least once in sera of approximately 6% of adult 

patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results 

from JIA patients were similar to those seen in adult RA patients treated with Enbrel. 

In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the 

percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 

weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of 

patients testing positive increased with an increase in the duration of study; however, 

the clinical significance of this finding is unknown. No apparent correlation of antibody 

development to clinical response or adverse events was observed. The immunogenicity 

data of Enbrel beyond 120 weeks of exposure are unknown. 

The data reflect the percentage of patients whose test results were considered positive 

for antibodies to etanercept in an ELISA assay, and are highly dependent on the 

sensitivity and specificity of the assay. Additionally, the observed incidence of any 

antibody positivity in an assay is highly dependent on several factors, including assay 

sensitivity and specificity, assay methodology, sample handling, timing of sample 

collection, concomitant medications, and underlying disease. For these reasons, 

comparison of the incidence of antibodies to etanercept with the incidence of antibodies 

to other products may be misleading. 

Autoantibodies 

Patients with RA had serum samples tested for autoantibodies at multiple time points. In 

RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) 

who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel 

(11%) than in placebo-treated patients (5%). The percentage of patients who developed 

new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay 

(15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by 

Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebotreated 

patients). The proportion of patients treated with Enbrel who developed 

anticardiolipin antibodies was similarly increased compared to placebo-treated patients. 

In RA Study III, no pattern of increased autoantibody development was seen in Enbrel 

patients compared to MTX patients [see Warnings and Precautions]. 

Other Adverse Reactions 

Table 3 summarizes adverse reactions reported in adult RA patients. The types of 

adverse reactions seen in patients with PsA or AS were similar to the types of adverse 

reactions seen in patients with RA. 

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in 

Controlled Clinical Trials 

Placebo Controlled a 

(Studies I, II, and a Phase 

2 Study) 

Placebo 

(N = 152) 

Enbrel c 

(N = 349) 

Active Controlled b 

(Study III) 

MTX 

(N = 217) 

Enbrel c 

(N = 415) 

Reaction Percent of Patients Percent of Patients 

Infection d (total) 

Upper Respiratory 

Infections e 

Non-upper Respiratory 

Infections 

Injection Site 

Reactions 

Diarrhea 

Rash 

Pruritus 

Pyrexia 

Urticaria 

Hypersensitivity 

39 

30 

15 

11 

9 

2 

1 

– 

1 

– 

50 

38 

21 

37 

8 

3 

2 

3 

– 

– 

86 

70 

59 

18 

16 

19 

5 

4 

4 

1 

81 

65 

54 

43 

16 

13 

5 

2 

2 

1 

a Includes data from the 6-month study in which patients received concurrent MTX 

therapy in both arms. 

b Study duration of 2 years. 

c Any dose. 

d Includes bacterial, viral, and fungal infections. 

e Most frequent Upper Respiratory Infections were upper respiratory tract infection, 

sinusitis, and influenza. 

In placebo-controlled PsO trials, the percentages of patients reporting adverse 

reactions in the 50 mg twice a week dose group were similar to those observed in the 

25 mg twice a week dose group or placebo group. 

Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. 

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in 

Placebo-Controlled Portions of Clinical Trials (Studies I & II) 

Reaction 

Infection b (total) 

Non-upper Respiratory 

Infections 

Upper Respiratory 

Infections c 

Injection Site 

Reactions 

Diarrhea 

Rash 

Pruritus 

Urticaria 

Hypersensitivity 

Pyrexia 

Placebo 

(N = 359) 

28 

14 

17 

6 

2 

1 

2 

– 

– 

1 

Percent of Patients 

Enbrel a 

(N = 876) 

27 

12 

a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. 

b Includes bacterial, viral and fungal infections. 

c Most frequent Upper Respiratory Infections were upper respiratory tract infection, 

nasopharyngitis and sinusitis. 

Adverse Reactions in Pediatric Patients 

In general, the adverse reactions in pediatric patients were similar in frequency and type 

as those seen in adult patients [see Warnings and Precautions]. The types of infections 

reported in pediatric patients were generally mild and consistent with those commonly 

seen in the general pediatric population. Two JIA patients developed varicella infection 

and signs and symptoms of aseptic meningitis, which resolved without sequelae. 

In open-label clinical studies of children with JIA, adverse reactions reported in those 

ages 2 to 4 years were similar to adverse reactions reported in older children. 

Postmarketing Experience 

Adverse reactions have been reported during post approval use of Enbrel in adults and 

pediatric patients. Because these reactions are reported voluntarily from a population of 

uncertain size, it is not always possible to reliably estimate their frequency or establish 

a causal relationship to Enbrel exposure. 

Adverse reactions are listed by body system below: 

Blood and lymphatic 

pancytopenia, anemia, leukopenia, neutropenia, 

system disorders: 

thrombocytopenia, lymphadenopathy, aplastic 

anemia [see Warnings and Precautions] 

Cardiac disorders: 

Gastrointestinal disorders: 

General disorders: 

Hepatobiliary disorders: 

Immune disorders: 

Musculoskeletal and 

connective tissue disorders: 

Neoplasms benign, 

malignant, and unspecified: 

Nervous system disorders: 

Ocular disorders: 

Respiratory, thoracic 

and mediastinal disorders: 

17 

15 

3 

1 

1 

1 

1 

– 

congestive heart failure [see Warnings 

and Precautions] 

inflammatory bowel disease (IBD) 

angioedema, chest pain 

autoimmune hepatitis, elevated transaminases, 

hepatitis B reactivation 

macrophage activation syndrome, 

systemic vasculitis 

lupus-like syndrome 

melanoma and non-melanoma skin cancers, 

merkel cell carcinoma [see Warnings and Precautions] 

convulsions, multiple sclerosis, demyelination, 

optic neuritis, transverse myelitis, paresthesias 

[see Warnings and Precautions] 

uveitis, scleritis 

interstitial lung disease 

Skin and subcutaneous 

tissue disorders: 

cutaneous lupus erythematous, cutaneous 

vasculitis (including leukocytoclastic vasculitis), erythema 

multiforme, Stevens-Johnson syndrome, toxic epidermal 

necrolysis, subcutaneous nodule, new or worsening psoriasis 

(all sub-types including pustular and palmoplantar) 

Opportunistic infections, including atypical mycobacterial infection, herpes zoster, 

aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also 

been reported in postmarketing use. 

DRUG INTERACTIONS 

Specific drug interaction studies have not been conducted with Enbrel. 

Vaccines 

Most PsA patients receiving Enbrel were able to mount effective B-cell immune 

responses to pneumococcal polysaccharide vaccine, but titers in aggregate were 

moderately lower and fewer patients had 2-fold rises in titers compared to patients not 

receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel 

may receive concurrent vaccinations, except for live vaccines. No data are available on 

the secondary transmission of infection by live vaccines in patients receiving Enbrel. 

Patients with a significant exposure to varicella virus should temporarily discontinue 

Enbrel therapy and be considered for prophylactic treatment with varicella zoster 

immune globulin [see Warnings and Precautions]. 

Immune-Modulating Biologic Products 

In a study in which patients with active RA were treated for up to 24 weeks with 

concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, 

which was higher than that observed with Enbrel alone (0%) [see Warnings and 

Precautions] and did not result in higher ACR response rates compared to Enbrel alone. 

The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 

cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory 

failure. Two percent of patients treated concurrently with Enbrel and anakinra 

developed neutropenia (ANC < 1 x 10 9 /L). 

In clinical studies, concurrent administration of abatacept and Enbrel resulted in 

increased incidences of serious adverse events, including infections, and did not 

demonstrate increased clinical benefit [see Warnings and Precautions]. 

Cyclophosphamide 

The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not 

recommended [see Warnings and Precautions]. 

Sulfasalazine 

Patients in a clinical study who were on established therapy with sulfasalazine, to which 

Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in 

comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical 

significance of this observation is unknown. 

USE IN SPECIFIC POPULATIONS 

Pregnancy 

Pregnancy Category B 

Pregnancy Surveillance Program 

There is a Pregnancy Surveillance Program that monitors outcomes in women exposed 

to Enbrel during pregnancy. Women who become pregnant during Enbrel treatment are 

encouraged to enroll. Patients or their physicians should call 1-800-77-AMGEN (1-800- 

772-6436) to enroll. 

Risk Summary 

There are no adequate and well controlled studies in pregnant women. Based on 

limited data, etanercept concentration in cord blood at the time of delivery showed 

that etanercept crossed the placenta in small amounts. 

Developmental toxicity studies have been performed in rats and rabbits at doses 

ranging from 60- to 100-fold higher than the human dose and have revealed no 

evidence of harm to the fetus due to Enbrel. Because animal reproduction studies are 

not always predictive of human response, this drug should be used during pregnancy 

only if clearly needed. 

Human Data 

Three case reports showed that cord blood levels of etanercept at delivery in infants, 

born to mothers administered etanercept during pregnancy, were between 3 and 32% 

of the maternal serum level. 

Nursing Mothers 

Limited data from published literature show that etanercept is present in low levels in 

human milk and minimally absorbed by a breastfed infant. Caution should be exercised 

when Enbrel is administered to a nursing woman. The development and health benefits 

of breastfeeding should be considered along with the mother’s clinical need for Enbrel 

and any potential adverse effects on the breastfed child from the drug or from the 

underlying maternal condition. 

Women who choose to continue Enbrel treatment while nursing are encouraged to enroll 

in Amgen’s Lactation Surveillance Program. Patients or their physicians should call 

1-800-77-AMGEN (1-800-772-6436) to enroll. 

Pediatric Use 

Enbrel has not been studied in children < 2 years of age with JIA. The safety and 

efficacy of Enbrel in pediatric patients with PsO have not been studied. 

Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is 

not effective for the treatment of IBD [see Adverse Reactions (6.2)]. 

The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of 

administering live or live-attenuated vaccines in exposed infants is unknown. Risks and 

benefits should be considered prior to administering live or live-attenuated vaccines to 

exposed infants. 

Geriatric Use 

A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In 

PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or 

placebo were age 65 or older. No overall differences in safety or effectiveness were 

observed between these patients and younger patients, but the number of geriatric PsO 

subjects is too small to determine whether they respond differently from younger 

subjects. Because there is a higher incidence of infections in the elderly population in 

general, caution should be used in treating the elderly. 

Use in Diabetics 

There have been reports of hypoglycemia following initiation of Enbrel therapy in 

patients receiving medication for diabetes, necessitating a reduction in anti-diabetic 

medication in some of these patients. 

Rx Only. 

This brief summary is based on ENBREL prescribing information. v.55 3/2015 

© 2015 Amgen Inc., Thousand Oaks, CA 91320 

All rights reserved. 

US License Number 1132 

© 1998 – 2015 Immunex Corporation. 

All rights reserved. 

US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. 

For more information please call 

1-888-436-2735 or visit www.enbrel.com 

PIV55

IMPORTANT SAFETY INFORMATION 

SERIOUS INFECTIONS 

Patients treated with ENBREL are at increased risk for developing serious infections 

that may lead to hospitalization or death. Most patients who developed these 

infections were taking concomitant immunosuppressants such as methotrexate 

or corticosteroids or were predisposed to infection because of their underlying 

disease. ENBREL should not be initiated in the presence of sepsis, active infections, 

or allergy to ENBREL or its components. ENBREL should be discontinued if a 

patient develops a serious infection or sepsis. Reported infections include: 1) Active 

tuberculosis (TB), including reactivation of latent TB. Patients with TB have 

frequently presented with disseminated or extrapulmonary disease. Patients 

should be tested for latent TB before ENBREL use and periodically during therapy. 

Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive 

fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, 

aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or 

other invasive fungal infections may present with disseminated, rather than localized, 

disease. Antigen and antibody testing for histoplasmosis may be negative in some 

patients with active infection. Empiric antifungal therapy should be considered in 

patients at risk for invasive fungal infections who develop severe systemic illness, 

and 3) Bacterial, viral, and other infections due to opportunistic pathogens, 

including Legionella and Listeria. 

The risks and benefi ts of treatment with ENBREL should be carefully considered 

prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who 

have been exposed to TB, 3) who have resided or traveled in areas of endemic TB 

or endemic mycoses, or 4) with underlying conditions that may predispose them 

to infections such as advanced or poorly controlled diabetes. Patients should be 

closely monitored for the development of signs and symptoms of infection during and 

after treatment with ENBREL, including the possible development of TB in patients 

who tested negative for latent TB prior to initiating therapy. 

MALIGNANCIES 

Lymphoma and other malignancies, some fatal, have been reported in children 

and adolescent patients treated with tumor necrosis factor (TNF) blockers, 

including ENBREL. 

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to 

control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis 

patients. The role of TNF blocker therapy in the development of malignancies is unknown. 

Cases of acute and chronic leukemia have been reported in association with postmarketing 

TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients 

with RA (approximately 2-fold) than the general population. 

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with 

TNF blockers, including ENBREL. Periodic skin examinations should be considered for all 

patients at increased risk for skin cancer. 

Pediatric Patients 

In patients who initiated therapy at ≤18 years of age, approximately half of the reported 

malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases 

included rare malignancies usually associated with immunosuppression and malignancies 

that are not usually observed in children and adolescents. Most of the patients were 

receiving concomitant immunosuppressants. 

NEUROLOGIC EVENTS 

Treatment with TNF-blocking agents, including ENBREL, has been associated with rare 

(

In moderately to severely active rheumatoid arthritis (RA) 

ENBREL gives you options down the road 

START WITH IF NEEDED, CONTINUE WITH 

In open-label extension trials with ENBREL, a substantial number of patients who 

initially received concomitant MTX were able to reduce their doses or discontinue 

MTX while maintaining their clinical responses 1 

ENBREL is proven in combination with MTX. 

ENBREL is strong enough to stand alone when needed. 

• ENBREL inhibits the progression of joint damage with MTX or as monotherapy 1 

Based on data from national registries, an estimated 30% of all patients on biologic therapy 

are on biologic monotherapy 2-6 

• These patients may either have been initiated on biologic monotherapy or started on combination therapy, but ended up 

on biologic monotherapy 2-6 

Prescription ENBREL is administered by injection. 

INDICATION 

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting 

the progression of structural damage, and improving physical function in patients with moderately to 

severely active rheumatoid arthritis (RA). ENBREL can be initiated in combination with methotrexate (MTX) 

or used alone. 

VISIT 

BOOTH 

#1007 

IMPORTANT SAFETY CONSIDERATIONS 

ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including 

opportunistic infections and TB. Other serious and sometimes fatal adverse events including malignancies, neurologic events, 

congestive heart failure, hematologic events, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune 

hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis. The most commonly reported adverse events 

in RA clinical trials were injection site reactions, infection, and headache. 

Please see additional Important Safety Information and 

Brief Summary on preceding pages. 

Enbrel ® and the Enbrel ® logo are registered trademarks of Immunex Corporation.

session plus

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?